In O
order O
to O
study O
the O
mechanism O
of O
the O
histone O
deacetylase O
( O
HDAC O
) O
inhibitors O
valproic B
acid I
( O
VPA B
) O
and O
suberoylanilide B
hydroxamic I
acid I
( O
SAHA B
) O
in O
breast O
cancer O
, O
we O
generated O
and O
validated O
genomic O
profiles O
of O
drug O
response O
using O
a O
series O
of O
breast O
cancer O
cell O
lines O
sensitive O
to O
each O
drug O
. O

Together O
, O
these O
results O
led O
us O
to O
hypothesize O
that O
VPA B
and O
SAHA B
may O
interact O
synergistically O
with O
CDK O
inhibitors O
such O
as O
PD B
- I
033299 I
. O

The O
main O
isolated O
compounds O
were O
triterpenes B
( O
alpha B
- I
amyrin I
, O
beta B
- I
amyrin I
, O
lupeol B
, O
betulin B
, O
betulinic B
acid I
, O
uvaol B
, O
erythrodiol B
and O
oleanolic B
acid I
) O
and O
phenolic B
acid I
derivatives O
from O
4 B
- I
hydroxybenzoic I
acid I
( O
gallic B
and I
protocatechuic I
acids I
and O
isocorilagin B
) O
. O

The O
main O
isolated O
compounds O
were O
triterpenes B
( O
alpha B
- I
amyrin I
, O
beta B
- I
amyrin I
, O
lupeol B
, O
betulin B
, O
betulinic B
acid I
, O
uvaol B
, O
erythrodiol B
and O
oleanolic B
acid I
) O
and O
phenolic B
acid I
derivatives O
from O
4 B
- I
hydroxybenzoic I
acid I
( O
gallic B
and I
protocatechuic I
acids I
and O
isocorilagin B
) O
. O

Accumulation O
profiles O
of O
fatty B
acids I
and O
alpha B
- I
tocopherol I
were O
analysed O
at O
three O
ripening O
stages O
in O
the O
seed O
oils O
of O
Primula O
and O
Echium O
species O
. O

Total O
seed O
oils O
were O
increased O
considerably O
with O
maturation O
, O
while O
alpha B
- I
tocopherol I
contents O
decreased O
in O
both O
species O
. O

Considerable O
amounts O
of O
alpha B
- I
tocopherol I
( O
27 O
. O
4 O
mg O
/ O
100 O
g O
) O
, O
linoleic B
acid I
( O
42 O
. O
76 O
% O
) O
and O
ALA B
( O
25 O
. O
46 O
% O
) O
and O
GLA B
( O
4 O
. O
11 O
% O
) O
were O
detected O
in O
Ribes O
alpinum O
. O

5 O
) O
: O
basal O
diet O
+ O
trans B
- I
anethole I
( O
4 O
. O
5 O
g O
/ O
kg O
diet O
) O
G O
( O
6 O
) O
: O
basal O
diet O
+ O
propylene B
glycol I
( O
0 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
7 O
) O
: O
basal O
diet O
+ O
vanillin B
( O
1 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
8 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
+ O
propylene B
glycol I
, O
G O
( O
9 O
) O
: O
basal O
diet O
+ O
carmoisine B
+ O
trans B
- I
anethole I
, O
G O
( O
10 O
) O
: O
basal O
diet O
+ O
tartrazine B
+ O
vanillin B
for O
42 O
successive O
days O

5 O
) O
: O
basal O
diet O
+ O
trans B
- I
anethole I
( O
4 O
. O
5 O
g O
/ O
kg O
diet O
) O
G O
( O
6 O
) O
: O
basal O
diet O
+ O
propylene B
glycol I
( O
0 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
7 O
) O
: O
basal O
diet O
+ O
vanillin B
( O
1 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
8 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
+ O
propylene B
glycol I
, O
G O
( O
9 O
) O
: O
basal O
diet O
+ O
carmoisine B
+ O
trans B
- I
anethole I
, O
G O
( O
10 O
) O
: O
basal O
diet O
+ O
tartrazine B
+ O
vanillin B
for O
42 O
successive O
days O

In O
vitro O
evaluation O
of O
the O
protective O
effects O
of O
4 B
- I
thujanol I
against O
mitomycin B
- I
C I
and O
cyclophosphamide B
- O
induced O
genotoxic O
damage O
in O
human O
peripheral O
lymphocytes O
. O

In O
vitro O
evaluation O
of O
the O
protective O
effects O
of O
4 B
- I
thujanol I
against O
mitomycin B
- I
C I
and O
cyclophosphamide B
- O
induced O
genotoxic O
damage O
in O
human O
peripheral O
lymphocytes O
. O

4 B
- I
Thujanol I
( O
sabinene B
hydrate I
) O
, O
a O
bicyclic B
monoterpene I
alcohol I
, O
is O
found O
in O
the O
essential O
oils O
of O
many O
aromatic O
and O
medicinal O
plants O
and O
is O
widely O
used O
as O
a O
fragrance O
and O
flavouring O
agent O
in O
many O
different O
products O
. O

4 B
- I
Thujanol I
( O
sabinene B
hydrate I
) O
, O
a O
bicyclic B
monoterpene I
alcohol I
, O
is O
found O
in O
the O
essential O
oils O
of O
many O
aromatic O
and O
medicinal O
plants O
and O
is O
widely O
used O
as O
a O
fragrance O
and O
flavouring O
agent O
in O
many O
different O
products O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
protective O
effects O
of O
4 B
- I
thujanol I
against O
the O
genotoxic O
effects O
induced O
by O
mitomycin B
C I
( O
MMC B
) O
and O
cyclophosphamide B
( O
CP O
) O
in O
human O
lymphocytes O
, O
using O
the O
chromosome O
aberrations O
, O
sister O
chromatid O
exchanges O
, O
and O
micronucleus O
tests O
, O
in O
the O
absence O
and O
in O
the O
presence O
of O
S9 O
mix O
, O
respectively O
. O

The O
cells O
were O
treated O
with O
0 O
. O
25 O
micro O
g O
/ O
mL O
MMC B
and O
28 O
micro O
g O
/ O
mL O
CP O
as O
alone O
and O
cotreated O
with O
13 O
+ O
0 O
. O
25 O
, O
26 O
+ O
0 O
. O
25 O
, O
and O
52 O
+ O
0 O
. O
25 O
micro O
g O
/ O
mL O
4 B
- I
thujanol I
+ O
MMC B
and O
with O
13 O
+ O
28 O
, O
26 O
+ O
28 O
, O
and O
52 O
+ O
28 O
micro O
g O
/ O
mL O
4 B
- I
thujanol I
+ O
CP O
as O
a O
mixture O
. O

The O
cells O
were O
treated O
with O
0 O
. O
25 O
micro O
g O
/ O
mL O
MMC B
and O
28 O
micro O
g O
/ O
mL O
CP O
as O
alone O
and O
cotreated O
with O
13 O
+ O
0 O
. O
25 O
, O
26 O
+ O
0 O
. O
25 O
, O
and O
52 O
+ O
0 O
. O
25 O
micro O
g O
/ O
mL O
4 B
- I
thujanol I
+ O
MMC B
and O
with O
13 O
+ O
28 O
, O
26 O
+ O
28 O
, O
and O
52 O
+ O
28 O
micro O
g O
/ O
mL O
4 B
- I
thujanol I
+ O
CP O
as O
a O
mixture O
. O

The O
present O
study O
showed O
that O
4 B
- I
thujanol I
was O
unable O
to O
reduce O
the O
genetic O
damage O
induced O
by O
MMC B
, O
in O
the O
absence O
of O
S9 O
mix O
. O

On O
the O
other O
hand O
, O
probably O
the O
metabolites O
of O
4 B
- I
thujanol I
act O
as O
an O
antagonist O
and O
markedly O
antagonize O
CP O
- O
induced O
genotoxicity O
, O
in O
the O
presence O
of O
S9 O
mix O
. O

In O
general O
, O
4 B
- I
thujanol I
+ O
MMC B
and O
4 B
- I
thujanol I
+ O
CP O
decreased O
the O
mitotic O
index O
, O
proliferation O
index O
and O
nuclear O
division O
index O
to O
the O
same O
extent O
or O
more O
than O
those O
of O
individual O
exposure O
of O
MMC B
or O
CP O
. O

In O
general O
, O
4 B
- I
thujanol I
+ O
MMC B
and O
4 B
- I
thujanol I
+ O
CP O
decreased O
the O
mitotic O
index O
, O
proliferation O
index O
and O
nuclear O
division O
index O
to O
the O
same O
extent O
or O
more O
than O
those O
of O
individual O
exposure O
of O
MMC B
or O
CP O
. O

In O
conclusion O
, O
4 B
- I
thujanol I
significantly O
reduced O
( O
p O
< O
0 O
. O
001 O
) O
the O
genotoxic O
damage O
induced O
by O
CP O
but O
not O
MMC B
when O
compared O
with O
the O
respective O
positive O
control O
alone O
. O

We O
can O
suggest O
that O
4 B
- I
thujanol I
may O
improve O
the O
chemopreventive O
effects O
and O
may O
also O
reduce O
the O
harmful O
side O
effects O
of O
CP O
, O
which O
is O
widely O
used O
in O
chemotherapy O
against O
cancer O
, O
without O
reducing O
its O
antiproliferative O
activities O
. O

Bromotheoynic B
acid I
, O
a O
brominated B
acetylenic I
acid I
from O
the O
marine O
sponge O
Theonella O
swinhoei O
. O

alpha B
- I
Thujone I
( O
36 O
. O
35 O
% O
) O
, O
beta B
- I
thujone I
( O
9 O
. O
37 O
% O
) O
, O
germacrene B
D I
( O
6 O
. O
32 O
% O
) O
, O
4 B
- I
terpineol I
( O
6 O
. O
31 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
5 O
. O
43 O
% O
) O
, O
camphene B
( O
5 O
. O
47 O
% O
) O
and O
borneol B
( O
4 O
. O
12 O
% O
) O
were O
identified O
as O
the O
major O
constituents O
. O

alpha B
- I
Thujone I
( O
36 O
. O
35 O
% O
) O
, O
beta B
- I
thujone I
( O
9 O
. O
37 O
% O
) O
, O
germacrene B
D I
( O
6 O
. O
32 O
% O
) O
, O
4 B
- I
terpineol I
( O
6 O
. O
31 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
5 O
. O
43 O
% O
) O
, O
camphene B
( O
5 O
. O
47 O
% O
) O
and O
borneol B
( O
4 O
. O
12 O
% O
) O
were O
identified O
as O
the O
major O
constituents O
. O

alpha B
- I
Thujone I
( O
36 O
. O
35 O
% O
) O
, O
beta B
- I
thujone I
( O
9 O
. O
37 O
% O
) O
, O
germacrene B
D I
( O
6 O
. O
32 O
% O
) O
, O
4 B
- I
terpineol I
( O
6 O
. O
31 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
5 O
. O
43 O
% O
) O
, O
camphene B
( O
5 O
. O
47 O
% O
) O
and O
borneol B
( O
4 O
. O
12 O
% O
) O
were O
identified O
as O
the O
major O
constituents O
. O

alpha B
- I
Thujone I
( O
36 O
. O
35 O
% O
) O
, O
beta B
- I
thujone I
( O
9 O
. O
37 O
% O
) O
, O
germacrene B
D I
( O
6 O
. O
32 O
% O
) O
, O
4 B
- I
terpineol I
( O
6 O
. O
31 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
5 O
. O
43 O
% O
) O
, O
camphene B
( O
5 O
. O
47 O
% O
) O
and O
borneol B
( O
4 O
. O
12 O
% O
) O
were O
identified O
as O
the O
major O
constituents O
. O

Modulated O
release O
of O
5 B
- I
fluorouracil I
from O
pH O
- O
sensitive O
and O
colon O
targeted O
pellets O
: O
an O
industrially O
feasible O
approach O
. O

5 B
- I
Fluorouracil I
( O
5 B
- I
FU I
) O
loaded O
pellets O
were O
prepared O
by O
extrusion O
- O
spheronization O
using O
Avicel O
( O
( O
R O
) O
) O
PH101 O
as O
a O
spheronization O
aid O
and O
hydroxypropylmethylc O
K4M O
( O
HPMC O
K4M O
) O
solution O
as O
a O
binder O
. O

5 B
- I
Fluorouracil I
( O
5 B
- I
FU I
) O
loaded O
pellets O
were O
prepared O
by O
extrusion O
- O
spheronization O
using O
Avicel O
( O
( O
R O
) O
) O
PH101 O
as O
a O
spheronization O
aid O
and O
hydroxypropylmethylc O
K4M O
( O
HPMC O
K4M O
) O
solution O
as O
a O
binder O
. O

Hence O
, O
the O
present O
study O
provides O
constructive O
results O
for O
colon O
targeting O
of O
5 B
- I
FU I
pellets O
with O
industrially O
feasible O
processes O
. O

Further O
, O
we O
used O
this O
model O
to O
test O
the O
efficacy O
of O
GDC B
- I
0941 I
, O
a O
PI3K O
inhibitor O
, O
in O
clinical O
development O
, O
and O
showed O
that O
the O
tumors O
respond O
to O
PI3K O
inhibition O
. O

In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
( O
Epi B
, O
cisplatin B
, O
5 B
- I
fluorouracil I
) O
chemotherapy O
. O

Three O
new O
compounds O
; O
epi B
- I
mukulin I
, O
( B
Z I
) I
- I
Delta I
( I
1 I
, I
2 I
) I
dehydroguggulsterone I
and O
Delta B
( I
6 I
, I
7 I
) I
dehydro I
- I
20 I
- I
hydroxygugglsterone I
were O
isolated O
from O
the O
n B
- I
hexane I
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol B
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin B
, O
( B
+ I
) I
- I
epi I
- I
magnolin I
, O
( B
+ I
) I
- I
diayangambin I
, O

Three O
new O
compounds O
; O
epi B
- I
mukulin I
, O
( B
Z I
) I
- I
Delta I
( I
1 I
, I
2 I
) I
dehydroguggulsterone I
and O
Delta B
( I
6 I
, I
7 I
) I
dehydro I
- I
20 I
- I
hydroxygugglsterone I
were O
isolated O
from O
the O
n B
- I
hexane I
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol B
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin B
, O
( B
+ I
) I
- I
epi I
- I
magnolin I
, O
( B
+ I
) I
- I
diayangambin I
, O

The O
IC O
( O
50 O
) O
values O
of O
epi B
- I
mukulin I
and O
( B
Z I
) I
- I
guggulsterone I
were O
found O
to O
be O
159 O
. O
33 O
and O
132 O
. O
14 O
micro O
M O
, O
respectively O
. O

f O
. O
against O
Coptotermes O
formosanus O
Shiraki O
, O
6 B
- I
desacetylnimbin I
( O
1 O
) O
, O
quercitrin B
( O
2 O
) O
and O
myricitrin B
( O
3 O
) O
were O
isolated O
from O
P O
. O
javanicum O
extract O
. O

Furthermore O
, O
the O
structure O
of O
6 B
- I
desacetylnimbin I
was O
confirmed O
by O
X O
- O
ray O
crystallography O
. O

At O
a O
dose O
of O
0 O
. O
5 O
mg O
, O
6 B
- I
desacetylnimbin I
exhibited O
the O
highest O
antifeedant O
activity O
among O
the O
isolates O
. O

Many O
common O
constituents O
were O
found O
in O
both O
species O
, O
including O
shikimic B
acid I
, O
5 B
- I
O I
- I
caffeoylshikimic I
acid I
, O
trans B
- I
resveratrol I
, O
taxifolin B
, O
astilbin B
and O
its O
three O
stereoisomers O
, O
engeletin B
and O
isoengeletin B
. O

The O
known O
compounds O
were O
identified O
as O
beta B
- I
sitosterol I
, O
stigmasterol B
and O
lupeol B
by O
comparing O
their O
spectral O
data O
with O
those O
reported O
in O
the O
literature O
. O

Thirteen O
N B
- I
alkylamides I
were O
detected O
in O
the O
extract O
by O
using O
HPLC O
/ O
UV O
/ O
electrospray O
ionization O
mass O
spectrometry O
method O
. O

Xanthurenic B
acid I
( O
XA O
) O
, O
a O
molecule O
arising O
from O
tryptophan B
metabolism O
by O
transamination O
of O
3 B
- I
hydroxykynurenine I
, O
has O
recently O
been O
identified O
as O
an O
endogenous O
Group O
II O
( O
mGlu2 O
and O
mGlu3 O
) O
metabotropic O
glutamate B
( O
mGlu O
) O
receptor O
ligand O
in O
vitro O
. O

The O
essential O
oil O
was O
obtained O
by O
hydrodistillation O
, O
and O
gas O
chromatography O
/ O
mass O
spectrometry O
analysis O
identified O
the O
main O
constituents O
: O
thymol B
( O
84 O
. O
9 O
% O
) O
and O
p B
- I
cymene I
( O
5 O
. O
33 O
% O
) O
. O

A O
series O
of O
F O
( O
D O
) O
LF O
( O
D O
) O
LF O
analogs O
has O
been O
synthesized O
, O
including O
either O
N B
- I
t I
- I
Boc I
or O
different O
N B
- I
ureido I
substituents O
. O

Their O
methyl B
- I
ester I
derivatives O
are O
ineffective O
. O

In O
addition O
, O
vascular O
strips O
and O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
were O
used O
in O
organ O
bath O
, O
Western O
blot O
, O
nitrite B
, O
and O
cyclic B
guanosine I
monophosphate I
( O
cGMP B
) O
measurements O
. O

In O
the O
livers O
of O
db O
/ O
db O
mice O
, O
SBE O
promoted O
5 B
' I
AMP I
- O
activated O
protein O
kinase O
activity O
and O
restored O
metabolic O
process O
and O
insulin O
signaling O
pathways O
. O

beta B
- I
Eudesmol I
induces O
JNK O
- O
dependent O
apoptosis O
through O
the O
mitochondrial O
pathway O
in O
HL60 O
cells O
. O

beta B
- I
eudesmol I
, O
a O
natural O
sesquiterpenol B
present O
in O
a O
variety O
of O
Chinese O
herbs O
, O
is O
known O
to O
inhibit O
the O
proliferation O
of O
human O
tumor O
cells O
. O

However O
, O
the O
molecular O
mechanisms O
of O
the O
effect O
of O
beta B
- I
eudesmol I
on O
human O
tumor O
cells O
are O
unknown O
. O

In O
the O
present O
study O
, O
we O
report O
the O
cytotoxic O
effect O
of O
beta B
- I
eudesmol I
on O
the O
human O
leukemia O
HL60 O
cells O
and O
its O
molecular O
mechanisms O
. O

The O
cytotoxic O
effect O
of O
beta B
- I
eudesmol I
on O
HL60 O
cells O
was O
associated O
with O
apoptosis O
, O
which O
was O
characterized O
by O
the O
presence O
of O
DNA O
fragmentation O
. O

beta B
- I
eudesmol I
- O
induced O
apoptosis O
was O
accompanied O
by O
cleavage O
of O
caspase O
- O
3 O
, O
caspase O
- O
9 O
, O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
; O
downregulation O
of O
Bcl O
- O
2 O
expression O
; O
release O
of O
cytochrome O
c O
from O
mitochondria O
; O
and O
decrease O
in O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
. O

Activation O
of O
c O
- O
Jun O
N B
- O
terminal O
kinases O
( O
JNK O
) O
mitogen O
- O
activated O
protein O
kinases O
was O
observed O
in O
beta B
- I
eudesmol I
- O
treated O
HL60 O
cells O
, O
and O
the O
inhibitor O
of O
JNK O
blocked O
the O
beta B
- I
eudesmol I
- O
induced O
apoptosis O
, O
downregulation O
of O
Bcl O
- O
2 O
, O
and O
the O
loss O
of O
MMP O
. O

Activation O
of O
c O
- O
Jun O
N B
- O
terminal O
kinases O
( O
JNK O
) O
mitogen O
- O
activated O
protein O
kinases O
was O
observed O
in O
beta B
- I
eudesmol I
- O
treated O
HL60 O
cells O
, O
and O
the O
inhibitor O
of O
JNK O
blocked O
the O
beta B
- I
eudesmol I
- O
induced O
apoptosis O
, O
downregulation O
of O
Bcl O
- O
2 O
, O
and O
the O
loss O
of O
MMP O
. O

These O
data O
suggest O
that O
beta B
- I
eudesmol I
induces O
apoptosis O
in O
HL60 O
cells O
via O
the O
mitochondrial O
apoptotic O
pathway O
, O
which O
is O
controlled O
through O
JNK O
signaling O
. O

Optimization O
of O
PLGA B
nanoparticles O
formulation O
containing O
L B
- I
DOPA I
by O
applying O
the O
central O
composite O
design O
. O

The O
aim O
of O
this O
work O
was O
to O
prepare O
L B
- I
DOPA I
loaded O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
nanoparticles O
by O
a O
modified O
water O
- O
in O
- O
oil O
- O
in O
- O
water O
( O
W O
( O
1 O
) O
/ O
O O
/ O
W O
( O
2 O
) O
) O
emulsification O
solvent O
evaporation O
method O
. O

FTIR O
investigation O
confirmed O
that O
the O
L B
- I
DOPA I
and O
PLGA B
polymer O
maintained O
its O
backbone O
structure O
in O
the O
fabrication O
of O
nanoparticles O
. O

The O
results O
suggested O
that O
PLGA B
nanoparticles O
might O
represent O
a O
promising O
formulation O
for O
brain O
delivery O
of O
L B
- I
DOPA I
. O

The O
preparation O
of O
L B
- I
DOPA I
loaded O
PLGA B
nanoparticles O
can O
be O
optimized O
by O
the O
central O
composite O
design O
. O

Previous O
studies O
demonstrated O
that O
the O
Group O
III O
mGlu O
receptor O
- O
selective O
orthosteric O
agonist O
, O
LSP1 B
- I
2111 I
produced O
anxiolytic O
- O
but O
not O
antidepressant O
- O
like O
effects O
upon O
peripheral O
administration O
. O

The O
anti O
- O
hyperthermic O
effect O
of O
Lu B
AF21934 I
( O
5 O
mg O
/ O
kg O
) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine B
receptor O
antagonist O
flumazenil B
( O
10 O
mg O
/ O
kg O
) O
and O
was O
not O
serotonin B
- O
dependent O
, O
as O
it O
persisted O
in O
serotonin B
- O
deficient O
mice O
and O
upon O
blockade O
of O
either O
5 B
- I
HT I
( O
1A O
) O
receptors O
by O
WAY100635 B
, O
or O
5 B
- I
HT I
( O
2A O
/ O
2C O
) O
receptors O
by O
ritanserin B
. O

The O
anti O
- O
hyperthermic O
effect O
of O
Lu B
AF21934 I
( O
5 O
mg O
/ O
kg O
) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine B
receptor O
antagonist O
flumazenil B
( O
10 O
mg O
/ O
kg O
) O
and O
was O
not O
serotonin B
- O
dependent O
, O
as O
it O
persisted O
in O
serotonin B
- O
deficient O
mice O
and O
upon O
blockade O
of O
either O
5 B
- I
HT I
( O
1A O
) O
receptors O
by O
WAY100635 B
, O
or O
5 B
- I
HT I
( O
2A O
/ O
2C O
) O
receptors O
by O
ritanserin B
. O

We O
herein O
demonstrate O
that O
in O
addition O
to O
non O
- O
selective O
group O
II O
mGlu O
receptor O
agonists O
, O
( B
2R I
, I
4R I
) I
- I
APDC I
, O
LY379268 B
and O
DCG B
- I
IV I
, O
a O
selective O
mGlu2 O
agonist O
, O
LY541850 B
, O
and O
mGlu2 O
positive O
allosteric O
modulators O
, O
BINA O
and O
CBiPES O
, O
inhibit O
the O
frequency O
of O
synchronised O
Ca B
( I
2 I
+ I
) I
oscillations O
in O
primary O
cultures O
of O
rat O
and O
mouse O
cortical O
neurons O
. O

Glycine B
release O
is O
regulated O
by O
metabotropic O
glutamate B
receptors O
sensitive O
to O
mGluR2 O
/ O
3 O
ligands O
and O
activated O
by O
N B
- I
acetylaspartylglutam I
( O
NAAG B
) O
. O

N B
- I
acetylaspartylglutam I
( O
NAAG B
) O
inhibited O
[ B
( I
3 I
) I
H I
] I
glycine I
overflow O
with O
extraordinary O
potency O
( O
EC O
( O
50 O
) O
about O
50 O
fmol O
) O
. O

The O
non O
- O
hydrolysable O
NAAG B
analogue O
N B
- I
acetylaspartyl I
- I
beta I
- I
linked I
glutamate I
( O
beta B
- I
NAAG I
) O
antagonized O
NAAG B
and O
LY379268 B
. O

When O
the O
cells O
were O
incubated O
in O
medium O
containing O
5 B
- I
fluorocytosine I
, O
cell O
survival O
ratio O
decreased O
dose O
dependently O
with O
5 B
- I
fluorocytosine I
only O
after O
sonication O
treatment O
, O
suggesting O
this O
promoter O
could O
be O
utilized O
for O
gene O
expression O
control O
with O
ultrasound O
. O

When O
the O
cells O
were O
incubated O
in O
medium O
containing O
5 B
- I
fluorocytosine I
, O
cell O
survival O
ratio O
decreased O
dose O
dependently O
with O
5 B
- I
fluorocytosine I
only O
after O
sonication O
treatment O
, O
suggesting O
this O
promoter O
could O
be O
utilized O
for O
gene O
expression O
control O
with O
ultrasound O
. O

The O
pinosylvin B
- O
induced O
cell O
proliferation O
was O
declined O
by O
treatment O
with O
L B
- I
NAME I
, O
an O
eNOS O
inhibitor O
. O

Dihydroxy B
- I
isosteviol I
methyl I
ester I
( O
DIME B
) O
, O
the O
principal O
biological O
compound O
isolated O
from O
the O
medicinal O
plant O
Pulsatilla O
nigricans O
( O
Fam O
: O
Ranunculaceae O
) O
having O
the O
molecular O
formula O
of O
C21 B
H34 I
O3 I
( O
molecular O
weight O
334 O
. O
25 O
) O
, O
was O
administered O
to O
cervical O
cancer O
cells O
( O
HeLa O
) O
in O
vitro O
to O
evaluate O
its O
possible O
apoptotic O
( O
anti O
- O
cancer O
) O
potentials O
. O

VP1 O
. O
1 O
. O
5 O
facilitated O
pre O
- O
pulse O
inhibition O
( O
PPI O
) O
, O
reversed O
amphetamine B
- O
but O
not O
MK B
- I
801 I
- O
induced O
PPI O
deficit O
. O

The O
novel O
phosphodiesterase O
10A O
inhibitor O
THPP B
- I
1 I
has O
antipsychotic O
- O
like O
effects O
in O
rat O
and O
improves O
cognition O
in O
rat O
and O
rhesus O
monkey O
. O

Here O
we O
describe O
effects O
of O
a O
potent O
and O
orally O
bioavailable O
PDE10A O
inhibitor O
[ O
2 B
- I
( I
6 I
- I
chloropyridin I
- I
3 I
- I
yl I
) I
- I
4 I
- I
( I
2 I
- I
methoxyethoxy I
) I
- I
7 I
, I
8 I
- I
dihydropyrido I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
6 I
( I
5H I
) I
- I
yl I
] I
( I
imidazo I
[ I
1 I
, I
5 I
- I
a I
] I
pyridin I
- I
1 I
- I
yl I
) I
methanone I
] O
( O
THPP B
- I
1 I
) O
on O
striatal O
signaling O
pathways O
, O
in O
behavioral O
tests O
that O

THPP B
- I
1 I
exhibits O
nanomolar O
potency O
on O
the O
PDE10A O
enzyme O
, O
demonstrates O
excellent O
pharmacokinetic O
properties O
in O
multiple O
preclinical O
animal O
species O
, O
and O
is O
selective O
for O
PDE10A O
over O
other O
PDE O
families O
of O
enzymes O
. O

THPP B
- I
1 I
significantly O
increased O
phosphorylation O
of O
proteins O
in O
the O
striatum O
involved O
in O
synaptic O
plasticity O
, O
including O
the O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
proprionic I
acid I
receptor O
( O
AMPA B
) O
GluR1 O
subunit O
, O
extracellular O
receptor O
kinase O
( O
ERK O
) O
, O
and O
cAMP B
- O
response O
element O
binding O
protein O
( O
CREB O
) O
. O

THPP B
- I
1 I
produced O
dose O
- O
dependent O
effects O
in O
preclinical O
assays O
predictive O
of O
antipsychotic O
activity O
including O
attenuation O
of O
MK B
- I
801 I
- O
induced O
psychomotor O
activation O
and O
condition O
avoidance O
responding O
in O
rats O
. O

THPP B
- I
1 I
produced O
dose O
- O
dependent O
effects O
in O
preclinical O
assays O
predictive O
of O
antipsychotic O
activity O
including O
attenuation O
of O
MK B
- I
801 I
- O
induced O
psychomotor O
activation O
and O
condition O
avoidance O
responding O
in O
rats O
. O

At O
similar O
plasma O
exposures O
, O
THPP B
- I
1 I
significantly O
increased O
object O
recognition O
memory O
in O
rat O
and O
attenuated O
a O
ketamine B
- O
induced O
deficit O
in O
the O
object O
retrieval O
detour O
task O
in O
rhesus O
monkey O
. O

beta B
- I
Orcinol I
- O
type O
depsides O
from O
the O
lichen O
Thamnolia O
vermicularis O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

Preliminary O
data O
with O
CX546 B
, O
in O
which O
beta B
- I
cyclodextrin I
was O
the O
vehicle O
, O
revealed O
behavioral O
effects O
of O
the O
acute O
intraperitoneal O
and O
oral O
administration O
of O
vehicle O
alone O
. O

Egis B
- I
11150 I
: O
a O
candidate O
antipsychotic O
compound O
with O
procognitive O
efficacy O
in O
rodents O
. O

Here O
, O
we O
report O
the O
preclinical O
properties O
of O
a O
candidate O
antipsychotic O
, O
Egis B
- I
11150 I
, O
that O
shows O
marked O
pro O
- O
cognitive O
efficacy O
. O

Egis B
- I
11150 I
displayed O
high O
affinity O
for O
adrenergic O
alpha O
( O
1 O
) O
, O
alpha O
( O
2c O
) O
, O
5 B
- I
HT I
( O
2A O
) O
5 O
- O
HT O
7 O
, O
moderate O
affinity O
for O
adrenergic O
alpha O
( O
2a O
) O
and O
D O
2 O
receptors O
. O

Egis B
- I
11150 I
displayed O
high O
affinity O
for O
adrenergic O
alpha O
( O
1 O
) O
, O
alpha O
( O
2c O
) O
, O
5 B
- I
HT I
( O
2A O
) O
5 O
- O
HT O
7 O
, O
moderate O
affinity O
for O
adrenergic O
alpha O
( O
2a O
) O
and O
D O
2 O
receptors O
. O

Egis B
- I
11150 I
( O
0 O
. O
01 O
- O
0 O
. O
3 O
mg O
/ O
kg O
, O
ip O
. O
) O
was O
effective O
in O
all O
of O
the O
preclinical O
models O
of O
schizophrenia O
examined O
. O

In O
summary O
, O
work O
in O
preclinical O
models O
indicates O
that O
Egis B
- I
11150 I
is O
a O
potential O
treatment O
for O
controlling O
the O
psychosis O
as O
well O
as O
the O
cognitive O
dysfunction O
in O
schizophrenia O
. O

n B
- I
Butyl I
- I
p I
- I
hydroxybenzoate I
( O
n B
- I
butylparaben I
, O
BPB B
) O
is O
an O
antioxidant O
used O
in O
foods O
, O
pharmaceuticals O
and O
cosmetics O
. O

Metabolites O
detected O
in O
urine O
included O
those O
previously O
reported O
, O
BPB B
- I
glucuronide I
, O
BPB B
- I
sulfate I
, O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
, O
but O
also O
novel O
metabolites O
arising O
from O
ring O
hydroxylation O
followed O
by O
glucuronidation O
and O
sulfation O
. O

Metabolites O
detected O
in O
urine O
included O
those O
previously O
reported O
, O
BPB B
- I
glucuronide I
, O
BPB B
- I
sulfate I
, O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
, O
but O
also O
novel O
metabolites O
arising O
from O
ring O
hydroxylation O
followed O
by O
glucuronidation O
and O
sulfation O
. O

Absorption O
of O
TAK B
- I
491 I
, O
a O
new O
angiotensin B
II I
receptor O
antagonist O
, O
in O
animals O
. O

The O
absorption O
process O
in O
animals O
of O
TAK B
- I
491 I
, O
designed O
as O
ester B
- O
based O
prodrug O
with O
medoxomil B
moiety O
, O
was O
evaluated O
. O

In O
the O
plasma O
of O
rats O
and O
dogs O
, O
TAK B
- I
536 I
, O
the O
pharmacologically O
active O
metabolite O
, O
was O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
oral O
administration O
of O
TAK B
- I
491 I
. O

In O
the O
plasma O
of O
rats O
and O
dogs O
, O
TAK B
- I
536 I
, O
the O
pharmacologically O
active O
metabolite O
, O
was O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
oral O
administration O
of O
TAK B
- I
491 I
. O

In O
the O
plasma O
of O
rats O
and O
dogs O
, O
TAK B
- I
536 I
, O
the O
pharmacologically O
active O
metabolite O
, O
was O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
oral O
administration O
of O
TAK B
- I
491 I
. O

In O
the O
rat O
portal O
plasma O
, O
TAK B
- I
536 I
was O
also O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
jejunal O
loop O
injection O
of O
TAK B
- I
491 I
, O
suggesting O
TAK B
- I
491 I
was O
absorbed O
from O
small O
intestine O
and O
hydrolyzed O
almost O
completely O
during O
absorption O
. O

In O
the O
rat O
portal O
plasma O
, O
TAK B
- I
536 I
was O
also O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
jejunal O
loop O
injection O
of O
TAK B
- I
491 I
, O
suggesting O
TAK B
- I
491 I
was O
absorbed O
from O
small O
intestine O
and O
hydrolyzed O
almost O
completely O
during O
absorption O
. O

In O
the O
rat O
portal O
plasma O
, O
TAK B
- I
536 I
was O
also O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
jejunal O
loop O
injection O
of O
TAK B
- I
491 I
, O
suggesting O
TAK B
- I
491 I
was O
absorbed O
from O
small O
intestine O
and O
hydrolyzed O
almost O
completely O
during O
absorption O
. O

In O
the O
rat O
portal O
plasma O
, O
TAK B
- I
536 I
was O
also O
present O
as O
the O
main O
component O
with O
hardly O
detectable O
concentrations O
of O
TAK B
- I
491 I
after O
jejunal O
loop O
injection O
of O
TAK B
- I
491 I
, O
suggesting O
TAK B
- I
491 I
was O
absorbed O
from O
small O
intestine O
and O
hydrolyzed O
almost O
completely O
during O
absorption O
. O

Caco O
- O
2 O
study O
indicated O
the O
permeability O
of O
TAK B
- I
491 I
was O
improved O
by O
prodrug O
modification O
and O
the O
compound O
could O
be O
mainly O
transferred O
as O
TAK B
- I
491 I
. O

Caco O
- O
2 O
study O
indicated O
the O
permeability O
of O
TAK B
- I
491 I
was O
improved O
by O
prodrug O
modification O
and O
the O
compound O
could O
be O
mainly O
transferred O
as O
TAK B
- I
491 I
. O

This O
is O
well O
consistent O
with O
the O
facts O
that O
the O
AUC O
and O
T O
( O
max O
) O
of O
TAK B
- I
536 I
after O
oral O
administration O
of O
TAK B
- I
491 I
were O
higher O
and O
shorter O
than O
those O
after O
oral O
administration O
of O
TAK B
- I
536 I
in O
dogs O
Hydrolysis O
of O
TAK B
- I
491 I
is O
observed O
not O
only O
by O
the O
intestinal O
and O
hepatic O
S9 O
fraction O
, O
but O
also O
by O
plasma O
and O
human O
serum O
albumin O
. O

This O
is O
well O
consistent O
with O
the O
facts O
that O
the O
AUC O
and O
T O
( O
max O
) O
of O
TAK B
- I
536 I
after O
oral O
administration O
of O
TAK B
- I
491 I
were O
higher O
and O
shorter O
than O
those O
after O
oral O
administration O
of O
TAK B
- I
536 I
in O
dogs O
Hydrolysis O
of O
TAK B
- I
491 I
is O
observed O
not O
only O
by O
the O
intestinal O
and O
hepatic O
S9 O
fraction O
, O
but O
also O
by O
plasma O
and O
human O
serum O
albumin O
. O

This O
is O
well O
consistent O
with O
the O
facts O
that O
the O
AUC O
and O
T O
( O
max O
) O
of O
TAK B
- I
536 I
after O
oral O
administration O
of O
TAK B
- I
491 I
were O
higher O
and O
shorter O
than O
those O
after O
oral O
administration O
of O
TAK B
- I
536 I
in O
dogs O
Hydrolysis O
of O
TAK B
- I
491 I
is O
observed O
not O
only O
by O
the O
intestinal O
and O
hepatic O
S9 O
fraction O
, O
but O
also O
by O
plasma O
and O
human O
serum O
albumin O
. O

This O
is O
well O
consistent O
with O
the O
facts O
that O
the O
AUC O
and O
T O
( O
max O
) O
of O
TAK B
- I
536 I
after O
oral O
administration O
of O
TAK B
- I
491 I
were O
higher O
and O
shorter O
than O
those O
after O
oral O
administration O
of O
TAK B
- I
536 I
in O
dogs O
Hydrolysis O
of O
TAK B
- I
491 I
is O
observed O
not O
only O
by O
the O
intestinal O
and O
hepatic O
S9 O
fraction O
, O
but O
also O
by O
plasma O
and O
human O
serum O
albumin O
. O

However O
, O
medoxomil B
alcohol I
wasn O
' O
t O
detected O
during O
the O
hydrolysis O
of O
TAK B
- I
491 I
. O

These O
metabolic O
features O
of O
TAK B
- I
491 I
were O
similar O
to O
olmesartan B
medoxomil I
, O
suggesting O
the O
hydrolytic O
pathway O
and O
enzymes O
for O
TAK B
- I
491 I
when O
catalyzing O
to O
TAK B
- I
536 I
would O
be O
the O
same O
as O
olmesartan B
medoxomil I
. O

These O
metabolic O
features O
of O
TAK B
- I
491 I
were O
similar O
to O
olmesartan B
medoxomil I
, O
suggesting O
the O
hydrolytic O
pathway O
and O
enzymes O
for O
TAK B
- I
491 I
when O
catalyzing O
to O
TAK B
- I
536 I
would O
be O
the O
same O
as O
olmesartan B
medoxomil I
. O

These O
metabolic O
features O
of O
TAK B
- I
491 I
were O
similar O
to O
olmesartan B
medoxomil I
, O
suggesting O
the O
hydrolytic O
pathway O
and O
enzymes O
for O
TAK B
- I
491 I
when O
catalyzing O
to O
TAK B
- I
536 I
would O
be O
the O
same O
as O
olmesartan B
medoxomil I
. O

Synthesis O
, O
characterization O
, O
screening O
and O
docking O
analysis O
of O
4 B
- I
anilinoquinazoline I
derivatives O
as O
tyrosine B
kinase O
inhibitors O
. O

We O
report O
here O
the O
design O
and O
synthesis O
of O
a O
series O
of O
4 B
- I
anilinoquinazoline I
derivatives O
, O
of O
which O
7 O
compounds O
were O
crystallographically O
characterized O
, O
as O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
inhibitors O
by O
modifications O
on O
the O
aniline B
ring O
or O
at O
the O
6 B
- I
alkoxy I
site O
of O
the O
6 B
, I
7 I
- I
dimethoxy I
- I
4 I
- I
anilinoquinazoline I
pharmacophore O
. O

We O
report O
here O
the O
design O
and O
synthesis O
of O
a O
series O
of O
4 B
- I
anilinoquinazoline I
derivatives O
, O
of O
which O
7 O
compounds O
were O
crystallographically O
characterized O
, O
as O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
inhibitors O
by O
modifications O
on O
the O
aniline B
ring O
or O
at O
the O
6 B
- I
alkoxy I
site O
of O
the O
6 B
, I
7 I
- I
dimethoxy I
- I
4 I
- I
anilinoquinazoline I
pharmacophore O
. O

Docking O
studies O
indicated O
that O
all O
4 B
- I
anilinoquinazoline I
derivatives O
could O
be O
inserted O
into O
the O
ATP B
- O
binding O
pocket O
of O
the O
EGFR O
via O
indirect O
docking O
, O
and O
that O
the O
modifications O
at O
the O
3 O
' O
- O
position O
of O
the O
anilino B
group O
and O
6 B
- I
alkoxy I
site O
of O
the O
quinazoline B
ring O
have O
little O
interference O
with O
the O
formation O
of O
the O
two O
essential O
H B
- O
bonds O
between O
the O
N3 O
of O
the O
quinazoline B
ring O
and O
Thr766 B
through O
a O
water O
molecule O
, O
and O
the O
N1 O
of O
the O
quinazoline B
ring O
and O
N B
- I
H I
of O
Met769 B
. O

Docking O
studies O
indicated O
that O
all O
4 B
- I
anilinoquinazoline I
derivatives O
could O
be O
inserted O
into O
the O
ATP B
- O
binding O
pocket O
of O
the O
EGFR O
via O
indirect O
docking O
, O
and O
that O
the O
modifications O
at O
the O
3 O
' O
- O
position O
of O
the O
anilino B
group O
and O
6 B
- I
alkoxy I
site O
of O
the O
quinazoline B
ring O
have O
little O
interference O
with O
the O
formation O
of O
the O
two O
essential O
H B
- O
bonds O
between O
the O
N3 O
of O
the O
quinazoline B
ring O
and O
Thr766 B
through O
a O
water O
molecule O
, O
and O
the O
N1 O
of O
the O
quinazoline B
ring O
and O
N B
- I
H I
of O
Met769 B
. O

Docking O
studies O
indicated O
that O
all O
4 B
- I
anilinoquinazoline I
derivatives O
could O
be O
inserted O
into O
the O
ATP B
- O
binding O
pocket O
of O
the O
EGFR O
via O
indirect O
docking O
, O
and O
that O
the O
modifications O
at O
the O
3 O
' O
- O
position O
of O
the O
anilino B
group O
and O
6 B
- I
alkoxy I
site O
of O
the O
quinazoline B
ring O
have O
little O
interference O
with O
the O
formation O
of O
the O
two O
essential O
H B
- O
bonds O
between O
the O
N3 O
of O
the O
quinazoline B
ring O
and O
Thr766 B
through O
a O
water O
molecule O
, O
and O
the O
N1 O
of O
the O
quinazoline B
ring O
and O
N B
- I
H I
of O
Met769 B
. O

The O
docking O
results O
also O
showed O
that O
the O
formation O
of O
new O
H B
- O
bonds O
between O
the O
N B
- I
H I
of O
the O
ethylenediamine B
group O
linked O
to O
the O
6 B
- I
alkoxy I
site O
and O
Asp776 B
/ O
Cys773 B
in O
the O
binding O
pocket O
of O
EGFR O
makes O
compounds O
19 O
( O
IC50 O
= O
12 O
. O
1 O
+ O
/ O
- O
1 O
. O
6 O
nM O
) O
and O
20 O
( O
IC50 O
= O
13 O
. O
6 O
+ O
/ O
- O
0 O
. O
8 O
nM O
) O
the O
most O
potent O
EGFR O
inhibitors O
in O
this O
class O
and O
worthy O
of O
further O
modification O
to O
obtain O
more O
potent O
anticancer O
compounds O
. O

The O
docking O
results O
also O
showed O
that O
the O
formation O
of O
new O
H B
- O
bonds O
between O
the O
N B
- I
H I
of O
the O
ethylenediamine B
group O
linked O
to O
the O
6 B
- I
alkoxy I
site O
and O
Asp776 B
/ O
Cys773 B
in O
the O
binding O
pocket O
of O
EGFR O
makes O
compounds O
19 O
( O
IC50 O
= O
12 O
. O
1 O
+ O
/ O
- O
1 O
. O
6 O
nM O
) O
and O
20 O
( O
IC50 O
= O
13 O
. O
6 O
+ O
/ O
- O
0 O
. O
8 O
nM O
) O
the O
most O
potent O
EGFR O
inhibitors O
in O
this O
class O
and O
worthy O
of O
further O
modification O
to O
obtain O
more O
potent O
anticancer O
compounds O
. O

In O
the O
present O
study O
, O
the O
interactions O
between O
this O
mGlu O
5 O
PAM O
and O
the O
NMDA B
receptor O
were O
explored O
further O
by O
assessing O
the O
effects O
of O
LSN2463359 B
against O
some O
of O
the O
motor O
, O
instrumental O
and O
cognitive O
effects O
induced O
by O
the O
non O
- O
competitive O
NMDA B
receptor O
antagonists O
PCP B
and O
MK B
- I
801 I
, O
the O
competitive O
NMDA B
receptor O
antagonist O
SDZ B
220 I
, I
581 I
and O
the O
GluN2B O
selective O
NMDA B
receptor O
antagonist O
, O
Ro B
63 I
- I
1908 I
. O

In O
contrast O
, O
LSN2463359 B
failed O
to O
alter O
both O
of O
the O
instrumental O
effects O
induced O
by O
the O
open O
channel O
blockers O
PCP B
and O
MK B
- I
801 I
. O

A O
crown B
- I
ether I
loop O
- O
derivatized O
oligothiophene B
doubly O
attached O
on O
gold O
surface O
as O
cation O
- O
binding O
switchable O
molecular O
junction O
. O

Of O
the O
regioisomeric O
phpy B
' O
s O
, O
2 B
- I
phpy I
behaves O
drastically O
different O
compared O
to O
3 B
- I
and I
4 I
- I
phpy I
. O

For O
2 B
- I
phpy I
, O
C B
- I
H I
bond O
activation O
in O
the O
[ B
NiCl I
( I
phpy I
) I
( I
2 I
) I
] I
( I
+ I
) I
complex O
is O
significant O
, O
whereas O
this O
route O
is O
almost O
suppressed O
for O
the O
corresponding O
complexes O
of O
3 B
- I
and I
4 I
- I
phpy I
and O
only O
occurs O
at O
elevated O
energies O
. O

For O
2 B
- I
phpy I
, O
C B
- I
H I
bond O
activation O
in O
the O
[ B
NiCl I
( I
phpy I
) I
( I
2 I
) I
] I
( I
+ I
) I
complex O
is O
significant O
, O
whereas O
this O
route O
is O
almost O
suppressed O
for O
the O
corresponding O
complexes O
of O
3 B
- I
and I
4 I
- I
phpy I
and O
only O
occurs O
at O
elevated O
energies O
. O

Cresyl B
saligenin I
phosphate I
makes O
multiple O
adducts O
on O
free O
histidine B
, O
but O
does O
not O
form O
an O
adduct O
on O
histidine B
438 O
of O
human O
butyrylcholinesteras O
. O

Cresyl B
saligenin I
phosphate I
( O
CBDP B
) O
is O
a O
suspected O
causative O
agent O
of O
" O
aerotoxic O
syndrome O
" O
, O
affecting O
pilots O
, O
crew O
members O
and O
passengers O
. O

Inhibited O
BChE O
undergoes O
aging O
to O
release O
saligenin B
and O
o B
- I
cresol I
. O

The O
active O
site O
histidine B
( O
His B
- O
438 O
) O
was O
hypothesized O
to O
abstract O
o B
- I
hydroxybenzyl I
moiety O
from O
the O
initial O
adduct O
on O
Ser B
- O
198 O
. O

Mass O
spectral O
analysis O
of O
CBDP B
- O
inhibited O
BChE O
digested O
with O
Glu B
- O
C O
showed O
an O
o B
- I
hydroxybenzyl I
adduct O
( O
+ O
106amu O
) O
on O
lysine B
499 O
, O
a O
residue O
far O
from O
the O
active O
site O
, O
but O
not O
on O
His B
- O
438 O
. O

Nevertheless O
, O
the O
nitrogen B
of O
the O
imidazole B
ring O
of O
free O
l B
- I
histidine I
formed O
a O
variety O
of O
adducts O
upon O
reaction O
with O
CBDP B
, O
including O
the O
o B
- I
hydroxybenzyl I
adduct O
, O
suggesting O
that O
histidine B
- O
CBDP B
adducts O
may O
form O
on O
other O
proteins O
. O

Nevertheless O
, O
the O
nitrogen B
of O
the O
imidazole B
ring O
of O
free O
l B
- I
histidine I
formed O
a O
variety O
of O
adducts O
upon O
reaction O
with O
CBDP B
, O
including O
the O
o B
- I
hydroxybenzyl I
adduct O
, O
suggesting O
that O
histidine B
- O
CBDP B
adducts O
may O
form O
on O
other O
proteins O
. O

A O
Mann O
- O
Whitney O
U O
test O
revealed O
significant O
difference O
in O
beta B
- I
HCH I
levels O
( O
U O
= O
1237 O
. O
00 O
, O
W O
= O
4087 O
. O
00 O
, O
z O
= O
- O
6 O
. O
296 O
, O
p O
= O
0 O
. O
000 O
, O
r O
= O
- O
0 O
. O
71 O
) O
, O
dieldrin B
levels O
( O
U O
= O
1449 O
. O
00 O
, O
W O
= O
4299 O
. O
00 O
, O
z O
= O
- O
5 O
. O
809 O
, O
p O
= O
0 O
. O
000 O
, O
r O
= O
- O
0 O
. O
68 O
) O
and O
pp B
' I
- I
DDE I
levels O
( O
U O
= O
2062 O
. O
00 O
, O
W O
= O
4912 O
. O
00 O
, O
z O
= O
- O
2 O
. O
698 O
, O
p O
= O

In O
conclusion O
, O
this O
study O
supports O
epidemiological O
studies O
that O
associate O
exposure O
to O
pesticides O
with O
increased O
risk O
of O
AD O
, O
and O
we O
identified O
the O
specific O
pesticides O
beta B
- I
HCH I
, O
dieldrin B
and O
pp B
' I
- I
DDE I
that O
are O
associated O
with O
the O
risk O
of O
AD O
in O
the O
north O
Indian O
population O
. O

The O
TBARS O
increase O
was O
consistent O
with O
an O
increment O
in O
saturated B
fatty I
acids I
at O
the O
expense O
of O
polyunsaturated O
acids O
in O
a O
Cu B
concentration O
- O
dependent O
fashion O
. O

Dose O
- O
dependent O
decreases O
in O
alpha B
- I
tocopherol I
and O
ferric B
reducing O
ability O
were O
observed O
. O

We O
previously O
demonstrated O
that O
the O
somatostatinergic O
system O
, O
implicated O
in O
neuronal O
survival O
control O
, O
can O
be O
modulated O
by O
alpha B
- I
tocopherol I
in O
the O
rat O
dentate O
gyrus O
, O
increasing O
cyclic B
adenosine I
monophosphate I
response O
element O
binding O
protein O
phosphorylation O
. O

We O
previously O
demonstrated O
that O
the O
somatostatinergic O
system O
, O
implicated O
in O
neuronal O
survival O
control O
, O
can O
be O
modulated O
by O
alpha B
- I
tocopherol I
in O
the O
rat O
dentate O
gyrus O
, O
increasing O
cyclic B
adenosine I
monophosphate I
response O
element O
binding O
protein O
phosphorylation O
. O

No O
changes O
in O
somatostatin B
expression O
were O
detected O
in O
vitamin B
- I
E I
- O
deficient O
rats O
. O

Subsequent O
alpha B
- I
tocopherol I
administration O
partially O
or O
completely O
reversed O
all O
these O
values O
to O
control O
levels O
. O

Skin O
phototoxicity O
of O
cosmetic O
formulations O
containing O
photounstable O
and O
photostable O
UV O
- O
filters O
and O
vitamin B
A I
palmitate I
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
in O
vitro O
skin O
phototoxicity O
of O
cosmetic O
formulations O
containing O
photounstable O
and O
photostable O
UV O
- O
filters O
and O
vitamin B
A I
palmitate I
, O
assessed O
by O
two O
in O
vitro O
techniques O
: O
3T3 O
Neutral O
Red O
Uptake O
Phototoxicity O
Test O
and O
Human O
3 O
- O
D O
Skin O
Model O
In O
Vitro O
Phototoxicity O
Test O
. O

For O
this O
, O
four O
different O
formulations O
containing O
vitamin B
A I
palmitate I
and O
different O
UV O
- O
filters O
combinations O
, O
two O
of O
them O
considered O
photostable O
and O
two O
of O
them O
considered O
photounstable O
, O
were O
prepared O
. O

A O
synergistic O
effect O
of O
vitamin B
A I
palmitate I
on O
the O
phototoxicity O
of O
combinations O
containing O
avobenzone B
was O
observed O
. O

Rats O
with O
chronic O
inhibition O
of O
GABA B
synthesis O
by O
infusion O
of O
l B
- I
allyglycine I
, O
a O
glutamic B
acid I
decarboxylase O
inhibitor O
, O
into O
their O
dorsomedial O
/ O
perifornical O
hypothalamus O
are O
anxious O
and O
exhibit O
panic O
- O
like O
cardio O
- O
respiratory O
responses O
to O
treatment O
with O
intravenous O
( O
i O
. O
v O
. O
) O
sodium B
lactate I
( O
NaLac B
) O
infusions O
, O
in O
a O
manner O
similar O
to O
what O
occurs O
in O
patients O
with O
panic O
disorder O
. O

Nowadays O
valganciclovir B
( O
V B
- I
GCV I
) O
, O
a O
mono B
- I
valyl I
ester I
pro O
- O
drug O
of O
GCV B
, O
is O
available O
as O
an O
oral O
syrup O
. O

The O
existing O
literature O
demonstrated O
that O
V B
- I
GCV I
is O
well O
absorbed O
from O
the O
gastrointestinal O
tract O
and O
is O
rapidly O
converted O
into O
GCV B
in O
the O
intestinal O
wall O
and O
liver O
. O

In O
neonates O
, O
V B
- I
GCV I
oral O
formulation O
proved O
stable O
and O
constant O
GVC O
plasma O
concentrations O
, O
in O
the O
suggested O
therapeutic O
range O
. O

This O
article O
reviews O
all O
the O
available O
literature O
about O
V B
- I
GCV I
syrup O
in O
the O
treatment O
of O
newborns O
and O
infants O
with O
congenital O
CMV O
infection O
with O
the O
regard O
to O
pharmacokinetics O
, O
pharmacodynamic O
properties O
and O
clinical O
use O
, O
focussing O
on O
new O
data O
and O
on O
our O
experience O
. O

Electron O
paramagnetic O
resonance O
( O
EPR O
) O
spectroscopy O
of O
the O
spin O
label O
5 B
- I
doxyl I
stearic I
acid I
( O
5 B
- I
DSA I
) O
was O
used O
to O
monitor O
the O
effect O
of O
sesquiterpene B
nerolidol B
and O
various O
monoterpenes B
on O
membrane O
fluidity O
in O
erythrocyte O
and O
fibroblast O
cells O
. O

The O
IC O
( O
50 O
) O
values O
for O
the O
terpenes B
in O
the O
cytotoxicity O
assay O
indicated O
that O
1 B
, I
8 I
- I
cineole I
showed O
lower O
cytotoxicity O
and O
alpha B
- I
terpineol I
and O
nerolidol B
showed O
higher O
cytotoxicity O
. O

Loss O
of O
A O
( O
1 O
) O
adenosine B
receptor O
attenuates O
alpha B
- I
naphthylisothiocyana I
- O
induced O
cholestatic O
liver O
injury O
in O
mice O
. O

The O
currently O
used O
therapy O
, O
focusing O
on O
the O
reactivation O
of O
inhibited O
AChE O
, O
is O
limited O
to O
peripheral O
tissues O
because O
commonly O
used O
quaternary B
pyridinium I
oxime I
reactivators O
do O
not O
cross O
the O
blood O
brain O
barrier O
( O
BBB O
) O
at O
therapeutically O
relevant O
levels O
. O

A O
directed O
library O
of O
thirty O
uncharged O
oximes B
that O
contain O
tertiary B
amine I
or O
imidazole B
protonable O
functional O
groups O
that O
should O
cross O
the O
BBB O
as O
unionized O
species O
was O
tested O
as O
tabun B
- O
hAChE O
conjugate O
reactivators O
along O
with O
three O
reference O
oximes B
: O
DAM B
( O
diacetylmonoxime B
) O
, O
MINA B
( O
monoisonitrosoaceton B
) O
, O
and O
2 B
- I
PAM I
. O

Six O
compounds O
were O
identified O
: O
a O
new O
flavonoid B
, O
3 B
' I
- I
hydroxy I
- I
isoscutellarein I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
; O
three O
iridoid B
glucosides I
: O
harpagide B
, O
acetyl B
harpagide I
and O
for O
the O
first O
time O
in O
this O
species O
, O
8 B
- I
epi I
- I
loganin I
; O
two O
known O
acetylated B
flavonoid I
glycosides I
: O
3 B
' I
- I
hydroxy I
- I
4 I

Identification O
of O
various O
antioxidant O
agents O
, O
such O
as O
thiol B
molecules O
( O
glutathione B
and O
mucolytic O
drugs O
, O
such O
as O
N B
- I
acetyl I
- I
Lcysteine I
, O
N B
- I
acystelyn I
, O
erdosteine B
, O
fudosteine B
, O
ergothioneine B
, O
and O
carbocysteine B
lysine I
salt O
) O
, O
dietary O
natural O
productderived O
polyphenols B
and O
other O
compounds O
( O
curcumin B
, O
resveratrol B
, O
green O
tea O
catechins B
, O
quercetin B
sulforaphane I
, O
lycopene B
, O

Adipocyte O
differentiation O
analysis O
was O
carried O
out O
by O
Oil B
Red I
O I
staining O
method O
. O

Putrescine B
was O
abundantly O
produced O
by O
exogenous O
L B
- I
ornithine I
( O
L B
- I
Orn I
) O
, O
and O
both O
spermidine B
and O
spermine B
were O
significantly O
accumulated O
in O
D B
- I
ornithine I
( O
D B
- I
Orn I
) O
- O
supplied O
tobacco O
cells O
. O

Putrescine B
was O
abundantly O
produced O
by O
exogenous O
L B
- I
ornithine I
( O
L B
- I
Orn I
) O
, O
and O
both O
spermidine B
and O
spermine B
were O
significantly O
accumulated O
in O
D B
- I
ornithine I
( O
D B
- I
Orn I
) O
- O
supplied O
tobacco O
cells O
. O

Putrescine B
was O
abundantly O
produced O
by O
exogenous O
L B
- I
ornithine I
( O
L B
- I
Orn I
) O
, O
and O
both O
spermidine B
and O
spermine B
were O
significantly O
accumulated O
in O
D B
- I
ornithine I
( O
D B
- I
Orn I
) O
- O
supplied O
tobacco O
cells O
. O

Putrescine B
was O
abundantly O
produced O
by O
exogenous O
L B
- I
ornithine I
( O
L B
- I
Orn I
) O
, O
and O
both O
spermidine B
and O
spermine B
were O
significantly O
accumulated O
in O
D B
- I
ornithine I
( O
D B
- I
Orn I
) O
- O
supplied O
tobacco O
cells O
. O

Furthermore O
, O
nicotine B
production O
was O
highly O
upregulated O
by O
L B
- I
Orn I
, O
while O
the O
addition O
of O
D B
- I
Orn I
had O
no O
effect O
on O
the O
nicotine B
content O
of O
tobacco O
cells O
. O

Furthermore O
, O
nicotine B
production O
was O
highly O
upregulated O
by O
L B
- I
Orn I
, O
while O
the O
addition O
of O
D B
- I
Orn I
had O
no O
effect O
on O
the O
nicotine B
content O
of O
tobacco O
cells O
. O

It O
was O
observed O
that O
transcript O
expression O
of O
S B
- I
adenosylmethionine I
decarboxylase O
, O
as O
the O
key O
enzyme O
of O
spermidine B
/ O
spermine B
biosynthesis O
, O
is O
coincident O
with O
their O
metabolic O
levels O
and O
is O
highly O
upregulated O
by O
D B
- I
Orn I
, O
as O
opposed O
to O
L B
- I
Orn I
. O

It O
was O
observed O
that O
transcript O
expression O
of O
S B
- I
adenosylmethionine I
decarboxylase O
, O
as O
the O
key O
enzyme O
of O
spermidine B
/ O
spermine B
biosynthesis O
, O
is O
coincident O
with O
their O
metabolic O
levels O
and O
is O
highly O
upregulated O
by O
D B
- I
Orn I
, O
as O
opposed O
to O
L B
- I
Orn I
. O

It O
was O
observed O
that O
transcript O
expression O
of O
S B
- I
adenosylmethionine I
decarboxylase O
, O
as O
the O
key O
enzyme O
of O
spermidine B
/ O
spermine B
biosynthesis O
, O
is O
coincident O
with O
their O
metabolic O
levels O
and O
is O
highly O
upregulated O
by O
D B
- I
Orn I
, O
as O
opposed O
to O
L B
- I
Orn I
. O

Regarding O
these O
observations O
, O
it O
is O
proposed O
that O
L B
- I
and I
D I
- I
Orn I
function O
differently O
in O
the O
same O
biological O
pathways O
in O
which O
the O
latter O
, O
D B
- I
Orn I
specifically O
regulates O
important O
polyamines B
in O
the O
plant O
cells O
. O

The O
aim O
of O
this O
work O
was O
to O
investigate O
the O
involvement O
of O
serotonin B
( O
5 B
- I
HT I
) O
and O
catecholamines B
, O
as O
well O
as O
the O
role O
of O
glutamatergic O
and O
GABAergic O
cannabinoid O
type O
1 O
( O
CB O
( O
1 O
) O
) O
receptor O
, O
in O
responses O
to O
the O
antidepressant O
- O
like O
doses O
of O
the O
CB O
( O
1 O
) O
receptor O
agonist O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
THC B
) O
and O
the O
antagonist O
rimonabant B
in O
the O
forced O
swim O
test O
( O
FST O
) O
. O

Mice O
received O
acute O
injections O
of O
low O
doses O
of O
THC B
( O
0 O
. O
1 O
or O
0 O
. O
5 O
mg O
/ O
kg O
) O
or O
high O
dose O
of O
rimonabant B
( O
3 O
or O
10 O
mg O
/ O
kg O
) O
after O
treatment O
with O
the O
5 B
- I
HT I
synthesis O
inhibitor O
pCPA B
( O
100 O
mg O
/ O
kg O
, O
4 O
days O
) O
, O
the O
5 B
- I
HT I
( O
1A O
) O
receptor O
antagonist O
WAY100635 B
( O
1 O
mg O
/ O
kg O
, O
acute O
) O
or O
the O
non O
- O
selective O
blocker O
of O
catecholamine B
synthesis O
, O
AMPT B
( O
20 O
mg O
/ O
kg O
, O
acute O
) O
. O

Mice O
received O
acute O
injections O
of O
low O
doses O
of O
THC B
( O
0 O
. O
1 O
or O
0 O
. O
5 O
mg O
/ O
kg O
) O
or O
high O
dose O
of O
rimonabant B
( O
3 O
or O
10 O
mg O
/ O
kg O
) O
after O
treatment O
with O
the O
5 B
- I
HT I
synthesis O
inhibitor O
pCPA B
( O
100 O
mg O
/ O
kg O
, O
4 O
days O
) O
, O
the O
5 B
- I
HT I
( O
1A O
) O
receptor O
antagonist O
WAY100635 B
( O
1 O
mg O
/ O
kg O
, O
acute O
) O
or O
the O
non O
- O
selective O
blocker O
of O
catecholamine B
synthesis O
, O
AMPT B
( O
20 O
mg O
/ O
kg O
, O
acute O
) O
. O

The O
present O
study O
was O
aimed O
at O
predicting O
the O
cytotoxic O
effects O
of O
mixtures O
of O
four O
amphetaminic O
derivatives O
: O
MDMA B
, O
methamphetamine B
, O
4 B
- I
methylthioamphetamin I
and O
d B
- I
amphetamine I
in O
a O
human O
hepatoma O
cell O
line O
. O

The O
present O
study O
was O
aimed O
at O
predicting O
the O
cytotoxic O
effects O
of O
mixtures O
of O
four O
amphetaminic O
derivatives O
: O
MDMA B
, O
methamphetamine B
, O
4 B
- I
methylthioamphetamin I
and O
d B
- I
amphetamine I
in O
a O
human O
hepatoma O
cell O
line O
. O

We O
examined O
in O
cats O
the O
1 O
) O
ulcerogenic O
effects O
of O
selective O
COX O
- O
1 O
( O
SC B
- I
560 I
, O
ketorolac B
) O
and O
COX O
- O
2 O
( O
celecoxib B
, O
meloxicam B
) O
inhibitors O
on O
the O
gastrointestinal O
mucosa O
, O
2 O
) O
effect O
of O
feeding O
and O
cimetidine B
on O
the O
expression O
of O
COX O
isoforms O
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
level O
in O
the O
duodenum O
, O
and O
3 O
) O
localization O
of O
COX O
isoforms O
in O
the O
duodenum O
. O

Coadministration O
of O
SC B
- I
560 I
and O
celecoxib B
produced O
marked O
lesions O
in O
the O
small O
intestine O
. O

The O
effect O
of O
fish O
oil O
recovered O
from O
fish O
visceral O
waste O
( O
FVW O
- O
FO O
) O
on O
serum O
and O
liver O
lipids O
, O
activity O
of O
HMG B
- I
CoA I
reductase O
in O
liver O
microsomes O
and O
EPA B
+ O
DHA B
incorporation O
in O
liver O
, O
heart O
and O
brain O
were O
evaluated O
. O

The O
activity O
of O
HMG B
- I
CoA I
reductase O
was O
reduced O
( O
p O
< O
0 O
. O
05 O
) O
in O
the O
FVW O
- O
FO O
fed O
groups O
compared O
to O
the O
control O
. O

Results O
show O
the O
hypolipidemic O
property O
of O
FVW O
- O
FO O
and O
reduced O
HMG B
- I
CoA I
reductase O
activity O
which O
is O
proportional O
to O
the O
incorporation O
of O
EPA B
+ O
DHA B
. O

Phytochemical O
investigation O
of O
the O
n B
- I
butanol I
( O
n B
- I
BuOH I
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 B
, I
6 I
- I
dideoxyhexose I
- I
C I
- I
glycosyl I
flavones I
, O
including O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranosyl I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranoside I
( O
2 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O

Phytochemical O
investigation O
of O
the O
n B
- I
butanol I
( O
n B
- I
BuOH I
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 B
, I
6 I
- I
dideoxyhexose I
- I
C I
- I
glycosyl I
flavones I
, O
including O
luteolin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranosyl I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
digitoxopyranoside I
( O
2 O
) O
, O
apigenin B
- I
8 I
- I
C I
- I
beta I
- I
boivinopyranoside I
( O

To O
understand O
the O
effect O
of O
l B
- I
phenylalanine I
( O
l B
- I
phe I
) O
on O
the O
PAL O
activity O
, O
total O
phenolic B
amount O
, O
and O
phenolic B
constituents O
, O
isolates O
were O
evaluated O
with O
100mg O
/ O
l O
l B
- I
phe I
. O

To O
understand O
the O
effect O
of O
l B
- I
phenylalanine I
( O
l B
- I
phe I
) O
on O
the O
PAL O
activity O
, O
total O
phenolic B
amount O
, O
and O
phenolic B
constituents O
, O
isolates O
were O
evaluated O
with O
100mg O
/ O
l O
l B
- I
phe I
. O

To O
understand O
the O
effect O
of O
l B
- I
phenylalanine I
( O
l B
- I
phe I
) O
on O
the O
PAL O
activity O
, O
total O
phenolic B
amount O
, O
and O
phenolic B
constituents O
, O
isolates O
were O
evaluated O
with O
100mg O
/ O
l O
l B
- I
phe I
. O

While O
PAL O
activities O
exhibited O
no O
significant O
change O
with O
l B
- I
phe I
addition O
, O
total O
phenolic B
amount O
of O
the O
isolates O
significantly O
increased O
. O

Results O
suggested O
that O
the O
two O
isolate O
mights O
be O
an O
important O
source O
for O
the O
l B
- I
phe I
inducible O
phenolic B
compounds O
. O

Ginger O
extract O
and O
zingerone B
ameliorated O
trinitrobenzene B
sulphonic I
acid I
- O
induced O
colitis O
in O
mice O
via O
modulation O
of O
nuclear O
factor O
- O
kappa O
B O
activity O
and O
interleukin O
- O
1 O
beta O
signalling O
pathway O
. O

On O
the O
other O
hand O
, O
treatments O
at O
1 O
. O
2kV O
/ O
cm O
and O
5 O
pulses O
led O
to O
maximum O
increases O
of O
alpha B
- I
carotene I
, O
9 B
- I
and I
13 I
- I
cis I
- I
lycopene I
, O
which O
increased O
by O
93 O
% O
, O
94 O
% O
and O
140 O
% O
, O
respectively O
. O

Effects O
of O
solvent O
and O
alkaline B
earth I
metals I
on O
the O
heat O
- O
induced O
precipitation O
process O
of O
sodium B
caseinate O
. O

Importantly O
, O
in O
humans O
, O
vitamin B
D I
is O
mainly O
derived O
from O
endogenous O
production O
of O
vitamin B
D I
3 I
from O
ultraviolet O
( O
UV O
) O
radiation O
exposure O
to O
the O
skin O
while O
a O
small O
part O
( O
< O
10 O
% O
) O
is O
obtained O
via O
dietary O
intake O
of O
dairy O
products O
and O
fatty O
fish O
( O
1 O
) O
. O

However O
, O
CYP2B4 O
is O
not O
an O
inhibitor O
of O
CYP2E1 O
- O
mediated O
p B
- I
nitrophenol I
hydroxylation O
. O

Five O
new O
highly O
oxygenated B
oplopane I
sesquiterpenes I
, O
songaricalarins B
A I
- I
E I
( O
1 O
- O
5 O
) O
, O
and O
two O
known O
analogues O
( O
6 O
and O
7 O
) O
were O
isolated O
from O
the O
roots O
and O
rhizomes O
of O
Ligularia O
songarica O
. O

Fumagillin B
, O
an O
anti O
- O
angiogenic O
agent O
, O
was O
used O
as O
the O
water O
soluble O
analogue O
TNP B
- I
470 I
( O
25mg O
/ O
kg O
) O
as O
well O
as O
incorporated O
into O
lipid O
- O
encapsulated O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrin O
targeted O
nanoparticles O
( O
0 O
. O
25mg O
/ O
kg O
) O
. O

In O
the O
first O
experiment O
, O
TNP B
- I
470 I
was O
administered O
daily O
for O
5 O
days O
following O
mechanical O
loading O
, O
and O
changes O
in O
gene O
expression O
, O
vascularity O
, O
and O
woven O
bone O
formation O
were O
quantified O
. O

Fenhexamid B
activation O
was O
inhibited O
by O
the O
arylhydrocarbon B
receptor O
antagonist O
alpha B
- I
napthoflavone I
. O

Acehytisine B
hydrochloride I
( O
previously O
named O
Guangfu B
base I
A I
) O
was O
isolated O
from O
the O
root O
of O
Aconitum O
coreanum O
( O
Levl O
. O
) O
, O
is O
an O
anti O
- O
arrhythmic O
drug O
in O
phase O
IV O
clinical O
trial O
. O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 B
- I
bromo I
- I
2 I
- I
bromomethyl I
glutaronitrile I
, O
cinnamaldehyde B
, O
citral B
, O
diethylmaleate B
, O
dinitrochlorobenzene B
, O
glyoxal B
, O
2 B
- I
mercaptobenzothiazol I
, O
nickel B
sulfate I
, O
4 B
- I
nitrobenzylbromide I
, O
oxazolone B
, O
penicillin B
G I
, O
resorcinol B
, O
tetramethylthiuram B
disulfide I
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 B
- I
bromo I
- I
2 I
- I
bromomethyl I
glutaronitrile I
, O
cinnamaldehyde B
, O
citral B
, O
diethylmaleate B
, O
dinitrochlorobenzene B
, O
glyoxal B
, O
2 B
- I
mercaptobenzothiazol I
, O
nickel B
sulfate I
, O
4 B
- I
nitrobenzylbromide I
, O
oxazolone B
, O
penicillin B
G I
, O
resorcinol B
, O
tetramethylthiuram B
disulfide I
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

phenol B
, O
salicylic B
acid I
, O
sodium B
lauryl I
sulphate I
, O
sulfamic B
acid I
) O
. O

Neurons O
harvested O
from O
the O
forebrain O
of O
newborn O
rats O
were O
maintained O
under O
normal O
control O
conditions O
or O
exposed O
to O
either O
ketamine B
( O
10 O
micro O
M O
) O
or O
ketamine B
plus O
L B
- I
carnitine I
( O
an O
antioxidant O
; O
1 O
- O
100 O
micro O
M O
) O
for O
24h O
, O
followed O
by O
a O
24 O
- O
h O
withdrawal O
period O
. O

Ketamine B
exposure O
resulted O
in O
elevated O
NMDA B
receptor O
( O
NR1 O
) O
expression O
, O
increased O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
as O
indicated O
by O
higher O
levels O
of O
8 B
- I
oxoguanine I
production O
, O
and O
enhanced O
neuronal O
damage O
. O

Coadministration O
of O
L B
- I
carnitine I
significantly O
diminished O
ROS O
generation O
and O
provided O
near O
complete O
protection O
of O
neurons O
from O
ketamine B
- O
induced O
cell O
death O
. O

L B
- I
Carnitine I
appears O
to O
be O
a O
promising O
agent O
in O
preventing O
or O
reversing O
ketamine B
' O
s O
toxic O
effects O
on O
neurons O
at O
an O
early O
developmental O
stage O
. O

Resonance O
Raman O
spectral O
imaging O
of O
intracellular O
uptake O
of O
beta B
- I
carotene I
loaded O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
nanoparticles O
. O

For O
this O
purpose O
, O
the O
particles O
were O
loaded O
with O
beta B
- I
carotene I
. O

beta B
- I
Carotene I
as O
a O
provitamin O
is O
not O
soluble O
in O
water O
and O
is O
thus O
usually O
of O
low O
bioavailability O
, O
which O
is O
enhanced O
by O
encapsulation O
into O
the O
nanoparticles O
. O

By O
using O
flow O
cytometry O
and O
Western O
blotting O
, O
we O
demonstrated O
that O
isoproterenol B
, O
S B
- I
propranolol I
, O
CGP B
- I
12177 I
[ O
4 B
- I
[ I
3 I
- I
[ I
( I
1 I
, I
1 I
- I
dimethylethyl I
) I
amino I
] I
2 I
- I
hydroxypropoxy I
] I
- I
1 I
, I
3 I
- I
dihydro I
- I
2H I
- I
benzimidazol I
- I
2 I
- I
one I
] O
, O
pindolol B
, O
and O
timolol B
, O
which O
displayed O
agonistic O
properties O
toward O
the O
beta O
( O
1 O
) O
AR O
in O
either O
the O
adenylyl B
cyclase O
or O

By O
using O
flow O
cytometry O
and O
Western O
blotting O
, O
we O
demonstrated O
that O
isoproterenol B
, O
S B
- I
propranolol I
, O
CGP B
- I
12177 I
[ O
4 B
- I
[ I
3 I
- I
[ I
( I
1 I
, I
1 I
- I
dimethylethyl I
) I
amino I
] I
2 I
- I
hydroxypropoxy I
] I
- I
1 I
, I
3 I
- I
dihydro I
- I
2H I
- I
benzimidazol I
- I
2 I
- I
one I
] O
, O
pindolol B
, O
and O
timolol B
, O
which O
displayed O
agonistic O
properties O
toward O
the O
beta O
( O
1 O
) O
AR O
in O
either O
the O
adenylyl B
cyclase O
or O

In O
contrast O
, O
metoprolol B
, O
bisoprolol B
, O
and O
CGP B
- I
20712 I
[ O
1 B
- I
[ I
2 I
- I
( I
( I
3 I
- I
carbamoyl I
- I
4 I
- I
hydroxy I
) I
phenoxy I
) I
ethylamino I
] I
- I
3 I
- I
[ I
4 I
- I
( I
1 I
- I
methyl I
- I
4 I
- I
trifluoromethyl I
- I
2 I
- I
imidazolyl I
) I
phenoxy I
] I
- I
2 I
- I
propanol I
] O
, O
which O
showed O
no O
agonistic O
activity O
, O
had O
only O
a O
marginal O
or O
no O
effect O
. O

We O
tested O
two O
types O
of O
PAMS O
, O
type O
I O
( O
NS1738 B
) O
and O
type O
II O
( O
PNU B
- I
120596 I
) O
in O
carrageenan O
- O
induced O
inflammatory O
pain O
and O
chronic O
constriction O
injury O
( O
CCI O
) O
neuropathic O
pain O
models O
. O

We O
found O
that O
both O
NS1738 B
and O
PNU B
- I
120596 I
significantly O
reduced O
thermal O
hyperalgesia O
, O
while O
only O
PNU B
- I
120596 I
significantly O
reduced O
edema O
caused O
by O
a O
hind O
paw O
infusion O
of O
carrageenan O
. O

We O
found O
that O
both O
NS1738 B
and O
PNU B
- I
120596 I
significantly O
reduced O
thermal O
hyperalgesia O
, O
while O
only O
PNU B
- I
120596 I
significantly O
reduced O
edema O
caused O
by O
a O
hind O
paw O
infusion O
of O
carrageenan O
. O

Importantly O
, O
PNU B
- I
120596 I
reversed O
established O
thermal O
hyperalgesia O
and O
edema O
induced O
by O
carrageenan O
. O

In O
the O
CCI O
model O
, O
PNU B
- I
120596 I
had O
long O
- O
lasting O
( O
up O
to O
6 O
h O
) O
, O
dose O
- O
dependent O
anti O
- O
hyperalgesic O
and O
anti O
- O
allodynic O
effects O
after O
a O
single O
injection O
, O
while O
NS1738 B
was O
inactive O
. O

Systemic O
administration O
of O
the O
alpha O
7 O
nAChR O
antagonist O
MLA B
reversed O
PNU B
- I
120596 I
' O
s O
effects O
, O
suggesting O
the O
involvement O
of O
central O
and O
peripheral O
alpha O
7 O
nAChRs O
. O

Furthermore O
, O
PNU B
- I
120596 I
enhanced O
an O
ineffective O
dose O
of O
selective O
agonist O
PHA B
- I
543613 I
to O
produce O
anti O
- O
allodynic O
effects O
in O
the O
CCI O
model O
. O

Furthermore O
, O
PNU B
- I
120596 I
enhanced O
an O
ineffective O
dose O
of O
selective O
agonist O
PHA B
- I
543613 I
to O
produce O
anti O
- O
allodynic O
effects O
in O
the O
CCI O
model O
. O

Our O
results O
indicate O
that O
the O
type O
II O
alpha O
7 O
nAChRs O
PAM O
PNU B
- I
120596 I
, O
but O
not O
the O
type O
I O
alpha O
7 O
nAChRs O
PAM O
NS1738 B
, O
shows O
significant O
anti O
- O
edematous O
and O
anti O
- O
allodynic O
effects O
in O
inflammatory O
and O
CCI O
pain O
models O
in O
mice O
. O

In O
this O
tutorial O
review O
we O
discuss O
the O
range O
of O
commonly O
used O
dienophiles O
and O
aza B
- I
dienes I
for O
this O
process O
whilst O
highlighting O
the O
reactivity O
trends O
, O
and O
illustrating O
their O
applications O
. O

Finally O
, O
we O
observed O
that O
Ts2 O
or O
Ts6 O
injection O
in O
5 O
- O
lipoxygenase O
( O
LO O
) O
deficient O
mice O
and O
in O
wild O
type O
( O
WT O
) O
129sv O
mice O
pre O
- O
treated O
with O
LTs O
and O
PGs O
inhibitors O
( O
MK B
- I
886 I
and O
celecoxib B
, O
respectively O
) O
a O
reduction O
the O
influx O
of O
leukocytes O
occurs O
in O
comparison O
to O
WT O
. O

Unlike O
the O
majority O
of O
G O
protein O
- O
coupled O
receptors O
, O
the O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
E B
- I
prostanoid I
3 O
( O
EP3 O
) O
receptor O
binds O
agonist O
with O
high O
affinity O
that O
is O
insensitive O
to O
the O
presence O
of O
guanosine B
5 I
[ I
prime I
] I
- I
O I
- I
( I
3 I
- I
thio I
) I
triphosphate I
( O
GTP B
gamma I
S I
) O
. O

Unlike O
the O
majority O
of O
G O
protein O
- O
coupled O
receptors O
, O
the O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
E B
- I
prostanoid I
3 O
( O
EP3 O
) O
receptor O
binds O
agonist O
with O
high O
affinity O
that O
is O
insensitive O
to O
the O
presence O
of O
guanosine B
5 I
[ I
prime I
] I
- I
O I
- I
( I
3 I
- I
thio I
) I
triphosphate I
( O
GTP B
gamma I
S I
) O
. O

We O
report O
the O
identification O
of O
mutations O
that O
confer O
GTP B
gamma I
S I
sensitivity O
to O
agonist O
binding O
. O

The O
[ B
( I
3 I
) I
H I
] I
PGE I
( I
2 I
) I
binding O
of O
W203A O
in O
broken O
cell O
membrane O
fractions O
was O
inhibited O
by O
addition O
of O
GTP B
gamma I
S I
( O
IC O
( O
50 O
) O
21 O
+ O
/ O
- O
1 O
. O
8 O
nM O
) O
. O

We O
examined O
the O
metabolic O
stability O
of O
linaclotide B
in O
conditions O
that O
mimic O
the O
gastrointestinal O
tract O
and O
characterized O
the O
metabolite O
MM B
- I
419447 I
( O
CCEYCCNPACTGC O
) O
, O
which O
contributes O
to O
the O
pharmacologic O
effects O
of O
linaclotide B
. O

Systemic O
exposure O
to O
these O
active O
peptides O
is O
low O
in O
rats O
and O
humans O
, O
and O
the O
low O
systemic O
and O
portal O
vein O
concentrations O
of O
linaclotide B
and O
MM B
- I
419447 I
observed O
in O
the O
rat O
confirmed O
both O
peptides O
are O
minimally O
absorbed O
after O
oral O
administration O
. O

Linaclotide B
is O
stable O
in O
the O
acidic O
environment O
of O
the O
stomach O
and O
is O
converted O
to O
MM B
- I
419447 I
in O
the O
small O
intestine O
. O

After O
oral O
administration O
of O
linaclotide B
, O
< O
1 O
% O
of O
the O
dose O
was O
excreted O
as O
active O
peptide O
in O
rat O
feces O
and O
a O
mean O
of O
3 O
- O
5 O
% O
in O
human O
feces O
; O
in O
both O
cases O
MM B
- I
419447 I
was O
the O
predominant O
peptide O
recovered O
. O

MM B
- I
419447 I
exhibits O
high O
- O
affinity O
binding O
in O
vitro O
to O
T84 O
cells O
, O
resulting O
in O
a O
significant O
, O
concentration O
- O
dependent O
accumulation O
of O
intracellular O
cyclic B
guanosine I
- I
3 I
' I
, I
5 I
' I
- I
monophosphate I
( O
cGMP B
) O
. O

In O
rat O
models O
of O
gastrointestinal O
function O
, O
orally O
dosed O
MM B
- I
419447 I
significantly O
increased O
fluid O
secretion O
into O
small O
intestinal O
loops O
, O
increased O
intraluminal O
cGMP B
, O
and O
caused O
a O
dose O
- O
dependent O
acceleration O
in O
gastrointestinal O
transit O
. O

Upregulation O
of O
phagocyte O
- O
like O
NADPH B
oxidase O
by O
cytokines O
in O
pancreatic O
beta O
- O
cells O
: O
attenuation O
of O
oxidative O
and O
nitrosative O
stress O
by O
2 B
- I
bromopalmitate I
. O

2 B
- I
Bromopalmitate I
( O
2 B
- I
BP I
) O
, O
a O
known O
inhibitor O
of O
protein O
palmitoylation O
, O
markedly O
attenuated O
cytokine O
- O
induced O
, O
Nox2 O
- O
mediated O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
and O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
- O
mediated O
nitric B
oxide I
( O
NO B
) O
generation O
. O

2 B
- I
Bromopalmitate I
( O
2 B
- I
BP I
) O
, O
a O
known O
inhibitor O
of O
protein O
palmitoylation O
, O
markedly O
attenuated O
cytokine O
- O
induced O
, O
Nox2 O
- O
mediated O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
and O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
- O
mediated O
nitric B
oxide I
( O
NO B
) O
generation O
. O

However O
, O
2 B
- I
BP I
failed O
to O
exert O
any O
significant O
effects O
on O
cytomix O
- O
induced O
CHOP O
expression O
, O
a O
marker O
for O
endoplasmic O
reticulum O
stress O
. O

Pharmacokinetic O
study O
of O
Growth B
Hormone I
- I
Releasing I
Peptide I
6 I
( O
GHRP B
- I
6 I
) O
in O
nine O
male O
healthy O
volunteers O
. O

GHRP B
- I
6 I
is O
a O
growth O
hormone O
secretagogue O
that O
also O
enhances O
tissue O
viability O
in O
different O
organs O
. O

GHRP B
- I
6 I
was O
quantified O
in O
human O
plasma O
by O
a O
specific O
LC O
- O
MS O
method O
, O
previously O
developed O
and O
validated O
following O
FDA O
guidelines O
, O
using O
( B
13 I
) I
C I
( I
3 I
) I
Ala I
- I
GHRP I
- I
6 I
as O
internal O
standard O
( O
Gil O
et O
al O
. O
, O
2012 O
, O
J O
. O
Pharm O
. O
Biomed O
. O
Anal O
. O
60 O
, O
19 O
- O
25 O
) O
. O

Disposition O
of O
GHRP B
- I
6 I
best O
fitted O
a O
bi O
- O
exponential O
function O
with O
R O
( O
2 O
) O
higher O
than O
0 O
. O
99 O
, O
according O
to O
a O
mathematic O
modeling O
and O
confirmed O
by O
an O
Akaike O
index O
( O
AIC O
) O
lower O
than O
that O
of O
the O
corresponding O
one O
- O
compartment O
model O
for O
all O
subjects O
. O

Averaging O
all O
three O
dose O
levels O
, O
the O
distribution O
and O
elimination O
half O
- O
life O
of O
GHRP B
- I
6 I
were O
7 O
. O
6 O
+ O
/ O
- O
1 O
. O
9 O
min O
and O
2 O
. O
5 O
+ O
/ O
- O
1 O
. O
1h O
, O
respectively O
. O

Atypical O
GHRP B
- I
6 I
concentration O
spikes O
were O
observed O
during O
the O
elimination O
phase O
in O
four O
out O
of O
the O
nine O
subjects O
studied O
. O

Apoptosis O
initiation O
of O
beta B
- I
ionone I
in O
SGC O
- O
7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K O
- O
AKT O
pathway O
. O

beta B
- I
ionone I
has O
been O
shown O
to O
hold O
potent O
anti O
- O
proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O

To O
investigate O
the O
effects O
of O
beta B
- I
ionone I
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol B
3 O
- O
kinase O
( O
PI3K O
) O
- O
AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC O
- O
7901 O
cells O
. O

The O
results O
demonstrated O
that O
beta B
- I
ionone I
- O
induced O
apoptosis O
in O
a O
dose O
- O
dependent O
manner O
in O
SGC O
- O
7901 O
cells O
treated O
with O
beta B
- I
ionone I
( O
25 O
, O
50 O
, O
100 O
and O
200 O
mu O
mol O
/ O
L O
) O
for O
24 O
h O
. O

The O
results O
demonstrated O
that O
beta B
- I
ionone I
- O
induced O
apoptosis O
in O
a O
dose O
- O
dependent O
manner O
in O
SGC O
- O
7901 O
cells O
treated O
with O
beta B
- I
ionone I
( O
25 O
, O
50 O
, O
100 O
and O
200 O
mu O
mol O
/ O
L O
) O
for O
24 O
h O
. O

beta B
- I
ionone I
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved O
- O
caspase O
- O
3 O
and O
inhibit O
bcl O
- O
2 O
expression O
in O
SGC O
- O
7901 O
cells O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
significantly O
decreased O
levels O
of O
p O
- O
PI3K O
and O
p O
- O
AKT O
expression O
were O
observed O
in O
SGC O
- O
7901 O
cells O
after O
beta B
- I
ionone I
treatments O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
( O
P O
< O
0 O
. O
01 O
) O
. O

Thus O
, O
the O
apoptosis O
induction O
in O
SGC O
- O
7901 O
cells O
by O
beta B
- I
ionone I
may O
be O
regulated O
through O
a O
PI3K O
- O
AKT O
pathway O
. O

These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
beta B
- I
ionone I
to O
induce O
apoptosis O
initiation O
in O
SGC O
- O
7901 O
cells O
. O

Here O
, O
we O
determined O
the O
metabolic O
stability O
, O
permeability O
and O
brain O
availability O
of O
six O
major O
BAs O
, O
that O
is O
, O
KBA B
, O
AKBA B
, O
beta B
BA I
, O
3 B
- I
acetyl I
- I
beta I
- I
boswellic I
acid I
( O
A B
beta I
BA I
) O
, O
alpha B
- I
boswellic I
acid I
( O
alpha B
BA I
) O
, O
and O
3 B
- I
acetyl I
- I
alpha I
- I
boswellic I
acid I
( O
A B
alpha I
BA I
) O
. O

Here O
, O
we O
determined O
the O
metabolic O
stability O
, O
permeability O
and O
brain O
availability O
of O
six O
major O
BAs O
, O
that O
is O
, O
KBA B
, O
AKBA B
, O
beta B
BA I
, O
3 B
- I
acetyl I
- I
beta I
- I
boswellic I
acid I
( O
A B
beta I
BA I
) O
, O
alpha B
- I
boswellic I
acid I
( O
alpha B
BA I
) O
, O
and O
3 B
- I
acetyl I
- I
alpha I
- I
boswellic I
acid I
( O
A B
alpha I
BA I
) O
. O

Under O
these O
conditions O
the O
four O
BAs O
lacking O
the O
11 B
- I
keto I
moiety O
revealed O
moderate O
permeability O
. O

Finally O
, O
the O
availability O
of O
all O
six O
major O
BAs O
could O
be O
confirmed O
in O
rat O
brain O
8h O
after O
oral O
administration O
of O
240mg O
/ O
kg O
BSE O
to O
rats O
showing O
mean O
concentrations O
of O
11 O
. O
6ng O
/ O
g O
for O
KBA B
, O
37 O
. O
5ng O
/ O
g O
for O
AKBA B
, O
485 O
. O
1ng O
/ O
g O
for O
alpha B
BA I
, O
1066 O
. O
6ng O
/ O
g O
for O
beta B
BA I
, O
43 O
. O
0ng O
/ O
g O
for O
A B
alpha I
BA I
and O
163 O
. O
7ng O
/ O
g O
for O
A B
beta I
BA I
. O

Finally O
, O
the O
availability O
of O
all O
six O
major O
BAs O
could O
be O
confirmed O
in O
rat O
brain O
8h O
after O
oral O
administration O
of O
240mg O
/ O
kg O
BSE O
to O
rats O
showing O
mean O
concentrations O
of O
11 O
. O
6ng O
/ O
g O
for O
KBA B
, O
37 O
. O
5ng O
/ O
g O
for O
AKBA B
, O
485 O
. O
1ng O
/ O
g O
for O
alpha B
BA I
, O
1066 O
. O
6ng O
/ O
g O
for O
beta B
BA I
, O
43 O
. O
0ng O
/ O
g O
for O
A B
alpha I
BA I
and O
163 O
. O
7ng O
/ O
g O
for O
A B
beta I
BA I
. O

Further O
we O
found O
stimulation O
of O
FAS O
- O
expression O
as O
a O
result O
of O
epigenetic O
DNA O
demethylation O
that O
was O
due O
to O
down O
- O
regulation O
of O
DNMT1 O
, O
which O
was O
rescued O
by O
re O
- O
isoprenylation O
by O
both O
geranylgeranyl B
- I
pyrophosphate I
and O
farnesylpyrophosphat B
. O

These O
CA O
- O
induced O
apoptosis O
- O
related O
signals O
were O
markedly O
prevented O
by O
the O
antioxidant O
N B
- I
acetylcysteine I
( O
NAC B
) O
. O

Enantioselective O
hydrolysis O
of O
oral O
racemic B
methylphenidate I
( O
dl B
- I
MPH I
) O
by O
carboxylesterase O
1 O
( O
CES1 O
) O
limits O
the O
absolute O
bioavailability O
of O
the O
pharmacologically O
active O
d B
- I
MPH I
isomer O
to O
approximately O
30 O
% O
and O
that O
of O
the O
inactive O
l B
- I
MPH I
to O
only O
1 O
- O
2 O
% O
. O

Enantioselective O
hydrolysis O
of O
oral O
racemic B
methylphenidate I
( O
dl B
- I
MPH I
) O
by O
carboxylesterase O
1 O
( O
CES1 O
) O
limits O
the O
absolute O
bioavailability O
of O
the O
pharmacologically O
active O
d B
- I
MPH I
isomer O
to O
approximately O
30 O
% O
and O
that O
of O
the O
inactive O
l B
- I
MPH I
to O
only O
1 O
- O
2 O
% O
. O

Enantioselective O
hydrolysis O
of O
oral O
racemic B
methylphenidate I
( O
dl B
- I
MPH I
) O
by O
carboxylesterase O
1 O
( O
CES1 O
) O
limits O
the O
absolute O
bioavailability O
of O
the O
pharmacologically O
active O
d B
- I
MPH I
isomer O
to O
approximately O
30 O
% O
and O
that O
of O
the O
inactive O
l B
- I
MPH I
to O
only O
1 O
- O
2 O
% O
. O

Coadministration O
of O
dl B
- I
MPH I
with O
ethanol B
results O
in O
elevated O
d B
- I
MPH I
plasma O
concentrations O
accompanied O
by O
CES1 O
- O
mediated O
enantioselective O
transesterification O
of O
l B
- I
MPH I
to O
l B
- I
ethylphenidate I
( O
EPH B
) O
. O

Coadministration O
of O
dl B
- I
MPH I
with O
ethanol B
results O
in O
elevated O
d B
- I
MPH I
plasma O
concentrations O
accompanied O
by O
CES1 O
- O
mediated O
enantioselective O
transesterification O
of O
l B
- I
MPH I
to O
l B
- I
ethylphenidate I
( O
EPH B
) O
. O

Coadministration O
of O
dl B
- I
MPH I
with O
ethanol B
results O
in O
elevated O
d B
- I
MPH I
plasma O
concentrations O
accompanied O
by O
CES1 O
- O
mediated O
enantioselective O
transesterification O
of O
l B
- I
MPH I
to O
l B
- I
ethylphenidate I
( O
EPH B
) O
. O

Coadministration O
of O
dl B
- I
MPH I
with O
ethanol B
results O
in O
elevated O
d B
- I
MPH I
plasma O
concentrations O
accompanied O
by O
CES1 O
- O
mediated O
enantioselective O
transesterification O
of O
l B
- I
MPH I
to O
l B
- I
ethylphenidate I
( O
EPH B
) O
. O

The O
present O
study O
tested O
the O
hypothesis O
that O
administration O
of O
the O
pure O
isomer O
dexmethylphenidate B
( O
d B
- I
MPH I
) O
will O
overcome O
the O
influence O
of O
ethanol B
on O
d B
- I
MPH I
absorption O
by O
eliminating O
competitive O
CES1 O
- O
mediated O
presystemic O
metabolism O
of O
l B
- I
MPH I
to O
l B
- I
EPH I
. O

The O
present O
study O
tested O
the O
hypothesis O
that O
administration O
of O
the O
pure O
isomer O
dexmethylphenidate B
( O
d B
- I
MPH I
) O
will O
overcome O
the O
influence O
of O
ethanol B
on O
d B
- I
MPH I
absorption O
by O
eliminating O
competitive O
CES1 O
- O
mediated O
presystemic O
metabolism O
of O
l B
- I
MPH I
to O
l B
- I
EPH I
. O

The O
present O
study O
tested O
the O
hypothesis O
that O
administration O
of O
the O
pure O
isomer O
dexmethylphenidate B
( O
d B
- I
MPH I
) O
will O
overcome O
the O
influence O
of O
ethanol B
on O
d B
- I
MPH I
absorption O
by O
eliminating O
competitive O
CES1 O
- O
mediated O
presystemic O
metabolism O
of O
l B
- I
MPH I
to O
l B
- I
EPH I
. O

The O
present O
study O
tested O
the O
hypothesis O
that O
administration O
of O
the O
pure O
isomer O
dexmethylphenidate B
( O
d B
- I
MPH I
) O
will O
overcome O
the O
influence O
of O
ethanol B
on O
d B
- I
MPH I
absorption O
by O
eliminating O
competitive O
CES1 O
- O
mediated O
presystemic O
metabolism O
of O
l B
- I
MPH I
to O
l B
- I
EPH I
. O

Twenty O
- O
four O
healthy O
volunteers O
received O
dl B
- I
MPH I
( O
0 O
. O
3 O
mg O
/ O
kg O
) O
or O
d B
- I
MPH I
( O
0 O
. O
15 O
mg O
/ O
kg O
) O
, O
with O
or O
without O
ethanol B
( O
0 O
. O
6 O
g O
/ O
kg O
) O
. O

Twenty O
- O
four O
healthy O
volunteers O
received O
dl B
- I
MPH I
( O
0 O
. O
3 O
mg O
/ O
kg O
) O
or O
d B
- I
MPH I
( O
0 O
. O
15 O
mg O
/ O
kg O
) O
, O
with O
or O
without O
ethanol B
( O
0 O
. O
6 O
g O
/ O
kg O
) O
. O

During O
the O
absorption O
phase O
of O
dl B
- I
MPH I
, O
concomitant O
ethanol B
significantly O
elevated O
d B
- I
MPH I
plasma O
concentrations O
( O
44 O
- O
99 O
% O
; O
P O
< O
0 O
. O
005 O
) O
. O

During O
the O
absorption O
phase O
of O
dl B
- I
MPH I
, O
concomitant O
ethanol B
significantly O
elevated O
d B
- I
MPH I
plasma O
concentrations O
( O
44 O
- O
99 O
% O
; O
P O
< O
0 O
. O
005 O
) O
. O

Plasma O
l B
- I
EPH I
concentrations O
exceeded O
those O
of O
l B
- I
MPH I
. O

Plasma O
l B
- I
EPH I
concentrations O
exceeded O
those O
of O
l B
- I
MPH I
. O

Ethanol B
combined O
with O
pure O
d B
- I
MPH I
did O
not O
elevate O
plasma O
d B
- I
MPH I
concentrations O
during O
the O
absorption O
phase O
, O
and O
the O
ethanol B
- O
induced O
potentiation O
of O
subjective O
effects O
was O
delayed O
relative O
to O
dl B
- I
MPH I
- O
ethanol B
. O

Ethanol B
combined O
with O
pure O
d B
- I
MPH I
did O
not O
elevate O
plasma O
d B
- I
MPH I
concentrations O
during O
the O
absorption O
phase O
, O
and O
the O
ethanol B
- O
induced O
potentiation O
of O
subjective O
effects O
was O
delayed O
relative O
to O
dl B
- I
MPH I
- O
ethanol B
. O

Ethanol B
combined O
with O
pure O
d B
- I
MPH I
did O
not O
elevate O
plasma O
d B
- I
MPH I
concentrations O
during O
the O
absorption O
phase O
, O
and O
the O
ethanol B
- O
induced O
potentiation O
of O
subjective O
effects O
was O
delayed O
relative O
to O
dl B
- I
MPH I
- O
ethanol B
. O

These O
findings O
are O
consistent O
with O
l B
- I
MPH I
competitively O
inhibiting O
presystemic O
CES1 O
metabolism O
of O
d B
- I
MPH I
. O

These O
findings O
are O
consistent O
with O
l B
- I
MPH I
competitively O
inhibiting O
presystemic O
CES1 O
metabolism O
of O
d B
- I
MPH I
. O

Ethanol B
increased O
the O
d B
- I
MPH I
area O
under O
the O
curve O
( O
AUC O
) O
( O
0 O
- O
inf O
) O
by O
21 O
% O
following O
dl B
- I
MPH I
( O
P O
< O
0 O
. O
001 O
) O
and O
14 O
% O
for O
d B
- I
MPH I
( O
P O
= O
0 O
. O
001 O
) O
. O

Ethanol B
increased O
the O
d B
- I
MPH I
area O
under O
the O
curve O
( O
AUC O
) O
( O
0 O
- O
inf O
) O
by O
21 O
% O
following O
dl B
- I
MPH I
( O
P O
< O
0 O
. O
001 O
) O
and O
14 O
% O
for O
d B
- I
MPH I
( O
P O
= O
0 O
. O
001 O
) O
. O

Ethanol B
increased O
the O
d B
- I
MPH I
area O
under O
the O
curve O
( O
AUC O
) O
( O
0 O
- O
inf O
) O
by O
21 O
% O
following O
dl B
- I
MPH I
( O
P O
< O
0 O
. O
001 O
) O
and O
14 O
% O
for O
d B
- I
MPH I
( O
P O
= O
0 O
. O
001 O
) O
. O

In O
men O
receiving O
d B
- I
MPH I
- O
ethanol B
, O
the O
d B
- I
MPH I
absorption O
partial O
AUC O
( O
0 O
. O
5 O
- O
2 O
hours O
) O
was O
2 O
. O
1 O
times O
greater O
and O
the O
time O
to O
maximum O
concentration O
( O
T O
( O
max O
) O
) O
occurred O
1 O
. O
1 O
hours O
earlier O
than O
in O
women O
, O
consistent O
with O
an O
increased O
rate O
of O
d B
- I
MPH I
absorption O
reducing O
hepatic O
extraction O
. O

In O
men O
receiving O
d B
- I
MPH I
- O
ethanol B
, O
the O
d B
- I
MPH I
absorption O
partial O
AUC O
( O
0 O
. O
5 O
- O
2 O
hours O
) O
was O
2 O
. O
1 O
times O
greater O
and O
the O
time O
to O
maximum O
concentration O
( O
T O
( O
max O
) O
) O
occurred O
1 O
. O
1 O
hours O
earlier O
than O
in O
women O
, O
consistent O
with O
an O
increased O
rate O
of O
d B
- I
MPH I
absorption O
reducing O
hepatic O
extraction O
. O

In O
men O
receiving O
d B
- I
MPH I
- O
ethanol B
, O
the O
d B
- I
MPH I
absorption O
partial O
AUC O
( O
0 O
. O
5 O
- O
2 O
hours O
) O
was O
2 O
. O
1 O
times O
greater O
and O
the O
time O
to O
maximum O
concentration O
( O
T O
( O
max O
) O
) O
occurred O
1 O
. O
1 O
hours O
earlier O
than O
in O
women O
, O
consistent O
with O
an O
increased O
rate O
of O
d B
- I
MPH I
absorption O
reducing O
hepatic O
extraction O
. O

More O
rapid O
absorption O
of O
d B
- I
MPH I
carries O
implications O
for O
increased O
abuse O
liability O
. O

Superparamagnetic O
nanoparticles O
grafted O
with O
hyperbranched O
polyglycerol B
( O
HPG O
) O
and O
conjugated O
with O
methotrexate B
( O
MTX B
) O
( O
MNP O
- O
g O
- O
HPG O
- O
MTX B
) O
were O
synthesized O
via O
a O
sol O
- O
gel O
reaction O
followed O
by O
thiol B
- I
ene I
click O
chemistry O
and O
esterification O
reaction O
. O

alpha O
/ O
beta O
- O
Hydrolase O
domain O
- O
containing O
6 O
( O
ABHD6 O
) O
represents O
a O
potentially O
attractive O
therapeutic O
target O
for O
indirectly O
potentiating O
2 B
- I
arachidonoylglycerol I
signaling O
; O
however O
, O
the O
enzyme O
is O
currently O
largely O
uncharacterized O
. O

We O
studied O
the O
viability O
and O
antiproliferative O
effects O
of O
griseofulvin B
on O
cultured O
NCI O
- O
H295R O
adrenocortical O
carcinoma O
cells O
using O
Wst B
- I
1 I
- O
, O
BrdUrd B
- O
, O
and O
[ B
3H I
] I
- I
thymidine I
assays O
. O

Significant O
effects O
could O
be O
observed O
after O
incubation O
with O
griseofulvin B
as O
measured O
by O
Wst B
- I
1 I
- O
, O
BrdUrd B
- O
, O
and O
[ B
3H I
] I
dT I
- O
uptake O
assays O
. O

Tetrazolium B
bromide I
salt I
and O
lactate B
dehydrogenase O
release O
assays O
were O
used O
to O
study O
the O
cytotoxicity O
. O

Testing O
type O
I O
[ O
N B
- I
( I
5 I
- I
chloro I
- I
2 I
- I
hydroxyphenyl I
) I
- I
N I
' I
- I
[ I
2 I
- I
chloro I
- I
5 I
- I
( I
trifluoromethyl I
) I
phenyl I
] O
( O
NS1738 B
) O
] O
and O
type O
II O
[ O
1 B
- I
( I
5 I
- I
chloro I
- I
2 I
, I
4 I
- I
dimethoxy I
- I
phenyl I
) I
- I
3 I
- I
( I
5 I
- I
methyl I
- I
isoxazol I
- I
3 I
- I
yl I
) I
( O
PNU B
- I
120596 I
) O
] O
alpha O
7 O
nAChR O
PAMs O
in O
acute O
and O
persistent O
pain O
, O
we O
found O

that O
, O
although O
neither O
reduced O
acute O
thermal O
pain O
, O
only O
PNU B
- I
120596 I
dose O
- O
dependently O
attenuated O
paw O
- O
licking O
behavior O
in O
the O
formalin B
test O
. O

The O
long O
- O
acting O
effect O
of O
PNU B
- I
120596 I
in O
this O
test O
was O
in O
discordance O
with O
its O
pharmacokinetic O
profile O
in O
mice O
, O
which O
suggests O
the O
involvement O
of O
postreceptor O
signaling O
mechanisms O
. O

Our O
results O
with O
selective O
mitogen O
- O
activated O
protein O
kinase O
kinase O
inhibitor O
1 B
, I
4 I
- I
diamino I
- I
2 I
, I
3 I
- I
dicyano I
- I
1 I
, I
4 I
- I
bis I
( I
o I
- I
aminophenylmercapto I
) I
butadiene I
monoethanolate I
( O
U0126 B
) O
argues O
for O
an O
important O
role O
of O
extracellular O
signal O
- O
regulated O
kinase O
- O
1 O
/ O
2 O
pathways O
activation O
in O
PNU B
- I
120596 I
' O
s O
antinociceptive O
effects O
. O

The O
alpha O
7 O
antagonist O
MLA B
, O
administered O
intrathecally O
, O
reversed O
PNU B
- I
120596 I
' O
s O
effects O
, O
confirming O
PNU B
- I
120596 I
' O
s O
action O
, O
in O
part O
, O
through O
central O
alpha O
7 O
nAChRs O
. O

The O
alpha O
7 O
antagonist O
MLA B
, O
administered O
intrathecally O
, O
reversed O
PNU B
- I
120596 I
' O
s O
effects O
, O
confirming O
PNU B
- I
120596 I
' O
s O
action O
, O
in O
part O
, O
through O
central O
alpha O
7 O
nAChRs O
. O

Importantly O
, O
tolerance O
to O
PNU B
- I
120596 I
was O
not O
developed O
after O
subchronic O
treatment O
of O
the O
drug O
. O

Surprisingly O
, O
PNU B
- I
120596 I
' O
s O
antinociceptive O
effects O
were O
blocked O
by O
NS1738 B
. O

Our O
results O
indicate O
that O
type O
II O
alpha O
7 O
nAChR O
PAM O
PNU B
- I
120596 I
, O
but O
not O
type O
I O
alpha O
7 O
nAChR O
PAM O
NS1738 B
, O
shows O
significant O
antinociception O
effects O
in O
persistent O
pain O
models O
in O
mice O
. O

A O
two O
- O
phase O
solvent O
system O
consisted O
of O
n B
- I
hexane I
- O
ethyl B
acetate I
- O
methanol B
- O
water O
( O
35 O
: O
100 O
: O
35 O
: O
100 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
was O
applied O
. O

Among O
the O
chemical O
inhibitors O
tested O
, O
l B
- I
cysteine I
showed O
the O
best O
inhibitory O
effect O
, O
with O
an O
IC O
( O
50 O
) O
of O
1 O
. O
3 O
+ O
/ O
- O
0 O
. O
002 O
mM O
followed O
by O
ascorbic B
acid I
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
06 O
mM O
) O
, O
glutathione B
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
07 O
mM O
) O
, O
EDTA B
( O
100 O
+ O
/ O
- O
0 O
. O
02 O
mM O
) O
and O
citric B
acid I
( O
186 O
+ O
/ O
- O
0 O
. O
16 O
mM O
) O
. O

The O
transesterification O
of O
total O
lipid O
extracts O
furnished O
FAME B
mixtures O
that O
enabled O
quantitation O
of O
fatty B
acid I
acyl I
chains O
in O
the O
acylglycerol B
and O
FFA O
portions O
. O

In O
all O
cases O
, O
oleyl B
chains O
were O
predominant O
, O
and O
high O
amounts O
of O
polyunsaturated B
fatty I
acid I
chains O
were O
observed O
. O

CS O
exposure O
caused O
significant O
lung O
damage O
, O
as O
evidenced O
by O
higher O
levels O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
neutrophil O
infiltration O
, O
dityrosine B
and O
4 B
- I
HNE I
, O
as O
well O
as O
lower O
levels O
of O
Mn B
- O
superoxide B
dismutase O
and O
catalase O
expression O
. O

The O
K O
( O
i O
) O
for O
sulphanilamide B
was O
determined O
to O
be O
3 O
. O
57 O
. O
10 O
( O
- O
5 O
) O
M O
and O
sulphanilamide B
showed O
competitive O
inhibition O
, O
which O
makes O
it O
a O
suitable O
ligand O
for O
constructing O
a O
Sepharose B
4B I
- O
L B
- I
tyrosine I
affinity O
matrix O
. O

The O
affinity O
matrix O
was O
synthesised O
by O
coupling O
sulphanilamide B
as O
the O
ligand O
and O
L B
- I
tyrosine I
as O
the O
spacer O
arm O
to O
a O
cyanogen B
bromide I
( O
CNBr B
) O
- O
activated O
- O
Sepharose B
4B I
matrix O
. O

Many O
major O
components O
( O
> O
50 O
) O
of O
beeswax O
, O
odd O
and O
even O
hydrocarbons B
, O
oleofin B
, O
palmitate B
, O
oleate B
and O
hydroxypalmitate B
monoesters I
were O
detected O
, O
and O
for O
the O
first O
time O
palmitate B
and I
oleate I
monoesters I
esterified O
with O
1 B
- I
octadecanol I
and O
1 B
- I
eicosanol I
are O
reported O
to O
be O
present O
in O
beeswax O
. O

Many O
major O
components O
( O
> O
50 O
) O
of O
beeswax O
, O
odd O
and O
even O
hydrocarbons B
, O
oleofin B
, O
palmitate B
, O
oleate B
and O
hydroxypalmitate B
monoesters I
were O
detected O
, O
and O
for O
the O
first O
time O
palmitate B
and I
oleate I
monoesters I
esterified O
with O
1 B
- I
octadecanol I
and O
1 B
- I
eicosanol I
are O
reported O
to O
be O
present O
in O
beeswax O
. O

In O
this O
study O
, O
a O
comparison O
between O
[ B
6S I
] I
- I
5 I
- I
methyltetrahydrofoli I
acid I
( O
5 B
- I
MTHF I
) O
and O
its O
racemate O
[ O
6R O
, O
S O
] O
form O
was O
made O
by O
TEAC O
assay O
at O
different O
pHs O
, O
FRAP O
assay O
, O
and O
ORAC O
assay O
. O

Results O
suggest O
that O
stereoisomeric O
difference O
could O
influence O
the O
antioxidant O
activity O
of O
5 B
- I
MTHF I
and O
hence O
should O
be O
taken O
into O
account O
when O
folates B
are O
added O
to O
foodstuffs O
to O
improve O
their O
nutritional O
value O
. O

Furthermore O
, O
ROS O
scavengers O
, O
N B
- I
acetylcystine I
( O
NAC B
) O
, O
and O
glutathione B
ethyl I
ester I
( O
GEE B
) O
, O
reduced O
helenalin B
- O
induced O
apoptosis O
. O

Furthermore O
, O
ROS O
scavengers O
, O
N B
- I
acetylcystine I
( O
NAC B
) O
, O
and O
glutathione B
ethyl I
ester I
( O
GEE B
) O
, O
reduced O
helenalin B
- O
induced O
apoptosis O
. O

beta B
- I
Chloroprene I
( O
2 B
- I
chloro I
- I
1 I
, I
3 I
- I
butadiene I
) O
, O
a O
monomer O
used O
in O
the O
production O
of O
neoprene B
elastomers O
, O
is O
of O
regulatory O
interest O
due O
to O
the O
production O
of O
multiorgan O
tumors O
in O
mouse O
and O
rat O
cancer O
bioassays O
. O

Lower O
contributions O
were O
obtained O
for O
non O
- O
extractable O
As B
( O
11 O
. O
3 O
- O
17 O
. O
5 O
% O
) O
and O
other O
molecules O
such O
as O
arsenocholine B
and O
methyl B
- I
arsonate I
( O
< O
5 O
% O
) O
. O

We O
report O
the O
bindings O
of O
several O
lipids O
cholesterol B
( O
Chol B
) O
, O
1 B
, I
2 I
- I
dioleoyl I
- I
3 I
- I
trimethylammonium I
- I
propane I
( O
DOTAP B
) O
, O
dioctadecyldimethyla B
( O
DDAB B
) O
, O
and O
dioleoylphosphatidyl B
( O
DOPE B
) O
to O
dendrimers O
of O
different O
compositions O
such O
as O
mPEG B
- I
PAMAM I
( O
G3 O
) O
, O
mPEG B
- I
PAMAM I
( O
G4 O
) O
, O
and O
PAMAM B
( O
G4 O
) O
under O
physiological O
conditions O
. O

We O
report O
the O
bindings O
of O
several O
lipids O
cholesterol B
( O
Chol B
) O
, O
1 B
, I
2 I
- I
dioleoyl I
- I
3 I
- I
trimethylammonium I
- I
propane I
( O
DOTAP B
) O
, O
dioctadecyldimethyla B
( O
DDAB B
) O
, O
and O
dioleoylphosphatidyl B
( O
DOPE B
) O
to O
dendrimers O
of O
different O
compositions O
such O
as O
mPEG B
- I
PAMAM I
( O
G3 O
) O
, O
mPEG B
- I
PAMAM I
( O
G4 O
) O
, O
and O
PAMAM B
( O
G4 O
) O
under O
physiological O
conditions O
. O

The O
free O
binding O
energies O
from O
docking O
were O
- O
5 O
. O
15 O
( O
cholesterol B
) O
, O
- O
5 O
. O
79 O
( O
DDAB B
) O
, O
and O
- O
5 O
. O
36 O
kcal O
/ O
mol O
( O
DOTAP B
) O
with O
the O
order O
of O
stability O
DDAB B
- I
PAMAM I
- I
G I
- I
4 I
> O
DOTAP B
- I
PAMAM I
- I
G4 I
> O
cholesterol B
- O
PAMAM B
- I
G4 I
, O
consistent O
with O
the O
spectroscopic O
results O
. O

The O
most O
oxidizable O
base O
in O
DNA O
is O
2 B
- I
deoxyguanosine I
( O
dG O
) O
, O
and O
the O
primary O
oxidation O
products O
are O
8 B
- I
oxodG I
and O
2 B
- I
amino I
- I
imidazolone I
. O

The O
most O
oxidizable O
base O
in O
DNA O
is O
2 B
- I
deoxyguanosine I
( O
dG O
) O
, O
and O
the O
primary O
oxidation O
products O
are O
8 B
- I
oxodG I
and O
2 B
- I
amino I
- I
imidazolone I
. O

The O
latter O
rapidly O
converts O
to O
2 B
, I
2 I
- I
diamino I
- I
oxazolone I
( O
Ox O
) O
, O
and O
8 B
- I
oxodG I
is O
further O
oxidized O
to O
spiroiminodihydantoi B
( O
Sp O
) O
and O
guanidinohydantoin B
( O
Gh O
) O
. O

8 B
- I
OxodG I
was O
the O
most O
abundant O
products O
in O
all O
cases O
, O
but O
its O
accumulation O
was O
highly O
dependent O
on O
the O
nature O
of O
the O
oxidizing O
agent O
and O
the O
subsequent O
conversion O
to O
Sp O
and O
Gh O
. O

In O
healthy O
controls O
, O
former O
smokers O
had O
significantly O
higher O
total O
NNAL B
and O
higher O
NNAL B
- I
Gluc I
than O
never O
smokers O
or O
current O
smokers O
. O

Significant O
dose O
- O
response O
associations O
between O
total O
NNAL B
, O
free O
NNAL B
, O
the O
ratios O
of O
free O
NNAL B
/ O
total O
NNAL B
and O
NNAL B
- I
Gluc I
/ O
total O
NNAL B
and O
UC O
risk O
were O
observed O
. O

Results O
demonstrate O
that O
these O
distinct O
maturational O
processes O
are O
differentially O
affected O
by O
pharmacological O
compounds O
( O
K252a B
, O
Na B
( I
3 I
) I
VO I
( I
4 I
) I
, O
Bis B
- I
1 I
) O
known O
to O
inhibit O
neurite O
outgrowth O
. O

Metabolism O
also O
occurred O
on O
the O
D O
- O
ring O
substituents O
, O
including O
the O
21 B
- I
carboxy I
metabolites O
for O
triamcinolone B
acetonide I
and O
flunisolide B
. O

Characteristic O
molecular O
signature O
for O
the O
early O
detection O
and O
prediction O
of O
polycyclic B
aromatic I
hydrocarbons I
in O
rat O
liver O
. O

Among O
the O
various O
environmental O
toxicants O
, O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
are O
an O
important O
class O
of O
environmental O
pollutant O
, O
and O
many O
PAHs B
are O
known O
or O
suspected O
carcinogens O
. O

SB B
- I
408124 I
( O
100 O
pmol O
/ O
100 O
nl O
, O
an O
antagonist O
of O
OX1R O
) O
or O
TCS B
OX2 I
29 I
( O
100 O
pmol O
/ O
100 O
nl O
, O
an O
antagonist O
of O
OX2R O
) O
partly O
abolished O
the O
cardiovascular O
effects O
of O
exogenously O
- O
administrated O
OXA O
into O
the O
RVLM O
of O
control O
rats O
and O
SIHR O
, O
and O
lowered O
the O
increased O
systolic O
blood O
pressure O
( O
SBP O
) O
and O
heart O
rate O
( O
HR O
) O
of O
SIHR O
, O
with O
no O
difference O
in O
statistical O
significance O
between O
the O
two O
antagonists O
' O
effects O
. O

SB B
- I
408124 I
( O
100 O
pmol O
/ O
100 O
nl O
, O
an O
antagonist O
of O
OX1R O
) O
or O
TCS B
OX2 I
29 I
( O
100 O
pmol O
/ O
100 O
nl O
, O
an O
antagonist O
of O
OX2R O
) O
partly O
abolished O
the O
cardiovascular O
effects O
of O
exogenously O
- O
administrated O
OXA O
into O
the O
RVLM O
of O
control O
rats O
and O
SIHR O
, O
and O
lowered O
the O
increased O
systolic O
blood O
pressure O
( O
SBP O
) O
and O
heart O
rate O
( O
HR O
) O
of O
SIHR O
, O
with O
no O
difference O
in O
statistical O
significance O
between O
the O
two O
antagonists O
' O
effects O
. O

Extraction O
of O
sediment O
- O
associated O
polycyclic B
aromatic I
hydrocarbons I
with O
granular O
activated O
carbon B
. O

The O
present O
study O
explores O
the O
effectiveness O
of O
granular O
AC O
( O
GAC O
) O
in O
extracting O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH B
) O
from O
highly O
contaminated O
sediments O
. O

This O
effect O
was O
abolished O
by O
a O
calcium B
chelator O
( O
BAPTA B
- I
AM I
) O
, O
but O
not O
by O
the O
absence O
of O
extracellular O
calcium B
. O

The O
cytotoxic O
antimetabolites O
, O
5 B
- I
flurouracil I
and O
mitomycin B
C I
both O
prolong O
success O
but O
with O
the O
increased O
risk O
of O
blinding O
complications O
. O

In O
order O
to O
investigate O
possible O
fibril O
remodeling O
mechanisms O
using O
this O
approach O
, O
we O
performed O
comparative O
studies O
on O
the O
structural O
features O
of O
the O
different O
amyloid O
- O
beta O
( O
A O
beta O
) O
aggregates O
remodeled O
from O
A O
beta O
fibrils O
by O
three O
biocompatible O
small O
molecules O
: O
methylene B
blue I
; O
brilliant B
blue I
G I
; O
and O
erythrosine B
B I
. O

Combined O
with O
circular O
dichroism O
( O
CD O
) O
, O
immuno O
- O
blotting O
, O
transmission O
electron O
microscopy O
( O
TEM O
) O
, O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
results O
, O
it O
was O
found O
that O
brilliant B
blue I
G I
- O
and O
erythrosine B
B I
- O
treatment O
generate O
fragmented O
A O
beta O
fibrils O
and O
protofibrils O
, O
respectively O
. O

The O
serotonin B
( O
5 B
- I
HT I
) O
receptors O
of O
type O
6 O
( O
5 O
- O
HT6 O
) O
are O
quite O
different O
from O
all O
other O
5 B
- I
HT I
receptors O
, O
as O
they O
include O
a O
short O
third O
cytoplasmatic O
loop O
and O
a O
long O
C B
- O
terminal O
tail O
, O
and O
one O
intron O
located O
in O
the O
middle O
of O
the O
third O
cytoplasmatic O
loop O
. O

The O
serotonin B
( O
5 B
- I
HT I
) O
receptors O
of O
type O
6 O
( O
5 O
- O
HT6 O
) O
are O
quite O
different O
from O
all O
other O
5 B
- I
HT I
receptors O
, O
as O
they O
include O
a O
short O
third O
cytoplasmatic O
loop O
and O
a O
long O
C B
- O
terminal O
tail O
, O
and O
one O
intron O
located O
in O
the O
middle O
of O
the O
third O
cytoplasmatic O
loop O
. O

A O
novel O
permeation O
enhancer O
: O
N B
- I
succinyl I
chitosan O
on O
the O
intranasal O
absorption O
of O
isosorbide B
dinitrate I
in O
rats O
. O

The O
purpose O
of O
this O
paper O
is O
to O
study O
the O
potential O
of O
N B
- I
succinyl I
chitosan O
as O
a O
novel O
permeation O
enhancer O
for O
the O
intranasal O
absorption O
of O
isosorbide B
dinitrate I
( O
ISDN B
) O
. O

A O
series O
of O
N B
- I
succinyl I
chitosan O
( O
NSCS O
) O
with O
different O
degree O
of O
succinylation O
( O
DS O
) O
and O
molecular O
weight O
were O
synthesized O
. O

Hydroxysafflor B
yellow I
a I
inhibits O
lipopolysaccharide O
- O
induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O

Hydroxysafflor B
yellow I
A I
( O
HSYA B
) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O

The O
products O
of O
the O
Yellow O
cocoon O
( O
C O
) O
gene O
and O
the O
Flesh O
( O
F O
) O
gene O
of O
the O
silkworm O
Bombyx O
mori O
determine O
the O
selectivity O
for O
transport O
of O
lutein B
and O
beta B
- I
carotene I
, O
respectively O
, O
to O
the O
silk O
gland O
. O

Transgenic O
expression O
of O
SCRB15 O
in O
the O
middle O
silk O
gland O
using O
the O
binary O
GAL4 O
- O
UAS O
expression O
system O
enhanced O
selective O
beta B
- I
carotene I
uptake O
by O
the O
middle O
silk O
gland O
, O
while O
transgenic O
expression O
of O
Cameo2 O
enhanced O
selective O
lutein B
uptake O
under O
the O
same O
GAL4 O
driver O
. O

Simultaneous O
ectopic O
overexpression O
of O
RBCK1 O
and O
PXR O
decreased O
PXR O
levels O
in O
AD O
- O
293 O
cells O
, O
and O
this O
decrease O
was O
inhibited O
by O
the O
proteasomal O
inhibitor O
MG B
- I
132 I
( O
carbobenzoxy B
- I
Leu I
- I
Leu I
- I
leucinal I
) O
. O

The O
aforementioned O
peptides O
were O
much O
less O
efficacious O
at O
mFpr2 O
, O
which O
responded O
better O
to O
the O
synthetic O
hexapeptide B
WKYMVm O
, O
the O
synthetic O
agonists O
Quin B
- I
C1 I
( O
a O
substituted O
quinazolinone B
) O
, O
and O
compound O
43 O
( O
a O
nitrosylated B
pyrazolone I
derivative O
) O
. O

Interspecific O
effects O
of O
4A B
- I
DNT I
( O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
) O
and O
RDX B
( O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
) O
in O
Japanese O
quail O
, O
Northern O
bobwhite O
, O
and O
Zebra O
finch O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
toxicological O
effects O
of O
two O
munition O
compounds O
, O
4 B
- I
amino I
- I
2 I
, I
6 I
- I
dinitrotoluene I
( O
4A B
- I
DNT I
) O
and O
1 B
, I
3 I
, I
5 I
- I
trinitro I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
( O
RDX B
) O
, O
on O
three O
different O
bird O
species O
: O
two O
common O
toxicological O
model O
species O
- O
the O
Northern O
Bobwhite O
( O
Colinus O
virginianus O
) O
and O
the O
Japanese O
Quail O
( O
Coturnix O
japonica O
) O
, O
and O
a O
representative O
passerine O
- O
the O
Zebra O
Finch O
( O
Taeniopygia O
guttata O

Bobwhite O
were O
exposed O
to O
4A B
- I
DNT I
at O
0 O
, O
8 O
, O
15 O
, O
30 O
, O
60 O
, O
or O
150 O
mg O
/ O
kg O
body O
weight O
( O
bw O
) O
d O
by O
oral O
gavage O
for O
seven O
days O
; O
because O
the O
high O
dose O
of O
4A B
- I
DNT I
was O
lethal O
to O
bobwhite O
, O
the O
maximum O
dose O
was O
changed O
to O
100 O
mg O
/ O
kg O
bw O
d O
for O
Japanese O
quail O
and O
finches O
to O
ensure O
tissue O
could O
be O
used O
for O
future O
toxicogenomic O
work O
. O

Bobwhite O
were O
exposed O
to O
4A B
- I
DNT I
at O
0 O
, O
8 O
, O
15 O
, O
30 O
, O
60 O
, O
or O
150 O
mg O
/ O
kg O
body O
weight O
( O
bw O
) O
d O
by O
oral O
gavage O
for O
seven O
days O
; O
because O
the O
high O
dose O
of O
4A B
- I
DNT I
was O
lethal O
to O
bobwhite O
, O
the O
maximum O
dose O
was O
changed O
to O
100 O
mg O
/ O
kg O
bw O
d O
for O
Japanese O
quail O
and O
finches O
to O
ensure O
tissue O
could O
be O
used O
for O
future O
toxicogenomic O
work O
. O

Finches O
were O
clearly O
least O
affected O
by O
4A B
- I
DNT I
as O
evidenced O
by O
a O
lack O
of O
observable O
effects O
. O

Bobwhite O
appeared O
to O
be O
the O
most O
sensitive O
species O
to O
4A B
- I
DNT I
as O
observed O
through O
changes O
in O
blood O
cellularity O
and O
plasma O
chemistry O
effects O
. O

Multiple O
geochemical O
markers O
, O
including O
aliphatic B
hydrocarbons I
( O
n B
- I
alkanes I
) O
, O
linear B
alkylbenzenes I
( O
LABs B
) O
, O
and O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
, O
were O
employed O
to O
relate O
sediment O
organic O
chemical O
pollution O
in O
the O
coastal O
zone O
off O
South O
China O
to O
socioeconomic O
development O
there O
. O

Multiple O
geochemical O
markers O
, O
including O
aliphatic B
hydrocarbons I
( O
n B
- I
alkanes I
) O
, O
linear B
alkylbenzenes I
( O
LABs B
) O
, O
and O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
, O
were O
employed O
to O
relate O
sediment O
organic O
chemical O
pollution O
in O
the O
coastal O
zone O
off O
South O
China O
to O
socioeconomic O
development O
there O
. O

Concentrations O
of O
Sigma O
n B
- I
C I
( I
15 I
- I
35 I
) I
( O
n B
- I
alkanes I
with O
15 O
- O
35 O
carbon B
atoms O
) O
, O
Sigma O
LAB B
( O
sum O
of O
C B
( I
10 I
) I
to I
C I
( I
13 I
) I
LABs I
) O
, O
and O
Sigma O
( O
26 O
) O
PAH B
( O
sum O
of O
26 O
PAH B
compounds O
) O
ranged O
from O
110 O
to O
3 O
, O
160 O
, O
11 O
to O
160 O
, O
and O
26 O
to O
600 O
ng O
/ O
g O
, O
with O
medians O
of O
730 O
, O
40 O
, O
and O
230 O
ng O
/ O
g O
, O
respectively O
. O

A O
new O
ganoderic B
acid I
( O
GA O
) O
, O
3 B
alpha I
, I
22 I
beta I
- I
diacetoxy I
- I
7 I
alpha I
- I
hydroxyl I
- I
5 I
alpha I
- I
lanost I
- I
8 I
, I
24E I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
together O
with O
four O
known O
compounds O
GA B
- I
Mk I
( O
2 O
) O
, O
- O
Mc O
( O
3 O
) O
, O
- O
S O
( O
4 O
) O
and O
- O
Mf O
( O
5 O
) O
, O
was O
isolated O
and O
characterized O
from O
Ganoderma O
lucidum O
mycelia O
. O

DNQX B
( O
1 O
. O
25 O
mu O
g O
) O
or O
muscimol B
( O
100 O
ng O
) O
infused O
into O
the O
AcbSh O
unilaterally O
elicited O
feeding O
, O
and O
this O
elicited O
intake O
was O
suppressed O
by O
bilateral O
LH O
injection O
of O
d B
- I
AP5 I
( O
2 O
mu O
g O
) O
or O
muscimol B
( O
25 O
ng O
) O
. O

The O
effectiveness O
of O
d B
- I
AP5 I
or O
muscimol B
infusion O
into O
either O
the O
LH O
site O
ipsilateral O
or O
contralateral O
to O
the O
AcbSh O
injection O
was O
compared O
. O

Ipsilateral O
LH O
injection O
of O
d B
- I
AP5 I
or O
muscimol B
was O
significantly O
more O
effective O
than O
contralateral O
injection O
in O
suppressing O
food O
intake O
initiated O
by O
AcbSh O
injection O
of O
DNQX B
or O
muscimol B
. O

Cisplatin B
( O
cis B
- I
diamminedichloroplat I
, O
CDDP B
) O
is O
widely O
used O
for O
treatment O
of O
patients O
with O
solid O
tumors O
formed O
in O
various O
organs O
including O
the O
lung O
, O
prostate O
and O
cervix O
, O
but O
is O
much O
less O
sensitive O
in O
colon O
and O
breast O
cancers O
. O

Local O
structure O
and O
dynamics O
of O
benzene B
confined O
in O
the O
IRMOF B
- I
1 I
nanocavity O
as O
studied O
by O
molecular O
dynamics O
simulation O
. O

The O
local O
structure O
and O
dynamic O
behaviour O
of O
a O
benzene B
molecular O
assembly O
confined O
within O
the O
nano O
- O
cavities O
of O
a O
zinc B
- O
based O
metal O
- O
organic O
framework O
, O
[ B
Zn I
( I
4 I
) I
O I
( I
CO I
( I
2 I
) I
C I
( I
6 I
) I
H I
( I
4 I
) I
CO I
( I
2 I
) I
) I
( I
3 I
) I
] I
( I
n I
) I
( O
IRMOF B
- I
1 I
) O
, O
were O
investigated O
by O
means O
of O
molecular O
dynamics O
( O
MD O
) O
simulations O
. O

The O
sites O
for O
adsorption O
of O
benzene B
in O
IRMOF B
- I
1 I
were O
well O
defined O
by O
the O
simulation O
. O

Decreasing O
the O
temperature O
gave O
rise O
to O
the O
aggregation O
of O
benzene B
in O
the O
IRMOF B
- I
1 I
frameworks O
. O

Molecular O
aggregation O
was O
attributed O
to O
the O
localization O
of O
benzene B
in O
the O
large O
and O
the O
small O
cavities O
of O
IRMOF B
- I
1 I
, O
respectively O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C B
( I
10 I
) I
H I
( I
10 I
) I
isomers O
( O
trans B
- I
1 I
, I
3 I
- I
butadienylbenzene I
, O
1 B
, I
4 I
- I
dihydronaphthalene I
, O
1 B
- I
methylindene I
) O
, O
three O
C B
( I
9 I
) I
H I
( I
8 I
) I
isomers O
( O
indene B
, O
phenylallene B
, O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
) O
, O
and O
a O
C B
( I
8 I
) I
H I
( I
8 I
) I
isomer O
( O
styrene B
) O
. O

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

1 B
- I
Methylindene I
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene B
( O
116 O
amu O
) O
, O
and O
1 B
- I
phenyl I
- I
1 I
- I
methylacetylene I
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C B
( I
4 I
) I
H I
( I
6 I
) I
isomers O
: O
1 B
, I
2 I
- I
butadiene I
( O
H B
( I
2 I
) I
CCCH I
( I
CH I
( I
3 I
) I
) I
) O
, O
1 B
- I
butyne I
( O
HCCC B
( I
2 I
) I
H I
( I
5 I
) I
) O
, O
and O
2 B
- I
butyne I
( O
CH B
( I
3 I
) I
CCCH I
( I

Competition O
experiments O
demonstrated O
that O
free O
heparin O
and O
heparan O
sulfate B
( O
HS O
) O
, O
but O
not O
selectively O
2 O
- O
O B
- O
, O
6 O
- O
O B
- O
, O
and O
N B
- I
O I
desulfated O
heparins O
, O
prevent O
p17 O
binding O
to O
substrate O
- O
immobilized O
heparin O
, O
indicating O
that O
the O
sulfate B
groups O
of O
the O
glycosaminoglycan O
mediate O
p17 O
interaction O
. O

Positive O
allosteric O
modulator O
of O
alpha O
7 O
nicotinic O
- O
acetylcholine B
receptors O
, O
PNU B
- I
120596 I
augments O
the O
effects O
of O
donepezil B
on O
learning O
and O
memory O
in O
aged O
rodents O
and O
non O
- O
human O
primates O
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
an O
adjunctive O
treatment O
strategy O
to O
memory O
enhancement O
, O
namely O
combining O
the O
commonly O
prescribed O
acetylcholinesterase O
inhibitor O
( O
AChEI O
) O
donepezil B
, O
with O
a O
positive O
allosteric O
modulator O
( O
PAM O
) O
of O
alpha O
7 O
nicotinic O
- O
acetylcholine B
receptors O
( O
alpha O
7 O
- O
nAChRs O
) O
, O
PNU B
- I
120596 I
. O

In O
all O
three O
experiments O
a O
similar O
drug O
response O
was O
observed O
, O
namely O
that O
donepezil B
administered O
alone O
improved O
task O
performance O
in O
a O
dose O
- O
dependent O
manner O
; O
that O
PNU B
- I
120596 I
administered O
alone O
was O
without O
significant O
effect O
, O
but O
that O
the O
combination O
of O
PNU B
- I
120596 I
with O
a O
subthreshold O
dose O
of O
donepezil B
was O
effective O
. O

In O
all O
three O
experiments O
a O
similar O
drug O
response O
was O
observed O
, O
namely O
that O
donepezil B
administered O
alone O
improved O
task O
performance O
in O
a O
dose O
- O
dependent O
manner O
; O
that O
PNU B
- I
120596 I
administered O
alone O
was O
without O
significant O
effect O
, O
but O
that O
the O
combination O
of O
PNU B
- I
120596 I
with O
a O
subthreshold O
dose O
of O
donepezil B
was O
effective O
. O

Collectively O
, O
these O
data O
indicate O
that O
PNU B
- I
120596 I
increases O
the O
effective O
dose O
range O
of O
donepezil B
in O
learning O
/ O
memory O
- O
related O
tasks O
in O
young O
and O
age O
- O
impaired O
animal O
models O
. O

The O
results O
suggest O
that O
alpha O
7 O
- O
nAChR O
- O
selective O
PAMs O
like O
PNU B
- I
120596 I
have O
potential O
as O
adjunctive O
treatments O
with O
acetylcholinesterase O
inhibitors O
( O
e O
. O
g O
. O
, O
donepezil B
) O
for O
age O
- O
related O
illnesses O
such O
as O
AD O
as O
well O
memory O
disorders O
not O
necessarily O
associated O
with O
advanced O
age O
. O

We O
recently O
reported O
that O
levulinate B
( O
4 B
- I
ketopentanoate I
) O
is O
converted O
in O
the O
liver O
to O
4 B
- I
hydroxypentanoate I
, O
a O
drug O
of O
abuse O
, O
and O
that O
the O
formation O
of O
4 B
- I
hydroxypentanoate I
is O
stimulated O
by O
ethanol B
oxidation O
. O

We O
recently O
reported O
that O
levulinate B
( O
4 B
- I
ketopentanoate I
) O
is O
converted O
in O
the O
liver O
to O
4 B
- I
hydroxypentanoate I
, O
a O
drug O
of O
abuse O
, O
and O
that O
the O
formation O
of O
4 B
- I
hydroxypentanoate I
is O
stimulated O
by O
ethanol B
oxidation O
. O

We O
recently O
reported O
that O
levulinate B
( O
4 B
- I
ketopentanoate I
) O
is O
converted O
in O
the O
liver O
to O
4 B
- I
hydroxypentanoate I
, O
a O
drug O
of O
abuse O
, O
and O
that O
the O
formation O
of O
4 B
- I
hydroxypentanoate I
is O
stimulated O
by O
ethanol B
oxidation O
. O

We O
also O
identified O
3 O
parallel O
beta O
- O
oxidation O
pathways O
by O
which O
levulinate B
and O
4 B
- I
hydroxypentanoate I
are O
catabolized O
to O
propionyl B
- I
CoA I
and O
acetyl B
- I
CoA I
. O

We O
also O
identified O
3 O
parallel O
beta O
- O
oxidation O
pathways O
by O
which O
levulinate B
and O
4 B
- I
hydroxypentanoate I
are O
catabolized O
to O
propionyl B
- I
CoA I
and O
acetyl B
- I
CoA I
. O

We O
also O
identified O
3 O
parallel O
beta O
- O
oxidation O
pathways O
by O
which O
levulinate B
and O
4 B
- I
hydroxypentanoate I
are O
catabolized O
to O
propionyl B
- I
CoA I
and O
acetyl B
- I
CoA I
. O

We O
now O
report O
that O
levulinate B
forms O
three O
seven O
- O
carbon B
cyclical O
CoA O
esters O
by O
processes O
starting O
with O
the O
elongation O
of O
levulinyl B
- I
CoA I
by O
acetyl B
- I
CoA I
to O
3 B
, I
6 I
- I
diketoheptanoyl I
- I
CoA I
. O

We O
now O
report O
that O
levulinate B
forms O
three O
seven O
- O
carbon B
cyclical O
CoA O
esters O
by O
processes O
starting O
with O
the O
elongation O
of O
levulinyl B
- I
CoA I
by O
acetyl B
- I
CoA I
to O
3 B
, I
6 I
- I
diketoheptanoyl I
- I
CoA I
. O

The O
second O
cyclization O
process O
yields O
a O
methyl B
- I
pyrrolyl I
- I
acetyl I
- I
CoA I
containing O
a O
nitrogen B
atom O
derived O
from O
the O
epsilon B
- I
nitrogen I
of O
lysine B
but O
without O
carbons B
from O
lysine B
. O

The O
cyclic B
CoA I
esters I
were O
identified O
in O
rat O
livers O
perfused O
with O
levulinate B
and O
in O
livers O
and O
brains O
from O
rats O
gavaged O
with O
calcium B
levulinate I
+ O
/ O
- O
ethanol B
. O

The O
cyclic B
CoA I
esters I
and O
related O
pyrrolation O
processes O
may O
play O
a O
role O
in O
the O
toxic O
effects O
of O
4 B
- I
hydroxypentanoate I
. O

The O
cyclic B
CoA I
esters I
and O
related O
pyrrolation O
processes O
may O
play O
a O
role O
in O
the O
toxic O
effects O
of O
4 B
- I
hydroxypentanoate I
. O

Cannabinoid O
agonists O
increase O
the O
interaction O
between O
beta O
- O
Arrestin O
2 O
and O
ERK1 O
/ O
2 O
and O
upregulate O
beta O
- O
Arrestin O
2 O
and O
5 B
- I
HT I
( O
2A O
) O
receptors O
. O

We O
have O
recently O
reported O
that O
selective O
cannabinoid O
2 O
( O
CB O
( O
2 O
) O
) O
receptor O
agonists O
upregulate O
5 B
- I
HT I
( O
2A O
) O
receptors O
by O
enhancing O
ERK1 O
/ O
2 O
signaling O
in O
prefrontal O
cortex O
( O
PFCx O
) O
. O

Increased O
activity O
of O
cortical O
5 B
- I
HT I
( O
2A O
) O
receptors O
has O
been O
associated O
with O
several O
neuropsychiatric O
disorders O
such O
as O
anxiety O
and O
schizophrenia O
. O

In O
a O
neuronal O
cell O
line O
, O
we O
found O
that O
selective O
CB O
( O
2 O
) O
receptor O
agonists O
upregulate O
beta O
- O
Arrestin O
2 O
, O
an O
effect O
that O
was O
prevented O
by O
selective O
CB O
( O
2 O
) O
receptor O
antagonist O
JTE B
- I
907 I
and O
CB O
( O
2 O
) O
shRNA O
lentiviral O
particles O
. O

Our O
results O
suggest O
that O
sustained O
activation O
of O
CB O
( O
2 O
) O
receptors O
would O
enhance O
beta O
- O
Arrestin O
2 O
expression O
possibly O
contributing O
to O
its O
increased O
interaction O
with O
ERK1 O
/ O
2 O
, O
thereby O
driving O
the O
upregulation O
of O
5 B
- I
HT I
( O
2A O
) O
receptors O
. O

Angiotensin O
AT2 O
receptor O
activates O
the O
cyclic B
- I
AMP I
signaling O
pathway O
in O
eel O
. O

Triazoyl B
- I
phenyl I
linker O
system O
enhancing O
the O
aqueous O
solubility O
of O
a O
molecular O
probe O
and O
its O
efficiency O
in O
affinity O
labeling O
of O
a O
target O
protein O
for O
jasmonate B
glucoside I
. O

We O
previously O
reported O
the O
synthesis O
of O
a O
jasmonate B
glucoside I
probe O
with O
a O
highly O
rigid O
linker O
consisting O
of O
a O
triazoyl B
- I
phenyl I
( O
TAzP B
) O
moiety O
, O
and O
this O
probe O
demonstrated O
effective O
target O
tagging O
. O

Synthesis O
and O
anti O
- O
tumor O
evaluation O
of O
novel O
25 B
- I
hydroxyprotopanaxadi I
analogs O
incorporating O
natural O
amino B
acids I
. O

In O
the O
current O
study O
, O
derivatives O
of O
25 B
- I
hydroxyprotopanaxadi I
( O
25 B
- I
OH I
- I
PPD I
) O
were O
prepared O
and O
their O
in O
vitro O
anti O
- O
tumor O
activities O
were O
tested O
on O
six O
different O
human O
tumor O
cell O
lines O
by O
standard O
MTT B
assay O
. O

Combining O
Akt O
inhibitor O
MK B
- I
2206 I
with O
erlotinib B
restored O
the O
sensitivity O
of O
HA59T O
cells O
to O
erlotinib B
. O

Pre O
- O
incubation O
with O
beta B
- I
NAPDH I
reduced O
the O
acetylcholine B
- O
induced O
endothelium O
- O
dependent O
relaxation O
; O
this O
attenuation O
was O
reversed O
by O
boldine B
. O

Decolourization O
of O
direct B
blue I
15 I
by O
Fenton O
/ O
ultrasonic O
process O
using O
a O
zero B
- I
valent I
iron I
aggregate O
catalyst O
. O

Decolourization O
of O
direct O
azo B
dye O
, O
direct B
blue I
15 I
( O
DB15 B
) O
, O
by O
an O
advanced O
Fenton O
process O
coupled O
with O
ultrasonic O
irradiation O
( O
Fenton O
/ O
US O
) O
was O
investigated O
. O

Effects O
of O
bidentate O
coordination O
on O
the O
molecular O
properties O
rapta B
- I
C I
based O
complex O
using O
theoretical O
approach O
. O

In O
this O
work O
several O
quantum O
properties O
including O
the O
NEDA O
and O
QTAIM O
are O
computed O
on O
three O
models O
of O
rapta B
- I
C I
complexes O
using O
DFT O
with O
hybrid O
functional O
and O
basis O
set O
with O
ECP O
and O
without O
ECP O
. O

The O
energy O
decomposition O
analysis O
indicated O
that O
inter O
- O
atomic O
interactions O
in O
the O
three O
forms O
of O
rapta B
- I
C I
complexes O
and O
their O
stability O
are O
governed O
by O
the O
charge O
transfer O
term O
with O
significant O
contributions O
from O
polarization O
and O
electrostatic O
terms O
. O

N B
, I
N I
- I
dihydroxypyromelliti I
( O
NDHPI B
) O
and O
N B
, I
N I
' I
, I
N I
' I
' I
- I
trihydroxyisocyanuri I
acid I
( O
THICA B
) O
have O
been O
recently O
demonstrated O
to O
act O
as O
better O
carbon B
- O
radical O
- O
producing O
catalysts O
than O
the O
popular O
N B
- I
hydroxyphthalimide I
( O
NHPI B
) O
. O

The O
chemopreventive O
effect O
of O
beta B
- I
cryptoxanthin I
from O
mandarin O
on O
human O
stomach O
cells O
( O
BGC O
- O
823 O
) O
. O

beta B
- I
Cryptoxanthin I
, O
a O
provitaminic O
carotenoid O
, O
present O
in O
many O
fruits O
and O
vegetables O
, O
has O
been O
associated O
with O
decreased O
risk O
of O
chronic O
diseases O
, O
including O
cancer O
. O

The O
influence O
of O
beta B
- I
cryptoxanthin I
derived O
from O
mandarin O
on O
the O
proliferation O
of O
the O
stomach O
tumor O
cell O
line O
BGC O
- O
823 O
was O
tested O
using O
MTT B
and O
cell O
count O
assay O
at O
72 O
h O
and O
dose O
- O
response O
( O
from O
0 O
. O
01 O
to O
20 O
mu O
M O
) O
. O

beta B
- I
Cryptoxanthin I
suppressed O
the O
cell O
migration O
by O
the O
scratch O
assay O
. O

Furthermore O
, O
beta B
- I
cryptoxanthin I
induced O
an O
accumulation O
of O
cells O
in O
the O
G1 O
/ O
G0 O
phase O
of O
the O
cell O
cycle O
( O
as O
detected O
by O
flow O
cytometry O
) O
, O
which O
was O
in O
accordance O
with O
an O
increased O
expression O
of O
p21 O
and O
down O
regulations O
of O
cyclin O
D1 O
and O
cyclin O
E O
, O
detected O
by O
Western O
blot O
analysis O
, O
and O
beta B
- I
cryptoxanthin I
increased O
the O
mRNA O
levels O
of O
retinoic B
acid I
receptor O
beta O
( O
RAR O
beta O
) O
with O
the O
treatment O
at O
10 O
mu O
M O
for O
24 O
h O
. O

Furthermore O
, O
beta B
- I
cryptoxanthin I
induced O
an O
accumulation O
of O
cells O
in O
the O
G1 O
/ O
G0 O
phase O
of O
the O
cell O
cycle O
( O
as O
detected O
by O
flow O
cytometry O
) O
, O
which O
was O
in O
accordance O
with O
an O
increased O
expression O
of O
p21 O
and O
down O
regulations O
of O
cyclin O
D1 O
and O
cyclin O
E O
, O
detected O
by O
Western O
blot O
analysis O
, O
and O
beta B
- I
cryptoxanthin I
increased O
the O
mRNA O
levels O
of O
retinoic B
acid I
receptor O
beta O
( O
RAR O
beta O
) O
with O
the O
treatment O
at O
10 O
mu O
M O
for O
24 O
h O
. O

Collectively O
, O
the O
above O
findings O
suggest O
that O
beta B
- I
cryptoxanthin I
could O
be O
therapeutic O
in O
the O
treatment O
of O
stomach O
cancer O
cell O
in O
vitro O
. O

Renal O
cancer O
was O
initiated O
by O
single O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
N B
- I
nitrosodiethylamine I
( O
DEN B
200 O
mg O
/ O
kg O
BW O
body O
weight O
) O
and O
promoted O
by O
twice O
weekly O
administration O
of O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
9 O
mg O
Fe B
/ O
kg O
BW O
for O
16 O
wk O
. O

Renal O
cancer O
was O
initiated O
by O
single O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
N B
- I
nitrosodiethylamine I
( O
DEN B
200 O
mg O
/ O
kg O
BW O
body O
weight O
) O
and O
promoted O
by O
twice O
weekly O
administration O
of O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
9 O
mg O
Fe B
/ O
kg O
BW O
for O
16 O
wk O
. O

In O
the O
present O
study O
, O
we O
report O
the O
chemopreventive O
effects O
of O
chrysin B
against O
( O
Fe B
- I
NTA I
) O
induced O
renal O
oxidative O
stress O
, O
inflammation O
, O
hyperproliferative O
response O
, O
and O
two O
- O
stage O
renal O
carcinogenesis O
. O

Further O
, O
Fe B
- I
NTA I
enhances O
renal O
lipid O
peroxidation O
, O
with O
concomitant O
reduction O
in O
reduced O
glutathione B
content O
( O
GSH B
) O
, O
antioxidant O
enzymes O
, O
and O
phase O
II O
metabolizing O
enzymes O
. O

Prophylactic O
treatment O
of O
animals O
with O
chrysin B
before O
the O
administration O
of O
Fe B
- I
NTA I
was O
effective O
in O
modulating O
oxidative O
and O
renal O
injury O
markers O
and O
resulted O
in O
the O
diminution O
of O
Fe B
- I
NTA I
mediated O
injury O
. O

Prophylactic O
treatment O
of O
animals O
with O
chrysin B
before O
the O
administration O
of O
Fe B
- I
NTA I
was O
effective O
in O
modulating O
oxidative O
and O
renal O
injury O
markers O
and O
resulted O
in O
the O
diminution O
of O
Fe B
- I
NTA I
mediated O
injury O
. O

These O
results O
suggest O
chrysin B
as O
an O
effective O
chemopreventive O
agent O
having O
the O
capability O
to O
obstruct O
DEN B
initiated O
and O
Fe B
- I
NTA I
promoted O
renal O
cancer O
in O
the O
rat O
model O
. O

The O
choice O
of O
dye O
moiety O
( O
e O
. O
g O
. O
Alexa B
Fluor I
488 I
) O
, O
attachment O
point O
and O
linker O
length O
can O
alter O
the O
selectivity O
and O
potency O
of O
the O
parent O
molecule O
. O

After O
PBZ B
exposure O
for O
50 O
days O
, O
hepatic O
lipid O
droplets O
were O
enlarged O
and O
the O
hepatic O
total O
lipid O
, O
triglyceride B
, O
total O
cholesterol B
and O
free B
fatty I
acid I
content O
had O
increased O
in O
a O
dose O
dependent O
manner O
compared O
to O
the O
control O
. O

The O
mRNA O
expression O
of O
lipid O
metabolism O
associated O
genes O
such O
as O
peroxisome O
proliferator O
- O
activated O
receptors O
( O
PPARs O
) O
, O
androgen B
receptor O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
fatty B
acid I
synthesis O
, O
fatty B
acid I
bing O
protein O
4 O
, O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
and O
stearoyl B
- I
CoA I
desaturase O
were O
up O
- O
regulated O
by O
PBZ B
exposure O
. O

The O
mRNA O
expression O
of O
lipid O
metabolism O
associated O
genes O
such O
as O
peroxisome O
proliferator O
- O
activated O
receptors O
( O
PPARs O
) O
, O
androgen B
receptor O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
fatty B
acid I
synthesis O
, O
fatty B
acid I
bing O
protein O
4 O
, O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
and O
stearoyl B
- I
CoA I
desaturase O
were O
up O
- O
regulated O
by O
PBZ B
exposure O
. O

Moreover O
, O
the O
as O
- O
prepared O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
hierarchical O
nanostructures O
as O
nanoheterojunction O
photocatalysts O
exhibited O
excellent O
UV O
and O
visible O
light O
photocatalytic O
activities O
for O
the O
degradation O
of O
organic O
dyes O
( O
rhodamine B
B I
and O
methyl B
orange I
) O
and O
phenols B
( O
4 B
- I
nitrophenol I
) O
, O
remarkably O
superior O
to O
the O
TiO B
( I
2 I
) I
nanofibers O
and O
the O
SnS B
( I
2 I
) I
nanosheets O
, O
mainly O
owing O
to O
the O
photoinduced O
interfacial O
charge O
transfer O
based O
on O
the O

Immortalized O
human O
bronchial O
epithelial O
cells O
( O
16HBE14o O
- O
) O
were O
exposed O
to O
0 O
, O
130 O
, O
or O
330nM O
arsenic B
( O
as O
Na B
- I
arsenite I
) O
for O
4 O
- O
5 O
weeks O
and O
examined O
for O
wound O
repair O
efficiency O
and O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
. O

To O
better O
model O
the O
effects O
of O
arsenic B
on O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
under O
conditions O
of O
natural O
exposure O
, O
we O
cultured O
tracheal O
epithelial O
cells O
obtained O
from O
mice O
exposed O
to O
control O
or O
50 O
ppb O
Na B
- I
arsenite I
supplemented O
drinking O
water O
for O
4 O
weeks O
. O

Combination O
of O
phenylpropanoids B
with O
5 B
- I
fluorouracil I
as O
anti O
- O
cancer O
agents O
against O
human O
cervical O
cancer O
( O
HeLa O
) O
cell O
line O
. O

The O
effect O
of O
eight O
phenylpropanoids B
in O
combination O
with O
5 B
- I
fluorouracil I
against O
the O
cervical O
cancer O
cells O
( O
HeLa O
) O
is O
reported O
here O
. O

The O
cytotoxic O
activity O
of O
these O
phenylpropanoids B
against O
HeLa O
cells O
is O
in O
the O
order O
of O
eugenol B
> O
ferulic B
> O
cinnamic B
> O
caffeic B
> O
chlorogenic B
> O
p B
- I
coumaric I
> O
3 B
, I
4 I
- I
dimethoxycinnamic I
> O
2 B
, I
4 I
, I
5 I
- I
trimethoxycinnamic I
acids I
. O

Flow O
cytometry O
results O
indicated O
that O
the O
combination O
of O
eugenol B
and O
5 B
- I
fluorouracil I
increased O
the O
number O
of O
cells O
in O
the O
S O
and O
G2 O
/ O
M O
phases O
when O
compared O
to O
treatment O
with O
the O
individual O
compounds O
alone O
. O

l B
- I
DOPA I
modifies O
the O
antidepressant O
- O
like O
effects O
of O
reboxetine B
and O
fluoxetine B
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
l B
- I
DOPA I
administration O
on O
the O
effect O
elicited O
by O
antidepressants O
on O
serotonergic O
and O
noradrenergic O
neurotransmission O
. O

l B
- I
DOPA I
did O
not O
modify O
the O
basal O
neuronal O
activity O
in O
either O
the O
LC O
or O
the O
DRN O
or O
induce O
any O
change O
in O
the O
modified O
forced O
swimming O
test O
. O

However O
, O
l B
- I
DOPA I
enhanced O
the O
neuronal O
response O
to O
reboxetine B
in O
the O
LC O
and O
increased O
its O
antidepressant O
- O
like O
effects O
but O
counteracted O
the O
effect O
of O
fluoxetine B
on O
neurons O
in O
the O
LC O
and O
decreased O
its O
antidepressant O
- O
like O
effect O
. O

The O
sensitivity O
of O
neurons O
in O
the O
DRN O
to O
reboxetine B
and O
fluoxetine B
was O
not O
altered O
by O
the O
administration O
of O
l B
- I
DOPA I
. O

Taken O
together O
, O
these O
results O
indicate O
that O
l B
- I
DOPA I
modifies O
the O
effect O
of O
SSRI O
and O
NRI O
antidepressants O
in O
opposing O
ways O
. O

New O
targeted O
therapies O
include O
5 B
- I
HT I
( O
1F O
) O
receptor O
agonists O
, O
calcitonin O
gene O
- O
related O
peptide O
( O
CGRP O
) O
antagonists O
, O
nitric B
oxide I
synthetase O
inhibitors O
, O
and O
ion O
channel O
antagonists O
. O

We O
have O
synthesized O
a O
series O
of O
potent O
FAAH O
inhibitors O
encompassing O
two O
classes O
of O
N B
- I
alkyl I
- I
O I
- I
arylcarbamates I
and O
radiolabeled O
eight O
of O
them O
with O
carbon B
- I
11 I
. O

Peptide O
groups O
in O
the O
alpha O
- O
helices O
and O
the O
beta O
- O
strands O
of O
the O
dimer O
( O
the O
beta O
- O
strands O
of O
the O
monomer O
) O
experience O
strong O
and O
highly O
asymmetric O
local O
ordering O
centered O
approximately O
at O
the O
C O
( O
i O
- O
1 O
) O
( O
alpha O
) O
- O
C O
( O
i O
) O
( O
alpha O
) O
axes O
( O
N B
- I
H I
bonds O
) O
. O

N B
- I
H I
fluctuations O
occur O
on O
the O
picosecond O
time O
scale O
. O

To O
explore O
the O
hitherto O
successful O
derivatization O
of O
the O
alpha B
- I
carbon I
of O
fosmidomycin B
, O
a O
series O
of O
new O
alpha O
- O
substituted O
analogues O
was O
prepared O
. O

Both O
the O
alpha B
- I
azido I
- O
analogue O
and O
the O
alpha O
- O
hydroxylated O
analogue O
proved O
most O
promising O
, O
and O
docking O
experiments O
were O
performed O
. O

The O
synthesized O
boron B
- I
dipyrromethene I
- O
based O
fluorescence O
dyes O
have O
one O
or O
two O
sulfonate B
groups O
, O
which O
confer O
solubility O
in O
aqueous O
media O
, O
and O
a O
dinitrophenyl B
group O
as O
a O
redox O
reaction O
site O
. O

The O
discovery O
of O
potent O
and O
selective O
4 B
- I
aminothienopyridines I
as O
B O
- O
Raf O
kinase O
inhibitors O
. O

A O
series O
of O
novel O
, O
potent O
4 B
- I
aminothienopyridine I
B O
- O
Raf O
kinase O
inhibitors O
was O
designed O
and O
synthesized O
using O
knowledge O
- O
based O
design O
. O

Based O
on O
the O
presence O
of O
the O
2 B
, I
2 I
' I
- I
biphenol I
core O
, O
we O
further O
studied O
whether O
achyrofuran B
killed O
bacteria O
through O
a O
mechanism O
of O
action O
similar O
to O
that O
reported O
for O
the O
naturally O
occurring O
antibiotic O
MC21 B
- I
A I
. O

Mutant O
receptors O
were O
then O
alkylated O
with O
methanethiosulfonate B
- I
ethylammonium I
( O
MTSEA B
) O
, O
and O
binding O
inhibition O
was O
monitored O
using O
the O
CXCR4 O
antagonist O
FC131 B
[ O
cyclo B
( I
- I
D I
- I
Tyr I
( I
1 I
) I
- I
Arg I
( I
2 I
) I
- I
Arg I
( I
3 I
) I
- I
Nal I
( I
4 I
) I
- I
Gly I
( I
5 I
) I
- I
) I
] O
, O
which O
displays O
anti O
- O
HIV O
activity O
. O

Within O
the O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
, O
proteins O
belonging O
to O
the O
ALDH9 O
, O
ALDH10 O
, O
ALDH25 O
, O
ALDH26 O
and O
ALDH27 O
families O
display O
activity O
as O
omega B
- I
aminoaldehyde I
dehydrogenases O
( O
AMADHs O
) O
. O

Active O
site O
aromatic O
and O
acidic O
residues O
are O
involved O
in O
binding O
the O
omega B
- I
aminoaldehydes I
in O
plant O
ALDH10 O
enzymes O
. O

The O
present O
findings O
revealed O
that O
the O
pituitary O
mechanisms O
involved O
in O
the O
effects O
of O
EQ O
and O
FLUT B
were O
different O
due O
to O
the O
opposite O
changes O
in O
the O
mRNA O
expression O
levels O
of O
estrogen B
receptor O
subtype O
alpha O
( O
ER O
alpha O
) O
- O
, O
truncated O
estrogen B
receptor O
product O
- O
1 O
( O
TERP O
- O
1 O
) O
- O
and O
- O
2 O
( O
TERP O
- O
2 O
) O
- O
, O
gonadotropin B
releasing I
hormone I
receptor O
( O
GnRH B
receptor O
) O
- O
, O
beta O
- O
subunit O
of O
LH O
( O
LH O
beta O
) O
- O
, O
and O
gonadotropin O
alpha O
subunit O
( O
alpha O
- O
subunit O
) O
genes O
. O

The O
selective O
SYK O
inhibitor O
P505 B
- I
15 I
( O
PRT062607 B
) O
inhibits O
B O
cell O
signaling O
and O
function O
in O
vitro O
and O
in O
vivo O
and O
augments O
the O
activity O
of O
fludarabine B
in O
chronic O
lymphocytic O
leukemia O
. O

P505 B
- I
15 I
( O
also O
known O
as O
PRT062607 B
) O
is O
a O
novel O
, O
highly O
selective O
, O
and O
orally O
bioavailable O
small O
molecule O
SYK O
inhibitor O
( O
SYK O
IC O
( O
50 O
) O
= O
1 O
nM O
) O
with O
anti O
- O
SYK O
activity O
that O
is O
at O
least O
80 O
- O
fold O
greater O
than O
its O
affinity O
for O
other O
kinases O
. O

We O
evaluated O
the O
preclinical O
characteristics O
of O
P505 B
- I
15 I
in O
models O
of O
NHL O
and O
CLL O
. O

P505 B
- I
15 I
successfully O
inhibited O
SYK O
- O
mediated O
B O
- O
cell O
receptor O
signaling O
and O
decreased O
cell O
viability O
in O
NHL O
and O
CLL O
. O

In O
addition O
, O
combination O
treatment O
of O
primary O
CLL O
cells O
with O
P505 B
- I
15 I
plus O
fludarabine B
produced O
synergistic O
enhancement O
of O
activity O
at O
nanomolar O
concentrations O
. O

Our O
findings O
support O
the O
ongoing O
development O
of O
P505 B
- I
15 I
as O
a O
therapeutic O
agent O
for O
B O
- O
cell O
malignancies O
. O

Human O
stearoyl B
- I
CoA I
desaturase O
1 O
( O
SCD O
- O
1 O
) O
gene O
expression O
is O
negatively O
regulated O
by O
thyroid B
hormone I
without O
direct O
binding O
of O
thyroid B
hormone I
receptor O
to O
the O
gene O
promoter O
. O

Stearoyl B
- I
CoA I
desaturase O
- O
1 O
( O
SCD O
- O
1 O
) O
plays O
a O
pivotal O
role O
in O
an O
increase O
of O
triglyceride B
by O
an O
excess O
of O
dietary O
carbohydrate B
intake O
. O

This O
mechanism O
for O
particle O
formation O
is O
compared O
with O
the O
mechanism O
previously O
reported O
for O
the O
radiolytic O
formation O
of O
gamma B
- I
FeOOH I
nanoparticles O
. O

In O
this O
paper O
we O
present O
detailed O
dynamic O
electrochemical O
measurements O
in O
a O
flame O
plasma O
electrolyte O
in O
the O
presence O
of O
tungsten B
oxide I
salts I
. O

These O
enzymes O
convert O
proline B
residues O
within O
the O
repeat O
regions O
of O
collagen O
polypeptides O
to O
4 B
- I
hydroxyproline I
, O
a O
modification O
essential O
for O
the O
stability O
of O
the O
final O
triple O
helix O
. O

Predicting O
dislocations O
and O
grain O
boundaries O
in O
two O
- O
dimensional O
metal B
- I
disulfides I
from O
the O
first O
principles O
. O

Guided O
by O
the O
principles O
of O
dislocation O
theory O
, O
we O
use O
the O
first O
- O
principles O
calculations O
to O
determine O
the O
structure O
and O
properties O
of O
dislocations O
and O
grain O
boundaries O
( O
GB O
) O
in O
single O
- O
layer O
transition B
metal I
disulfides I
MS B
( I
2 I
) I
( O
M O
= O
Mo B
or O
W B
) O
. O

In O
sharp O
contrast O
to O
other O
two O
- O
dimensional O
materials O
( O
truly O
planar O
graphene B
and O
h B
- I
BN I
) O
, O
here O
the O
edge O
dislocations O
extend O
in O
third O
dimension O
, O
forming O
concave O
dreidel O
- O
shaped O
polyhedra O
. O

Photoresponsivity O
of O
the O
prepared O
GO B
- I
Fc I
composite O
was O
investigated O
by O
fabricating O
a O
metal O
/ O
GO B
- I
Fc I
/ O
metal O
device O
. O

Photoresponsivity O
of O
the O
prepared O
GO B
- I
Fc I
composite O
was O
investigated O
by O
fabricating O
a O
metal O
/ O
GO B
- I
Fc I
/ O
metal O
device O
. O

The O
fabricated O
device O
shows O
enhanced O
current O
density O
under O
light O
illumination O
, O
suggesting O
a O
photo O
- O
induced O
charge O
transfer O
process O
in O
the O
developed O
GO B
- I
Fc I
composite O
. O

Relative O
oral O
bioavailability O
of O
3 B
- I
MCPD I
from O
3 B
- I
MCPD I
fatty I
acid I
esters I
in O
rats O
. O

In O
order O
to O
quantify O
the O
relative O
oral O
bioavailability O
of O
3 B
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
) O
from O
3 B
- I
MCPD I
fatty I
acid I
diesters I
in O
vivo O
, O
1 B
, I
2 I
- I
dipalmitoyl I
- I
3 I
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
diester I
) O
and O
3 B
- I
MCPD I
were O
orally O
applied O
to O
rats O
in O
equimolar O
doses O
. O

In O
order O
to O
quantify O
the O
relative O
oral O
bioavailability O
of O
3 B
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
) O
from O
3 B
- I
MCPD I
fatty I
acid I
diesters I
in O
vivo O
, O
1 B
, I
2 I
- I
dipalmitoyl I
- I
3 I
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
diester I
) O
and O
3 B
- I
MCPD I
were O
orally O
applied O
to O
rats O
in O
equimolar O
doses O
. O

In O
both O
cases O
, O
the O
time O
courses O
of O
3 B
- I
MCPD I
concentrations O
were O
measured O
in O
blood O
, O
various O
organs O
, O
tissues O
and O
intestinal O
luminal O
contents O
. O

The O
results O
show O
that O
3 B
- I
MCPD I
is O
released O
by O
enzymatic O
hydrolysis O
from O
the O
3 B
- I
MCPD I
diester I
in O
the O
gastrointestinal O
tract O
and O
distributed O
to O
blood O
, O
organs O
and O
tissues O
. O

Based O
on O
the O
measurements O
in O
blood O
, O
the O
areas O
under O
the O
curve O
( O
AUC O
) O
for O
3 B
- I
MCPD I
were O
calculated O
. O

By O
comparing O
both O
AUC O
, O
the O
relative O
amount O
of O
3 B
- I
MCPD I
bioavailable O
from O
the O
3 B
- I
MCPD I
diester I
was O
calculated O
to O
be O
86 O
% O
on O
average O
of O
the O
amount O
bioavailable O
following O
administration O
of O
3 B
- I
MCPD I
. O

By O
comparing O
both O
AUC O
, O
the O
relative O
amount O
of O
3 B
- I
MCPD I
bioavailable O
from O
the O
3 B
- I
MCPD I
diester I
was O
calculated O
to O
be O
86 O
% O
on O
average O
of O
the O
amount O
bioavailable O
following O
administration O
of O
3 B
- I
MCPD I
. O

Therefore O
, O
assessment O
of O
the O
extent O
of O
exposure O
to O
3 B
- I
MCPD I
released O
from O
its O
fatty B
acid I
esters I
should O
be O
performed O
in O
the O
same O
way O
as O
exposure O
to O
the O
same O
molar O
quantity O
of O
3 B
- I
MCPD I
. O

Therefore O
, O
assessment O
of O
the O
extent O
of O
exposure O
to O
3 B
- I
MCPD I
released O
from O
its O
fatty B
acid I
esters I
should O
be O
performed O
in O
the O
same O
way O
as O
exposure O
to O
the O
same O
molar O
quantity O
of O
3 B
- I
MCPD I
. O

Therefore O
, O
assessment O
of O
the O
extent O
of O
exposure O
to O
3 B
- I
MCPD I
released O
from O
its O
fatty B
acid I
esters I
should O
be O
performed O
in O
the O
same O
way O
as O
exposure O
to O
the O
same O
molar O
quantity O
of O
3 B
- I
MCPD I
. O

Enantioresolution O
of O
chiral O
derivatives O
of O
xanthones B
on O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
and O
L B
- I
phenylglycine I
stationary O
phases O
and O
chiral O
recognition O
mechanism O
by O
docking O
approach O
for O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
. O

The O
resolution O
of O
seven O
enantiomeric O
pairs O
of O
chiral O
derivatives O
of O
xanthones B
( O
CDXs O
) O
on O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
and O
L B
- I
phenylglycine I
chiral O
stationary O
phases O
( O
CSPs O
) O
was O
systematically O
investigated O
using O
multimodal O
elution O
conditions O
( O
normal O
- O
phase O
, O
polar O
- O
organic O
, O
and O
reversed O
- O
phase O
) O
. O

Surfactant O
- O
free O
microemulsion O
composed O
of O
oleic B
acid I
, O
n B
- I
propanol I
, O
and O
H2O B
. O

Herein O
, O
we O
report O
a O
surfactant O
- O
free O
microemulsion O
( O
denoted O
as O
SFME O
) O
, O
consisting O
of O
oleic B
acid I
( O
oil O
phase O
) O
, O
water O
, O
and O
n B
- I
propanol I
without O
the O
amphiphilic O
molecular O
structure O
of O
a O
traditional O
surfactant O
. O

We O
previously O
described O
a O
chemical O
inhibitor O
of O
RAD51 O
, O
called O
RI B
- I
1 I
( O
referred O
to O
as O
compound O
1 O
in O
this O
report O
) O
. O

This O
compound O
, O
1 B
- I
( I
3 I
, I
4 I
- I
dichlorophenyl I
) I
- I
3 I
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
4 I
- I
morpholino I
- I
1H I
- I
pyrrole I
- I
2 I
, I
5 I
- I
dione I
, O
named O
RI B
- I
2 I
( O
referred O
to O
as O
compound O
7a O
in O
this O
report O
) O
, O
appears O
to O
bind O
reversibly O
to O
the O
same O
site O
on O
the O
RAD51 O
protein O
as O
does O
compound O
1 O
. O

4 B
- I
Hydroxynonenal I
( O
HNE B
) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys B
, O
His B
, O
or O
Lys B
residues O
. O

Fish O
and O
macroinvertebrate O
assemblages O
, O
fish O
biomarkers O
( O
i O
. O
e O
. O
, O
polycyclic B
aromatic I
hydrocarbon I
[ O
PAH B
] O
metabolite O
levels O
in O
white O
sucker O
[ O
Castostomus O
commersoni O
] O
and O
common O
carp O
[ O
Cyprinus O
carpio O
] O
bile O
and O
DNA O
damage O
) O
, O
sediment O
chemistry O
, O
and O
water O
quality O
were O
assessed O
at O
five O
locations O
relative O
to O
the O
primary O
source O
of O
historical O
PAH B
contamination O
- O
upstream O
( O
RM O
9 O
. O
2 O
) O
, O
adjacent O
( O
RM O
6 O
. O
5 O
) O
, O
and O
downstream O
( O
RMs O
5 O
. O
7 O
, O
4 O
. O
4 O

5 B
' I
- I
Beta I
enzylglycinyl I
- I
amiloride I
( O
UCD38B B
) O
and O
glycinyl B
- I
amiloride I
( O
UCD74A B
) O
are O
cell O
- O
permeant O
and O
cell O
- O
impermeant O
derivatives O
of O
amiloride B
, O
respectively O
, O
and O
used O
here O
to O
identify O
the O
cellular O
mechanisms O
of O
action O
underlying O
their O
antiglioma O
effects O
. O

17 B
beta I
estradiol I
regulation O
of O
connexin O
43 O
- O
based O
gap O
junction O
and O
mechanosensitivity O
through O
classical O
estrogen B
receptor O
pathway O
in O
osteocyte O
- O
like O
MLO O
- O
Y4 O
cells O
. O

We O
found O
that O
17 B
beta I
estradiol I
( O
E2 O
) O
up O
- O
regulated O
Cx43 O
, O
and O
enhanced O
GJIC O
in O
osteocyte O
- O
like O
MLO O
- O
Y4 O
cells O
in O
fluorescence O
recovery O
after O
photobleaching O
( O
FRAP O
) O
assay O
. O

Zirconium B
- O
based O
metal O
organic O
framework O
( O
Zr B
- O
MOF O
) O
, O
UiO B
- I
66 I
and O
UiO B
- I
67 I
, O
were O
synthesized O
and O
used O
as O
adsorbents O
of O
NO B
( I
2 I
) I
at O
ambient O
temperatures O
in O
either O
dry O
or O
moist O
conditions O
. O

Zirconium B
- O
based O
metal O
organic O
framework O
( O
Zr B
- O
MOF O
) O
, O
UiO B
- I
66 I
and O
UiO B
- I
67 I
, O
were O
synthesized O
and O
used O
as O
adsorbents O
of O
NO B
( I
2 I
) I
at O
ambient O
temperatures O
in O
either O
dry O
or O
moist O
conditions O
. O

While O
the O
large O
size O
of O
the O
4 B
, I
4 I
- I
benzenebiphenyldicar I
acid I
( O
BDPC B
) O
ligand O
has O
a O
positive O
impact O
on O
the O
adsorption O
of O
NO B
( I
2 I
) I
on O
UiO B
- I
67 I
in O
moist O
conditions O
, O
the O
opposite O
effect O
is O
found O
in O
dry O
conditions O
. O

The O
large O
pore O
volume O
of O
UiO B
- I
67 I
enhances O
the O
adsorption O
of O
moisture O
and O
formation O
of O
nitric B
and I
nitrous I
acids I
. O

The O
small O
pore O
sizes O
of O
UiO B
- I
66 I
favor O
the O
NO B
( I
2 I
) I
removal O
in O
dry O
conditions O
via O
dispersive O
forces O
. O

In O
this O
study O
we O
investigated O
the O
intersection O
between O
TLR4 O
- O
mediated O
inflammatory O
signaling O
and O
saturated B
fatty I
acids I
with O
regard O
to O
ceramide B
generation O
. O

Formation O
and O
infrared O
absorption O
of O
protonated B
naphthalenes I
( O
1 B
- I
C10H9 I
+ I
and O
2 B
- I
C10H9 I
+ I
) O
and O
their O
neutral O
counterparts O
in O
solid O
para B
- I
hydrogen I
. O

We O
report O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
trapped O
in O
solid O
para B
- I
hydrogen I
( O
p B
- I
H I
( I
2 I
) I
) O
; O
the O
latter O
three O
are O
new O
. O

Iodine B
- I
129 I
microdosing O
for O
protein O
and O
peptide O
drug O
development O
: O
erythropoietin O
as O
a O
case O
study O
. O

Application O
of O
a O
liquid O
chromatography O
- O
electrospray O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
method O
to O
the O
biodistribution O
and O
excretion O
studies O
of O
novel O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
( I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
) I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
in O
tumour O
- O
bearing O
mice O
. O

Novel O
betulinic B
acid I
derivative O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
[ I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
] I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
is O
a O
new O
effective O
lupane B
type O
triterpenes B
with O
greater O
anticancer O
activity O
and O
efficacy O
than O
betulinic B
acid I
and O
currently O
under O
advanced O
preclinical O
investigation O
phase O
. O

In O
this O
study O
, O
a O
sensitive O
and O
rapid O
liquid O
chromatography O
- O
electrospray O
mass O
spectrometric O
( O
LC O
/ O
MS O
) O
method O
has O
been O
developed O
for O
the O
determination O
of O
DRF B
- I
4012 I
in O
tumour O
- O
bearing O
mice O
plasma O
, O
urine O
, O
feces O
and O
tissues O
( O
liver O
, O
brain O
, O
lungs O
, O
heart O
, O
spleen O
, O
stomach O
, O
thigh O
muscle O
, O
kidneys O
, O
urinary O
bladder O
, O
small O
intestine O
and O
tumour O
) O
. O

Biodistribution O
and O
excretion O
studies O
were O
performed O
for O
DRF B
- I
4012 I
nanoparticle O
( O
30 O
mg O
/ O
kg O
body O
weight O
) O
after O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
in O
tumour O
- O
bearing O
mice O
. O

DRF B
- I
4012 I
rapidly O
distributed O
throughout O
the O
body O
. O

After O
4 O
and O
24 O
h O
, O
the O
highest O
concentration O
of O
DRF B
- I
4012 I
was O
found O
in O
tumour O
indicating O
its O
retention O
in O
tumour O
site O
for O
a O
longer O
time O
. O

Excretion O
studies O
revealed O
that O
very O
low O
amount O
of O
unchanged O
DRF B
- I
4012 I
was O
observed O
in O
urine O
and O
primarily O
excreted O
through O
fecal O
route O
. O

This O
study O
may O
be O
useful O
to O
explain O
the O
manner O
in O
which O
DRF B
- I
4012 I
can O
inhibit O
tumour O
growth O
without O
apparent O
toxicity O
and O
preclinical O
/ O
clinical O
evaluation O
of O
this O
potential O
antitumour O
agent O
. O

The O
main O
metabolic O
pathway O
of O
luotonin B
A I
in O
human O
liver O
microsomes O
was O
hydroxylation O
, O
resulting O
in O
the O
generation O
of O
two O
mono B
- I
hydroxyl I
metabolites O
( O
M1 O
and O
M2 O
) O
and O
two O
di B
- I
hydroxyl I
metabolites O
( O
M3 O
and O
M4 O
) O
. O

The O
main O
metabolic O
pathway O
of O
luotonin B
A I
in O
human O
liver O
microsomes O
was O
hydroxylation O
, O
resulting O
in O
the O
generation O
of O
two O
mono B
- I
hydroxyl I
metabolites O
( O
M1 O
and O
M2 O
) O
and O
two O
di B
- I
hydroxyl I
metabolites O
( O
M3 O
and O
M4 O
) O
. O

Central O
and O
peripheral O
administration O
of O
kisspeptin O
stimulates O
the O
hypothalamic O
- O
pituitary O
- O
gonadal O
( O
HPG O
) O
axis O
whilst O
pre O
- O
administration O
of O
a O
gonadotrophin B
releasing I
hormone I
( O
GnRH B
) O
antagonist O
abolishes O
this O
effect O
. O

Herein O
we O
describe O
a O
process O
for O
making O
hydrogels O
composed O
of O
hydroxyphenyl B
propionic I
acid I
( O
HPA B
) O
conjugated O
, O
branched O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
via O
an O
enzyme O
mediated O
, O
oxidative O
cross O
- O
linking O
method O
. O

Cross O
- O
linking O
of O
the O
PEG B
- I
HPA I
conjugate O
with O
a O
recombinantly O
produced O
Fibronectin O
fragment O
( O
Type O
III O
domains O
7 O
- O
10 O
) O
encouraged O
attachment O
and O
spreading O
of O
human O
mesenchymal O
stem O
cells O
( O
hMSCs O
) O
when O
assessed O
in O
both O
two O
- O
dimensional O
and O
three O
- O
dimensional O
formats O
. O

Interestingly O
, O
when O
encapsulated O
in O
both O
nonfunctionalized O
and O
functionalized O
cross O
- O
linked O
PEG B
- I
HPA I
gels O
, O
MSCs O
showed O
good O
viability O
over O
all O
time O
periods O
assessed O
. O

In O
SN O
and O
hippocampus O
, O
we O
detected O
increased O
oxidative O
stress O
in O
the O
neurons O
based O
on O
NeuN O
/ O
8 B
- I
OHdG I
immunofluorescence O
double O
labeling O
and O
laser O
cofocal O
microscopy O
. O

Intriguingly O
, O
SKN B
- O
mediated O
cell O
death O
was O
in O
part O
protected O
by O
necrostatin B
- I
1 I
( O
Nec B
- I
1 I
) O
, O
a O
specific O
inhibitor O
of O
programmed O
necrosis O
, O
but O
not O
zVAD O
a O
pan O
- O
caspase O
inhibitor O
. O

Intriguingly O
, O
SKN B
- O
mediated O
cell O
death O
was O
in O
part O
protected O
by O
necrostatin B
- I
1 I
( O
Nec B
- I
1 I
) O
, O
a O
specific O
inhibitor O
of O
programmed O
necrosis O
, O
but O
not O
zVAD O
a O
pan O
- O
caspase O
inhibitor O
. O

Additionally O
, O
SKN B
- O
caused O
cell O
death O
was O
reversed O
by O
a O
reactive O
oxygen B
species O
( O
ROS O
) O
scavenger O
N B
- I
acetylcysteine I
( O
NAC B
) O
whereas O
TNF O
alpha O
- O
mediated O
necrosis O
was O
successfully O
protected O
by O
butylated B
hydroxyanisole I
( O
BHA B
) O
, O
implying O
that O
ROS O
may O
be O
differentially O
derived O
from O
death O
inducing O
agents O
. O

Concurrently O
with O
the O
protective O
effect O
of O
the O
ROS O
scavenger O
or O
Nec B
- I
1 I
on O
TNF O
alpha O
or O
SKN O
, O
the O
RIP1 O
- O
RIP3 O
complex O
was O
significantly O
affected O
in O
the O
presence O
of O
those O
agents O
. O

During O
our O
recent O
search O
for O
AKR1C O
inhibitors O
, O
we O
found O
a O
cyclopentanol B
derivative O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanol I
, O
CBCP B
- I
ol I
) O
and O
its O
respective O
cyclopentanone B
counterpart O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanone I
, O
CBCP B
- I
one I
) O
that O
acted O
as O
AKR1C O
substrates O
. O

During O
our O
recent O
search O
for O
AKR1C O
inhibitors O
, O
we O
found O
a O
cyclopentanol B
derivative O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanol I
, O
CBCP B
- I
ol I
) O
and O
its O
respective O
cyclopentanone B
counterpart O
( O
2 B
- I
( I
4 I
- I
chlorobenzylidene I
) I
cyclopentanone I
, O
CBCP B
- I
one I
) O
that O
acted O
as O
AKR1C O
substrates O
. O

We O
determined O
the O
kinetic O
parameters O
KM O
, O
kcat O
and O
kcat O
/ O
KM O
for O
oxidation O
of O
CBCP B
- I
ol I
and O
reduction O
of O
CBCP B
- I
one I
by O
AKR1C O
enzymes O
in O
the O
presence O
of O
NAD B
( I
+ I
) I
/ O
NADP B
( I
+ I
) I
and O
NADH B
/ O
NADPH B
, O
respectively O
. O

We O
determined O
the O
kinetic O
parameters O
KM O
, O
kcat O
and O
kcat O
/ O
KM O
for O
oxidation O
of O
CBCP B
- I
ol I
and O
reduction O
of O
CBCP B
- I
one I
by O
AKR1C O
enzymes O
in O
the O
presence O
of O
NAD B
( I
+ I
) I
/ O
NADP B
( I
+ I
) I
and O
NADH B
/ O
NADPH B
, O
respectively O
. O

The O
catalytic O
efficiencies O
for O
the O
oxidation O
of O
CBCP B
- I
ol I
in O
the O
presence O
of O
NAD B
( I
+ I
) I
or O
NADP B
( I
+ I
) I
were O
in O
general O
higher O
when O
compared O
to O
the O
catalytic O
efficiencies O
for O
reduction O
of O
CBCP B
- I
one I
in O
the O
presence O
of O
NADH B
or O
NADPH B
. O

The O
catalytic O
efficiencies O
for O
the O
oxidation O
of O
CBCP B
- I
ol I
in O
the O
presence O
of O
NAD B
( I
+ I
) I
or O
NADP B
( I
+ I
) I
were O
in O
general O
higher O
when O
compared O
to O
the O
catalytic O
efficiencies O
for O
reduction O
of O
CBCP B
- I
one I
in O
the O
presence O
of O
NADH B
or O
NADPH B
. O

When O
NADPH B
was O
used O
, O
as O
compared O
to O
NADH B
, O
the O
reductions O
of O
CBCP B
- I
one I
by O
AKR1C1 O
, O
AKR1C2 O
and O
AKR1C3 O
were O
14 O
- O
, O
51 O
- O
and O
31 O
- O
fold O
more O
efficient O
, O
respectively O
. O

When O
comparing O
to O
oxidations O
of O
the O
well O
- O
known O
artificial O
substrates O
, O
1 B
- I
acenaphthenol I
and O
S B
- I
tetralol I
, O
we O
observed O
similar O
catalytic O
efficiencies O
as O
for O
CBCP B
- I
ol I
oxidation O
with O
NAD B
( I
+ I
) I
and O
NADP B
( I
+ I
) I
. O

When O
comparing O
to O
oxidations O
of O
the O
well O
- O
known O
artificial O
substrates O
, O
1 B
- I
acenaphthenol I
and O
S B
- I
tetralol I
, O
we O
observed O
similar O
catalytic O
efficiencies O
as O
for O
CBCP B
- I
ol I
oxidation O
with O
NAD B
( I
+ I
) I
and O
NADP B
( I
+ I
) I
. O

When O
comparing O
to O
oxidations O
of O
the O
well O
- O
known O
artificial O
substrates O
, O
1 B
- I
acenaphthenol I
and O
S B
- I
tetralol I
, O
we O
observed O
similar O
catalytic O
efficiencies O
as O
for O
CBCP B
- I
ol I
oxidation O
with O
NAD B
( I
+ I
) I
and O
NADP B
( I
+ I
) I
. O

The O
comparison O
of O
CBCP B
- I
one I
reduction O
with O
NADPH B
to O
reductions O
of O
physiological O
substrates O
revealed O
in O
general O
higher O
efficiencies O
, O
except O
for O
reduction O
of O
9 B
- I
cis I
- I
retinaldehyde I
by O
AKR1C3 O
. O

This O
NADPH B
- O
dependent O
reduction O
of O
CBCP B
- I
one I
was O
then O
used O
to O
re O
- O
evaluate O
inhibitory O
potencies O
of O
the O
known O
inhibitors O
of O
the O
target O
AKR1C3 O
and O
the O
anti O
- O
target O
AKR1C2 O
, O
medroxyprogesterone B
acetate I
and O
ursodeoxycholic B
acid I
, O
respectively O
, O
showing O
Ki O
constants O
similar O
to O
the O
reported O
values O
. O

Our O
data O
thus O
confirm O
that O
the O
new O
enzymatic O
assays O
with O
two O
cyclopentane B
substrates O
CBP B
- I
ol I
and O
CBP B
- I
one I
, O
and O
especially O
reduction O
of O
CBCP B
- I
one I
with O
NADPH B
, O
are O
appropriate O
for O
the O
evaluation O
of O
AKR1C O
inhibitors O
. O

Our O
data O
thus O
confirm O
that O
the O
new O
enzymatic O
assays O
with O
two O
cyclopentane B
substrates O
CBP B
- I
ol I
and O
CBP B
- I
one I
, O
and O
especially O
reduction O
of O
CBCP B
- I
one I
with O
NADPH B
, O
are O
appropriate O
for O
the O
evaluation O
of O
AKR1C O
inhibitors O
. O

Our O
data O
thus O
confirm O
that O
the O
new O
enzymatic O
assays O
with O
two O
cyclopentane B
substrates O
CBP B
- I
ol I
and O
CBP B
- I
one I
, O
and O
especially O
reduction O
of O
CBCP B
- I
one I
with O
NADPH B
, O
are O
appropriate O
for O
the O
evaluation O
of O
AKR1C O
inhibitors O
. O

Pretreatment O
with O
the O
nitric B
oxide I
inhibitor O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
l B
- I
NAME I
) O
reduced O
the O
locomotor O
activating O
effects O
of O
paraxanthine B
, O
but O
not O
caffeine B
. O

Finally O
, O
in O
vivo O
microdialysis O
experiments O
showed O
that O
paraxanthine B
, O
but O
not O
caffeine B
, O
significantly O
increases O
extracellular O
levels O
of O
dopamine B
in O
the O
dorsolateral O
striatum O
, O
which O
was O
blocked O
by O
l B
- I
NAME I
. O

Two O
new O
trisaccharide B
intermediates O
of O
phenylethanoid B
glycosides I
, O
peiioside B
A I
( I
1 I
) I
/ I
A I
( I
2 I
) I
( O
1a O
/ O
1b O
) O
and O
peiioside B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
n B
- I
BuOH I
fraction O
of O
MeOH B
extract O
of O
the O
stems O
of O
Callicarpa O
peii O
H O
. O
T O
. O

Among O
the O
isolated O
compounds O
, O
trans B
- I
dihydromorin I
( O
8 O
) O
, O
oxyresveratrol B
( O
9 O
) O
, O
and O
steppogenin B
( O
12 O
) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O

Selenium B
chloride I
oxide I
( O
SeCl B
( I
2 I
) I
O I
) O
was O
added O
to O
the O
EPS O
to O
synthesize O
selenium B
- O
exopolysaccharide O
( O
Se B
- O
EPS O
) O
. O

Characterization O
of O
modified O
high O
- O
amylose O
maize O
starch O
- O
alpha B
- I
naphthol I
complexes O
and O
their O
influence O
on O
rheological O
properties O
of O
wheat O
starch O
. O

In O
this O
study O
, O
chemically O
/ O
enzymatically O
modified O
high O
- O
amylose O
maize O
starches O
were O
used O
to O
make O
inclusion O
complexes O
with O
alpha B
- I
naphthol I
, O
and O
the O
physical O
properties O
of O
complexes O
and O
their O
influences O
on O
the O
rheology O
of O
wheat O
starch O
were O
characterized O
. O

This O
study O
showed O
that O
beta B
- I
CDs I
were O
the O
most O
versatile O
CDs O
and O
that O
beta B
- I
CD I
polymers O
could O
perform O
the O
controlled O
release O
of O
aroma O
compounds O
. O

This O
study O
showed O
that O
beta B
- I
CDs I
were O
the O
most O
versatile O
CDs O
and O
that O
beta B
- I
CD I
polymers O
could O
perform O
the O
controlled O
release O
of O
aroma O
compounds O
. O

Identification O
of O
xyloglucan O
endotransglucosylase O
/ O
hydrolase O
genes O
( O
XTHs O
) O
and O
their O
expression O
in O
persimmon O
fruit O
as O
influenced O
by O
1 B
- I
methylcyclopropene I
and O
gibberellic B
acid I
during O
storage O
at O
ambient O
temperature O
. O

1 B
- I
Methylcyclopropene I
( O
1 B
- I
MCP I
) O
and O
gibberellic B
acid I
( O
GA B
( I
3 I
) I
) O
treatments O
delayed O
the O
softening O
and O
ethylene B
peak O
of O
persimmon O
fruit O
, O
as O
well O
as O
suppressed O
the O
expression O
of O
both O
XTH O
genes O
, O
especially O
DKXTH1 O
. O

1 B
- I
Methylcyclopropene I
( O
1 B
- I
MCP I
) O
and O
gibberellic B
acid I
( O
GA B
( I
3 I
) I
) O
treatments O
delayed O
the O
softening O
and O
ethylene B
peak O
of O
persimmon O
fruit O
, O
as O
well O
as O
suppressed O
the O
expression O
of O
both O
XTH O
genes O
, O
especially O
DKXTH1 O
. O

Production O
of O
the O
alpha O
- O
glycosidase O
inhibitor O
1 B
- I
deoxynojirimycin I
from O
Bacillus O
species O
. O

1 B
- I
Deoxynojirimycin I
( O
DNJ B
) O
, O
a O
potent O
alpha O
- O
glycosidase O
inhibitor O
, O
has O
therapeutic O
applications O
in O
treatments O
of O
HIV O
, O
Gaucher O
' O
s O
disease O
, O
and O
diabetes O
. O

In O
a O
separate O
model O
reaction O
, O
a O
solution O
containing O
an O
equimolar O
concentration O
of O
L B
- I
asparagine I
and O
D B
- I
glucose I
showed O
a O
significant O
inhibition O
of O
acrylamide B
formation O
when O
heated O
at O
150 O
degrees O
C O
for O
30 O
min O
in O
the O
presence O
of O
vanadyl B
sulphate I
( O
VOSO B
( I
4 I
) I
) O
. O

In O
a O
separate O
model O
reaction O
, O
a O
solution O
containing O
an O
equimolar O
concentration O
of O
L B
- I
asparagine I
and O
D B
- I
glucose I
showed O
a O
significant O
inhibition O
of O
acrylamide B
formation O
when O
heated O
at O
150 O
degrees O
C O
for O
30 O
min O
in O
the O
presence O
of O
vanadyl B
sulphate I
( O
VOSO B
( I
4 I
) I
) O
. O

Determination O
of O
fluorine B
in O
milk O
samples O
via O
calcium B
- I
monofluoride I
by O
electrothermal O
molecular O
absorption O
spectrometry O
. O

In O
addition O
, O
Raman O
microspectroscopy O
demonstrated O
that O
different O
cations O
affected O
structures O
of O
aromatic B
amino I
acid I
residues O
differently O
, O
which O
indicates O
that O
cation O
- O
pi O
interactions O
play O
an O
important O
role O
in O
determination O
of O
the O
final O
structure O
of O
protein O
molecules O
. O

3 O
' O
- O
Modified O
oligodeoxyribonucleo O
for O
the O
study O
of O
2 B
- I
deoxyribose I
damage O
in O
DNA O
. O

We O
have O
synthesized O
3 O
' O
- O
modified O
oligodeoxyribonucleo O
( O
ODNs O
) O
using O
5 O
' O
- O
- O
> O
3 O
' O
' O
reverse O
' O
DNA O
synthesis O
for O
the O
study O
of O
2 B
- I
deoxyribose I
oxidative O
damage O
to O
DNA O
. O

The O
modified O
monomers O
designed O
for O
these O
studies O
all O
share O
a O
common O
feature O
, O
they O
lack O
the O
naturally O
occurring O
3 B
' I
- I
hydroxyl I
group O
found O
in O
2 B
- I
deoxyribonucleosides I
. O

Modified O
H B
- I
phosphonates I
containing O
3 B
' I
- I
phenyl I
selenides I
as O
well O
as O
saturated B
and I
unsaturated I
sugars I
were O
obtained O
and O
incorporated O
in O
ODNs B
. O

The O
present O
study O
examined O
the O
protective O
effects O
of O
ganodermanondiol B
against O
tert B
- I
butyl I
hydroperoxide I
( O
t B
- I
BHP I
) O
- O
induced O
hepatotoxicity O
. O

This O
study O
indicates O
that O
ganodermanondiol B
exhibits O
potent O
cytoprotective O
effects O
on O
t B
- I
BHP I
- O
induced O
hepatotoxicity O
in O
human O
liver O
- O
derived O
HepG2 O
cells O
, O
presumably O
through O
Nrf2 O
- O
mediated O
antioxidant O
enzymes O
and O
AMPK O
. O

We O
therefore O
investigated O
the O
effects O
of O
combinations O
of O
commonly O
abused O
stimulant O
drugs O
( O
cocaine B
, O
MDMA B
, O
3 B
, I
4 I
- I
methylenedioxyamphet I
( O
MDA B
) O
and O
meta B
- I
chlorophenylpiperazi I
( O
mCPP B
) O
) O
on O
the O
function O
of O
the O
human O
alpha O
1 O
beta O
2 O
gamma O
2 O
GABAA O
receptor O
( O
hGABAA O
- O
R O
) O
, O
expressed O
in O
Xenopus O
oocytes O
, O
using O
the O
two O
- O
electrode O
voltage O
- O
clamp O
technique O
. O

The O
antioxidant O
activity O
was O
evaluated O
by O
DPPH B
, O
ABTS B
, O
beta B
- I
carotene I
bleaching O
test O
and O
Fe B
- O
chelating O
activity O
assay O
. O

Roggiano O
peppers O
exhibited O
the O
highest O
antioxidant O
activity O
using O
beta B
- I
carotene I
bleaching O
test O
with O
IC O
( O
50 O
) O
values O
of O
38 O
. O
1 O
and O
24 O
. O
9 O
mu O
g O
/ O
mL O
for O
total O
extract O
and O
n B
- I
hexane I
fraction O
, O
respectively O
. O

Roggiano O
peppers O
exhibited O
the O
highest O
antioxidant O
activity O
using O
beta B
- I
carotene I
bleaching O
test O
with O
IC O
( O
50 O
) O
values O
of O
38 O
. O
1 O
and O
24 O
. O
9 O
mu O
g O
/ O
mL O
for O
total O
extract O
and O
n B
- I
hexane I
fraction O
, O
respectively O
. O

Expression O
profiles O
of O
hippocampal O
regenerative O
sprouting O
- O
related O
genes O
and O
their O
regulation O
by O
E B
- I
64d I
in O
a O
developmental O
rat O
model O
of O
penicillin B
- O
induced O
recurrent O
epilepticus O
. O

E B
- I
64d I
( O
a O
calpain O
and O
autophagy O
inhibitor O
) O
has O
previously O
been O
shown O
safe O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
in O
humans O
. O

In O
the O
present O
study O
, O
the O
potential O
protective O
mechanism O
of O
E B
- I
64d I
on O
hippocampal O
aberrant O
mossy O
fiber O
sprouting O
was O
examined O
in O
a O
developmental O
rat O
model O
of O
penicillin B
- O
induced O
recurrent O
epilepticus O
. O

The O
rats O
were O
randomly O
assigned O
into O
the O
control O
group O
( O
CONT1 O
) O
, O
the O
control O
plus O
E B
- I
64d I
( O
CONT2 O
) O
, O
the O
seizure O
group O
( O
EXP1 O
) O
and O
the O
seizure O
plus O
E B
- I
64d I
( O
EXP2 O
) O
. O

The O
rats O
were O
randomly O
assigned O
into O
the O
control O
group O
( O
CONT1 O
) O
, O
the O
control O
plus O
E B
- I
64d I
( O
CONT2 O
) O
, O
the O
seizure O
group O
( O
EXP1 O
) O
and O
the O
seizure O
plus O
E B
- I
64d I
( O
EXP2 O
) O
. O

E B
- I
64d I
obviously O
suppressed O
the O
aberrant O
mossy O
fiber O
sprouting O
in O
the O
supragranular O
region O
of O
dentate O
gyrus O
and O
CA3 O
subfield O
of O
hippocampus O
. O

Up O
- O
regulation O
of O
ApoE O
and O
Clusterin O
was O
blocked O
by O
pretreatment O
with O
E B
- I
64d I
both O
in O
mRNA O
and O
protein O
levels O
. O

Further O
, O
E B
- I
64d I
- O
pretreated O
seizure O
rats O
( O
EXP2 O
) O
showed O
a O
significant O
downregulation O
of O
mRNA O
expression O
of O
PRG O
- O
1 O
, O
PRG O
- O
3 O
and O
PRG O
- O
5 O
, O
cathepsin O
B O
and O
ApoE O
, O
as O
well O
as O
up O
- O
regulated O
nSMase O
and O
ANX7 O
in O
hippocampus O
when O
compared O
with O
EXP1 O
rats O
. O

The O
results O
of O
the O
present O
study O
suggest O
that O
E B
- I
64d I
, O
an O
elective O
inhibitor O
of O
calpain O
and O
autophagy O
, O
is O
potentially O
useful O
in O
the O
treatment O
of O
developmental O
seizure O
- O
induced O
brain O
damage O
both O
by O
regulating O
abnormal O
zinc B
signal O
transduction O
and O
through O
the O
modulation O
of O
altered O
lipid O
metabolism O
via O
ApoE O
/ O
clusterin O
pathway O
in O
hippocampus O
. O

Its O
dominant O
active O
constituents O
are O
anthraquinones B
including O
emodin B
, O
aloe B
- I
emodin I
, O
rhein B
, O
etc O
. O

DNA O
polymerase O
minor O
groove O
interactions O
modulate O
mutagenic O
bypass O
of O
a O
templating O
8 B
- I
oxoguanine I
lesion O
. O

A O
major O
base O
lesion O
resulting O
from O
oxidative O
stress O
is O
8 B
- I
oxo I
- I
7 I
, I
8 I
- I
dihydro I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxoG I
) O
that O
has O
ambiguous O
coding O
potential O
. O

Error O
- O
free O
DNA O
synthesis O
involves O
8 B
- I
oxoG I
adopting O
an O
anti O
- O
conformation O
to O
base O
pair O
with O
cytosine B
whereas O
mutagenic O
bypass O
involves O
8 B
- I
oxoG I
adopting O
a O
syn O
- O
conformation O
to O
base O
pair O
with O
adenine B
. O

Error O
- O
free O
DNA O
synthesis O
involves O
8 B
- I
oxoG I
adopting O
an O
anti O
- O
conformation O
to O
base O
pair O
with O
cytosine B
whereas O
mutagenic O
bypass O
involves O
8 B
- I
oxoG I
adopting O
a O
syn O
- O
conformation O
to O
base O
pair O
with O
adenine B
. O

During O
base O
excision O
repair O
of O
this O
mispair O
, O
DNA O
polymerase O
( O
pol O
) O
beta O
is O
confronted O
with O
gap O
filling O
opposite O
8 B
- I
oxoG I
. O

Kinetic O
studies O
demonstrate O
that O
this O
substitution O
results O
in O
an O
increased O
fidelity O
opposite O
8 B
- I
oxoG I
. O

Structural O
studies O
with O
R283K O
pol O
beta O
show O
that O
the O
binary O
DNA O
complex O
has O
8 B
- I
oxoG I
in O
equilibrium O
between O
anti O
- O
and O
syn O
- O
forms O
. O

In O
contrast O
to O
wild O
- O
type O
pol O
beta O
, O
the O
ternary O
complex O
of O
the O
R283K O
mutant O
with O
an O
incoming O
dATP B
- O
analogue O
and O
templating O
8 B
- I
oxoG I
resembles O
a O
G O
- O
A O
mismatched O
structure O
with O
8 B
- I
oxoG I
adopting O
an O
anti O
- O
conformation O
. O

In O
contrast O
to O
wild O
- O
type O
pol O
beta O
, O
the O
ternary O
complex O
of O
the O
R283K O
mutant O
with O
an O
incoming O
dATP B
- O
analogue O
and O
templating O
8 B
- I
oxoG I
resembles O
a O
G O
- O
A O
mismatched O
structure O
with O
8 B
- I
oxoG I
adopting O
an O
anti O
- O
conformation O
. O

These O
results O
demonstrate O
that O
the O
incoming O
nucleotide B
is O
unable O
to O
induce O
a O
syn B
- I
8 I
- I
oxoG I
conformation O
without O
minor O
groove O
DNA O
polymerase O
interactions O
that O
influence O
templating O
( O
anti O
- O
/ O
syn O
- O
equilibrium O
) O
of O
8 B
- I
oxoG I
while O
modulating O
fidelity O
. O

The O
A110V O
, O
S172L O
, O
and O
D253 O
variants O
showed O
reduced O
basal O
activity O
; O
the O
S172L O
mutant O
displayed O
a O
decrease O
in O
potency O
to O
the O
endogenous O
ligand O
L B
- I
lactate I
. O

This O
study O
assesses O
hydroxyl B
radical O
( O
OH B
) O
generation O
and O
measures O
malondialdehyde B
( O
MDA B
) O
levels O
in O
the O
cerebral O
tissue O
of O
rats O
exposed O
to O
six O
solvents O
( O
n B
- I
hexane I
, O
n B
- I
octane I
, O
toluene B
, O
n B
- I
butylbenzene I
, O
cyclohexane B
and O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
) O
. O

This O
study O
assesses O
hydroxyl B
radical O
( O
OH B
) O
generation O
and O
measures O
malondialdehyde B
( O
MDA B
) O
levels O
in O
the O
cerebral O
tissue O
of O
rats O
exposed O
to O
six O
solvents O
( O
n B
- I
hexane I
, O
n B
- I
octane I
, O
toluene B
, O
n B
- I
butylbenzene I
, O
cyclohexane B
and O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
) O
. O

This O
study O
assesses O
hydroxyl B
radical O
( O
OH B
) O
generation O
and O
measures O
malondialdehyde B
( O
MDA B
) O
levels O
in O
the O
cerebral O
tissue O
of O
rats O
exposed O
to O
six O
solvents O
( O
n B
- I
hexane I
, O
n B
- I
octane I
, O
toluene B
, O
n B
- I
butylbenzene I
, O
cyclohexane B
and O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
) O
. O

Extracellular O
MDA B
was O
quantified O
in O
microdialysates O
collected O
from O
the O
prefrontal O
cortex O
of O
rats O
exposed O
, O
6h O
/ O
day O
for O
ten O
days O
, O
to O
1000ppm O
of O
the O
solvents O
( O
except O
for O
n B
- I
butylbenzene I
, O
generated O
at O
830ppm O
) O
in O
inhalation O
chambers O
. O

On O
the O
other O
hand O
, O
a O
decrease O
in O
the O
concentrations O
of O
free O
MDA B
in O
brain O
structures O
was O
observed O
after O
acute O
administration O
of O
n B
- I
hexane I
, O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
, O
toluene B
and O
n B
- I
butylbenzene I
. O

On O
the O
other O
hand O
, O
a O
decrease O
in O
the O
concentrations O
of O
free O
MDA B
in O
brain O
structures O
was O
observed O
after O
acute O
administration O
of O
n B
- I
hexane I
, O
1 B
, I
2 I
, I
4 I
- I
trimethylcyclohexane I
, O
toluene B
and O
n B
- I
butylbenzene I
. O

The O
vasorelaxant O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
did O
not O
depend O
on O
endothelial O
layer O
integrity O
, O
and O
the O
effects O
were O
refractory O
to O
L B
- I
N I
( I
G I
) I
- I
nitroarginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
- O
induced O
nitric B
oxide I
synthase O
inhibition O
. O

Vasorelaxation O
was O
similarly O
resistant O
to O
treatment O
with O
indomethacin B
, O
cis B
- I
N I
- I
( I
2 I
- I
phenylcyclopentyl I
) I
- I
azacyclotridec I
- I
1 I
- I
en I
- I
2 I
- I
amine I
hydrochloride I
( O
MDL B
- I
12330A I
) O
, O
and O
KT5720 B
, O
indicating O
that O
neither O
prostaglandin B
release O
nor O
adenylyl B
cyclase O
activation O
is O
involved O
. O

The O
pharmacological O
blockade O
of O
K B
( I
+ I
) I
channels O
with O
tetraethylammonium B
, O
glybenclamide B
, O
and O
4 B
- I
aminopyridine I
also O
blunted O
vasorelaxation O
induced O
by O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
. O

Both O
NaZn B
1 I
3 I
- O
and O
MgZn B
2 I
- O
type O
CoFe B
2 I
O I
4 I
- O
- O
Fe B
3 I
O I
4 I
binary O
nanocrystal O
superlattices O
have O
been O
formed O
by O
the O
liquid O
- O
air O
interfacial O
assembly O
approach O
. O

The O
NaZn B
1 I
3 I
- O
type O
CoFe B
2 I
O I
4 I
- O
- O
Fe B
3 I
O I
4 I
binary O
nanocrystal O
superlattices O
annealed O
at O
500 O
degrees O
C O
even O
exhibit O
bistable O
magnetoresistance O
switching O
behavior O
at O
room O
temperature O
constituting O
a O
simple O
nonvolatile O
memory O
function O
. O

In O
this O
study O
we O
describe O
the O
effect O
of O
PDA B
- I
66 I
, O
a O
newly O
synthesised O
indolylmaleimide B
, O
showing O
a O
strong O
dose O
dependent O
anti O
- O
proliferative O
effect O
on O
immortalised O
human O
progenitor O
and O
cancer O
cells O
. O

We O
demonstrated O
a O
highly O
depolymerizing O
effect O
on O
in O
vitro O
tubulin O
assembly O
and O
conclude O
that O
PDA B
- I
66 I
acts O
as O
microtubule O
destabilising O
agent O
. O

In O
addition O
we O
found O
that O
PDA B
- I
66 I
induces O
mitotic O
arrest O
of O
cells O
in O
the O
G O
2 O
/ O
M O
phase O
of O
the O
cell O
cycle O
. O

To O
prove O
a O
potential O
anti O
- O
cancer O
activity O
of O
PDA B
- I
66 I
we O
examined O
the O
effect O
of O
PDA B
- I
66 I
on O
human O
SH O
- O
SY5Y O
neuroblastoma O
and O
A O
- O
459 O
lung O
cancer O
cells O
, O
showing O
a O
significant O
reduction O
in O
cancer O
cell O
proliferation O
in O
a O
dose O
dependent O
manner O
. O

To O
prove O
a O
potential O
anti O
- O
cancer O
activity O
of O
PDA B
- I
66 I
we O
examined O
the O
effect O
of O
PDA B
- I
66 I
on O
human O
SH O
- O
SY5Y O
neuroblastoma O
and O
A O
- O
459 O
lung O
cancer O
cells O
, O
showing O
a O
significant O
reduction O
in O
cancer O
cell O
proliferation O
in O
a O
dose O
dependent O
manner O
. O

Thus O
PDA B
- I
66 I
is O
a O
new O
anti O
- O
mitotic O
compound O
with O
an O
indole B
- O
core O
with O
the O
potential O
to O
be O
used O
for O
cancer O
therapy O
. O

alpha B
- I
Terpineol I
induces O
fatty O
liver O
in O
mice O
mediated O
by O
the O
AMP B
- O
activated O
kinase O
and O
sterol B
response O
element O
binding O
protein O
pathway O
. O

alpha B
- I
Terpineol I
is O
a O
monoterpene B
alcoholic B
component O
of O
Melaleuca O
alternifolia O
, O
Salvia O
officinalis O
and O
Carthamus O
tinctorius O
that O
is O
used O
widely O
as O
a O
flavor O
and O
essential O
oil O
in O
food O
. O

The O
present O
study O
showed O
that O
alpha B
- I
terpineol I
induces O
fatty O
liver O
via O
the O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
- O
mTOR O
- O
sterol B
regulatory O
element O
- O
binding O
protein O
- O
1 O
( O
SREBP O
- O
1 O
) O
pathway O
. O

alpha B
- I
Terpineol I
- O
treated O
hepatocytes O
had O
significantly O
increased O
neutral O
lipid O
accumulation O
. O

alpha B
- I
Terpineol I
suppressed O
AMPK O
phosphorylation O
, O
and O
increased O
p70S6 O
kinase O
( O
p70S6K O
) O
phosphorylation O
and O
SREBP O
- O
1 O
activation O
. O

Inhibition O
of O
mTOR O
signaling O
by O
co O
- O
treatment O
with O
rapamycin B
or O
co O
- O
transfection O
with O
dominant O
negative O
p70S6K O
blocked O
completely O
the O
effects O
of O
alpha B
- I
terpineol I
. O

alpha B
- I
Terpineol I
oral O
administration O
to O
mice O
for O
2weeks O
led O
to O
decreased O
AMPK O
phosphorylation O
and O
increased O
SREBP O
- O
1 O
activation O
in O
the O
liver O
, O
followed O
by O
hepatic O
lipid O
accumulation O
. O

Conversely O
, O
rapamycin B
co O
- O
treatment O
reversed O
alpha B
- I
terpineol I
- O
induced O
SREBP O
- O
1 O
activation O
and O
fatty O
liver O
in O
mice O
. O

These O
data O
provide O
evidence O
that O
alpha B
- I
terpineol I
causes O
fatty O
liver O
, O
an O
effect O
mediated O
by O
the O
AMPK O
/ O
mTOR O
/ O
SREBP O
- O
1 O
pathway O
. O

Naphthoquinones B
( O
e O
. O
g O
. O
diospyrin B
and O
7 B
- I
methyljuglone I
) O
have O
been O
shown O
to O
have O
therapeutic O
potential O
, O
particularly O
against O
Mycobacterium O
tuberculosis O
. O

Structure O
, O
stability O
and O
function O
of O
5 B
- I
chlorouracil I
modified O
A O
: O
U O
and O
G O
: O
U O
base O
pairs O
. O

The O
thymine B
analog O
5 B
- I
chlorouridine I
, O
first O
reported O
in O
the O
1950s O
as O
anti O
- O
tumor O
agent O
, O
is O
known O
as O
an O
effective O
mutagen O
, O
clastogen O
and O
toxicant O
as O
well O
as O
an O
effective O
inducer O
of O
sister O
- O
chromatid O
exchange O
. O

Importantly O
, O
3 B
- I
aminopyridine I
- I
2 I
- I
carboxaldehyde I
thiosemicarbazone I
( O
3 B
- I
AP I
) O
has O
been O
investigated O
in O
> O
20 O
phase O
I O
and O
II O
clinical O
trials O
. O

However O
, O
side O
effects O
associated O
with O
3 B
- I
AP I
administration O
include O
methemoglobinemia O
. O

Major O
findings O
include O
that O
methemoglobin O
formation O
mediated O
by O
the O
lipophilic O
t B
- I
BuBpT I
series O
was O
significantly O
( O
p O
< O
0 O
. O
05 O
- O
0 O
. O
001 O
) O
decreased O
in O
comparison O
to O
3 B
- I
AP I
in O
intact O
red O
blood O
cells O
and O
were O
generally O
comparable O
to O
the O
control O
. O

Major O
findings O
include O
that O
methemoglobin O
formation O
mediated O
by O
the O
lipophilic O
t B
- I
BuBpT I
series O
was O
significantly O
( O
p O
< O
0 O
. O
05 O
- O
0 O
. O
001 O
) O
decreased O
in O
comparison O
to O
3 B
- I
AP I
in O
intact O
red O
blood O
cells O
and O
were O
generally O
comparable O
to O
the O
control O
. O

These O
data O
indicate O
the O
t B
- I
BuBpT I
ligands O
may O
minimize O
methemoglobinemia O
, O
which O
is O
a O
marked O
advantage O
over O
3 B
- I
AP I
and O
other O
potent O
thiosemicarbazones B
. O

These O
data O
indicate O
the O
t B
- I
BuBpT I
ligands O
may O
minimize O
methemoglobinemia O
, O
which O
is O
a O
marked O
advantage O
over O
3 B
- I
AP I
and O
other O
potent O
thiosemicarbazones B
. O

A O
series O
of O
naphthyridinol B
analogs O
of O
alpha B
- I
tocopherol I
( O
alpha B
- I
TOH I
, O
right O
) O
with O
varying O
sidechain O
substitution O
was O
synthesized O
to O
determine O
how O
systematic O
changes O
in O
the O
lipophilicity O
of O
these O
potent O
antioxidants O
impact O
their O
radical O
- O
trapping O
activities O
in O
lipid O
bilayers O
, O
regenerability O
by O
water O
- O
soluble O
reductants O
, O
and O
binding O
to O
human O
tocopherol B
transport O
protein O
( O
TTP O
) O
. O

A O
series O
of O
naphthyridinol B
analogs O
of O
alpha B
- I
tocopherol I
( O
alpha B
- I
TOH I
, O
right O
) O
with O
varying O
sidechain O
substitution O
was O
synthesized O
to O
determine O
how O
systematic O
changes O
in O
the O
lipophilicity O
of O
these O
potent O
antioxidants O
impact O
their O
radical O
- O
trapping O
activities O
in O
lipid O
bilayers O
, O
regenerability O
by O
water O
- O
soluble O
reductants O
, O
and O
binding O
to O
human O
tocopherol B
transport O
protein O
( O
TTP O
) O
. O

The O
activities O
of O
the O
naphthyridinols B
were O
assayed O
in O
phosphatidylcholine B
unilamellar O
liposomes O
using O
a O
recently O
developed O
high O
- O
throughput O
assay O
that O
employs O
a O
boron B
dipyrromethene I
conjugate O
of O
alpha B
- I
TOH I
( O
H O
( O
2 O
) O
B O
- O
PMHC O
) O
that O
undergoes O
fluorescence O
enhancement O
upon O
oxidation O
. O

The O
cooperativity O
of O
a O
lipophilic O
naphthyridinol B
with O
water O
- O
soluble O
reducing O
agents O
was O
also O
studied O
in O
liposomes O
using O
H O
( O
2 O
) O
B O
- O
PMHC O
and O
revealed O
superior O
regenerability O
by O
each O
of O
ascorbate B
, O
N B
- I
acetylcysteine I
, O
and O
urate B
when O
compared O
to O
alpha B
- I
TOH I
. O

The O
cooperativity O
of O
a O
lipophilic O
naphthyridinol B
with O
water O
- O
soluble O
reducing O
agents O
was O
also O
studied O
in O
liposomes O
using O
H O
( O
2 O
) O
B O
- O
PMHC O
and O
revealed O
superior O
regenerability O
by O
each O
of O
ascorbate B
, O
N B
- I
acetylcysteine I
, O
and O
urate B
when O
compared O
to O
alpha B
- I
TOH I
. O

In O
fact O
, O
naphthyridinols B
with O
sidechains O
of O
eight O
or O
more O
carbons B
had O
affinities O
for O
TTP O
which O
were O
similar O
to O
, O
and O
in O
one O
case O
10 O
- O
fold O
better O
than O
, O
alpha B
- I
TOH I
. O

Chondroitin O
sulfate B
( O
CS O
) O
is O
a O
natural O
glycosaminoglycan O
, O
formed O
by O
the O
1 O
- O
3 O
linkage O
of O
d B
- I
glucuronic I
acid I
to O
N B
- I
acetylgalactosamine I
, O
present O
in O
the O
extracellular O
matrix O
. O

The O
case O
studied O
is O
the O
energetics O
of O
the O
water O
oxidation O
reaction O
by O
an O
iridium B
- I
oxo I
complex O
. O

The O
structure O
of O
the O
new O
brevipolide B
J I
( O
10 O
) O
was O
characterized O
through O
NMR O
and O
MS O
data O
as O
having O
the O
same O
6 B
- I
heptyl I
- I
5 I
, I
6 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
one I
framework O
possessing O
the O
cyclopropane B
moiety O
of O
all O
brevipolides B
but O
substituted O
by O
an O
isoferuloyl B
group O
instead O
of O
the O
p B
- I
methoxycinnamoyl I
moiety O
found O
in O
8 O
and O
9 O
. O

The O
inhibition O
was O
shown O
to O
be O
noncompetitive O
for O
both O
natural O
enzyme O
substrates O
( O
d B
- I
luciferin I
and O
ATP B
) O
and O
selective O
to O
FLuc O
and O
proven O
to O
arise O
from O
a O
direct O
interaction O
between O
the O
enzyme O
and O
the O
inhibitor O
. O

These O
effects O
may O
attribute O
to O
pigeon O
pea O
contained O
large O
of O
unsaturated B
fatty I
acids I
( O
UFA B
; O
C18 O
: O
2 O
) O
and O
phytosterol B
( O
beta B
- I
sitosterol I
, O
campesterol B
, O
and O
stigmasterol B
) O
. O

These O
effects O
may O
attribute O
to O
pigeon O
pea O
contained O
large O
of O
unsaturated B
fatty I
acids I
( O
UFA B
; O
C18 O
: O
2 O
) O
and O
phytosterol B
( O
beta B
- I
sitosterol I
, O
campesterol B
, O
and O
stigmasterol B
) O
. O

Moreover O
, O
the O
effects O
of O
pigeon O
pea O
on O
dyslipidemia O
were O
greater O
than O
beta B
- I
sitosterol I
administration O
( O
4 O
% O
) O
, O
suggesting O
that O
phytosterone B
in O
pigeon O
pea O
could O
prevent O
metabolic O
syndrome O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
( O
SAR O
) O
studies O
around O
the O
3 B
, I
5 I
- I
dimethylphenyl I
and O
4 B
- I
methoxyphenyl I
regions O
resulted O
in O
the O
identification O
of O
a O
novel O
series O
of O
non O
- O
peptidic O
submicromolar O
NPBWR1 O
antagonists O
based O
on O
a O
5 B
- I
chloro I
- I
4 I
- I
( I
4 I
- I
alkoxyphenoxy I
) I
- I
2 I
- I
( I
benzyl I
) I
pyridazin I
- I
3 I
( I
2H I
) I
- I
one I
chemotype O
. O

Previous O
studies O
showed O
that O
polyunsaturated B
fatty I
acids I
exhibit O
an O
anti O
- O
cancer O
effect O
in O
various O
human O
carcinoma O
cells O
, O
but O
the O
effect O
of O
docosahexaenoic B
acid I
( O
DHA B
) O
and O
linoleic B
acid I
( O
LA O
) O
on O
metastasis O
of O
breast O
cancer O
cells O
is O
not O
fully O
clarified O
. O

A O
new O
crystallographic O
structure O
is O
described O
for O
Sudan B
I I
, O
revealing O
the O
presence O
of O
intramolecular O
hydrogen B
bonds O
and O
supramolecular O
interactions O
, O
such O
as O
the O
unconventional O
C B
- I
H I
. O
. O
. O
O B
hydrogen B
bond O
type O
, O
pi O
- O
stacking O
, O
and O
charge O
- O
dipole O
interactions O
. O

The O
earlier O
broadly O
- O
used O
adamantyl B
- O
containing O
sEHI O
, O
trans B
- I
4 I
- I
[ I
4 I
- I
( I
3 I
- I
adamantan I
- I
1 I
- I
yl I
- I
ureido I
) I
- I
cyclohexyloxy I
] I
- I
benzoic I
acid I
( O
t B
- I
AUCB I
) O
, O
was O
used O
for O
comparison O
. O

Moreover O
, O
oral O
administration O
of O
TPPU B
dramatically O
reversed O
the O
shifts O
caused O
by O
LPS O
- O
challenge O
in O
plasma O
levels O
of O
inflammatory O
cytokines O
, O
epoxides B
and O
corresponding O
diols O
, O
which O
is O
more O
potent O
than O
t B
- I
AUCB I
. O

We O
evaluated O
the O
relationships O
between O
the O
plasma O
and O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
of O
cholesterol B
, O
the O
cholesterol B
precursors O
lanosterol B
, O
lathosterol B
and O
desmosterol B
, O
and O
the O
cholesterol B
elimination O
products O
24S B
- I
hydroxycholesterol I
and O
27 B
- I
hydroxycholesterol I
, O
and O
the O
CSF O
markers O
for O
AD O
pathology O
A O
beta O
1 O
- O
42 O
and O
p O
- O
tau181 O
in O
86 O
subjects O
with O
normal O
cognition O
and O
in O
107 O
AD O
patients O
. O

We O
evaluated O
the O
relationships O
between O
the O
plasma O
and O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
of O
cholesterol B
, O
the O
cholesterol B
precursors O
lanosterol B
, O
lathosterol B
and O
desmosterol B
, O
and O
the O
cholesterol B
elimination O
products O
24S B
- I
hydroxycholesterol I
and O
27 B
- I
hydroxycholesterol I
, O
and O
the O
CSF O
markers O
for O
AD O
pathology O
A O
beta O
1 O
- O
42 O
and O
p O
- O
tau181 O
in O
86 O
subjects O
with O
normal O
cognition O
and O
in O
107 O
AD O
patients O
. O

CSF O
desmosterol B
, O
cholesterol B
and O
24S B
- I
hydroxycholesterol I
in O
the O
AD O
group O
, O
and O
CSF O
24S B
- I
hydroxycholesterol I
in O
the O
control O
group O
correlated O
with O
the O
p O
- O
tau181 O
levels O
. O

CSF O
desmosterol B
, O
cholesterol B
and O
24S B
- I
hydroxycholesterol I
in O
the O
AD O
group O
, O
and O
CSF O
24S B
- I
hydroxycholesterol I
in O
the O
control O
group O
correlated O
with O
the O
p O
- O
tau181 O
levels O
. O

In O
multivariate O
regression O
tests O
including O
age O
, O
gender O
, O
albumin O
ratio O
, O
number O
of O
the O
APOE O
epsilon O
4 O
alleles O
, O
and O
diagnosis O
, O
p O
- O
tau181 O
levels O
independently O
predicted O
the O
CSF O
desmosterol B
, O
cholesterol B
and O
24S B
- I
hydroxycholesterol I
concentrations O
. O

The O
associations O
remained O
significant O
for O
CSF O
cholesterol B
and O
24S B
- I
hydroxycholesterol I
when O
analyses O
were O
separately O
performed O
in O
the O
AD O
group O
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
aqueous O
extract O
of O
Corchorus O
olitorius O
leaves O
against O
Pb B
- I
acetate I
induced O
toxic O
manifestation O
in O
blood O
, O
liver O
, O
kidney O
, O
brain O
and O
heart O
of O
Wistar O
rats O
. O

The O
Pb B
- I
acetate I
( O
5mg O
/ O
kg O
body O
weight O
) O
treated O
rats O
exhibited O
a O
significant O
inhibition O
of O
co B
- I
enzymes I
Q I
, O
antioxidant O
enzymes O
and O
reduced O
glutathione B
levels O
in O
the O
tissues O
. O

In O
addition O
, O
the O
extent O
of O
lipid O
peroxidation O
, O
DNA O
fragmentation O
and O
haematological O
parameters O
were O
significantly O
altered O
in O
the O
Pb B
- I
acetate I
treated O
rats O
as O
compared O
to O
control O
. O

Results O
show O
that O
the O
main O
components O
were O
alpha B
- I
thujone I
, O
camphor B
, O
borneol B
, O
gamma B
- I
muurolene I
and O
sclareol B
for O
all O
the O
samples O
, O
but O
the O
percentages O
of O
these O
compounds O
varied O
depending O
on O
environmental O
factors O
such O
as O
altitude O
, O
water O
availability O
and O
pedo O
- O
climatic O
conditions O
. O

Results O
show O
that O
the O
main O
components O
were O
alpha B
- I
thujone I
, O
camphor B
, O
borneol B
, O
gamma B
- I
muurolene I
and O
sclareol B
for O
all O
the O
samples O
, O
but O
the O
percentages O
of O
these O
compounds O
varied O
depending O
on O
environmental O
factors O
such O
as O
altitude O
, O
water O
availability O
and O
pedo O
- O
climatic O
conditions O
. O

Chlamydophila O
pneumoniae O
endonuclease O
IV O
prefers O
to O
remove O
mismatched O
3 B
' I
ribonucleotides I
: O
implication O
in O
proofreading O
mismatched O
3 O
' O
- O
terminal O
nucleotides B
in O
short O
- O
patch O
repair O
synthesis O
. O

Confluent O
cells O
were O
maintained O
for O
1 O
day O
in O
the O
low O
- O
zinc B
medium O
without O
GF O
, O
then O
loaded O
with O
Fluo B
- I
4 I
, O
and O
stimulated O
with O
GF O
. O

Plasmon O
dynamics O
in O
colloidal O
Au B
2 I
Cd I
alloy O
- O
CdSe B
core O
/ O
shell O
nanocrystals O
. O

Here O
we O
report O
the O
synthesis O
of O
colloidal O
Au B
2 I
Cd I
( O
core O
) O
/ O
CdSe B
( O
shell O
) O
nanocrystal O
heterostructures O
, O
which O
were O
characterized O
extensively O
with O
several O
structural O
and O
optical O
techniques O
, O
including O
time O
- O
resolved O
fluorescence O
and O
broad O
- O
band O
transient O
absorption O
spectroscopy O
( O
both O
below O
and O
above O
the O
CdSe B
band O
gap O
) O
. O

Discovery O
of O
a O
potent O
and O
selective O
free B
fatty I
acid I
receptor O
1 O
agonist O
with O
low O
lipophilicity O
and O
high O
oral O
bioavailability O
. O

The O
free B
fatty I
acid I
receptor O
1 O
( O
FFA1 O
, O
also O
known O
as O
GPR40 O
) O
mediates O
enhancement O
of O
glucose B
- O
stimulated O
insulin O
secretion O
and O
is O
emerging O
as O
a O
new O
target O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

We O
have O
previously O
reported O
the O
FFA1 O
agonist O
3 O
( O
TUG B
- I
424 I
) O
. O

The O
discovered O
synthetic O
route O
to O
introduce O
three O
different O
substituents O
independently O
paves O
the O
way O
for O
versatile O
applications O
of O
the O
7 B
- I
azaindole I
core O
. O

Aldh1l1 O
, O
also O
known O
as O
10 B
- I
formyltetrahydrofola I
dehydrogenase O
( O
FDH O
) O
, O
contains O
the O
carboxy B
- O
terminal O
domain O
( O
Ct O
- O
FDH O
) O
, O
which O
is O
a O
structural O
and O
functional O
homolog O
of O
aldehyde B
dehydrogenases O
( O
ALDHs O
) O
. O

A O
TRPA1 O
- O
specific O
antagonist O
, O
HC B
- I
030031 I
, O
was O
shown O
to O
suppress O
skin O
sensitization O
in O
the O
presence O
of O
DBP B
. O

TRPA1 O
- O
antagonist O
HC B
- I
030031 I
did O
not O
inhibit O
TRPM8 O
activation O
induced O
by O
menthol B
or O
icilin B
. O

Ab O
initio O
molecular O
dynamics O
simulation O
on O
the O
formation O
process O
of O
He B
@ O
C B
6 I
0 I
synthesized O
by O
explosion O
. O

Recently O
, O
an O
explosive O
method O
developed O
in O
our O
group O
shows O
promise O
to O
prepare O
He B
@ O
C B
6 I
0 I
at O
fairly O
high O
yield O
, O
but O
the O
mechanism O
of O
He B
inserting O
into O
C B
6 I
0 I
cage O
at O
explosive O
conditions O
was O
not O
clear O
. O

Recently O
, O
an O
explosive O
method O
developed O
in O
our O
group O
shows O
promise O
to O
prepare O
He B
@ O
C B
6 I
0 I
at O
fairly O
high O
yield O
, O
but O
the O
mechanism O
of O
He B
inserting O
into O
C B
6 I
0 I
cage O
at O
explosive O
conditions O
was O
not O
clear O
. O

Here O
, O
ab O
initio O
molecular O
dynamics O
analysis O
has O
been O
used O
to O
simulate O
the O
collision O
between O
C B
6 I
0 I
molecules O
at O
high O
- O
temperature O
and O
high O
- O
pressure O
induced O
by O
explosion O
. O

The O
results O
show O
that O
defects O
formed O
on O
the O
fullerene B
cage O
by O
collidsion O
can O
effectively O
decrease O
the O
reaction O
barrier O
for O
the O
insertion O
of O
He B
into O
C B
6 I
0 I
, O
and O
the O
self O
- O
healing O
capability O
of O
the O
defects O
was O
also O
observed O
. O

Because O
of O
its O
potent O
IAP O
inhibitory O
activities O
, O
compound O
45 O
( O
T B
- I
3256336 I
) O
caused O
tumor O
regression O
in O
a O
MDA O
- O
MB O
- O
231 O
tumor O
xenograft O
model O
( O
T O
/ O
C O
: O
- O
53 O
% O
at O
30 O
mg O
/ O
kg O
) O
. O

Claisen O
- O
Schmidt O
condensation O
reaction O
of O
4 B
- I
acetamidoacetophenon I
with O
aromatic B
aldehydes I
under O
ultrasonic O
irradiation O
affords O
acetylaminochalcones B
( O
yields O
: O
71 O
- O
90 O
% O
) O
which O
also O
under O
ultrasonic O
irradiation O
and O
in O
the O
presence O
of O
sodium B
acetate I
and O
acetic B
acid I
aqueous O
undergo O
facile O
and O
clean O
cyclocondensation O
with O
hydrazine B
to O
afford O
3 B
- I
( I
4 I
- I
acetamidophenyl I
) I
- I
5 I
- I
( I
aryl I
) I
- I
1 I
- I
H I
- I
pyrazolines I
. O

Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibitor O
TAK B
- I
441 I
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice O
. O

6 B
- I
Ethyl I
- I
N I
- I
[ I
1 I
- I
( I
hydroxyacetyl I
) I
piperidin I
- I
4 I
- I
yl I
] I
- I
1 I
- I
methyl I
- I
4 I
- I
oxo I
- I
5 I
- I
( I
2 I
- I
oxo I
- I
2 I
- I
phenylethyl I
) I
- I
3 I
- I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
- I
4 I
, I
5 I
- I
dihydro I
- I
1H I
- I
pyrrolo I
[ I
3 I
, I
2 I
- I
c I
] I
pyridine I
- I
2 I
- I
carboxamide I
( O
TAK B
- I
441 I
) O
is O
a O
potent O
, O
selective O
hedgehog O

The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK B
- I
441 I
and O
the O
responses O
of O
Gli1 O
mRNA O
in O
tumor O
- O
associated O
stromal O
or O
skin O
cells O
and O
the O
antitumor O
effect O
of O
hedgehog O
inhibition O
. O

To O
this O
end O
, O
we O
built O
pharmacokinetic O
and O
pharmacodynamic O
models O
that O
describe O
the O
relationship O
of O
the O
concentrations O
of O
TAK B
- I
441 I
plasma O
to O
the O
responses O
of O
Gli1 O
mRNA O
in O
the O
tumor O
( O
target O
) O
and O
skin O
( O
surrogate O
) O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
( O
PAN O
- O
04 O
) O
. O

The O
IC50 O
values O
for O
Gli1 O
mRNA O
inhibition O
in O
the O
tumor O
and O
skin O
by O
TAK B
- I
441 I
were O
estimated O
to O
be O
0 O
. O
0457 O
and O
0 O
. O
113 O
mu O
g O
/ O
ml O
, O
respectively O
. O

Protective O
effects O
of O
alpha B
lipoic I
acid I
versus O
N B
- I
acetylcysteine I
on O
ifosfamide B
- O
induced O
nephrotoxicity O
. O

Protective O
effects O
of O
alpha B
lipoic I
acid I
versus O
N B
- I
acetylcysteine I
on O
ifosfamide B
- O
induced O
nephrotoxicity O
. O

Therefore O
, O
this O
study O
was O
carried O
out O
to O
investigate O
the O
possible O
underlying O
mechanisms O
that O
may O
be O
involved O
in O
IFO B
- O
induced O
nephrotoxicity O
, O
including O
free O
radical O
generation O
and O
the O
possible O
role O
of O
alpha B
lipoic I
acid I
( O
ALA B
) O
versus O
N B
- I
acetylcysteine I
( O
NAC B
) O
in O
protection O
against O
this O
toxicity O
. O

Therefore O
, O
this O
study O
was O
carried O
out O
to O
investigate O
the O
possible O
underlying O
mechanisms O
that O
may O
be O
involved O
in O
IFO B
- O
induced O
nephrotoxicity O
, O
including O
free O
radical O
generation O
and O
the O
possible O
role O
of O
alpha B
lipoic I
acid I
( O
ALA B
) O
versus O
N B
- I
acetylcysteine I
( O
NAC B
) O
in O
protection O
against O
this O
toxicity O
. O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

chebuloside B
II I
, O
bellericoside B
, O
arjunetin B
, O
and O
arjunglucoside B
- I
II I
) O
could O
be O
separated O
within O
20 O
minutes O
. O

( B
99m I
) I
Tc I
labeling O
was O
performed O
by O
using O
different O
co O
- O
ligands O
: O
tricine B
and O
ethylenediamine B
diacetic I
acid I
( O
EDDA B
) O
. O

Discovering O
some O
novel O
7 B
- I
chloroquinolines I
carrying O
a O
biologically O
active O
benzenesulfonamide B
moiety O
as O
a O
new O
class O
of O
anticancer O
agents O
. O

Based O
on O
the O
reported O
anticancer O
activity O
of O
quinolines B
, O
a O
new O
series O
of O
7 B
- I
chloroquinoline I
derivatives O
bearing O
the O
biologically O
active O
benzenesulfonamide B
moiety O
2 O
- O
17 O
and O
19 O
- O
25 O
were O
synthesized O
starting O
with O
4 B
, I
7 I
- I
dichloroquinolne I
1 O
. O

Syntheses O
of O
2 B
- I
deoxy I
- I
2 I
, I
3 I
- I
didehydro I
- I
N I
- I
acetylneuraminic I
acid I
analogues O
modified O
by O
alpha B
- I
acylaminoamido I
groups O
at O
the O
C O
- O
4 O
position O
using O
isocyanide B
- O
based O
four O
- O
component O
coupling O
and O
biological O
evaluation O
as O
inhibitors O
of O
human O
parainfluenza O
virus O
type O
1 O
. O

Novel O
sialidase O
inhibitors O
11 O
having O
an O
alpha B
- I
acylaminoamido I
group O
at O
the O
C O
- O
4 O
position O
of O
Neu5Ac2en O
1 O
against O
human O
parainfluenza O
virus O
type O
1 O
( O
hPIV O
- O
1 O
) O
were O
synthesized O
using O
one O
- O
pot O
isocyanide B
- O
based O
four O
- O
component O
condensation O
, O
and O
their O
inhibitory O
activities O
against O
hPIV O
- O
1 O
sialidase O
were O
studied O
. O

DPA B
- I
713 I
is O
the O
lead O
compound O
of O
a O
recently O
reported O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidineacetamide I
series O
, O
targeting O
the O
translocator O
protein O
( O
TSPO O
18 O
kDa O
) O
, O
and O
as O
such O
, O
this O
structure O
, O
as O
well O
as O
closely O
related O
derivatives O
, O
have O
been O
already O
successfully O
used O
as O
positron O
emission O
tomography O
radioligands O
. O

On O
the O
basis O
of O
the O
pharmacological O
core O
of O
this O
ligands O
series O
, O
a O
new O
magnetic O
resonance O
imaging O
probe O
, O
coded O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
was O
designed O
and O
successfully O
synthesized O
in O
six O
steps O
and O
13 O
% O
overall O
yield O
from O
DPA B
- I
713 I
. O

The O
Gd B
- I
DOTA I
monoamide I
cage O
( O
DOTA B
= O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I
1 I
, I
4 I
, I
7 I
, I
10 I
- I
tetraacetic I
acid I
) O
represents O
the O
magnetic O
resonance O
imaging O
reporter O
, O
which O
is O
spaced O
from O
the O
phenylpyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidineacetamide I
moiety O
( O
DPA B
- I
713 I
motif O
) O
by O
a O
six O
carbon B
- O
atom O
chain O
. O

The O
good O
hydrophilicity O
of O
the O
metal O
chelate O
makes O
DPA B
- I
C I
( I
6 I
) I
- I
( I
Gd I
) I
DOTAMA I
soluble O
in O
water O
, O
affecting O
thus O
its O
biodistribution O
with O
respect O
to O
the O
parent O
lipophilic O
DPA B
- I
713 I
molecule O
. O

Whereas O
the O
meta B
- I
carbaboranyl I
- O
substituted O
derivatives O
lacked O
COX O
inhibitory O
activity O
, O
an O
ortho B
- I
carbaboranyl I
analogue O
was O
active O
, O
but O
showed O
a O
selectivity O
shift O
toward O
COX O
- O
1 O
. O

Whereas O
the O
meta B
- I
carbaboranyl I
- O
substituted O
derivatives O
lacked O
COX O
inhibitory O
activity O
, O
an O
ortho B
- I
carbaboranyl I
analogue O
was O
active O
, O
but O
showed O
a O
selectivity O
shift O
toward O
COX O
- O
1 O
. O

This O
publication O
uses O
both O
steady O
- O
state O
and O
time O
- O
resolved O
2 B
- I
aminopurine I
fluorescence O
to O
show O
pronounced O
unwinding O
of O
primer O
- O
templates O
with O
Pyrococcus O
furiosus O
( O
Pfu O
) O
polymerase O
- O
DNA O
complexes O
containing O
uracil B
at O
+ O
2 O
; O
much O
less O
strand O
separation O
is O
seen O
with O
uracil B
at O
+ O
4 O
. O

M247 O
appears O
to O
be O
unimportant O
, O
but O
2 B
- I
aminopurine I
fluorescence O
measurements O
show O
that O
Y261 O
plays O
a O
role O
in O
primer O
- O
template O
strand O
separation O
. O

However O
, O
at O
high O
concentrations O
( O
= O
~ O
0 O
. O
2 O
mg O
/ O
mL O
) O
, O
( B
1 I
) I
H I
NMR O
and O
DOSY O
measurements O
confirmed O
that O
irradiating O
BBS B
at O
350 O
nm O
induced O
a O
conversion O
from O
the O
trans B
- I
BBS I
into O
its O
cis O
isomer O
by O
photoisomerization O
. O

Synthesis O
and O
dual O
biological O
effects O
of O
hydroxycinnamoyl B
phenylalanyl I
/ O
prolyl B
hydroxamic I
acid I
derivatives O
as O
tyrosinase O
inhibitor O
and O
antioxidant O
. O

Here O
, O
various O
hydroxycinnamic B
acid I
( O
HCA B
) O
derivatives O
were O
further O
conjugated O
with O
phenylalanyl B
hydroxamic I
acid I
and O
prolyl B
hydroxamic I
acid I
( O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
) O
to O
study O
the O
structure O
and O
activity O
relationship O
as O
both O
antioxidants O
and O
tyrosinase O
inhibitors O
. O

Here O
, O
various O
hydroxycinnamic B
acid I
( O
HCA B
) O
derivatives O
were O
further O
conjugated O
with O
phenylalanyl B
hydroxamic I
acid I
and O
prolyl B
hydroxamic I
acid I
( O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
) O
to O
study O
the O
structure O
and O
activity O
relationship O
as O
both O
antioxidants O
and O
tyrosinase O
inhibitors O
. O

In O
this O
context O
, O
it O
has O
been O
postulated O
that O
the O
uptake O
of O
toxic O
substances O
formed O
during O
meat O
and O
fish O
processing O
such O
as O
heterocyclic B
aromatic I
amines I
( O
HCAs B
) O
may O
be O
causally O
related O
to O
colon O
carcinogenesis O
. O

2 B
- I
Aminophenethyl I
analogs O
demonstrate O
excellent O
potency O
but O
moderate O
kinase O
selectivity O
, O
while O
2 B
- I
aminobenzyl I
analogs O
that O
fill O
the O
Ala571 O
subpocket O
exhibit O
good O
inhibition O
activity O
and O
excellent O
kinase O
selectivity O
. O

2 B
- I
Aminophenethyl I
analogs O
demonstrate O
excellent O
potency O
but O
moderate O
kinase O
selectivity O
, O
while O
2 B
- I
aminobenzyl I
analogs O
that O
fill O
the O
Ala571 O
subpocket O
exhibit O
good O
inhibition O
activity O
and O
excellent O
kinase O
selectivity O
. O

The O
results O
obtained O
show O
that O
laur B
- I
HyT I
has O
a O
protective O
antioxidant O
effect O
against O
H2O2 B
treatment O
, O
greater O
than O
HyT B
, O
so O
having O
a O
role O
in O
the O
prevention O
of O
apoptotic O
death O
in O
normal O
and O
tumor O
cells O
. O

In O
rat O
kidney O
slices O
, O
uptake O
of O
entecavir B
was O
markedly O
inhibited O
by O
p B
- I
aminohippurate I
, O
benzylpenicillin B
, O
JBP485 B
, O
and O
tetraethyl B
ammonium I
. O

In O
hOAT1 O
- O
and O
hOAT3 O
- O
HEK293 O
cells O
, O
uptake O
of O
entecavir B
was O
significantly O
higher O
compared O
to O
vector O
- O
HEK293 O
cells O
and O
was O
markedly O
inhibited O
by O
p B
- I
aminohippurate I
, O
benzylpenicillin B
, O
and O
JBP485 B
. O

The O
present O
study O
employs O
an O
in O
vivo O
MMR O
assay O
developed O
in O
our O
laboratory O
to O
assess O
how O
prevalent O
environmental O
carcinogens O
such O
as O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
affect O
MMR O
activity O
in O
human O
breast O
carcinoma O
cells O
. O

We O
found O
that O
only O
the O
presence O
of O
a O
polyphenolic B
moiety O
anchored O
to O
the O
beta B
- I
lactam I
ring O
ensured O
an O
adequate O
antioxidant O
potency O
. O

By O
dissecting O
S1 O
, O
we O
identified O
the O
compound O
4 O
with O
a O
2 B
- I
hydroxypyridine I
core O
as O
the O
starting O
fragment O
. O

A O
physiologically O
based O
pharmacokinetic O
model O
for O
the O
oxime B
TMB B
- I
4 I
: O
simulation O
of O
rodent O
and O
human O
data O
. O

The O
current O
U O
. O
S O
. O
military O
and O
civilian O
oxime B
countermeasure O
, O
2 B
- I
[ I
( I
hydroxyimino I
) I
methyl I
] I
- I
1 I
- I
methylpyridin I
- I
1 I
- I
ium I
chloride I
( O
2 B
- I
PAM I
) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase O
reactivator O
, O
1 B
, I
1 I
' I
- I
methylenebis I
{ I
4 I
- I
hydroxyiminomethyl I
} I
pyridinium I
dimethanesulfonate I
( O
MMB B
- I
4 I
) O
. O

The O
current O
U O
. O
S O
. O
military O
and O
civilian O
oxime B
countermeasure O
, O
2 B
- I
[ I
( I
hydroxyimino I
) I
methyl I
] I
- I
1 I
- I
methylpyridin I
- I
1 I
- I
ium I
chloride I
( O
2 B
- I
PAM I
) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase O
reactivator O
, O
1 B
, I
1 I
' I
- I
methylenebis I
{ I
4 I
- I
hydroxyiminomethyl I
} I
pyridinium I
dimethanesulfonate I
( O
MMB B
- I
4 I
) O
. O

Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB B
- I
4 I
are O
limited O
; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
( O
PBPK O
) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime B
, O
1 B
, I
1 I
' I
- I
trimethylenebis I
{ I
4 I
- I
hydroximinomethyl I
} I
pyridinium I
dibromide I
. O

Rheological O
measurement O
was O
employed O
to O
study O
the O
mutarotation O
of O
D B
- I
fructose I
in O
anhydrous O
state O
. O

Optimized O
formulation O
PTSso O
and O
commercial O
formulation O
Ciplar B
LA I
80 I
were O
subjected O
to O
bioavailability O
studies O
in O
healthy O
human O
volunteers O
by O
estimating O
pharmacokinetic O
parameters O
such O
as O
C O
( O
max O
) O
, O
T O
( O
max O
) O
, O
area O
under O
curve O
( O
AUC O
) O
( O
, O
) O
elimination O
rate O
constant O
( O
K O
( O
el O
) O
) O
, O
biological O
half O
- O
life O
( O
t O
( O
1 O
/ O
2 O
) O
) O
and O
mean O
residence O
time O
( O
MRT O
) O
. O

There O
was O
a O
significant O
increase O
in O
the O
bioavailability O
of O
the O
propranolol B
HCl I
from O
PTSso O
formulation O
, O
which O
was O
evident O
from O
increased O
AUC O
levels O
and O
larger O
MRT O
values O
than O
Ciplar B
LA I
80 I
. O

A O
series O
of O
surface O
characterization O
experiments O
were O
performed O
to O
ensure O
a O
good O
understanding O
of O
the O
gold B
- I
thiol I
bond O
stability O
in O
a O
caustic O
solution O
. O

Ordered O
mesoporous O
boron B
- I
doped I
carbons I
( O
BOMCs O
) O
were O
prepared O
by O
co O
- O
impregnation O
and O
carbonization O
of O
sucrose B
and O
4 B
- I
hydroxyphenylboronic I
acid I
into O
SBA B
- I
15 I
silica B
template O
. O

The O
inhibitory O
effects O
of O
tobacco O
extracts O
on O
platelet O
adhesion O
were O
independent O
of O
nicotine B
content O
and O
the O
nitric B
- I
oxide I
- O
pathway O
and O
not O
mediated O
through O
a O
platelet O
- O
nicotine B
- O
receptor O
. O

ICA B
- I
105574 I
interacts O
with O
a O
common O
binding O
site O
to O
elicit O
opposite O
effects O
on O
inactivation O
gating O
of O
EAG O
and O
ERG O
potassium B
channels O
. O

ICA B
- I
105574 I
( O
ICA B
, O
or O
3 B
- I
nitro I
- I
N I
- I
[ I
4 I
- I
phenoxyphenyl I
] I
- I
benzamide I
) O
has O
opposite O
effects O
on O
inactivation O
of O
these O
two O
channel O
types O
. O

The O
pharmacology O
of O
L B
- I
DOPA I
- O
induced O
dyskinesia O
in O
Parkinson O
' O
s O
disease O
. O

L B
- I
3 I
, I
4 I
- I
Dihydroxyphenylalani I
( O
L B
- I
DOPA I
) O
remains O
the O
most O
effective O
symptomatic O
treatment O
of O
Parkinson O
' O
s O
disease O
( O
PD O
) O
. O

However O
, O
long O
- O
term O
administration O
of O
L B
- I
DOPA I
is O
marred O
by O
the O
emergence O
of O
abnormal O
involuntary O
movements O
, O
i O
. O
e O
. O
, O
L B
- I
DOPA I
- O
induced O
dyskinesia O
( O
LID O
) O
. O

However O
, O
long O
- O
term O
administration O
of O
L B
- I
DOPA I
is O
marred O
by O
the O
emergence O
of O
abnormal O
involuntary O
movements O
, O
i O
. O
e O
. O
, O
L B
- I
DOPA I
- O
induced O
dyskinesia O
( O
LID O
) O
. O

In O
order O
to O
assess O
whether O
caffeine B
and O
theophylline B
have O
the O
same O
potency O
and O
efficacy O
to O
reverse O
the O
impairment O
of O
motor O
function O
caused O
by O
acute O
or O
chronic O
interruption O
of O
striatal O
dopamine B
transmission O
, O
a O
comparison O
of O
their O
dose O
- O
response O
relationship O
was O
made O
in O
the O
acute O
model O
of O
haloperidol B
- O
induced O
catalepsy O
, O
and O
the O
chronic O
model O
of O
unilateral O
lesion O
of O
the O
dopamine B
nigrostriatal O
pathway O
with O
6 B
- I
hydroxydopamine I
. O

Folic B
acid I
modified O
cationic O
gamma B
- I
cyclodextrin I
- O
oligoethylenimine B
star O
polymer O
with O
bioreducible O
disulfide B
linker O
for O
efficient O
targeted O
gene O
delivery O
. O

Herein O
, O
we O
demonstrate O
a O
design O
and O
synthesis O
of O
a O
new O
star O
- O
shaped O
cationic O
polymer O
containing O
a O
gamma B
- I
cyclodextrin I
( O
gamma B
- I
CD I
) O
core O
and O
multiple O
oligoethylenimine B
( O
OEI B
) O
arms O
with O
folic B
acid I
( O
FA O
) O
linked O
by O
a O
bioreducible O
disulfide B
bond O
for O
efficient O
targeted O
gene O
delivery O
. O

Herein O
, O
we O
demonstrate O
a O
design O
and O
synthesis O
of O
a O
new O
star O
- O
shaped O
cationic O
polymer O
containing O
a O
gamma B
- I
cyclodextrin I
( O
gamma B
- I
CD I
) O
core O
and O
multiple O
oligoethylenimine B
( O
OEI B
) O
arms O
with O
folic B
acid I
( O
FA O
) O
linked O
by O
a O
bioreducible O
disulfide B
bond O
for O
efficient O
targeted O
gene O
delivery O
. O

Because O
sumatriptan B
decreases O
5 B
- I
HT I
release O
into O
the O
extracellular O
space O
, O
the O
potentiation O
of O
SPST O
- O
induced O
fear O
caused O
by O
the O
drug O
supports O
the O
hypothesis O
that O
5 B
- I
HT I
attenuates O
this O
emotional O
state O
. O

Because O
sumatriptan B
decreases O
5 B
- I
HT I
release O
into O
the O
extracellular O
space O
, O
the O
potentiation O
of O
SPST O
- O
induced O
fear O
caused O
by O
the O
drug O
supports O
the O
hypothesis O
that O
5 B
- I
HT I
attenuates O
this O
emotional O
state O
. O

As O
acute O
administration O
of O
antidepressants O
has O
also O
been O
shown O
to O
enhance O
speaking O
fear O
and O
increase O
plasma O
prolactin O
, O
in O
contrast O
to O
sumatriptan B
, O
the O
5 B
- I
HT I
regulation O
of O
stress O
- O
hormone O
release O
is O
likely O
to O
be O
different O
from O
that O
of O
emotion O
. O

A O
series O
of O
3 B
- I
[ I
( I
4 I
- I
substituted I
- I
benzylidene I
) I
- I
amino I
] I
- I
2 I
- I
phenyl I
- I
3H I
- I
quinazolin I
- I
4 I
- I
ones I
( O
5a O
- O
k O
) O
were O
synthesized O
by O
reacting O
3 B
- I
amino I
- I
2 I
- I
phenyl I
- I
1H I
- I
quinazolin I
- I
4 I
- I
one I
with O
p B
- I
hydroxybenzaldehyde I
, O
and O
then O
further O
with O
various O
alkyl B
/ I
benzyl I
halides I
or O
substituted O
phenacyl B
bromides I
. O

Only O
few O
extracellular O
targets O
of O
Trx O
- O
mediated O
thiol B
- I
disulfide I
exchange O
are O
known O
. O

Its O
pathogenesis O
is O
complex O
, O
and O
involves O
a O
state O
of O
' O
lipotoxicity O
' O
in O
which O
insulin O
resistance O
, O
with O
increased O
free B
fatty I
acid I
release O
from O
adipose O
tissue O
to O
the O
liver O
, O
play O
a O
key O
role O
in O
the O
onset O
of O
a O
' O
lipotoxic O
liver O
disease O
' O
and O
its O
progression O
to O
NASH O
. O

Bile B
- I
acid I
- O
based O
drugs O
targeting O
nuclear O
receptors O
are O
in O
clinical O
trials O
for O
treating O
cholestatic O
liver O
diseases O
and O
fatty O
liver O
disease O
. O

From O
our O
chemical O
bonding O
analysis O
, O
we O
concluded O
that O
the O
2D O
- O
3D O
transition O
occurs O
at O
B B
( I
6 I
) I
H I
( I
4 I
) I
( I
- I
) I
because O
the O
addition O
of O
one O
extra O
hydrogen B
atom O
further O
destroys O
the O
network O
of O
the O
peripheral O
2c O
- O
2e O
B B
- I
B I
sigma O
- O
bonding O
, O
making O
planar O
structures O
less O
stable O
, O
and O
because O
the O
distorted O
octahedral O
structure O
provides O
some O
occupation O
of O
all O
s O
- O
and O
p O
- O
AOs O
of O
boron B
, O
avoiding O
the O
presence O
of O
any O
empty O
atomic O
orbitals O
. O

A O
cooperative O
Jahn O
- O
Teller O
distortion O
is O
formed O
by O
an O
ordering O
of O
the O
longest O
Mn B
- I
O I
bonds O
between O
two O
neighboring O
octahedra O
along O
the O
chain O
direction O
. O

Furthermore O
, O
the O
potential O
of O
ANP O
in O
terms O
of O
blood O
glucose B
homeostasis O
was O
explored O
using O
cyclic B
adenosine I
monophosphate I
( O
cAMP B
) O
/ O
dexamethasone B
stimulated O
primary O
mouse O
hepatocytes O
and O
multiple O
low O
dose O
streptozocin B
( O
MLD O
- O
STZ B
) O
treated O
mice O
. O

With O
the O
primary O
hepatocytes O
, O
ANP O
dose O
- O
dependently O
inhibited O
gluconeogenesis O
and O
reduced O
the O
mRNA O
expression O
of O
two O
gluconeogenic O
key O
enzymes O
, O
phosphoenol B
- I
pyruvate I
carboxykinase O
( O
PEPCK O
) O
and O
glucose B
- O
6 O
- O
phosphatase O
( O
G6Pase O
) O
. O

Pinosylvin B
, O
a O
naturally O
occurring O
trans B
- I
stilbenoid I
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O

Administration O
of O
the O
optimized O
beta B
- I
Lapachone I
- O
poloxamer B
- O
cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model O
. O

beta B
- I
Lapachone I
( O
beta B
- I
Lap I
) O
is O
a O
1 B
, I
2 I
- I
orthonaphthoquinone I
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
- O
1 O
( O
NQO1 O
) O
. O

beta B
- I
Lapachone I
( O
beta B
- I
Lap I
) O
is O
a O
1 B
, I
2 I
- I
orthonaphthoquinone I
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
- O
1 O
( O
NQO1 O
) O
. O

However O
, O
the O
low O
solubility O
and O
non O
- O
specific O
distribution O
of O
beta B
- I
Lap I
limit O
its O
suitability O
for O
clinical O
assays O
. O

We O
formulated O
beta B
- I
Lap I
in O
an O
optimal O
random O
methylated B
- I
beta I
- I
cyclodextrin I
/ O
poloxamer B
407 I
mixture O
( O
i O
. O
e O
. O
, O
beta B
- I
Lap I
ternary O
system O
) O
and O
, O
using O
human O
breast O
adenocarcinoma O
MCF O
- O
7 O
cells O
and O
immunodeficient O
mice O
, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti O
- O
tumor O
effects O
on O
proliferation O
, O
cell O
cycle O
, O
apoptosis O
, O
DNA O
damage O
, O
and O
tumor O
growth O
. O

We O
formulated O
beta B
- I
Lap I
in O
an O
optimal O
random O
methylated B
- I
beta I
- I
cyclodextrin I
/ O
poloxamer B
407 I
mixture O
( O
i O
. O
e O
. O
, O
beta B
- I
Lap I
ternary O
system O
) O
and O
, O
using O
human O
breast O
adenocarcinoma O
MCF O
- O
7 O
cells O
and O
immunodeficient O
mice O
, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti O
- O
tumor O
effects O
on O
proliferation O
, O
cell O
cycle O
, O
apoptosis O
, O
DNA O
damage O
, O
and O
tumor O
growth O
. O

Administration O
of O
beta B
- I
Lap I
ternary O
system O
to O
MCF O
- O
7 O
cells O
induces O
an O
increase O
in O
apoptosis O
and O
DNA O
damage O
, O
while O
producing O
no O
changes O
in O
cell O
cycle O
. O

DHPG B
outward O
current O
was O
also O
blocked O
by O
ryanodine B
and O
2 B
- I
aminoethoxydiphenylb I
, O
suggesting O
mediation O
by O
ryanodine B
- O
and O
inositol B
1 I
, I
4 I
, I
5 I
- I
triphosphate I
- O
sensitive O
Ca B
( I
2 I
+ I
) I
release O
. O

To O
investigate O
the O
toxicological O
relevance O
of O
these O
findings O
, O
we O
tested O
the O
effects O
of O
19 B
- I
epi I
- I
OKA I
on O
cultured O
cerebellar O
cells O
and O
compared O
them O
with O
those O
of O
OKA B
and O
its O
isomer O
dinophysistoxin B
- I
2 I
. O

The O
concentration O
of O
19 B
- I
epi I
- I
OKA I
that O
reduced O
after O
24h O
the O
maximum O
neuronal O
survival O
( O
EC5024 O
) O
by O
50 O
% O
was O
~ O
300nM O
compared O
with O
~ O
2nM O
and O
~ O
8nM O
for O
OKA B
and O
dinophysistoxin B
- I
2 I
, O
respectively O
. O

19 B
- I
epi I
- I
OKA I
induced O
apoptotic O
condensation O
and O
fragmentation O
of O
chromatin O
, O
activation O
of O
caspases O
, O
and O
activation O
of O
ERK1 O
/ O
2 O
MAP O
kinases O
, O
features O
previously O
reported O
for O
OKA B
and O
dinophysistoxin B
- I
2 I
. O

Also O
, O
differential O
sensitivity O
to O
19 B
- I
epi I
- I
OKA I
was O
observed O
between O
neuronal O
and O
glial O
cells O
, O
a O
specific O
characteristic O
shared O
by O
OKA B
and O
dinophysistoxin B
- I
2 I
but O
not O
by O
other O
toxins O
. O

5 B
- I
Hydroxytryptamine I
type O
7 O
receptor O
neuroprotection O
against O
NMDA B
- O
induced O
excitotoxicity O
is O
PDGF O
beta O
receptor O
dependent O
. O

The O
serotonin B
( O
5 B
- I
HT I
) O
type O
7 O
receptor O
is O
expressed O
throughout O
the O
CNS O
including O
the O
hippocampus O
. O

Treatment O
with O
anagliptin B
for O
16 O
wk O
significantly O
reduced O
accumulation O
of O
monocytes O
and O
macrophages O
in O
the O
vascular O
wall O
, O
SMC O
content O
in O
plaque O
areas O
, O
and O
oil B
red I
O I
- O
stained O
area O
around O
the O
aortic O
valve O
without O
affecting O
glucose B
tolerance O
or O
body O
weight O
. O

Prevalent O
use O
of O
bisphenol B
- I
A I
( O
BPA B
) O
in O
the O
manufacture O
of O
resins O
, O
plastics O
and O
paper O
products O
has O
led O
to O
frequent O
exposure O
of O
most O
people O
to O
this O
endocrine O
disruptor O
. O

Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
( O
CYP3A O
) O
in O
rats O
using O
dexamethasone B
21 I
- I
phosphate I
( O
DEX B
- I
P I
) O
and O
midazolam B
( O
MDZ B
) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O

2 O
. O
The O
number O
of O
times O
DEX B
- I
P I
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A O
; O
however O
, O
administration O
of O
DEX B
- I
P I
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX B
- I
P I
by O
self O
- O
induction O
of O
CYP3A O
. O

2 O
. O
The O
number O
of O
times O
DEX B
- I
P I
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A O
; O
however O
, O
administration O
of O
DEX B
- I
P I
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX B
- I
P I
by O
self O
- O
induction O
of O
CYP3A O
. O

2 O
. O
The O
number O
of O
times O
DEX B
- I
P I
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A O
; O
however O
, O
administration O
of O
DEX B
- I
P I
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX B
- I
P I
by O
self O
- O
induction O
of O
CYP3A O
. O

3 O
. O
CYP3A O
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX B
- I
P I
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX B
- I
P I
. O

3 O
. O
CYP3A O
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX B
- I
P I
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX B
- I
P I
. O

4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX B
- I
P I
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX B
- I
P I
administration O
. O

4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX B
- I
P I
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX B
- I
P I
administration O
. O

We O
suppose O
that O
there O
are O
some O
enzymes O
responsible O
for O
converting O
intermediate O
JI B
- I
20A I
to O
3 O
' O
, O
4 O
' O
- O
bisdehydroxylated O
final O
product O
gentamicin B
C I
( O
1a O
) O
, O
while O
phosphorylation O
of O
3 B
' I
- I
OH I
is O
possibly O
the O
first O
step O
for O
C O
- O
3 O
' O
dehydroxylation O
. O

Elucidation O
of O
NMR O
data O
of O
phosphorylated B
kanamycin I
B I
has O
unambiguously O
demonstrated O
a O
regiospecific O
phosphorylation O
of O
3 B
' I
- I
hydroxyl I
of O
the O
6 B
- I
aminohexose I
ring O
. O

Elucidation O
of O
NMR O
data O
of O
phosphorylated B
kanamycin I
B I
has O
unambiguously O
demonstrated O
a O
regiospecific O
phosphorylation O
of O
3 B
' I
- I
hydroxyl I
of O
the O
6 B
- I
aminohexose I
ring O
. O

The O
dehydration O
mechanisms O
for O
glucose B
in O
beta B
- I
pyranose I
( O
BP O
) O
and O
in O
open O
- O
chain O
( O
OC O
) O
forms O
, O
catalyzed O
by O
acids O
homogeneously O
and O
heterogeneously O
, O
were O
investigated O
using O
density O
functional O
and O
two O
- O
layer O
ONIOM O
calculations O
. O

An O
aqueous O
self O
- O
assembled O
micellar O
system O
( O
sodium B
dodecyl I
sulfate I
, O
SDS B
, O
decorated O
with O
various O
adhesive O
sites O
, O
cryptand B
Kryptofix B
222 I
and O
crown B
ether I
18 B
- I
Crown I
- I
6 I
molecules O
) O
has O
been O
investigated O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
and O
small O
angle O
x O
- O
ray O
scattering O
( O
SAXS O
) O
to O
have O
insights O
into O
the O
micellar O
structure O
, O
the O
micellar O
interactions O
, O
and O
the O
aggregation O
properties O
of O
the O
system O
. O

Personality O
and O
the O
acute O
subjective O
effects O
of O
d B
- I
amphetamine I
in O
humans O
. O

Here O
, O
we O
extend O
previous O
findings O
by O
examining O
personality O
measures O
in O
relation O
to O
acute O
responses O
to O
d B
- I
amphetamine I
( O
AMPH B
) O
in O
a O
large O
sample O
of O
healthy O
volunteers O
. O

Second O
, O
ICRF B
- I
187 I
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2 O
beta O
, O
specifically O
sensitized O
MEFs O
to O
CPT B
. O

Together O
with O
twelve O
known O
compounds O
( O
2 O
- O
13 O
) O
, O
melodamide B
A I
( O
1 O
) O
, O
a O
new O
phenolic B
amide I
possessing O
p B
- I
quinol I
moiety O
, O
was O
purified O
and O
characterized O
from O
the O
methanolic O
extracts O
of O
the O
leaves O
of O
Melodorum O
fruticosum O
. O

The O
effects O
of O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
and O
recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
on O
the O
viability O
of O
tumor O
cell O
lines O
with O
a O
distinct O
potential O
of O
growth O
from O
the O
same O
tissue O
were O
compared O
to O
those O
of O
the O
clinical O
cytotoxic O
drug O
5 B
- I
fluorouracil I
. O

At O
12 O
. O
5 O
micro O
M O
concentration O
, O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
and O
recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
were O
more O
efficient O
than O
5 B
- I
fluorouracil I
in O
inhibiting O
MKN O
- O
28 O
and O
Hs746T O
( O
gastric O
) O
, O
HCT116 O
and O
HT29 O
( O
colorectal O
) O
, O
SkBr O
- O
3 O
and O
MCF O
- O
7 O
( O
breast O
) O
, O
and O
THP O
- O
1 O
and O
K562 O
( O
leukemia O
) O
cell O
lines O
. O

Recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
and O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
, O
even O
at O
high O
doses O
, O
did O
not O
affect O
hMSC O
proliferation O
while O
5 B
- I
fluorouracil I
greatly O
reduced O
the O
proliferation O
rates O
of O
hMSCs O
. O

Therefore O
, O
both O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
and O
recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
might O
be O
considered O
for O
further O
studies O
to O
block O
peptidase O
activities O
in O
order O
to O
target O
specific O
peptidase O
- O
mediated O
growth O
and O
invasion O
characteristics O
of O
individual O
tumors O
, O
mainly O
in O
patients O
resistant O
to O
5 B
- I
fluorouracil I
chemotherapy O
. O

Mass O
spectrometry O
method O
to O
identify O
aging O
pathways O
of O
Sp B
- I
and I
Rp I
- I
tabun I
adducts O
on O
human O
butyrylcholinesteras O
based O
on O
the O
acid O
labile O
P B
- I
N I
bond O
. O

We O
began O
by O
studying O
the O
tetraisopropyl B
pyrophosphoramide I
adduct O
of O
BChE O
because O
this O
adduct O
has O
two O
P B
- I
N I
bonds O
. O

Mass O
spectra O
showed O
that O
the O
P B
- I
N I
bonds O
were O
stable O
during O
trypsin O
digestion O
at O
pH O
8 O
but O
were O
cleaved O
during O
pepsin O
digestion O
at O
pH O
2 O
. O

The O
P B
- I
N I
bond O
in O
tabun B
was O
also O
acid O
labile O
, O
whereas O
the O
P B
- I
O I
bond O
was O
stable O
. O

The O
P B
- I
N I
bond O
in O
tabun B
was O
also O
acid O
labile O
, O
whereas O
the O
P B
- I
O I
bond O
was O
stable O
. O

A O
scheme O
to O
distinguish O
aging O
by O
deamination O
from O
aging O
by O
O B
- O
dealkylation O
was O
based O
on O
the O
acid O
labile O
P B
- I
N I
bond O
. O

When O
grafted O
beta B
- I
cyclodextrin I
is O
used O
as O
targeting O
sites O
, O
Pluronic O
polymers O
have O
been O
introduced O
on O
the O
surface O
of O
cellulose O
nanocrystals O
by O
means O
of O
inclusion O
interaction O
between O
beta B
- I
cyclodextrin I
and O
hydrophobic O
segment O
of O
the O
polymer O
. O

When O
grafted O
beta B
- I
cyclodextrin I
is O
used O
as O
targeting O
sites O
, O
Pluronic O
polymers O
have O
been O
introduced O
on O
the O
surface O
of O
cellulose O
nanocrystals O
by O
means O
of O
inclusion O
interaction O
between O
beta B
- I
cyclodextrin I
and O
hydrophobic O
segment O
of O
the O
polymer O
. O

Meanwhile O
, O
uncovered O
poly B
( I
ethylene I
glycol I
) I
segments O
render O
the O
participating O
inclusion O
of O
alpha B
- I
cyclodextrin I
for O
the O
architecture O
of O
in O
situ O
hydrogels O
. O

Grafting O
efficiency O
of O
beta B
- I
cyclodextrin I
and O
inclusion O
efficiency O
of O
Pluronic O
on O
the O
surface O
of O
nanocrystals O
were O
confirmed O
by O
UV O
spectroscopy O
and O
elemental O
analysis O
. O

Nanocomposites O
made O
from O
Na B
- O
montmorillonite B
and O
metallo O
- O
supramolecular O
polyelectrolytes O
( O
MEPE O
) O
based O
on O
nickel B
and O
ditopic O
bis B
- I
terpyridine I
ligands O
are O
prepared O
by O
an O
aqueous O
synthesis O
. O

5 B
- I
Iodo I
- I
2 I
- I
aminoindan I
( O
5 B
- I
IAI I
) O
: O
chemistry O
, O
pharmacology O
, O
and O
toxicology O
of O
a O
research O
chemical O
producing O
MDMA B
- O
like O
effects O
. O

In O
2010 O
, O
an O
internet O
snapshot O
of O
EMCDDA O
anticipated O
the O
presence O
of O
5 B
- I
iodo I
- I
2 I
- I
aminoindan I
( O
5 B
- I
IAI I
) O
within O
the O
recreational O
drug O
market O
. O

In O
2011 O
, O
this O
compound O
, O
a O
psychoactive O
derivative O
of O
2 B
- I
aminoindane I
, O
was O
identified O
in O
recreational O
products O
sold O
in O
the O
United O
Kingdom O
. O

5 B
- I
IAI I
is O
a O
rigid O
analogue O
of O
p B
- I
iodoamphetamine I
producing O
MDMA B
- O
like O
effects O
. O

5 B
- I
IAI I
is O
a O
rigid O
analogue O
of O
p B
- I
iodoamphetamine I
producing O
MDMA B
- O
like O
effects O
. O

Motivational O
properties O
of O
D2 O
and O
D3 O
dopamine B
receptors O
agonists O
and O
cocaine B
, O
but O
not O
with O
D1 O
dopamine B
receptors O
agonist O
and O
l B
- I
dopa I
, O
in O
bilateral O
6 B
- I
OHDA I
- O
lesioned O
rat O
. O

Motivational O
properties O
of O
D2 O
and O
D3 O
dopamine B
receptors O
agonists O
and O
cocaine B
, O
but O
not O
with O
D1 O
dopamine B
receptors O
agonist O
and O
l B
- I
dopa I
, O
in O
bilateral O
6 B
- I
OHDA I
- O
lesioned O
rat O
. O

Using O
the O
conditioned O
place O
preference O
( O
CPP O
) O
paradigm O
, O
we O
investigated O
the O
motivational O
effects O
of O
l B
- I
dopa I
, O
dopamine B
receptor O
agonists O
( O
DRAs O
) O
, O
and O
cocaine B
in O
rat O
with O
a O
bilateral O
6 B
- I
OHDA I
lesion O
of O
the O
nigrostriatal O
dopaminergic O
pathway O
. O

Using O
the O
conditioned O
place O
preference O
( O
CPP O
) O
paradigm O
, O
we O
investigated O
the O
motivational O
effects O
of O
l B
- I
dopa I
, O
dopamine B
receptor O
agonists O
( O
DRAs O
) O
, O
and O
cocaine B
in O
rat O
with O
a O
bilateral O
6 B
- I
OHDA I
lesion O
of O
the O
nigrostriatal O
dopaminergic O
pathway O
. O

In O
6 B
- I
OHDA I
animals O
, O
D1 O
receptors O
agonist O
( O
SKF81297 B
) O
revealed O
significantly O
a O
conditioned O
place O
aversion O
( O
CPA O
) O
at O
3 O
mg O
/ O
kg O
and O
9 O
mg O
/ O
kg O
doses O
. O

However O
, O
l B
- I
dopa I
induced O
no O
significant O
effect O
while O
cocaine B
induced O
CPP O
in O
both O
lesioned O
and O
sham O
animals O
. O

We O
identified O
two O
molecules O
, O
AA B
- I
861 I
and O
parthenolide B
, O
which O
efficiently O
inhibited O
biofilms O
by O
preventing O
the O
formation O
of O
amyloid O
- O
like O
fibers O
. O

Development O
of O
amino B
- I
pyrimidine I
inhibitors O
of O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
: O
kinase O
profiling O
guided O
optimization O
of O
a O
1 B
, I
2 I
, I
3 I
- I
benzotriazole I
lead O
. O

A O
series O
of O
amino B
- I
pyrimidines I
was O
developed O
based O
upon O
an O
initial O
kinase O
cross O
- O
screening O
hit O
from O
a O
CDK2 O
program O
. O

Comparative O
properties O
of O
A O
beta O
1 O
- O
42 O
, O
A O
beta O
11 O
- O
42 O
, O
and O
[ O
Pyr O
( O
1 O
) O
( O
1 O
) O
] O
A O
beta O
11 O
- O
42 O
generated O
from O
O B
- I
acyl I
isopeptides O
. O

The O
use O
of O
water O
- O
soluble O
O B
- I
acyl I
isopeptides O
enabled O
us O
to O
investigate O
the O
biochemical O
properties O
of O
A O
beta O
11 O
- O
42 O
species O
, O
by O
preparing O
highly O
concentrated O
stock O
solutions O
after O
a O
pretreatment O
. O

Design O
, O
synthesis O
and O
SAR O
of O
piperidyl B
- I
oxadiazoles I
as O
11 B
beta I
- I
hydroxysteroid I
dehydrogenase O
1 O
inhibitors O
. O

To O
elaborate O
this O
series O
of O
piperidyl B
- I
oxadiazole I
derivatives O
as O
human O
11 O
beta O
- O
HSD1 O
inhibitors O
, O
we O
explored O
the O
structure O
- O
activity O
relationship O
of O
several O
parts O
of O
the O
lead O
compound O
. O

Design O
, O
synthesis O
and O
biological O
evaluation O
of O
novel O
hybrid O
compounds O
of O
imidazole B
scaffold O
- O
based O
2 B
- I
benzylbenzofuran I
as O
potent O
anticancer O
agents O
. O

A O
series O
of O
novel O
hybrid O
compounds O
between O
2 B
- I
benzylbenzofuran I
and O
imidazole B
has O
been O
prepared O
and O
evaluated O
in O
vitro O
against O
a O
panel O
of O
human O
tumor O
cell O
lines O
. O

The O
results O
suggest O
that O
the O
existence O
of O
benzimidazole B
ring O
and O
substitution O
of O
the O
imidazolyl B
- O
3 O
- O
position O
with O
a O
naphthylacyl B
or O
4 B
- I
methoxyphenacyl I
group O
were O
vital O
for O
modulating O
cytotoxic O
activity O
. O

The O
polymer O
was O
synthesized O
by O
graft O
polymerization O
of O
methacrylic B
acid I
( O
MAA B
) O
and O
polysorbate B
80 I
( O
PS B
80 I
) O
onto O
starch O
with O
multiple O
, O
chemically O
bound O
diethylenetriaminepe B
acetic I
acid I
( O
DTPA B
) O
groups O
for O
gadolinium B
chelating O
. O

The O
Gd B
- O
loaded O
polymer O
( O
PolyGd B
) O
, O
and O
Gd B
- O
Dox B
co O
- O
loaded O
nanoparticles O
( O
PolyGd B
- I
Dox I
) O
significantly O
enhanced O
MR O
signals O
, O
with O
ionic O
T1 O
relaxivities O
3 O
- O
5 O
times O
higher O
than O
those O
from O
Omniscan B
( O
R O
) O
, O
a O
small O
molecule O
contrast O
agent O
. O

Spray O
- O
dried O
SLH O
microparticles O
comprising O
Capmul B
MCM I
( O
mono B
- I
diglycerides I
of O
C8 O
/ O
C12 O
fatty B
acids I
) O
and O
silica B
nanoparticles O
( O
Aerosil B
( O
R O
) O
380 O
) O
were O
shown O
to O
significantly O
enhance O
the O
fasted O
state O
oral O
bioavailability O
of O
celecoxib B
( O
CEL B
) O
( O
6 O
. O
5 O
fold O
, O
relative O
to O
an O
aqueous O
suspension O
and O
more O
than O
2 O
- O
fold O
higher O
relative O
to O
the O
fed O
state O
) O
after O
oral O
administration O
to O
beagle O
dogs O
. O

These O
requirements O
limit O
BNCT O
availability O
with O
the O
latter O
pharmaceutical O
issue O
related O
to O
the O
extremely O
short O
shelf O
- O
life O
and O
clinical O
acceptability O
of O
the O
current O
fructose B
based O
L B
- I
boronphenylalanine I
( O
BPA B
) O
formulation O
. O

For O
CIT B
and O
its O
metabolite O
dihydrocitrinone B
( O
HO B
- I
CIT I
) O
, O
the O
LOD O
and O
LOQ O
determined O
by O
external O
calibration O
curves O
in O
matrix O
were O
0 O
. O
02 O
and O
0 O
. O
05 O
ng O
/ O
mL O
for O
CIT B
, O
and O
those O
for O
HO B
- I
CIT I
were O
0 O
. O
05 O
and O
0 O
. O
1 O
ng O
/ O
mL O
urine O
. O

For O
CIT B
and O
its O
metabolite O
dihydrocitrinone B
( O
HO B
- I
CIT I
) O
, O
the O
LOD O
and O
LOQ O
determined O
by O
external O
calibration O
curves O
in O
matrix O
were O
0 O
. O
02 O
and O
0 O
. O
05 O
ng O
/ O
mL O
for O
CIT B
, O
and O
those O
for O
HO B
- I
CIT I
were O
0 O
. O
05 O
and O
0 O
. O
1 O
ng O
/ O
mL O
urine O
. O

CIT B
was O
detected O
in O
8 O
/ O
10 O
urines O
( O
from O
4 O
adults O
and O
6 O
infants O
) O
in O
a O
range O
of O
0 O
. O
16 O
- O
0 O
. O
79 O
ng O
/ O
mL O
, O
and O
HO B
- I
CIT I
was O
present O
in O
5 O
/ O
10 O
samples O
at O
similar O
concentrations O
. O

3 B
- I
Methylglutaconic I
aciduria O
- O
lessons O
from O
50 O
genes O
and O
977 O
patients O
. O

In O
all O
other O
disorders O
with O
3 B
- I
methylglutaconic I
aciduria O
the O
origin O
is O
unknown O
, O
yet O
mitochondrial O
dysfunction O
is O
thought O
to O
be O
the O
common O
denominator O
. O

We O
investigate O
the O
biochemical O
, O
clinical O
and O
genetic O
data O
of O
388 O
patients O
referred O
to O
our O
centre O
under O
suspicion O
of O
a O
metabolic O
disorder O
showing O
3 B
- I
methylglutaconic I
aciduria O
in O
routine O
metabolic O
screening O
. O

Furthermore O
, O
we O
investigate O
591 O
patients O
with O
50 O
different O
, O
genetically O
proven O
, O
mitochondrial O
disorders O
for O
the O
presence O
of O
3 B
- I
methylglutaconic I
aciduria O
. O

Three O
percent O
of O
all O
urine O
samples O
of O
the O
patients O
referred O
showed O
3 B
- I
methylglutaconic I
aciduria O
, O
often O
in O
correlation O
with O
disorders O
not O
reported O
earlier O
in O
association O
with O
3 B
- I
methylglutaconic I
aciduria O
( O
e O
. O
g O
. O
organic O
acidurias O
, O
urea B
cycle O
disorders O
, O
haematological O
and O
neuromuscular O
disorders O
) O
. O

Three O
percent O
of O
all O
urine O
samples O
of O
the O
patients O
referred O
showed O
3 B
- I
methylglutaconic I
aciduria O
, O
often O
in O
correlation O
with O
disorders O
not O
reported O
earlier O
in O
association O
with O
3 B
- I
methylglutaconic I
aciduria O
( O
e O
. O
g O
. O
organic O
acidurias O
, O
urea B
cycle O
disorders O
, O
haematological O
and O
neuromuscular O
disorders O
) O
. O

In O
the O
patient O
cohort O
with O
genetically O
proven O
mitochondrial O
disorders O
11 O
% O
presented O
3 B
- I
methylglutaconic I
aciduria O
. O

3 B
- I
methylglutaconic I
aciduria O
is O
found O
quite O
frequently O
in O
patients O
suspected O
of O
a O
metabolic O
disorder O
, O
and O
mitochondrial O
dysfunction O
is O
indeed O
a O
common O
denominator O
. O

These O
conditions O
should O
therefore O
be O
referred O
to O
as O
inborn O
errors O
of O
metabolism O
with O
3 B
- I
methylglutaconic I
aciduria O
as O
discriminative O
feature O
. O

Design O
and O
synthesis O
of O
cyclopropylamide B
analogues O
of O
combretastatin B
- I
A4 I
as O
novel O
microtubule O
- O
stabilizing O
agents O
. O

A O
series O
of O
novel O
cyclopropylamide B
analogues O
of O
combretastatin B
- I
A4 I
( O
CA B
- I
4 I
) O
were O
designed O
and O
synthesized O
. O

A O
series O
of O
novel O
cyclopropylamide B
analogues O
of O
combretastatin B
- I
A4 I
( O
CA B
- I
4 I
) O
were O
designed O
and O
synthesized O
. O

Interestingly O
, O
the O
novel O
cyclopropylamide B
analogues O
had O
different O
binding O
mechanisms O
from O
CA B
- I
4 I
. O

Instead O
of O
inhibiting O
tubulin O
polymerization O
, O
these O
CA B
- I
4 I
derivatives O
were O
able O
to O
stimulate O
tubulin O
polymerization O
. O

Identification O
of O
alpha B
- I
tocopherol I
and O
alpha B
- I
tocopheryl I
acetate I
from O
the O
cuticle O
of O
soybean O
pods O
armyworm O
( O
Spodoptera O
cosmioides O
) O
. O

Among O
the O
usual O
lipids O
found O
in O
the O
insect O
cuticle O
, O
alpha B
- I
tocopherol I
and O
alpha B
- I
tocopheryl I
acetate I
were O
also O
isolated O
from O
S O
. O
cosmioides O
. O

Its O
head O
- O
space O
aroma O
displayed O
new O
volatile O
phytomolecules O
and O
also O
had O
higher O
levels O
of O
green O
volatiles O
from O
the O
lipoxygenase O
( O
LOX O
) O
- O
pathway O
( O
one O
having O
as O
precursors O
the O
polyunsaturated B
fatty I
acids I
containing O
a O
cis B
- I
cis I
- I
1 I
, I
4 I
- I
pentadiene I
system O
) O
. O

Improvement O
of O
p B
- I
cymene I
antinociceptive O
and O
anti O
- O
inflammatory O
effects O
by O
inclusion O
in O
beta B
- I
cyclodextrin I
. O

Improvement O
of O
p B
- I
cymene I
antinociceptive O
and O
anti O
- O
inflammatory O
effects O
by O
inclusion O
in O
beta B
- I
cyclodextrin I
. O

Previously O
, O
we O
have O
demonstrated O
the O
analgesic O
- O
like O
property O
of O
p B
- I
cymene I
in O
rodents O
. O

Short O
half O
- O
life O
is O
a O
limitation O
for O
p B
- I
cymene I
application O
and O
several O
approaches O
have O
been O
used O
to O
improve O
pharmaceutical O
properties O
of O
monoterpenes B
, O
including O
the O
employment O
of O
drug O
- O
delivery O
systems O
. O

Here O
, O
we O
used O
p B
- I
cymene I
/ O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
complex O
and O
p B
- I
cymene I
( O
PC O
) O
isolated O
to O
evaluated O
whether O
the O
complex O
formulation O
is O
able O
to O
improve O
the O
antinociceptive O
activity O
of O
this O
monoterpene B
. O

Here O
, O
we O
used O
p B
- I
cymene I
/ O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
complex O
and O
p B
- I
cymene I
( O
PC O
) O
isolated O
to O
evaluated O
whether O
the O
complex O
formulation O
is O
able O
to O
improve O
the O
antinociceptive O
activity O
of O
this O
monoterpene B
. O

Here O
, O
we O
used O
p B
- I
cymene I
/ O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
complex O
and O
p B
- I
cymene I
( O
PC O
) O
isolated O
to O
evaluated O
whether O
the O
complex O
formulation O
is O
able O
to O
improve O
the O
antinociceptive O
activity O
of O
this O
monoterpene B
. O

Here O
, O
we O
used O
p B
- I
cymene I
/ O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
complex O
and O
p B
- I
cymene I
( O
PC O
) O
isolated O
to O
evaluated O
whether O
the O
complex O
formulation O
is O
able O
to O
improve O
the O
antinociceptive O
activity O
of O
this O
monoterpene B
. O

Male O
mice O
( O
26 O
- O
30g O
) O
were O
pretreated O
with O
PC O
/ O
beta B
- I
CD I
( O
20 O
or O
40mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
, O
PC O
( O
20 O
or O
40mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
or O
vehicle O
( O
distilled O
water O
) O
, O
0 O
. O
5h O
before O
painful O
tests O
and O
antinociceptive O
effect O
was O
evaluated O
at O
times O
: O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
4 O
, O
8 O
, O
and O
16h O
after O
treatment O
. O

We O
evaluated O
the O
analgesic O
- O
like O
effect O
of O
PC O
/ O
beta B
- I
CD I
and O
PC O
in O
acetic B
acid I
- O
induced O
abdominal O
writhes O
, O
hot O
- O
plate O
, O
carrageenan O
- O
induced O
paw O
edema O
and O
in O
rota O
- O
rod O
apparatus O
. O

Our O
results O
demonstrated O
that O
acute O
treatment O
with O
complex O
PC O
/ O
beta B
- I
CD I
produced O
an O
antinocicepitve O
effect O
( O
p O
< O
0 O
. O
01 O
or O
p O
< O
0 O
. O
001 O
) O
for O
8h O
followed O
whereas O
isolated O
PC O
produced O
the O
same O
effect O
for O
2h O
. O

Similar O
results O
were O
obtained O
in O
hot O
- O
plate O
test O
, O
PC O
/ O
beta B
- I
CD I
, O
in O
all O
doses O
, O
significantly O
reduces O
( O
p O
< O
0 O
. O
01 O
or O
p O
< O
0 O
. O
001 O
) O
nociceptive O
behavior O
for O
8h O
while O
isolated O
PC O
for O
1h O
, O
did O
so O
only O
in O
higher O
dose O
. O

Systemic O
pretreatment O
with O
PC O
/ O
beta B
- I
CD I
and O
PC O
inhibited O
the O
development O
paw O
edema O
by O
carrageenan O
1 O
% O
, O
but O
PC O
/ O
beta B
- I
CD I
did O
so O
during O
a O
longer O
period O
when O
compared O
with O
isolated O
monoterpene B
alone O
. O

Systemic O
pretreatment O
with O
PC O
/ O
beta B
- I
CD I
and O
PC O
inhibited O
the O
development O
paw O
edema O
by O
carrageenan O
1 O
% O
, O
but O
PC O
/ O
beta B
- I
CD I
did O
so O
during O
a O
longer O
period O
when O
compared O
with O
isolated O
monoterpene B
alone O
. O

Our O
results O
provide O
evidence O
to O
propose O
that O
the O
complex O
with O
beta B
- I
CD I
improved O
analgesic O
and O
anti O
- O
inflammatory O
effects O
of O
p B
- I
cymene I
. O

Our O
results O
provide O
evidence O
to O
propose O
that O
the O
complex O
with O
beta B
- I
CD I
improved O
analgesic O
and O
anti O
- O
inflammatory O
effects O
of O
p B
- I
cymene I
. O

Dichloro B
- I
dihydro I
- I
fluorescein I
diacetate I
( O
DCFH B
- I
DA I
) O
assay O
: O
a O
quantitative O
method O
for O
oxidative O
stress O
assessment O
of O
nanoparticle O
- O
treated O
cells O
. O

No O
consensus O
exists O
on O
how O
to O
address O
possible O
toxicity O
of O
nanomaterials O
as O
they O
interfere O
with O
most O
in O
vitro O
screening O
tests O
based O
on O
colorimetric O
and O
fluorimetric O
probes O
such O
as O
the O
dichloro B
- I
dihydro I
- I
fluorescein I
diacetate I
( O
DCFH B
- I
DA I
) O
assay O
for O
detection O
of O
oxidative O
species O
. O

In O
the O
present O
research O
, O
nanomaterial O
interaction O
with O
DCFH B
- I
DA I
was O
studied O
in O
relation O
to O
its O
nature O
and O
/ O
or O
assay O
conditions O
( O
cell O
- O
based O
and O
time O
exposure O
) O
by O
incubating O
Rhodamine B
( O
Rhd B
) O
- O
labeled O
25nm O
and O
50nm O
silica B
( O
SiO2 B
) O
, O
naked O
and O
oleic B
acid I
coated I
magnetite I
, O
( O
Fe3O4 B
) O
and O
maghemite B
( O
Fe2O3 B
) O
iron B
oxide I
, O
titanium B
dioxide I
( O
TiO2 B
) O
and O
poly B
( I
ethylene I
oxide I
) I
- I
poly I
( I
lactide I
/ I

Overall O
data O
indicate O
that O
despite O
the O
quenching O
effect O
of O
nanoparticles O
on O
DCFH B
- I
DA I
assay O
, O
it O
can O
be O
considered O
as O
a O
useful O
tool O
for O
quantitative O
measurement O
of O
NPs O
- O
induced O
oxidative O
stress O
by O
minor O
modifications O
of O
standardized O
protocols O
. O

PC2 O
and O
PC3 O
cluster O
American O
- O
and O
Virginia O
- O
blends O
, O
revealing O
inverse O
correlations O
: O
Nitrogen B
oxides I
and O
amino B
- O
or O
nitroso B
- O
aromatic O
compounds O
inversely O
correlate O
to O
either O
formaldehyde B
and O
acrolein B
, O
or O
benzo B
( I
a I
) I
pyrene I
and O
di B
- I
hydroxybenzenes I
. O

induces O
the O
amino B
acid I
starvation O
response O
. O

By O
use O
of O
rational O
drug O
design O
, O
a O
targeted O
covalent O
inhibitor O
3 O
( O
CNX B
- I
1351 I
) O
was O
created O
that O
potently O
and O
specifically O
inhibits O
PI3K O
alpha O
. O

A O
covalent O
probe O
, O
8 O
( O
CNX B
- I
1220 I
) O
, O
which O
selectively O
bonds O
to O
PI3K O
alpha O
, O
was O
used O
to O
investigate O
the O
duration O
of O
occupancy O
of O
3 O
with O
PI3K O
alpha O
in O
vivo O
. O

In O
addition O
to O
vascular O
disrupting O
activity O
verified O
by O
in O
vitro O
assays O
, O
compounds O
21 O
and O
31 O
displayed O
much O
higher O
selectivity O
for O
activated O
HUVECs O
versus O
quiescent O
HUVECs O
than O
those O
of O
colchicine B
and O
combretastatinA B
- I
4 I
. O

Sodium B
selenite I
( O
Na2SeO3 B
) O
, O
selenomethionine B
( O
SeMet B
) O
, O
seleno B
- I
l I
- I
cystine I
( O
SeCySS B
) O
, O
and O
Se B
- I
methylselenocysteine I
( O
MeSeCys B
) O
did O
not O
have O
these O
effects O
on O
macrophages O
under O
the O
same O
treatment O
conditions O
. O

Based O
on O
microarray O
analysis O
followed O
by O
comparative O
metabolomics O
of O
overexpression O
/ O
knockout O
mutants O
, O
we O
identified O
a O
tryptophan B
- O
derived O
iron B
( I
III I
) I
- O
complex O
, O
hexadehydro B
- I
astechrome I
( O
HAS B
) O
, O
as O
the O
major O
product O
of O
the O
cryptic O
has O
nonribosomal O
peptide O
synthetase O
( O
NRPS O
) O
gene O
cluster O
in O
the O
human O
pathogen O
Aspergillus O
fumigatus O
. O

Secondary O
interactions O
are O
demonstrated O
to O
direct O
the O
stability O
of O
well O
- O
defined O
Ru B
- I
NHC I
- O
based O
heterogeneous O
alkene B
metathesis O
catalysts O
. O

The O
intercalation O
pathway O
of O
lithium B
iron I
phosphate I
( O
LFP B
) O
in O
the O
positive O
electrode O
of O
a O
lithium B
- O
ion O
battery O
was O
probed O
at O
the O
~ O
40 O
nm O
length O
scale O
using O
oxidation O
- O
state O
- O
sensitive O
X O
- O
ray O
microscopy O
. O

The O
TEM O
and O
SEM O
images O
of O
the O
formulation O
suggested O
that O
particle O
size O
was O
within O
20 O
- O
100 O
nm O
and O
spherical O
in O
shape O
, O
smooth O
morphology O
and O
coating O
of O
Tween B
- I
80 I
on O
the O
NPs O
was O
clearly O
observed O
. O

We O
also O
found O
that O
amphetamine B
abstinence O
increased O
levels O
of O
4 B
- I
hydroxynonenal I
- O
protein O
adducts O
and O
8 B
- I
hydroxyguanosine I
in O
rat O
medial O
frontal O
cortex O
and O
in O
CA3 O
and O
dentate O
gyrus O
regions O
of O
the O
hippocampus O
. O

We O
also O
found O
that O
amphetamine B
abstinence O
increased O
levels O
of O
4 B
- I
hydroxynonenal I
- O
protein O
adducts O
and O
8 B
- I
hydroxyguanosine I
in O
rat O
medial O
frontal O
cortex O
and O
in O
CA3 O
and O
dentate O
gyrus O
regions O
of O
the O
hippocampus O
. O

A O
variety O
of O
other O
drugs O
, O
such O
as O
topiramate B
, O
TG41 B
, O
( B
+ I
) I
- I
and I
( I
- I
) I
- I
borneol I
, O
apigenin B
, O
and O
6 B
- I
methylflavone I
could O
also O
have O
modulatory O
effects O
on O
the O
GABA B
A O
receptors O
. O

A O
signal O
- O
on O
electrochemiluminesc O
( O
ECL O
) O
biosensor O
devoted O
to O
the O
detection O
of O
Ramos O
cells O
was O
fabricated O
based O
on O
a O
novel O
conducting O
polymer O
, O
poly B
( I
5 I
- I
formylindole I
) I
( O
P5FIn B
) O
, O
which O
was O
synthesized O
electrochemically O
by O
direct O
anodic O
oxidation O
of O
5 B
- I
formylindole I
( O
5FIn B
) O
. O

Critical O
role O
of O
a O
methyl B
group O
on O
the O
gamma B
- I
lactone I
ring O
of O
annonaceous O
acetogenins B
in O
the O
potent O
inhibition O
of O
mitochondrial O
complex O
I O
. O

C34 O
- O
epi O
and O
C34 B
- I
epi I
- I
C35 I
- I
trifluoro I
analogues O
of O
solamin B
, O
a O
mono B
- I
THF I
annonaceous O
acetogenin B
, O
were O
synthesized O
. O

The O
present O
study O
revealed O
that O
the O
methyl B
group O
on O
the O
gamma B
- I
lactone I
moiety O
is O
critical O
to O
the O
potent O
inhibition O
of O
complex O
I O
by O
natural O
acetogenins B
. O

Synthesis O
and O
antibacterial O
activity O
of O
9 B
- I
oxime I
ether B
non O
- O
ketolides B
, O
and O
novel O
binding O
mode O
of O
alkylides B
with O
bacterial O
rRNA O
. O

We O
report O
a O
series O
of O
new O
9 B
- I
oxime I
ether B
non O
- O
ketolides B
, O
including O
3 B
- I
hydroxyl I
, I
3 I
- I
O I
- I
acyl I
and I
3 I
- I
O I
- I
alkyl I
clarithromycin I
derivatives O
, O
and O
thiophene B
- O
containing O
ketolides B
1b O
- O
1d O
. O

N B
- I
methyl I
- I
d I
- I
aspartate I
receptors O
( O
NMDARs O
) O
are O
ligand O
- O
gated O
ion O
channels O
( O
' O
ionotropic O
' O
receptors O
) O
activated O
by O
the O
major O
excitatory O
neurotransmitter O
, O
l B
- I
glutamate I
. O

Catalytic O
- O
site O
conformational O
equilibrium O
in O
nerve O
- O
agent O
adducts O
of O
acetylcholinesterase O
: O
Possible O
implications O
for O
the O
HI B
- I
6 I
antidote O
substrate O
specificity O
. O

The O
oxime B
HI B
- I
6 I
shows O
a O
notably O
low O
activity O
on O
tabun B
adducts O
but O
can O
effectively O
reactivate O
adducts O
of O
cyclosarin B
and O
Russian B
VX I
. O

To O
examine O
the O
structural O
basis O
for O
the O
pronounced O
substrate O
specificity O
of O
HI B
- I
6 I
, O
we O
determined O
the O
binary O
crystal O
structures O
of O
Mus O
musculus O
AChE O
( O
mAChE O
) O
conjugated O
by O
cyclosarin B
and O
Russian B
VX I
and O
found O
a O
conformational O
mobility O
of O
the O
side O
chains O
of O
Phe338 B
and O
His447 B
. O

The O
interaction O
between O
HI B
- I
6 I
and O
tabun B
- O
adducts O
of O
AChE O
were O
subsequently O
investigated O
using O
a O
combination O
of O
time O
resolved O
fluorescence O
spectroscopy O
and O
X O
- O
ray O
crystallography O
. O

Our O
findings O
show O
that O
HI B
- I
6 I
binds O
to O
tabun B
inhibited O
Homo O
sapiens O
AChE O
( O
hAChE O
) O
with O
an O
IC50 O
value O
of O
300 O
mu O
M O
and O
suggest O
that O
the O
reactive O
nucleophilic O
moiety O
of O
HI B
- I
6 I
is O
excluded O
from O
the O
phosphorus B
atom O
of O
tabun B
. O

Our O
findings O
show O
that O
HI B
- I
6 I
binds O
to O
tabun B
inhibited O
Homo O
sapiens O
AChE O
( O
hAChE O
) O
with O
an O
IC50 O
value O
of O
300 O
mu O
M O
and O
suggest O
that O
the O
reactive O
nucleophilic O
moiety O
of O
HI B
- I
6 I
is O
excluded O
from O
the O
phosphorus B
atom O
of O
tabun B
. O

We O
also O
suggest O
that O
the O
conformational O
mobility O
allow O
HI B
- I
6 I
to O
reactivate O
conjugates O
of O
cyclosarin B
and O
Russian B
VX I
while O
a O
reduced O
mobility O
in O
tabun B
conjugated O
AChE O
results O
in O
steric O
hindrance O
that O
prevents O
efficient O
reactivation O
. O

Cellular O
mechanisms O
of O
the O
cytotoxic O
effects O
of O
the O
zearalenone B
metabolites O
alpha B
- I
zearalenol I
and O
beta B
- I
zearalenol I
on O
RAW264 O
. O
7 O
macrophages O
. O

Cellular O
mechanisms O
of O
the O
cytotoxic O
effects O
of O
the O
zearalenone B
metabolites O
alpha B
- I
zearalenol I
and O
beta B
- I
zearalenol I
on O
RAW264 O
. O
7 O
macrophages O
. O

The O
major O
ZEN B
metabolites O
are O
alpha B
- I
zearalenol I
( O
alpha B
- I
ZOL I
) O
and O
beta B
- I
zearalenol I
( O
beta B
- I
ZOL I
) O
. O

The O
major O
ZEN B
metabolites O
are O
alpha B
- I
zearalenol I
( O
alpha B
- I
ZOL I
) O
and O
beta B
- I
zearalenol I
( O
beta B
- I
ZOL I
) O
. O

The O
major O
ZEN B
metabolites O
are O
alpha B
- I
zearalenol I
( O
alpha B
- I
ZOL I
) O
and O
beta B
- I
zearalenol I
( O
beta B
- I
ZOL I
) O
. O

The O
major O
ZEN B
metabolites O
are O
alpha B
- I
zearalenol I
( O
alpha B
- I
ZOL I
) O
and O
beta B
- I
zearalenol I
( O
beta B
- I
ZOL I
) O
. O

Although O
many O
studies O
have O
demonstrated O
the O
cytotoxic O
effects O
of O
these O
metabolites O
, O
the O
mechanisms O
by O
which O
alpha B
- I
ZOL I
or O
beta B
- I
ZOL I
mediates O
their O
cytotoxic O
effects O
appear O
to O
differ O
according O
to O
cell O
type O
and O
the O
exposed O
toxins O
. O

Although O
many O
studies O
have O
demonstrated O
the O
cytotoxic O
effects O
of O
these O
metabolites O
, O
the O
mechanisms O
by O
which O
alpha B
- I
ZOL I
or O
beta B
- I
ZOL I
mediates O
their O
cytotoxic O
effects O
appear O
to O
differ O
according O
to O
cell O
type O
and O
the O
exposed O
toxins O
. O

We O
evaluated O
the O
toxicity O
of O
alpha B
- I
ZOL I
and O
beta B
- I
ZOL I
on O
RAW264 O
. O
7 O
macrophages O
and O
investigated O
the O
underlying O
mechanisms O
. O

We O
evaluated O
the O
toxicity O
of O
alpha B
- I
ZOL I
and O
beta B
- I
ZOL I
on O
RAW264 O
. O
7 O
macrophages O
and O
investigated O
the O
underlying O
mechanisms O
. O

beta B
- I
ZOL I
not O
only O
more O
strongly O
reduced O
the O
viability O
of O
cells O
than O
did O
alpha B
- I
ZOL I
, O
but O
it O
also O
induced O
cell O
death O
mainly O
by O
apoptosis O
rather O
than O
necrosis O
. O

beta B
- I
ZOL I
not O
only O
more O
strongly O
reduced O
the O
viability O
of O
cells O
than O
did O
alpha B
- I
ZOL I
, O
but O
it O
also O
induced O
cell O
death O
mainly O
by O
apoptosis O
rather O
than O
necrosis O
. O

Use O
of O
an O
inhibitor O
specific O
to O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
, O
p38 O
kinase O
or O
p53 O
, O
but O
not O
pan O
- O
caspase O
or O
caspase O
- O
8 O
, O
decreased O
the O
toxin O
- O
induced O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
also O
attenuated O
the O
alpha B
- I
ZOL I
- O
or O
beta B
- I
ZOL I
- O
induced O
decrease O
of O
cell O
viability O
. O

Use O
of O
an O
inhibitor O
specific O
to O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
, O
p38 O
kinase O
or O
p53 O
, O
but O
not O
pan O
- O
caspase O
or O
caspase O
- O
8 O
, O
decreased O
the O
toxin O
- O
induced O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
also O
attenuated O
the O
alpha B
- I
ZOL I
- O
or O
beta B
- I
ZOL I
- O
induced O
decrease O
of O
cell O
viability O
. O

Arsenite B
- O
induced O
ROS O
generation O
and O
COX O
- O
2 O
expression O
were O
significantly O
attenuated O
by O
treatment O
with O
melatonin B
( O
a O
ROS O
scavenger O
) O
, O
but O
enhanced O
by O
DL B
- I
buthionine I
- I
( I
S I
, I
R I
) I
- I
sulfoximine I
( O
BSO B
, O
an O
inhibitor O
of O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
resulting O
in O
lower O
GSH B
and O
increased O
ROS O
levels O
) O
. O

8 B
- I
Oxoguanine I
DNA O
glycosylase O
1 O
( O
OGG1 O
) O
plays O
an O
important O
role O
in O
repairing O
oxidative O
DNA O
damage O
induced O
by O
chemical O
agents O
, O
such O
as O
tobacco O
. O

Sperm O
8 B
- I
hydroxydeoxyguanine I
( O
8 B
- I
OHdG I
) O
was O
measured O
by O
immunofluorescent O
assay O
using O
flow O
cytometry O
and O
genotypes O
were O
determined O
by O
OpenArray O
platform O
with O
a O
chip O
- O
based O
Taq O
- O
Man O
genotyping O
technology O
. O

Sperm O
8 B
- I
hydroxydeoxyguanine I
( O
8 B
- I
OHdG I
) O
was O
measured O
by O
immunofluorescent O
assay O
using O
flow O
cytometry O
and O
genotypes O
were O
determined O
by O
OpenArray O
platform O
with O
a O
chip O
- O
based O
Taq O
- O
Man O
genotyping O
technology O
. O

Our O
results O
demonstrated O
that O
both O
cigarette O
smoking O
and O
OGG1 O
polymorphism O
can O
affect O
the O
sperm O
8 B
- I
OHdG I
levels O
. O

Individuals O
with O
variant O
Cys B
/ O
Cys B
homozygote O
showed O
higher O
levels O
of O
sperm O
8 B
- I
OHdG I
than O
wide O
- O
type O
homozygote O
carriers O
( O
Ser B
/ O
Ser B
) O
. O

Stratified O
analysis O
found O
that O
the O
association O
between O
OGG1 O
polymorphism O
and O
sperm O
8 B
- I
OHdG I
levels O
was O
only O
observed O
among O
smokers O
with O
pack O
- O
years O
> O
= O
5 O
but O
not O
among O
those O
subjects O
with O
pack O
- O
years O
< O
5 O
( O
pack O
- O
years O
= O
packs O
smoked O
per O
day O
x O
years O
as O
a O
smoker O
) O
. O

Catechins B
are O
not O
major O
components O
responsible O
for O
the O
beneficial O
effect O
of O
Camellia O
sinensis O
on O
the O
ovarian O
delta B
- I
ALA I
- O
D O
activity O
inhibited O
by O
cadmium B
. O

This O
investigation O
evaluated O
the O
protective O
role O
of O
Camellia O
sinensis O
( O
green O
, O
white O
and O
red O
teas O
) O
in O
the O
cadmium B
- O
induced O
inhibition O
of O
ovarian O
delta B
- I
aminolevulinate I
dehydratase O
( O
delta B
- I
ALA I
- O
D O
) O
activity O
in O
vitro O
and O
ex O
vivo O
. O

This O
investigation O
evaluated O
the O
protective O
role O
of O
Camellia O
sinensis O
( O
green O
, O
white O
and O
red O
teas O
) O
in O
the O
cadmium B
- O
induced O
inhibition O
of O
ovarian O
delta B
- I
aminolevulinate I
dehydratase O
( O
delta B
- I
ALA I
- O
D O
) O
activity O
in O
vitro O
and O
ex O
vivo O
. O

This O
study O
demonstrated O
that O
green O
and O
white O
teas O
restored O
the O
cow O
ovary O
delta B
- I
ALA I
- O
D O
activity O
inhibited O
by O
cadmium B
whereas O
red O
tea O
had O
no O
effect O
in O
vitro O
. O

4 B
- I
Nerolidylcatechol I
and O
its O
synthetic O
analogues O
: O
Antioxidant O
activity O
and O
toxicity O
evaluation O
. O

4 B
- I
Nerolidylcatechol I
( O
1 O
) O
is O
a O
secondary O
metabolite O
of O
plants O
and O
is O
described O
as O
a O
promising O
anti O
- O
inflammatory O
, O
antimalarial O
, O
antiulcerogenic O
, O
analgesic O
and O
cytotoxic O
compound O
possibly O
due O
to O
its O
antioxidant O
profile O
. O

Compound O
5 O
showed O
, O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
and O
beta B
- I
carotene I
systems O
, O
similar O
antioxidant O
activity O
when O
compared O
to O
compound O
( O
1 O
) O
. O

The O
possible O
antimutagenic O
potential O
of O
A7G B
was O
examined O
against O
mutagens O
ethyl B
methanesulfonate I
and O
acridine B
in O
an O
eukaryotic O
cell O
system O
Saccharomyces O
cerevisiae O
and O
sodium B
azide I
in O
Salmonella O
typhimurium O
TA1535 O
and O
9 B
- I
aminoacridine I
in O
S O
. O
typhimurium O
TA1537 O
. O

Upamostat B
is O
the O
orally O
available O
amidoxime B
- O
( O
i O
. O
e O
. O
hydroxyamidine B
- O
) O
prodrug O
of O
the O
pharmacologically O
active O
form O
, O
WX B
- I
UK1 I
. O

In O
this O
study O
, O
the O
reductive O
enzymatic O
activation O
of O
upamostat B
to O
its O
corresponding O
amidine O
WX B
- I
UK1 I
was O
analyzed O
. O

Chorismatases O
and O
isochorismatases O
catalyse O
the O
hydrolysis O
of O
chorismate B
or O
isochorismate B
leading O
to O
unsaturated B
cyclohexenoic I
acid I
derivatives O
. O

The O
Fe B
- I
- I
- I
Fe I
bond O
elongates O
to O
2 O
. O
80 O
from O
2 O
. O
66 O
A O
, O
but O
the O
Fe B
- I
P I
bonds O
only O
change O
subtly O
. O

Although O
the O
Fe B
- I
H I
distances O
are O
indistinguishable O
in O
the O
precursor O
, O
they O
differ O
by O
0 O
. O
2 O
A O
in O
[ O
H1 B
] O
( O
0 O
) O
. O

Inclusion O
of O
parameters O
describing O
the O
N B
- I
acetyl I
moiety O
had O
little O
effect O
on O
the O
predictive O
ability O
of O
a O
stepwise O
parent O
to O
N B
- I
acetyl I
to O
N B
- I
oxanilic I
acid I
PLS O
- O
DA O
model O
, O
and O
had O
a O
negative O
impact O
on O
that O
of O
SIMCA O
models O
. O

Inclusion O
of O
parameters O
describing O
the O
N B
- I
acetyl I
moiety O
had O
little O
effect O
on O
the O
predictive O
ability O
of O
a O
stepwise O
parent O
to O
N B
- I
acetyl I
to O
N B
- I
oxanilic I
acid I
PLS O
- O
DA O
model O
, O
and O
had O
a O
negative O
impact O
on O
that O
of O
SIMCA O
models O
. O

We O
show O
that O
Cys31 B
initiates O
the O
reaction O
with O
sulfite B
through O
the O
formation O
of O
S B
- I
sulfocysteine I
( O
RS B
- I
SO3 I
( I
2 I
- I
) I
) O
and O
Cys60 B
is O
required O
to O
fully O
derivatize O
CstR O
to O
CstR2 O
( O
RS B
- I
SR I
' I
) O
and O
CstR2 O
( O
RS B
- I
S I
- I
SR I
' I
) O
. O

Refining O
the O
UGT1A O
haplotype O
associated O
with O
irinotecan B
- O
induced O
hematological O
toxicity O
in O
metastatic O
colorectal O
cancer O
patients O
treated O
with O
5 B
- I
fluorouracil I
/ O
irinotecan B
- O
based O
regimens O
. O

We O
aimed O
at O
identifying O
novel O
genetic O
markers O
that O
would O
improve O
prediction O
of O
irinotecan B
toxicity O
and O
response O
in O
advanced O
colorectal O
cancer O
patients O
treated O
with O
folic B
acid I
( O
leucovorin B
) O
, O
fluorouracil B
( O
5 B
- I
FU I
) O
, O
and O
irinotecan B
( O
camptosar B
) O
- O
based O
regimens O
. O

A O
new O
program O
, O
PHI O
, O
with O
the O
ability O
to O
calculate O
the O
magnetic O
properties O
of O
large O
spin O
systems O
and O
complex O
orbitally O
degenerate O
systems O
, O
such O
as O
clusters O
of O
d B
- I
block I
and O
f B
- I
block I
ions O
, O
is O
presented O
. O

A O
new O
program O
, O
PHI O
, O
with O
the O
ability O
to O
calculate O
the O
magnetic O
properties O
of O
large O
spin O
systems O
and O
complex O
orbitally O
degenerate O
systems O
, O
such O
as O
clusters O
of O
d B
- I
block I
and O
f B
- I
block I
ions O
, O
is O
presented O
. O

The O
fecal O
elimination O
, O
IC O
, O
and O
systemic O
clearance O
of O
apixaban B
were O
increased O
upon O
AC O
administration O
in O
both O
BDC O
rats O
and O
dogs O
and O
were O
decreased O
in O
BDC O
rats O
dosed O
with O
GF B
- I
120918 I
, O
a O
dual O
BCRP O
and O
P O
- O
gp O
inhibitor O
) O
. O

In O
this O
review O
, O
recent O
developments O
are O
described O
by O
emphasizing O
the O
synthesis O
of O
polymers O
and O
/ O
or O
coatings O
having O
N B
- I
halamine I
moieties O
. O

Identification O
and O
characterization O
of O
the O
formation O
of O
the O
N B
- I
halamine I
bonds O
( O
> O
N B
- O
X O
with O
X O
= O
Cl B
or O
Br B
or O
I B
) O
by O
physical O
techniques O
such O
as O
Fourier O
transform O
infrared O
spectroscopy O
( O
FTIR O
) O
, O
nuclear O
magnetic O
resonance O
spectroscopy O
( O
NMR O
) O
, O
energy O
- O
dispersive O
X O
- O
ray O
spectroscopy O
( O
EDX O
) O
, O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
, O
and O
by O
chemical O
reactions O
are O
described O
. O

In O
order O
to O
check O
the O
antimicrobial O
activity O
of O
the O
N B
- I
halamine I
compounds O
, O
bacterial O
tests O
are O
also O
described O
. O

Finally O
, O
some O
examples O
of O
application O
of O
these O
N B
- I
halamines I
in O
the O
water O
treatment O
, O
paints O
, O
healthcare O
equipment O
, O
and O
textile O
industries O
are O
presented O
and O
discussed O
. O

In O
some O
of O
these O
cases O
radioiodine B
treatment O
may O
not O
be O
effective O
in O
eradicating O
nodal O
metastases O
due O
to O
scant O
131 B
- I
I I
uptake O
. O

Specifically O
, O
a O
series O
of O
PDMS B
coatings O
containing O
either O
a O
QAS O
with O
a O
single O
ammonium B
salt O
group O
per O
molecule O
or O
a O
quaternary O
ammonium B
- O
functionalized O
polyhedral B
oligomeric I
silsesquioxane I
( O
Q O
- O
POSS B
) O
were O
measured O
with O
SFG O
in O
air O
, O
water O
, O
and O
artificial O
seawater O
( O
ASW O
) O
to O
investigate O
the O
relationships O
between O
the O
interfacial O
surface O
structures O
of O
these O
materials O
and O
their O
antifouling O
properties O
. O

Elevation O
of O
4 B
- I
hydroxynonenal I
and O
malondialdehyde B
modified O
protein O
levels O
in O
cerebral O
cortex O
with O
cognitive O
dysfunction O
in O
rats O
exposed O
to O
1 B
- I
bromopropane I
. O

Elevation O
of O
4 B
- I
hydroxynonenal I
and O
malondialdehyde B
modified O
protein O
levels O
in O
cerebral O
cortex O
with O
cognitive O
dysfunction O
in O
rats O
exposed O
to O
1 B
- I
bromopropane I
. O

1 B
- I
Bromopropane I
( O
1 B
- I
BP I
) O
, O
an O
alternative O
to O
ozone B
- O
depleting O
solvents O
( O
ODS O
) O
, O
exhibits O
central O
nervous O
system O
( O
CNS O
) O
toxicity O
in O
animals O
and O
humans O
. O

1 B
- I
Bromopropane I
( O
1 B
- I
BP I
) O
, O
an O
alternative O
to O
ozone B
- O
depleting O
solvents O
( O
ODS O
) O
, O
exhibits O
central O
nervous O
system O
( O
CNS O
) O
toxicity O
in O
animals O
and O
humans O
. O

This O
study O
was O
designed O
to O
relate O
CNS O
damage O
by O
Morris O
water O
maze O
( O
MWM O
) O
test O
and O
oxidative O
stress O
to O
1 B
- I
BP I
exposure O
in O
the O
rat O
. O

Male O
Wistar O
rats O
were O
randomly O
divided O
into O
4 O
groups O
( O
n O
= O
10 O
) O
, O
and O
treated O
with O
0 O
, O
200 O
, O
400 O
and O
800mg O
/ O
kgbw O
1 B
- I
BP I
for O
consecutive O
12 O
days O
, O
respectively O
. O

Glutathione B
( O
GSH B
) O
, O
oxidized B
glutathione I
( O
GSSG B
) O
and O
total O
thiol B
( O
total O
- O
SH B
) O
content O
, O
GSH B
reductase O
( O
GR O
) O
and O
GSH B
peroxidase O
( O
GSH B
- O
Px O
) O
activities O
, O
malondialdehyde B
( O
MDA B
) O
level O
, O
as O
well O
as O
4 B
- I
hydroxynonenal I
( O
4 B
- I
HNE I
) O
and O
MDA B
modified O
proteins O
in O
homogenates O
of O
cerebral O
cortex O
were O
measured O
. O

Glutathione B
( O
GSH B
) O
, O
oxidized B
glutathione I
( O
GSSG B
) O
and O
total O
thiol B
( O
total O
- O
SH B
) O
content O
, O
GSH B
reductase O
( O
GR O
) O
and O
GSH B
peroxidase O
( O
GSH B
- O
Px O
) O
activities O
, O
malondialdehyde B
( O
MDA B
) O
level O
, O
as O
well O
as O
4 B
- I
hydroxynonenal I
( O
4 B
- I
HNE I
) O
and O
MDA B
modified O
proteins O
in O
homogenates O
of O
cerebral O
cortex O
were O
measured O
. O

The O
obtained O
results O
showed O
that O
1 B
- I
BP I
led O
to O
cognitive O
dysfunction O
of O
rats O
, O
which O
was O
evidenced O
by O
delayed O
escape O
latency O
time O
and O
swimming O
distances O
in O
MWM O
performance O
. O

4 B
- I
HNE I
and O
MDA B
modified O
protein O
levels O
obviously O
elevated O
after O
1 B
- I
BP I
exposure O
. O

4 B
- I
HNE I
and O
MDA B
modified O
protein O
levels O
obviously O
elevated O
after O
1 B
- I
BP I
exposure O
. O

These O
data O
suggested O
that O
1 B
- I
BP I
resulted O
in O
enhanced O
lipid O
peroxidation O
of O
brain O
, O
which O
might O
play O
an O
important O
role O
in O
CNS O
damage O
induced O
by O
1 B
- I
BP I
. O

These O
data O
suggested O
that O
1 B
- I
BP I
resulted O
in O
enhanced O
lipid O
peroxidation O
of O
brain O
, O
which O
might O
play O
an O
important O
role O
in O
CNS O
damage O
induced O
by O
1 B
- I
BP I
. O

Treatment O
of O
cells O
with O
alpha B
- I
amanitin I
or O
actinomycin B
D I
revealed O
that O
extension O
of O
B2 O
RNA O
by O
Pol O
II O
destabilizes O
the O
RNA O
. O

Uptake O
of O
dioscin B
by O
rat O
liver O
slices O
and O
isolated O
rat O
hepatocytes O
was O
inhibited O
significantly O
by O
Oatp O
modulators O
, O
such O
as O
ibuprofen B
( O
Oatp1a1 O
inhibitor O
) O
, O
digoxin B
( O
Oatp1a4 O
substrate O
) O
, O
and O
glycyrrhizic B
acid I
( O
Oatp1b2 O
inhibitor O
) O
, O
but O
not O
by O
TEA B
or O
p B
- I
aminohippurate I
. O

, O
methimazole B
, O
3 B
- I
methylcholanthrene I
, O
aminotriazole B
, O
amiodarone B
, O
cadmium B
chloride I
, O
dimethoate B
, O
fenvalerate B
, O
octylmethoxycinnamat B
, O
iopanoic B
acid I
, O
methoxychlor B
, O
and O
4 B
- I
methylbenzylidene I
- I
camphor I
) O
. O

We O
modified O
the O
nanopore O
surface O
with O
ionizable O
functional O
groups O
, O
by O
forming O
a O
monolayer O
of O
L B
- I
cysteine I
or O
by O
surface O
- O
initiated O
polymerization O
of O
methacrylic B
acid I
. O

Diffusion O
experiments O
for O
the O
cationic O
dye O
Rhodamine B
B I
through O
L B
- I
cysteine I
- O
modified O
membranes O
showed O
a O
decrease O
in O
flux O
upon O
addition O
of O
an O
acid O
due O
to O
the O
nanopore O
surface O
becoming O
positively O
charged O
. O

In O
contrast O
, O
the O
I O
( O
2 O
) O
receptor O
agonist O
, O
2 B
- I
BFI I
( O
5 O
mg O
/ O
kg O
) O
and O
I O
( O
1 O
) O
receptor O
agonist O
, O
moxonidine B
( O
0 O
. O
4 O
mg O
/ O
kg O
) O
alone O
, O
or O
a O
combination O
of O
their O
subeffective O
doses O
, O
significantly O
attenuated O
the O
effect O
of O
agmatine B
( O
20 O
mg O
/ O
kg O
) O
on O
acquisition O
of O
ethanol B
CPP O
. O

They O
authors O
conclude O
that O
AML B
possesses O
an O
enhancement O
effect O
in O
beta B
- I
lactam I
antibiotic O
bioavailability O
( O
in O
this O
case O
, O
LEX B
) O
, O
and O
this O
interaction O
may O
be O
specific O
to O
the O
peptidomimetic O
beta B
- I
lactam I
antibiotics O
. O

They O
authors O
conclude O
that O
AML B
possesses O
an O
enhancement O
effect O
in O
beta B
- I
lactam I
antibiotic O
bioavailability O
( O
in O
this O
case O
, O
LEX B
) O
, O
and O
this O
interaction O
may O
be O
specific O
to O
the O
peptidomimetic O
beta B
- I
lactam I
antibiotics O
. O

These O
drugs O
are O
mainly O
beta B
- I
lactams I
, O
aminoglycosides B
, O
and O
fluoroquinolones B
. O

The O
imipenem B
and O
meropenem B
resistance O
rates O
are O
significantly O
correlated O
with O
resistance O
rates O
to O
numerous O
antimicrobial O
drugs O
( O
eg O
, O
beta B
- I
lactams I
, O
aminoglycosides B
, O
and O
fluoroquinolones B
) O
in O
A O
baumannii O
. O

Cross O
- O
resistance O
possibly O
occurs O
among O
imipenem B
/ O
cilastatin B
and O
meropenem B
, O
as O
well O
as O
with O
beta B
- I
lactams I
, O
aminoglycosides B
, O
and O
fluoroquinolones B
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
cause O
neurobehavioral O
toxicity O
, O
but O
their O
effects O
on O
visual O
behavior O
remain O
unknown O
. O

Zebrafish O
embryos O
were O
exposed O
to O
pentabrominated B
diphenyl I
ethers I
mixture O
( O
DE O
- O
71 O
) O
at O
concentrations O
of O
0 O
, O
0 O
. O
32 O
, O
3 O
. O
58 O
, O
and O
31 O
. O
0 O
micro O
g O
/ O
L O
until O
15 O
d O
postfertilization O
. O

The O
binding O
of O
beta B
- I
galactosides I
and O
galectin O
- O
3 O
- O
a O
protein O
that O
is O
correlated O
to O
the O
progress O
of O
tumor O
and O
metastasis O
- O
is O
examined O
. O

However O
, O
we O
did O
not O
find O
any O
proof O
for O
protonation O
of O
CPT B
when O
it O
is O
encased O
by O
a O
beta B
- I
cyclodextrin I
cavity O
, O
which O
has O
a O
cavity O
size O
almost O
the O
same O
as O
that O
of O
CB7 B
. O

Furthermore O
, O
without O
the O
use O
of O
catalysts O
, O
the O
battery O
shows O
a O
low O
discharge O
/ O
charge O
potential O
gap O
of O
less O
than O
50 O
mV O
at O
a O
modest O
current O
density O
, O
which O
is O
the O
lowest O
one O
that O
has O
ever O
been O
reported O
in O
metal B
- I
oxygen I
batteries O
. O

CDCF B
uptake O
was O
time O
- O
and O
concentration O
- O
dependent O
( O
K O
( O
m O
) O
of O
4 O
. O
0 O
+ O
/ O
- O
1 O
. O
2 O
micro O
M O
and O
a O
V O
( O
max O
) O
of O
7 O
. O
8 O
+ O
/ O
- O
0 O
. O
9 O
pmol O
/ O
mg O
/ O
min O
) O
and O
inhibited O
by O
benzbromarone B
and O
MK B
- I
571 I
with O
IC O
( O
50 O
) O
values O
of O
1 O
. O
2 O
and O
7 O
. O
6 O
micro O
M O
, O
respectively O
. O

The O
meta B
- I
amino I
systems O
. O

To O
rationalize O
the O
efficient O
quenching O
of O
the O
fluorescence O
and O
the O
Z O
- O
- O
> O
E O
photoisomerization O
of O
m B
- I
ABDI I
, O
the O
meta B
- I
amino I
analogue O
of O
the O
green O
fluorescent O
protein O
( O
GFP O
) O
chromophore O
, O
in O
protic O
solvents O
, O
the O
femtosecond O
time O
- O
resolved O
fluorescence O
and O
transient O
infrared O
( O
TRIR O
) O
spectra O
of O
m B
- I
ABDI I
in O
CD3CN B
, O
CH3OH B
, O
and O
CD3OD B
are O
determined O
. O

To O
rationalize O
the O
efficient O
quenching O
of O
the O
fluorescence O
and O
the O
Z O
- O
- O
> O
E O
photoisomerization O
of O
m B
- I
ABDI I
, O
the O
meta B
- I
amino I
analogue O
of O
the O
green O
fluorescent O
protein O
( O
GFP O
) O
chromophore O
, O
in O
protic O
solvents O
, O
the O
femtosecond O
time O
- O
resolved O
fluorescence O
and O
transient O
infrared O
( O
TRIR O
) O
spectra O
of O
m B
- I
ABDI I
in O
CD3CN B
, O
CH3OH B
, O
and O
CD3OD B
are O
determined O
. O

To O
rationalize O
the O
efficient O
quenching O
of O
the O
fluorescence O
and O
the O
Z O
- O
- O
> O
E O
photoisomerization O
of O
m B
- I
ABDI I
, O
the O
meta B
- I
amino I
analogue O
of O
the O
green O
fluorescent O
protein O
( O
GFP O
) O
chromophore O
, O
in O
protic O
solvents O
, O
the O
femtosecond O
time O
- O
resolved O
fluorescence O
and O
transient O
infrared O
( O
TRIR O
) O
spectra O
of O
m B
- I
ABDI I
in O
CD3CN B
, O
CH3OH B
, O
and O
CD3OD B
are O
determined O
. O

For O
solutions O
in O
CD3CN B
, O
the O
fluorescence O
decay O
lifetime O
is O
~ O
7 O
. O
9 O
ns O
and O
IR O
absorption O
lines O
near O
1513 O
, O
1531 O
, O
1557 O
, O
and O
1613 O
cm O
( O
- O
1 O
) O
of O
m B
- I
ABDI I
in O
its O
electronically O
excited O
state O
were O
observed O
with O
a O
decay O
time O
> O
5 O
ns O
. O

In O
addition O
to O
IR O
absorption O
lines O
of O
m B
- I
ABDI I
in O
its O
electronically O
excited O
state O
with O
a O
decay O
time O
of O
~ O
16 O
ps O
, O
new O
features O
near O
1513 O
, O
1532 O
, O
1554 O
, O
and O
1592 O
cm O
( O
- O
1 O
) O
were O
observed O
to O
have O
a O
rise O
time O
of O
~ O
19 O
ps O
and O
a O
decay O
constant O
of O
~ O
58 O
ps O
, O
indicating O
formation O
of O
an O
intermediate O
. O

We O
conclude O
that O
the O
torsion O
of O
the O
exocyclic O
C B
= I
C I
bond O
( O
the O
tau O
torsion O
) O
is O
responsible O
for O
the O
nonradiative O
decay O
of O
electronically O
excited O
m B
- I
ABDI I
in O
CD3CN B
. O

We O
conclude O
that O
the O
torsion O
of O
the O
exocyclic O
C B
= I
C I
bond O
( O
the O
tau O
torsion O
) O
is O
responsible O
for O
the O
nonradiative O
decay O
of O
electronically O
excited O
m B
- I
ABDI I
in O
CD3CN B
. O

The O
new O
pathway O
is O
likely O
associated O
with O
excited O
- O
state O
proton O
transfer O
( O
ESPT O
) O
from O
the O
solvent O
to O
m B
- I
ABDI I
, O
particularly O
the O
carbonyl B
group O
, O
and O
generates O
an O
intermediate O
( O
ESPT O
* O
) O
that O
is O
weakly O
fluorescent O
. O

The O
surface O
containing O
a O
dimethylamine B
N I
- I
oxide I
headgroup O
and O
ethyl B
secondary I
amide I
linker O
showed O
the O
largest O
difference O
in O
adsorption O
of O
both O
proteins O
. O

Furthermore O
, O
inhibition O
of O
HO O
- O
1 O
with O
zinc B
protoporphyrin I
IX I
( O
ZNPP B
) O
significantly O
reversed O
the O
protective O
effect O
of O
Paeoniflorin B
against O
radiation O
- O
induced O
damage O
in O
EA O
. O
hy926 O
cells O
. O

At O
two O
sites O
that O
received O
high O
aqueous O
- O
phase O
entries O
of O
the O
pyrethroid O
lambda B
- I
cyhalothrin I
( O
logTUMax O
> O
- O
0 O
. O
6 O
) O
, O
the O
abundance O
and O
number O
of O
sensitive O
species O
in O
terms O
of O
the O
species O
at O
risk O
index O
decreased O
during O
the O
pesticide O
application O
period O
. O

The O
adsorption O
of O
the O
model O
perfumes O
phenyl B
ethanol I
, O
PE O
, O
and O
linalool B
, O
LL O
, O
at O
the O
air O
- O
solution O
interface O
by O
coadsorption O
with O
the O
anionic O
surfactant O
sodium B
dodecyl I
6 I
- I
benezene I
sulfonate I
, O
LAS B
- I
6 I
, O
has O
been O
studied O
primarily O
by O
neutron O
reflectivity O
, O
NR O
. O

At O
a O
LAS B
- I
6 I
concentration O
of O
0 O
. O
5 O
mM O
the O
adsorption O
of O
PE O
and O
LL O
is O
broadly O
similar O
but O
with O
the O
LL O
systematically O
more O
surface O
active O
, O
and O
at O
2 O
mM O
the O
LL O
completes O
more O
effectively O
for O
the O
surface O
than O
the O
PE O
. O

Changing O
the O
geometry O
of O
the O
LAS B
isomer O
, O
from O
the O
symmetrical O
LAS B
- I
6 I
geometry O
to O
the O
more O
asymmetrical O
LAS B
- I
4 I
, O
results O
in O
the O
LL O
competing O
more O
effectively O
for O
the O
surface O
due O
to O
changes O
in O
the O
packing O
constraints O
associated O
with O
the O
hydrophobic O
region O
. O

Changing O
the O
geometry O
of O
the O
LAS B
isomer O
, O
from O
the O
symmetrical O
LAS B
- I
6 I
geometry O
to O
the O
more O
asymmetrical O
LAS B
- I
4 I
, O
results O
in O
the O
LL O
competing O
more O
effectively O
for O
the O
surface O
due O
to O
changes O
in O
the O
packing O
constraints O
associated O
with O
the O
hydrophobic O
region O
. O

We O
found O
that O
the O
reaction O
is O
almost O
complete O
in O
solution O
at O
25 O
ms O
, O
giving O
rise O
to O
a O
major O
population O
composed O
of O
the O
trans B
- I
enamine I
intermediate O
. O

Exposure O
to O
lambda B
- I
cyhalothrin I
, O
a O
synthetic O
pyrethroid B
, O
increases O
reactive O
oxygen B
species O
production O
and O
induces O
genotoxicity O
in O
rat O
peripheral O
blood O
. O

Lambda B
- I
cyhalothrin I
( O
LTC B
) O
is O
a O
synthetic O
pyrethroid B
with O
a O
broad O
spectrum O
of O
insecticidal O
and O
acaricidal O
activities O
used O
to O
control O
a O
wide O
range O
of O
insect O
pests O
in O
a O
variety O
of O
applications O
. O

Protective O
role O
of O
L B
- I
carnitine I
and O
vitamin B
E I
on O
the O
testis O
of O
atherosclerotic O
rats O
. O

Triton B
WR I
1339 I
is O
a O
non O
- O
ionic O
detergent O
, O
which O
induces O
severe O
hyperlipidemia O
by O
inhibition O
of O
lipoprotein O
lipase O
. O

Data O
showed O
a O
significant O
increase O
in O
the O
levels O
of O
total O
cholesterol B
( O
TC O
) O
, O
triglycerides B
( O
TGs O
) O
, O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
, O
17 B
beta I
hydroxysteroid I
dehydrogenase O
( O
17 O
beta O
HSD O
) O
, O
testicular O
catalase O
and O
malondialdehyde B
( O
MDA B
) O
in O
G O
( O
2 O
) O
when O
compared O
with O
G O
( O
1 O
) O
, O
whereas O
high O
- O
density O
lipoprotein O
cholesterol B
( O
HDL O
- O
C O
) O
, O
serum O
testosterone B
, O
testicular O
17 O

The O
CRF O
( O
1 O
) O
receptor O
antagonist O
SSR125543 B
prevents O
stress O
- O
induced O
cognitive O
deficit O
associated O
with O
hippocampal O
dysfunction O
: O
Comparison O
with O
paroxetine B
and O
D B
- I
cycloserine I
. O

Effects O
of O
SSR125543 B
were O
compared O
to O
those O
of O
the O
5 B
- I
HT I
reuptake O
inhibitor O
, O
paroxetine B
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
and O
the O
partial O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
agonist O
, O
D B
- I
cycloserine I
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
two O
compounds O
which O
have O
demonstrated O
clinical O
efficacy O
against O
PTSD O
. O

Effects O
of O
SSR125543 B
were O
compared O
to O
those O
of O
the O
5 B
- I
HT I
reuptake O
inhibitor O
, O
paroxetine B
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
and O
the O
partial O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
agonist O
, O
D B
- I
cycloserine I
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
two O
compounds O
which O
have O
demonstrated O
clinical O
efficacy O
against O
PTSD O
. O

Both O
stress O
- O
induced O
effects O
were O
prevented O
by O
repeated O
administration O
of O
SSR125543 B
, O
paroxetine B
and O
D B
- I
cycloserine I
. O

Antimalarial O
activities O
of O
6 B
- I
iodouridine I
and O
its O
prodrugs O
and O
potential O
for O
combination O
therapy O
. O

6 B
- I
Iodouridine I
( O
15 O
) O
, O
a O
novel O
and O
potent O
inhibitor O
of O
orotidine B
5 I
' I
- I
monophosphate I
decarboxylase O
( O
ODCase O
) O
, O
exhibited O
efficacy O
in O
a O
mouse O
model O
infected O
by O
P O
. O
chabaudi O
chabaudi O
. O

To O
accommodate O
these O
observations O
, O
we O
propose O
that O
in O
aqueous O
media O
at O
neutral O
to O
slightly O
alkaline O
pH O
about O
3 O
% O
of O
the O
ethephon B
is O
converted O
( O
t1 O
/ O
2 O
= O
9 O
. O
9 O
h O
at O
pH O
7 O
. O
0 O
) O
into O
a O
cyclic B
oxaphosphetane I
which O
is O
the O
actual O
BChE O
inhibitor O
forming O
the O
2 B
- I
hydroxyethylphosphon I
adduct O
on O
BChE O
at O
Ser198 B
while O
about O
97 O
% O
of O
the O
ethephon B
breaks O
down O
to O
ethylene B
( O
t1 O
/ O
2 O
= O
11 O
- O
48 O
h O
at O
pH O
7 O
. O
0 O
) O
which O
is O
responsible O
for O
plant O
growth O

NSPCs O
were O
also O
more O
resistant O
than O
neurons O
to O
mitochondrial O
cyanide B
toxicity O
, O
less O
capable O
of O
utilizing O
galactose B
as O
an O
alternative O
substrate O
to O
glucose B
, O
and O
more O
susceptible O
to O
pharmacological O
inhibition O
of O
the O
pentose B
phosphate I
pathway O
by O
6 B
- I
aminonicotinamide I
. O

These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd B
/ O
C B
- I
Cu I
mediated O
coupling O
- O
cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O
1 B
- I
( I
prop I
- I
2 I
- I
ynyl I
) I
- I
1 I
' I
H I
- I
spiro I
[ I
indoline I
- I
3 I
, I
2 I
' I
- I
quinazoline I
] I
- I
2 I
, I
4 I
' I
( I
3 I
' I
H I
) I
- I
dione I
with O
2 B
- I
iodoanilides I
. O

These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd B
/ O
C B
- I
Cu I
mediated O
coupling O
- O
cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O
1 B
- I
( I
prop I
- I
2 I
- I
ynyl I
) I
- I
1 I
' I
H I
- I
spiro I
[ I
indoline I
- I
3 I
, I
2 I
' I
- I
quinazoline I
] I
- I
2 I
, I
4 I
' I
( I
3 I
' I
H I
) I
- I
dione I
with O
2 B
- I
iodoanilides I
. O

The O
multi O
- O
differentiation O
capacity O
of O
hBMSC O
was O
evaluated O
by O
Oil B
Red I
O I
and O
van O
Kossa O
staining O
. O

Linoleic B
acid I
autoxidation O
inhibitions O
on O
all O
fractions O
were O
higher O
than O
that O
on O
alpha B
- I
tocopherol I
. O

These O
compounds O
effectively O
ameliorated O
all O
the O
altered O
cardiovascular O
risk O
parameters O
via O
a O
reduction O
in O
HMG B
- I
CoA I
reductase O
activity O
, O
along O
with O
an O
increase O
in O
arylesterase O
activity O
. O

Emulsified O
oils O
had O
lower O
detectable O
lipid O
hydroperoxide B
and O
p B
- I
Anisidine I
values O
than O
their O
corresponding O
bulk O
oils O
( O
P O
< O
0 O
. O
05 O
) O
. O

The O
lipid O
hydroperoxide B
and O
p B
- I
Anisidine I
values O
of O
emulsions O
generally O
decreased O
as O
sodium B
caseinate O
concentration O
increased O
, O
and O
similarly O
decreased O
as O
microfluidisation O
pressure O
increased O
( O
P O
< O
0 O
. O
05 O
) O
. O

Major O
antioxidant O
phenolic B
compounds O
identified O
in O
this O
study O
included O
proanthocyanidins B
, O
phenolic B
acids I
and O
gamma B
- I
oryzanols I
( O
ferulic B
acid I
derivatives O
) O
. O

Hydroxytyrosyl B
ethyl I
ether I
exhibits O
stronger O
intestinal O
anticarcinogenic O
potency O
and O
effects O
on O
transcript O
profiles O
compared O
to O
hydroxytyrosol B
. O

The O
anticarcinogenic O
activity O
of O
hydroxytyrosyl B
ethyl I
ether I
( O
HTy B
- I
Et I
) O
compared O
to O
its O
precursor O
hydroxytyrosol B
( O
HTy B
) O
has O
been O
studied O
in O
human O
Caco O
- O
2 O
colon O
adenocarcinoma O
cells O
. O

The O
anticarcinogenic O
activity O
of O
hydroxytyrosyl B
ethyl I
ether I
( O
HTy B
- I
Et I
) O
compared O
to O
its O
precursor O
hydroxytyrosol B
( O
HTy B
) O
has O
been O
studied O
in O
human O
Caco O
- O
2 O
colon O
adenocarcinoma O
cells O
. O

451 O
and O
977 O
genes O
were O
differentially O
expressed O
in O
Caco O
- O
2 O
cells O
exposed O
to O
HTy B
or O
HTy B
- I
Et I
for O
24h O
, O
respectively O
, O
compared O
with O
untreated O
cells O
( O
P O
< O
0 O
. O
005 O
; O
FDR O
= O
0 O
) O
, O
using O
Affymetrix O
microarrays O
. O

Results O
showed O
that O
both O
HTy B
and O
HTy B
- I
Et I
inhibited O
cell O
proliferation O
and O
arrested O
the O
cell O
cycle O
by O
up O
- O
regulating O
p21 O
and O
CCNG2 O
and O
down O
- O
regulating O
CCNB1 O
protein O
expression O
. O

HTy B
and O
HTy B
- I
Et I
also O
altered O
the O
transcription O
of O
specific O
genes O
involved O
in O
apoptosis O
, O
as O
suggested O
by O
the O
up O
- O
regulation O
of O
BNIP3 O
, O
BNIP3L O
, O
PDCD4 O
and O
ATF3 O
and O
the O
activation O
of O
caspase O
- O
3 O
. O

In O
conclusion O
, O
these O
results O
highlight O
that O
HTy B
and O
its O
derivative O
HTy B
- I
Et I
modulate O
molecular O
mechanisms O
involved O
in O
colon O
cancer O
, O
with O
HTy B
- I
Et I
being O
more O
effective O
than O
HTy B
. O

In O
conclusion O
, O
these O
results O
highlight O
that O
HTy B
and O
its O
derivative O
HTy B
- I
Et I
modulate O
molecular O
mechanisms O
involved O
in O
colon O
cancer O
, O
with O
HTy B
- I
Et I
being O
more O
effective O
than O
HTy B
. O

The O
aim O
of O
this O
research O
was O
to O
characterise O
the O
dialdehydic B
form O
of O
decarboxymethyl B
elenolic I
acid I
linked O
to O
hydroxytyrosol B
( O
3 B
, I
4 I
- I
DHPEA I
- I
EDA I
) O
oxidation O
products O
to O
find O
analytical O
indicators O
that O
could O
be O
used O
as O
early O
evaluation O
index O
of O
the O
VOO O
autoxidation O
state O
. O

The O
highest O
alpha B
- I
amino I
group O
content O
was O
observed O
in O
gelatin O
extracted O
at O
55 O
degrees O
C O
without O
SBTI O
incorporated O
. O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

pyrazine B
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

pyrazine B
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

pyrazine B
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

pyrazine B
, O
and O
several O
alkyl B
- I
pyrazines I
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 B
- I
methylfurfural I
/ O
2 B
, I
5 I
- I
dimethylpyrazine I
, O
5 B
- I
methylfurfural I
/ O
2 B
- I
methylpyrazine I
, O
2 B
, I
5 I
- I
dimethylpyrazine I
/ O
2 B
, I
3 I
- I
dimethylpyrazine I
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

Concentrations O
of O
PCDD B
/ I
Fs I
, O
dioxin B
- I
like I
PCBs I
, O
PBDEs B
, O
and O
hexachlorobenzene B
in O
fat O
samples O
from O
cattle O
of O
different O
ages O
and O
gender O
in O
Korea O
. O

Polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and I
dibenzofurans I
( O
PCDD B
/ I
Fs I
) O
, O
dioxin B
- I
like I
polychlorinated I
biphenyls I
( O
DL B
- I
PCBs I
) O
, O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
and O
hexachlorobenzene B
( O
HCB B
) O
concentrations O
were O
determined O
in O
abdominal O
fat O
samples O
from O
30 O
cattle O
. O

Polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and I
dibenzofurans I
( O
PCDD B
/ I
Fs I
) O
, O
dioxin B
- I
like I
polychlorinated I
biphenyls I
( O
DL B
- I
PCBs I
) O
, O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
and O
hexachlorobenzene B
( O
HCB B
) O
concentrations O
were O
determined O
in O
abdominal O
fat O
samples O
from O
30 O
cattle O
. O

Polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and I
dibenzofurans I
( O
PCDD B
/ I
Fs I
) O
, O
dioxin B
- I
like I
polychlorinated I
biphenyls I
( O
DL B
- I
PCBs I
) O
, O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
and O
hexachlorobenzene B
( O
HCB B
) O
concentrations O
were O
determined O
in O
abdominal O
fat O
samples O
from O
30 O
cattle O
. O

The O
concentration O
of O
PCDD B
/ I
Fs I
ranged O
from O
0 O
. O
01 O
to O
1 O
. O
36 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
DL B
- I
PCBs I
ranged O
from O
0 O
. O
17 O
to O
1 O
. O
64 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
PBDEs B
ranged O
from O
135 O
to O
725 O
pgg O
( O
- O
1 O
) O
fat O
, O
and O
HCB B
ranged O
from O
25 O
. O
5 O
to O
2061 O
pgg O
( O
- O
1 O
) O
fat O
. O

The O
concentration O
of O
PCDD B
/ I
Fs I
ranged O
from O
0 O
. O
01 O
to O
1 O
. O
36 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
DL B
- I
PCBs I
ranged O
from O
0 O
. O
17 O
to O
1 O
. O
64 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
PBDEs B
ranged O
from O
135 O
to O
725 O
pgg O
( O
- O
1 O
) O
fat O
, O
and O
HCB B
ranged O
from O
25 O
. O
5 O
to O
2061 O
pgg O
( O
- O
1 O
) O
fat O
. O

A O
comparison O
between O
cattle O
' O
s O
age O
and O
gender O
vs O
. O
the O
concentration O
of O
contaminants O
revealed O
higher O
concentrations O
of O
PCDD B
/ I
Fs I
and O
DL B
- I
PCBs I
in O
cattle O
aged O
more O
than O
3 O
years O
; O
no O
difference O
between O
genders O
was O
apparent O
. O

A O
comparison O
between O
cattle O
' O
s O
age O
and O
gender O
vs O
. O
the O
concentration O
of O
contaminants O
revealed O
higher O
concentrations O
of O
PCDD B
/ I
Fs I
and O
DL B
- I
PCBs I
in O
cattle O
aged O
more O
than O
3 O
years O
; O
no O
difference O
between O
genders O
was O
apparent O
. O

A O
single O
band O
was O
observed O
at O
58 O
kDa O
using O
sodium B
dodecyl I
sulphate I
gel O
electrophoresis O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate B
, O
EGTA B
, O
Na B
( I
2 I
) I
EDTA I
, O
l B
- I
cysteine I
and O
beta B
- I
mercaptoethanol I
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

Using O
RT O
- O
PCR O
, O
the O
GAD O
cDNA O
was O
sequenced O
which O
indicated O
1787 O
bp O
long O
, O
containing O
a O
1527 O
bp O
open O
reading O
frame O
( O
ORF O
) O
that O
encoded O
509 O
amino B
- I
acid I
peptides O
with O
a O
calculated O
molecular O
weight O
of O
57 O
. O
74 O
kDa O
and O
a O
pI O
of O
5 O
. O
41 O
( O
GenBank O
accession O
number O
: O
JX444699 O
) O
. O

Vibrational O
and O
quantum O
chemical O
studies O
suggest O
the O
presence O
of O
the O
syn O
and O
anti O
conformers O
( O
SCN B
group O
with O
respect O
to O
the O
C B
= I
O I
bond O
) O
in O
the O
gas O
phase O
for O
both O
constitutional O
isomers O
. O

Here O
the O
CAF O
is O
applied O
to O
fluidity O
data O
of O
pure O
n B
- I
acetates I
, O
2 B
- I
ketones I
, O
n B
- I
nitriles I
, O
and O
n B
- I
alcohols I
over O
the O
temperature O
range O
5 O
- O
85 O
degrees O
C O
. O

Here O
the O
CAF O
is O
applied O
to O
fluidity O
data O
of O
pure O
n B
- I
acetates I
, O
2 B
- I
ketones I
, O
n B
- I
nitriles I
, O
and O
n B
- I
alcohols I
over O
the O
temperature O
range O
5 O
- O
85 O
degrees O
C O
. O

Here O
the O
CAF O
is O
applied O
to O
fluidity O
data O
of O
pure O
n B
- I
acetates I
, O
2 B
- I
ketones I
, O
n B
- I
nitriles I
, O
and O
n B
- I
alcohols I
over O
the O
temperature O
range O
5 O
- O
85 O
degrees O
C O
. O

Here O
the O
CAF O
is O
applied O
to O
fluidity O
data O
of O
pure O
n B
- I
acetates I
, O
2 B
- I
ketones I
, O
n B
- I
nitriles I
, O
and O
n B
- I
alcohols I
over O
the O
temperature O
range O
5 O
- O
85 O
degrees O
C O
. O

We O
find O
that O
the O
activation O
energies O
for O
fluidity O
of O
the O
aprotic O
liquids O
are O
comparable O
in O
value O
, O
whereas O
a O
higher O
average O
E O
( O
a O
) O
value O
is O
observed O
for O
the O
n B
- I
alcohol I
data O
. O

A O
novel O
4 B
- I
fluoroquinuclidine I
significantly O
lowered O
the O
pKa O
of O
the O
quinuclidine B
moiety O
, O
reducing O
efflux O
as O
measured O
by O
a O
Caco O
- O
2 O
assay O
. O

Colitis O
was O
induced O
in O
mice O
by O
intracolonic O
administration O
of O
dinitrobenzene B
sulphonic I
acid I
( O
DNBS B
) O
. O

11 B
beta I
- I
Hydroxysteroid I
dehydrogenase O
1 O
( O
11 O
beta O
HSD1 O
; O
EC O
1 O
. O
1 O
. O
1 O
. O
146 O
) O
generates O
active O
glucocorticoids O
from O
inert O
11 B
- I
keto I
metabolites O
. O

However O
, O
it O
can O
also O
metabolize O
alternative O
substrates O
, O
including O
7 B
beta I
- I
hydroxy I
- I
and I
7 I
- I
keto I
- I
cholesterol I
( O
7 B
beta I
OHC I
, O
7KC B
) O
. O

We O
used O
genetically O
modified O
mice O
to O
investigate O
the O
contribution O
of O
11 O
beta O
HSD1 O
to O
the O
balance O
of O
circulating O
levels O
of O
7KC B
and O
7 B
beta I
OHC I
in O
vivo O
, O
and O
dissected O
in O
vitro O
the O
kinetics O
of O
the O
interactions O
between O
oxysterols B
and O
glucocorticoids O
for O
metabolism O
by O
the O
mouse O
enzyme O
. O

Circulating O
levels O
of O
7KC B
and O
7 B
beta I
OHC I
in O
mice O
were O
91 O
. O
3 O
+ O
/ O
- O
22 O
. O
3 O
and O
22 O
. O
6 O
+ O
/ O
- O
5 O
. O
7nM O
respectively O
, O
increasing O
to O
1240 O
+ O
/ O
- O
220 O
and O
406 O
+ O
/ O
- O
39nM O
in O
ApoE O
( O
- O
/ O
- O
) O
mice O
receiving O
atherogenic O
western O
diet O
. O

Disruption O
of O
11 O
beta O
HSD1 O
in O
mice O
increased O
( O
p O
< O
0 O
. O
05 O
) O
the O
7KC B
/ O
7 B
beta I
OHC I
ratio O
in O
plasma O
( O
by O
20 O
% O
) O
and O
also O
in O
isolated O
microsomes O
( O
2 O
fold O
) O
. O

The O
7KC B
/ O
7 B
beta I
OHC I
ratio O
was O
similarly O
increased O
when O
NADPH B
generation O
was O
restricted O
by O
disruption O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

Reduction O
and O
oxidation O
of O
7 B
- I
oxysterols I
by O
murine O
11 O
beta O
HSD1 O
proceeded O
more O
slowly O
and O
substrate O
affinity O
was O
lower O
than O
for O
glucocorticoids O
. O
in O
vitro O
7 B
beta I
OHC I
was O
a O
competitive O
inhibitor O
of O
oxidation O
of O
corticosterone B
( O
Ki O
= O
0 O
. O
9 O
mu O
M O
) O
, O
whereas O
7KC B
only O
weakly O
inhibited O
reduction O
of O
11 B
- I
dehydrocorticosteron I
. O

Reduction O
and O
oxidation O
of O
7 B
- I
oxysterols I
by O
murine O
11 O
beta O
HSD1 O
proceeded O
more O
slowly O
and O
substrate O
affinity O
was O
lower O
than O
for O
glucocorticoids O
. O
in O
vitro O
7 B
beta I
OHC I
was O
a O
competitive O
inhibitor O
of O
oxidation O
of O
corticosterone B
( O
Ki O
= O
0 O
. O
9 O
mu O
M O
) O
, O
whereas O
7KC B
only O
weakly O
inhibited O
reduction O
of O
11 B
- I
dehydrocorticosteron I
. O

Reduction O
and O
oxidation O
of O
7 B
- I
oxysterols I
by O
murine O
11 O
beta O
HSD1 O
proceeded O
more O
slowly O
and O
substrate O
affinity O
was O
lower O
than O
for O
glucocorticoids O
. O
in O
vitro O
7 B
beta I
OHC I
was O
a O
competitive O
inhibitor O
of O
oxidation O
of O
corticosterone B
( O
Ki O
= O
0 O
. O
9 O
mu O
M O
) O
, O
whereas O
7KC B
only O
weakly O
inhibited O
reduction O
of O
11 B
- I
dehydrocorticosteron I
. O

However O
, O
supplementation O
of O
7 B
- I
oxysterols I
in O
cultured O
cells O
, O
secondary O
to O
cholesterol B
loading O
, O
preferentially O
slowed O
reduction O
of O
glucocorticoids O
, O
rather O
than O
oxidation O
. O

Thus O
, O
in O
mouse O
, O
11 O
beta O
HSD1 O
influenced O
the O
abundance O
and O
balance O
of O
circulating O
and O
tissue O
levels O
of O
7 B
beta I
OHC I
and O
7KC B
, O
promoting O
reduction O
of O
7KC B
. O

In O
health O
, O
7 B
- I
oxysterols I
are O
unlikely O
to O
regulate O
glucocorticoid O
metabolism O
. O

However O
, O
in O
hyperlipidaemia O
, O
7 B
- I
oxysterols I
may O
inhibit O
glucocorticoid O
metabolism O
and O
modulate O
signaling O
through O
corticosteroid B
receptors O
. O

Aza B
- I
BODIPY I
: O
improved O
synthesis O
and O
interaction O
with O
soluble O
A O
beta O
1 O
- O
42 O
oligomers O
. O

Aza B
- I
BODIPY I
dye O
, O
which O
has O
both O
excitation O
and O
emission O
maxima O
above O
600nm O
, O
exhibits O
a O
significant O
increase O
in O
its O
fluorescence O
intensity O
in O
the O
presence O
of O
soluble O
oligomers O
of O
A O
beta O
1 O
- O
42 O
. O

These O
results O
indicate O
that O
aza B
- I
BODIPY I
could O
serve O
as O
a O
near O
- O
IR O
probe O
for O
detecting O
conformational O
changes O
of O
A O
beta O
1 O
- O
42 O
soluble O
oligomers O
in O
vitro O
, O
and O
it O
should O
eliminate O
false O
- O
positive O
effects O
that O
are O
associated O
with O
currently O
utilized O
thioflavin B
T I
- O
based O
dyes O
. O

In O
addition O
, O
a O
facile O
synthesis O
of O
aza B
- I
BODIPY I
has O
been O
developed O
, O
which O
might O
further O
expand O
the O
applications O
of O
this O
dye O
. O

Plasma O
samples O
of O
0 O
. O
2 O
ml O
were O
processed O
by O
liquid O
- O
liquid O
extraction O
with O
n B
- I
hexane I
/ O
ethyl B
acetate I
( O
2 O
: O
1 O
, O
v O
/ O
v O
) O
. O

Three O
new O
norlignans B
, O
glechomols B
A I
- I
C I
( O
1 O
- O
3 O
, O
respectively O
) O
, O
together O
with O
a O
known O
compound O
, O
4 B
- I
ethylcatechol I
( O
4 O
) O
, O
were O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
Glechoma O
longituba O
( O
NaKai O
) O
Kupr O
. O

Co O
- O
delivery O
of O
10 B
- I
Hydroxycamptothecin I
with O
Doxorubicin B
Conjugated O
Prodrugs O
for O
Enhanced O
Anticancer O
Efficacy O
. O

The O
amphiphilic O
prodrugs O
form O
self O
- O
assembled O
nanoparticles O
in O
deionized O
water O
and O
encapsulate O
the O
hydrophobic O
anticancer O
drug O
10 B
- I
hydroxycamptothecin I
( O
HCPT B
) O
with O
a O
high O
drug O
loading O
efficiency O
. O

In O
vitro O
methyl B
thiazolyl I
tetrazolium I
( O
MTT B
) O
assays O
and O
drug O
- O
induced O
apoptosis O
tests O
demonstrate O
the O
HCPT B
- O
loaded O
nanoparticles O
suppress O
cancer O
cell O
growth O
more O
efficiently O
than O
the O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
prodrugs O
, O
free O
HCPT B
, O
and O
physical O
mixtures O
of O
MPEG B
- I
b I
- I
PAMAM I
- I
DOX I
and O
HCPT B
at O
equivalent O
DOX B
or O
HCPT B
doses O
. O

Pharmacokinetics O
of O
lactone B
form O
( O
GB B
- I
lac I
) O
and O
the O
total O
of O
the O
lactone B
and O
carboxylate B
form O
( O
GB O
- O
tot O
) O
of O
ginkgolide B
B I
were O
investigated O
after O
intravenous O
administration O
of O
a O
dose O
of O
4 O
mg O
/ O
kg O
ginkgolide B
B I
. O

The O
AUC0 O
- O
infinity O
of O
GB B
- I
lac I
constituted O
63 O
. O
5 O
+ O
/ O
- O
17 O
. O
4 O
% O
of O
the O
AUC0 O
- O
infinity O
of O
GB O
- O
tot O
. O

Metabolic O
dephenylation O
of O
the O
rubber O
antioxidant O
N B
- I
phenyl I
- I
2 I
- I
naphthylamine I
to O
carcinogenic O
2 B
- I
naphthylamine I
in O
rats O
. O

Technical O
- O
grade O
P2NA B
was O
contaminated O
with O
carcinogenic O
2 B
- I
naphthylamine I
( O
2NA B
) O
, O
and O
bladder O
cancer O
risk O
in O
exposed O
workers O
was O
attributed O
to O
this O
impurity O
. O

Effect O
of O
bisphenol B
- I
A I
on O
insulin O
signal O
transduction O
and O
glucose B
oxidation O
in O
skeletal O
muscle O
of O
adult O
male O
albino O
rat O
. O

The O
estrogenic O
monomer O
bisphenol B
- I
A I
( O
BPA B
) O
is O
an O
endocrine O
- O
disrupting O
chemical O
used O
in O
the O
production O
of O
epoxy B
resins O
, O
plastic O
food O
and O
beverage O
containers O
, O
leading O
to O
ubiquitous O
human O
exposure O
. O

Antinociceptive O
effect O
of O
7 B
- I
methoxyflavone I
isolated O
from O
Zornia O
brasiliensis O
. O

In O
this O
study O
, O
we O
investigated O
the O
antinociceptive O
effect O
of O
7 B
- I
methoxyflavone I
( O
7MF B
) O
in O
mice O
using O
the O
following O
tests O
: O
acetic B
acid I
- O
induced O
writhing O
, O
glutamate B
- O
and O
formalin B
- O
induced O
nociception O
and O
hotplate O
. O

Tetraarylmethane B
compounds O
consisting O
of O
two O
pyrogallol B
and O
two O
aniline B
units O
, O
namely O
, O
Ar2CAr B
' I
2 I
{ O
Ar O
= O
3 B
, I
4 I
, I
5 I
- I
C6H2 I
( I
OH I
) I
3 I
and O
Ar O
' O
= O
3 B
, I
5 I
- I
R2 I
- I
4 I
- I
C6H2NH2 I
[ O
R O
= O
Me O
( O
1 O
) O
, O
iPr B
( O
2 O
) O
] O
} O
exhibit O
excellent O
self O
- O
assembly O
behavior O
. O

A O
transition O
from O
soft O
to O
exchange O
coupled O
to O
hard O
magnetic O
properties O
was O
obtained O
by O
varying O
the O
composition O
of O
NdxFe1 B
- I
xB8 I
( O
x O
varies O
from O
7 O
% O
to O
40 O
% O
) O
. O

Acyl B
- I
CoA I
Synthetase O
1 O
Is O
Induced O
by O
Gram O
- O
negative O
Bacteria O
and O
Lipopolysaccharide O
and O
Is O
Required O
for O
Phospholipid O
Turnover O
in O
Stimulated O
Macrophages O
. O

The O
enzyme O
acyl B
- I
CoA I
synthetase O
1 O
( O
ACSL1 O
) O
is O
induced O
by O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
( O
PPAR O
alpha O
) O
and O
PPAR O
gamma O
in O
insulin O
target O
tissues O
, O
such O
as O
skeletal O
muscle O
and O
adipose O
tissue O
, O
and O
plays O
an O
important O
role O
in O
beta O
- O
oxidation O
in O
these O
tissues O
. O

A O
self O
- O
assembled O
monolayer O
of O
11 B
- I
mercaptoundecanols I
on O
the O
gold O
microshell O
offered O
an O
easy O
and O
reliable O
way O
to O
electrically O
insulate O
from O
the O
underlying O
flat O
Pt B
electrode O
and O
accomplish O
in O
situ O
monitoring O
the O
electrochemical O
reaction O
with O
minimal O
interference O
. O

Form O
- O
stable O
resorbable O
networks O
are O
prepared O
by O
gamma O
irradiating O
trimethylene B
carbonate I
( O
TMC B
) O
- O
and O
epsilon B
- I
caprolactone I
( O
CL O
) O
- O
based O
( O
co O
) O
polymer O
films O
. O

The O
entrapment O
efficiency O
of O
fluorescein B
- I
isothiocyanate I
( O
FITC B
) O
- O
dextran O
as O
model O
drug O
was O
determined O
to O
50 O
% O
with O
no O
substantial O
effect O
on O
particle O
size O
. O

We O
found O
that O
atorvastatin B
withdrawal O
decreased O
levels O
of O
nitric B
oxide I
and O
mitochondrial O
superoxide B
dismutase O
activity O
, O
whereas O
increased O
NADPH B
oxidase O
activity O
and O
immunoreactivity O
for O
the O
protein O
nitration O
marker O
3 B
- I
nitrotyrosine I
in O
the O
cerebral O
cortex O
. O

Immunoprecipitation O
of O
mitochondrial O
SOD O
followed O
by O
analysis O
of O
3 B
- I
nitrotyrosine I
revealed O
increased O
levels O
of O
nitrated O
mitochondrial O
SOD O
, O
suggesting O
the O
mechanism O
underlying O
the O
atorvastatin B
withdrawal O
- O
induced O
decrease O
in O
enzyme O
activity O
. O

We O
administered O
a O
mixture O
of O
AFCAs O
( O
Eritrosin B
, O
Ponceau B
4R I
, O
Allura B
Red I
AC I
, O
Sunset B
Yellow I
FCF I
, O
Tartrazin B
, O
Amaranth B
, O
Brilliant B
Blue I
, O
Azorubin B
and O
Indigotin B
) O
to O
female O
rats O
before O
and O
during O
gestation O
. O

We O
administered O
a O
mixture O
of O
AFCAs O
( O
Eritrosin B
, O
Ponceau B
4R I
, O
Allura B
Red I
AC I
, O
Sunset B
Yellow I
FCF I
, O
Tartrazin B
, O
Amaranth B
, O
Brilliant B
Blue I
, O
Azorubin B
and O
Indigotin B
) O
to O
female O
rats O
before O
and O
during O
gestation O
. O

Metallothionein O
1A O
polymorphisms O
may O
influence O
urine O
uric B
acid I
and O
N B
- I
acetyl I
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
) O
excretion O
in O
chronic O
lead O
- O
exposed O
workers O
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
association O
of O
blood O
lead O
levels O
, O
urinary O
uric B
acid I
( O
UA O
) O
and O
N B
- I
acetyl I
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
) O
in O
chronic O
occupational O
lead O
- O
exposed O
workers O
, O
and O
to O
study O
whether O
the O
association O
was O
influenced O
by O
MT1A O
gene O
polymorphisms O
. O

Effect O
of O
Ketoconazole B
on O
the O
Pharmacokinetics O
of O
the O
11 B
beta I
- I
Hydroxysteroid I
Dehydrogenase O
Type O
1 O
Inhibitor O
ABT B
- I
384 I
and O
Its O
Two O
Active O
Metabolites O
in O
Healthy O
Volunteers O
: O
Population O
Analysis O
of O
Data O
from O
a O
Drug O
- O
Drug O
Interaction O
Study O
. O

ABT B
- I
384 I
[ O
1 B
- I
piperazineacetamide I
, I
N I
- I
[ I
5 I
- I
( I
aminocarbonyl I
) I
tricyclo I
[ I
3 I
. I
3 I
. I
1 I
. I
13 I
, I
7 I
] I
dec I
- I
2 I
- I
yl I
] I
- I
alpha I
, I
alpha I
- I
dimethyl I
- I
4 I
- I
[ I
5 I
- I
( I
trifluoromethyl I
) I
- I
2 I
- I
pyridinyl I
] I
- O
, O
stereoisomer O
] O
is O
a O
potent O
and O
selective O
inhibitor O
of O
11 B
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
( O
HSD O
- O
1 O
) O
. O

ABT B
- I
384 I
has O
been O
shown O
to O
be O
safe O
and O
well O
tolerated O
in O
humans O
at O
doses O
up O
to O
100 O
mg O
daily O
, O
and O
to O
fully O
inhibit O
both O
peripheral O
and O
brain O
HSD O
- O
1 O
at O
a O
dose O
of O
2 O
mg O
daily O
. O

The O
effect O
of O
ketoconazole B
on O
the O
pharmacokinetics O
of O
ABT B
- I
384 I
and O
its O
two O
active O
metabolites O
, O
A B
- I
1331480 I
and O
A B
- I
847082 I
, O
was O
investigated O
in O
healthy O
volunteers O
. O

The O
effect O
of O
ketoconazole B
on O
the O
pharmacokinetics O
of O
ABT B
- I
384 I
and O
its O
two O
active O
metabolites O
, O
A B
- I
1331480 I
and O
A B
- I
847082 I
, O
was O
investigated O
in O
healthy O
volunteers O
. O

The O
effect O
of O
ketoconazole B
on O
the O
pharmacokinetics O
of O
ABT B
- I
384 I
and O
its O
two O
active O
metabolites O
, O
A B
- I
1331480 I
and O
A B
- I
847082 I
, O
was O
investigated O
in O
healthy O
volunteers O
. O

When O
10 O
mg O
of O
ABT B
- I
384 I
was O
coadministered O
with O
ketoconazole B
, O
ABT B
- I
384 I
exposures O
increased O
18 O
- O
fold O
for O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
from O
time O
0 O
to O
infinity O
and O
3 O
. O
5 O
- O
fold O
for O
Cmax O
. O

When O
10 O
mg O
of O
ABT B
- I
384 I
was O
coadministered O
with O
ketoconazole B
, O
ABT B
- I
384 I
exposures O
increased O
18 O
- O
fold O
for O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
from O
time O
0 O
to O
infinity O
and O
3 O
. O
5 O
- O
fold O
for O
Cmax O
. O

The O
results O
suggest O
that O
ABT B
- I
384 I
is O
a O
sensitive O
substrate O
of O
CYP3A O
. O

After O
ketoconazole B
coadministration O
, O
exposures O
of O
A B
- I
1331480 I
and O
A B
- I
847082 I
were O
also O
greatly O
increased O
. O

After O
ketoconazole B
coadministration O
, O
exposures O
of O
A B
- I
1331480 I
and O
A B
- I
847082 I
were O
also O
greatly O
increased O
. O

A O
population O
pharmacokinetic O
model O
was O
constructed O
for O
ABT B
- I
384 I
and O
its O
metabolites O
using O
NonMEM O
. O

A O
two O
- O
compartment O
model O
with O
three O
transit O
absorption O
compartments O
best O
described O
ABT B
- I
384 I
data O
. O

The O
model O
predicted O
a O
69 O
. O
3 O
% O
decrease O
in O
ABT B
- I
384 I
clearance O
and O
91 O
. O
1 O
% O
increase O
in O
the O
volume O
of O
distribution O
of O
ABT B
- I
384 I
in O
the O
presence O
of O
ketoconazole B
. O

The O
model O
predicted O
a O
69 O
. O
3 O
% O
decrease O
in O
ABT B
- I
384 I
clearance O
and O
91 O
. O
1 O
% O
increase O
in O
the O
volume O
of O
distribution O
of O
ABT B
- I
384 I
in O
the O
presence O
of O
ketoconazole B
. O

A B
- I
1331480 I
was O
shown O
to O
be O
formation O
rate O
- O
limited O
and O
A B
- I
847082 I
was O
elimination O
rate O
- O
limited O
. O

A B
- I
1331480 I
was O
shown O
to O
be O
formation O
rate O
- O
limited O
and O
A B
- I
847082 I
was O
elimination O
rate O
- O
limited O
. O

Overall O
the O
model O
adequately O
captured O
the O
concentration O
- O
time O
profiles O
of O
ABT B
- I
384 I
, O
A B
- I
1331480 I
, O
and O
A B
- I
847082 I
in O
both O
ABT B
- I
384 I
- O
alone O
and O
ketoconazole B
- O
coadministration O
conditions O
. O

Overall O
the O
model O
adequately O
captured O
the O
concentration O
- O
time O
profiles O
of O
ABT B
- I
384 I
, O
A B
- I
1331480 I
, O
and O
A B
- I
847082 I
in O
both O
ABT B
- I
384 I
- O
alone O
and O
ketoconazole B
- O
coadministration O
conditions O
. O

Overall O
the O
model O
adequately O
captured O
the O
concentration O
- O
time O
profiles O
of O
ABT B
- I
384 I
, O
A B
- I
1331480 I
, O
and O
A B
- I
847082 I
in O
both O
ABT B
- I
384 I
- O
alone O
and O
ketoconazole B
- O
coadministration O
conditions O
. O

Overall O
the O
model O
adequately O
captured O
the O
concentration O
- O
time O
profiles O
of O
ABT B
- I
384 I
, O
A B
- I
1331480 I
, O
and O
A B
- I
847082 I
in O
both O
ABT B
- I
384 I
- O
alone O
and O
ketoconazole B
- O
coadministration O
conditions O
. O

Although O
ABT B
- I
384 I
exposures O
were O
greatly O
increased O
in O
the O
presence O
of O
ketoconazole B
, O
coadministration O
of O
ABT B
- I
384 I
with O
ketoconazole B
or O
other O
strong O
/ O
moderate O
CYP3A O
inhibitors O
is O
not O
expected O
to O
contribute O
to O
any O
major O
clinical O
safety O
issues O
considering O
the O
favorable O
safety O
profile O
of O
ABT B
- I
384 I
. O

Although O
ABT B
- I
384 I
exposures O
were O
greatly O
increased O
in O
the O
presence O
of O
ketoconazole B
, O
coadministration O
of O
ABT B
- I
384 I
with O
ketoconazole B
or O
other O
strong O
/ O
moderate O
CYP3A O
inhibitors O
is O
not O
expected O
to O
contribute O
to O
any O
major O
clinical O
safety O
issues O
considering O
the O
favorable O
safety O
profile O
of O
ABT B
- I
384 I
. O

Although O
ABT B
- I
384 I
exposures O
were O
greatly O
increased O
in O
the O
presence O
of O
ketoconazole B
, O
coadministration O
of O
ABT B
- I
384 I
with O
ketoconazole B
or O
other O
strong O
/ O
moderate O
CYP3A O
inhibitors O
is O
not O
expected O
to O
contribute O
to O
any O
major O
clinical O
safety O
issues O
considering O
the O
favorable O
safety O
profile O
of O
ABT B
- I
384 I
. O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

In O
addition O
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
2 B
, I
3 I
- I
dihydroxy I
- I
2 I
, I
3 I
- I
dihydrofluoranthene I
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 B
- I
nitropyrene I
, O
1 B
- I
acetylpyrene I
, O
2 B
- I
acetylpyrene I
, O
2 B
, I
5 I
, I
2 I
' I
, I
5 I
' I
- I
tetrachlorobiphenyl I
, O
7 B
- I
hydroxyflavone I
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

Coumarin B
7 O
- O
hydroxylation O
, O
catalyzed O
by O
P450 O
2A13 O
, O
was O
strongly O
inhibited O
by O
2 B
' I
- I
methoxy I
- I
5 I
, I
7 I
- I
dihydroxyflavone I
, O
2 B
- I
ethynylnaphthalene I
, O
2 B
' I
- I
methoxyflavone I
, O
2 B
- I
naphththalene I
propargyl I
ether I
, O
acenaphthene B
, O
acenaphthylene B
, O
naphthalene B
, O
1 B
- I
acetylpyrene I
, O
flavanone B
, O
chrysin B
, O
3 B
- I
ethynylphenanthrene I
, O

Coumarin B
7 O
- O
hydroxylation O
, O
catalyzed O
by O
P450 O
2A13 O
, O
was O
strongly O
inhibited O
by O
2 B
' I
- I
methoxy I
- I
5 I
, I
7 I
- I
dihydroxyflavone I
, O
2 B
- I
ethynylnaphthalene I
, O
2 B
' I
- I
methoxyflavone I
, O
2 B
- I
naphththalene I
propargyl I
ether I
, O
acenaphthene B
, O
acenaphthylene B
, O
naphthalene B
, O
1 B
- I
acetylpyrene I
, O
flavanone B
, O
chrysin B
, O
3 B
- I
ethynylphenanthrene I
, O

Coumarin B
7 O
- O
hydroxylation O
, O
catalyzed O
by O
P450 O
2A13 O
, O
was O
strongly O
inhibited O
by O
2 B
' I
- I
methoxy I
- I
5 I
, I
7 I
- I
dihydroxyflavone I
, O
2 B
- I
ethynylnaphthalene I
, O
2 B
' I
- I
methoxyflavone I
, O
2 B
- I
naphththalene I
propargyl I
ether I
, O
acenaphthene B
, O
acenaphthylene B
, O
naphthalene B
, O
1 B
- I
acetylpyrene I
, O
flavanone B
, O
chrysin B
, O
3 B
- I
ethynylphenanthrene I
, O

flavone B
, O
and O
7 B
- I
hydroxyflavone I
; O
these O
chemicals O
induced O
Type O
I O
spectral O
changes O
with O
low O
Ks O
values O
. O

Two O
- O
dimensional O
( O
2D O
) O
layered O
transition B
metal I
dichalcogenides I
( O
TMDs B
) O
have O
recently O
attracted O
tremendous O
interest O
as O
potential O
valleytronic O
and O
nanoelectronic O
materials O
, O
in O
addition O
to O
being O
well O
- O
known O
as O
excellent O
lubricants O
in O
the O
bulk O
. O

Here O
we O
demonstrated O
that O
Rad9 O
was O
involved O
in O
nucleotide B
excision O
repair O
and O
loss O
of O
Rad9 O
led O
to O
defective O
removal O
of O
the O
UV O
- O
derived O
photoproduct O
6 B
- I
4PP I
( O
6 B
, I
4 I
pyrimidine I
- I
pyrimidone I
) O
and O
the O
BPDE B
( O
anti O
- O
benzo B
( I
a I
) I
pyrene I
- I
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
- I
9 I
, I
10 I
- I
epoxide I
) O
- O
DNA O
adducts O
in O
mammalian O
cells O
. O

Synthesis O
, O
biological O
evaluation O
of O
new O
oxazolidino B
- I
sulfonamides I
as O
potential O
antimicrobial O
agents O
. O

A O
number O
of O
linezolid B
- O
like O
oxazolidino B
- I
sulfonamides I
( O
7a O
- O
y O
and O
8a O
- O
b O
) O
were O
designed O
and O
synthesized O
with O
a O
view O
to O
develop O
antimicrobial O
agents O
with O
improved O
properties O
. O

Synthesis O
and O
cytotoxicity O
of O
3 B
- I
aryl I
acrylic I
amide I
derivatives O
of O
the O
simplified O
saframycin B
- O
ecteinascidin B
skeleton O
prepared O
from O
l B
- I
dopa I
. O

Twenty O
four O
compounds O
with O
diversified O
3 B
- I
aryl I
acrylic I
amide I
side O
chains O
of O
the O
simplified O
saframycin B
- O
ecteinascidin B
pentacyclic O
skeleton O
were O
synthesized O
via O
a O
14 O
- O
step O
stereospecific O
route O
starting O
from O
l B
- I
dopa I
. O

The O
cobrotoxin O
- O
induced O
IA O
response O
was O
blocked O
by O
the O
M3R O
- O
selective O
antagonists O
DAU B
- I
5884 I
and O
4 B
- I
DAMP I
. O

The O
cobrotoxin O
- O
induced O
IA O
response O
was O
blocked O
by O
the O
M3R O
- O
selective O
antagonists O
DAU B
- I
5884 I
and O
4 B
- I
DAMP I
. O

Pretreatment O
of O
the O
cells O
with O
4 B
- I
aminopyridine I
, O
a O
selective O
blocker O
of O
IA O
, O
abolished O
this O
effect O
. O

In O
the O
modified O
test O
, O
earthworms O
had O
greatly O
inhibited O
AChE O
activity O
( O
0 O
. O
088 O
+ O
/ O
- O
0 O
. O
034 O
U O
/ O
mg O
protein O
, O
n O
= O
72 O
) O
, O
which O
was O
supported O
by O
reactivation O
of O
the O
inhibited O
enzyme O
activity O
in O
the O
presence O
of O
pralidoxime B
( O
2 B
- I
PAM I
) O
. O

Cobalt B
- I
protoporphyrin I
( O
CoPP B
) O
- O
dependent O
induction O
of O
heme B
oxygenase O
( O
HO O
) O
- O
1 O
has O
been O
shown O
to O
protect O
the O
liver O
from O
I O
/ O
R O
injury O
. O

Inhibitory O
effect O
of O
ketoconazole B
on O
the O
pharmacokinetics O
of O
a O
multireceptor O
tyrosine B
kinase O
inhibitor O
BMS B
- I
690514 I
in O
healthy O
participants O
: O
assessing O
the O
mechanism O
of O
the O
interaction O
with O
physiologically O
- O
based O
pharmacokinetic O
simulations O
. O

BMS B
- I
690514 I
, O
a O
selective O
inhibitor O
of O
the O
ErbB O
and O
vascular O
endothelial O
growth O
factor O
receptors O
, O
has O
shown O
antitumor O
activity O
in O
early O
clinical O
development O
. O

To O
assess O
the O
effect O
of O
ketoconazole B
on O
BMS B
- I
690514 I
pharmacokinetics O
, O
17 O
healthy O
volunteers O
received O
200 O
mg O
BMS B
- I
690514 I
alone O
followed O
by O
100 O
mg O
BMS B
- I
690514 I
with O
ketoconazole B
( O
400 O
mg O
once O
daily O
for O
4 O
days O
) O
. O

To O
assess O
the O
effect O
of O
ketoconazole B
on O
BMS B
- I
690514 I
pharmacokinetics O
, O
17 O
healthy O
volunteers O
received O
200 O
mg O
BMS B
- I
690514 I
alone O
followed O
by O
100 O
mg O
BMS B
- I
690514 I
with O
ketoconazole B
( O
400 O
mg O
once O
daily O
for O
4 O
days O
) O
. O

To O
assess O
the O
effect O
of O
ketoconazole B
on O
BMS B
- I
690514 I
pharmacokinetics O
, O
17 O
healthy O
volunteers O
received O
200 O
mg O
BMS B
- I
690514 I
alone O
followed O
by O
100 O
mg O
BMS B
- I
690514 I
with O
ketoconazole B
( O
400 O
mg O
once O
daily O
for O
4 O
days O
) O
. O

The O
AUC O
( O
infinity O
) O
of O
100 O
mg O
BMS B
- I
690514 I
concomitantly O
administered O
with O
ketoconazole B
was O
similar O
to O
that O
of O
200 O
mg O
BMS B
- I
690514 I
alone O
. O

The O
AUC O
( O
infinity O
) O
of O
100 O
mg O
BMS B
- I
690514 I
concomitantly O
administered O
with O
ketoconazole B
was O
similar O
to O
that O
of O
200 O
mg O
BMS B
- I
690514 I
alone O
. O

The O
dose O
- O
normalized O
C O
( O
max O
) O
and O
AUC O
( O
infinity O
) O
of O
BMS B
- I
690514 I
from O
the O
100 O
- O
mg O
BMS B
- I
690514 I
/ O
400 O
- O
mg O
ketoconazole B
treatment O
increased O
by O
55 O
% O
and O
127 O
% O
, O
respectively O
, O
relative O
to O
those O
from O
200 O
mg O
BMS B
- I
690514 I
alone O
. O

The O
dose O
- O
normalized O
C O
( O
max O
) O
and O
AUC O
( O
infinity O
) O
of O
BMS B
- I
690514 I
from O
the O
100 O
- O
mg O
BMS B
- I
690514 I
/ O
400 O
- O
mg O
ketoconazole B
treatment O
increased O
by O
55 O
% O
and O
127 O
% O
, O
respectively O
, O
relative O
to O
those O
from O
200 O
mg O
BMS B
- I
690514 I
alone O
. O

The O
dose O
- O
normalized O
C O
( O
max O
) O
and O
AUC O
( O
infinity O
) O
of O
BMS B
- I
690514 I
from O
the O
100 O
- O
mg O
BMS B
- I
690514 I
/ O
400 O
- O
mg O
ketoconazole B
treatment O
increased O
by O
55 O
% O
and O
127 O
% O
, O
respectively O
, O
relative O
to O
those O
from O
200 O
mg O
BMS B
- I
690514 I
alone O
. O

It O
has O
been O
shown O
to O
be O
at O
least O
tenfold O
more O
potent O
than O
combretastatin B
A4 I
( O
CA4 B
) O
in O
terms O
of O
vascular O
shutdown O
, O
which O
correlates O
with O
its O
metabolism O
to O
reactive O
ortho B
- I
quinone I
species O
that O
are O
assumed O
to O
be O
directly O
cytotoxic O
in O
tumor O
cells O
. O

Metabolism O
experiments O
demonstrate O
that O
27 O
retains O
the O
ability O
to O
form O
ortho B
- I
quinone I
species O
, O
while O
the O
pyrazole B
ring O
shows O
high O
metabolic O
stability O
, O
suggesting O
that O
this O
compound O
might O
result O
in O
better O
pharmacokinetic O
profiles O
than O
CA1 B
, O
with O
similar O
pharmacodynamic O
properties O
and O
clinical O
potential O
. O

In O
the O
present O
study O
, O
QSPR O
- O
induced O
uncertainty O
in O
overall O
persistence O
( O
POV O
) O
and O
long O
- O
range O
transport O
potential O
( O
LRTP O
) O
was O
studied O
by O
integrating O
QSPRs O
into O
probabilistic O
assessments O
of O
five O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
using O
the O
multimedia O
fate O
model O
Simplebox O
. O

Polymer O
/ O
silica B
composite O
films O
, O
stable O
to O
calcination O
, O
were O
produced O
using O
catanionic O
surfactant O
mixtures O
( O
hexadecyltrimethylam B
bromide I
( O
CTAB B
) O
and O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
) O
and O
polymers O
( O
polyethylenimine B
( O
PEI B
) O
or O
polyacrylamide B
( O
PAAm B
) O
) O
at O
the O
air O
/ O
water O
interface O
. O

A O
combination O
of O
in O
vitro O
metabolism O
experiments O
and O
a O
pharmacokinetic O
study O
in O
monkeys O
with O
the O
inhibitor O
4 B
- I
methylpyrazole I
provided O
strong O
evidence O
that O
alcohol B
dehydrogenase O
, O
potentially O
in O
association O
with O
aldehyde B
dehydrogenase O
, O
is O
the O
primary O
enzyme O
involved O
in O
the O
formation O
of O
the O
M3 O
metabolite O
. O

F B
- I
Ti I
- O
MWW O
was O
post O
- O
synthesized O
by O
implanting O
fluorine B
species O
into O
a O
Ti B
- O
MWW O
framework O
through O
an O
acid O
treatment O
process O
in O
the O
presence O
of O
ammonium B
fluoride I
. O

The O
negative O
effect O
of O
SiO4 B
/ O
2F B
( I
- I
) I
units O
in O
F B
- I
Ti I
- O
MWW O
was O
eliminated O
selectively O
by O
convenient O
anion O
- O
exchange O
with O
various O
alkali B
chlorides I
. O

F B
- I
Ti I
- O
MWW O
containing O
the O
SiO3 B
/ O
2F B
units O
possessed O
better O
catalytic O
activity O
and O
reusability O
, O
and O
a O
longer O
catalyst O
lifetime O
than O
conventional O
Ti B
- O
MWW O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
effects O
of O
different O
bile B
salts I
and O
bile B
acids I
on O
the O
growth O
of O
lecithin O
reverse O
worms O
in O
cyclohexane B
and O
n B
- I
decane I
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
possible O
ameliorating O
effect O
of O
butylated B
hydroxyl I
toluene I
( O
BHT B
) O
, O
associated O
with O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
- O
induced O
oxidative O
stress O
and O
liver O
injury O
in O
mice O
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
possible O
ameliorating O
effect O
of O
butylated B
hydroxyl I
toluene I
( O
BHT B
) O
, O
associated O
with O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
- O
induced O
oxidative O
stress O
and O
liver O
injury O
in O
mice O
. O

The O
treatment O
of O
mice O
with O
Fe B
- I
NTA I
alone O
enhances O
ornithine B
decarboxylase O
activity O
to O
4 O
. O
6 O
folds O
, O
protein O
carbonyl B
formation O
increased O
up O
to O
2 O
. O
9 O
folds O
and O
DNA O
synthesis O
expressed O
in O
terms O
of O
[ B
( I
3 I
) I
H I
] I
thymidine I
incorporation O
increased O
to O
3 O
. O
2 O
folds O
, O
and O
antioxidants O
and O
antioxidant O
enzymes O
decreased O
to O
1 O
. O
8 O
- O
2 O
. O
5 O
folds O
, O
compared O
with O
the O
corresponding O
saline O
- O
treated O
controls O
. O

Our O
data O
show O
that O
BHT B
can O
reciprocate O
the O
toxic O
effects O
of O
Fe B
- I
NTA I
and O
can O
serve O
as O
a O
potent O
chemopreventive O
agent O
. O

Temperature O
dependence O
of O
transport O
properties O
of O
spiro B
- I
MeOTAD I
as O
a O
hole O
transport O
material O
in O
solid O
- O
state O
dye O
- O
sensitized O
solar O
cells O
. O

The O
internal O
transport O
and O
recombination O
parameters O
of O
solid O
- O
state O
dye O
- O
sensitized O
solar O
cells O
( O
ssDSCs O
) O
using O
the O
amorphous O
organic O
semiconductor O
2 B
, I
2 I
' I
, I
7 I
, I
7 I
' I
- I
tetrakis I
( I
N I
, I
N I
- I
di I
- I
p I
- I
methoxyphenylamine I
) I
- I
9 I
, I
9 I
' I
- I
spirobifluorene I
( O
spiro B
- I
MeOTAD I
) O
as O
a O
hole O
transport O
material O
( O
HTM O
) O
are O
investigated O
using O
electrical O
impedance O
spectroscopy O
. O

Using O
this O
approach O
the O
activation O
energy O
of O
the O
hole O
hopping O
transport O
within O
the O
undoped O
spiro B
- I
MeOTAD I
film O
was O
determined O
to O
be O
0 O
. O
34 O
+ O
/ O
- O
0 O
. O
02 O
and O
0 O
. O
40 O
+ O
/ O
- O
0 O
. O
02 O
eV O
for O
the O
mesoporous O
TiO2 B
and O
ZrO2 B
systems O
, O
respectively O
. O

In O
this O
study O
, O
the O
ethanolic O
extract O
obtained O
from O
piqui O
a O
pulp O
was O
assessed O
for O
genotoxicity O
and O
oxidative O
stress O
by O
employing O
the O
micronucleus O
test O
in O
bone O
marrow O
and O
peripheral O
blood O
cells O
in O
addition O
to O
comet O
, O
thiobarbituric B
- I
acid I
- O
reactive O
substances O
( O
TBARS O
) O
, O
and O
reduced B
glutathione I
assays O
in O
the O
liver O
, O
kidney O
, O
and O
heart O
. O

Acyclic B
nucleoside I
phosphonates I
containing O
a O
second O
phosphonate B
group O
are O
potent O
inhibitors O
of O
6 B
- I
oxopurine I
phosphoribosyltransf O
and O
have O
antimalarial O
activity O
. O

Acyclic B
nucleoside I
phosphonates I
containing O
a O
second O
phosphonate B
group O
are O
potent O
inhibitors O
of O
6 B
- I
oxopurine I
phosphoribosyltransf O
and O
have O
antimalarial O
activity O
. O

Acyclic B
nucleoside I
phosphonates I
( O
ANPs B
) O
that O
contain O
a O
6 B
- I
oxopurine I
base O
are O
good O
inhibitors O
of O
the O
Plasmodium O
falciparum O
( O
Pf O
) O
and O
Plasmodium O
vivax O
( O
Pv O
) O
6 B
- I
oxopurine I
phosphoribosyltransf O
( O
PRTs O
) O
. O

Acyclic B
nucleoside I
phosphonates I
( O
ANPs B
) O
that O
contain O
a O
6 B
- I
oxopurine I
base O
are O
good O
inhibitors O
of O
the O
Plasmodium O
falciparum O
( O
Pf O
) O
and O
Plasmodium O
vivax O
( O
Pv O
) O
6 B
- I
oxopurine I
phosphoribosyltransf O
( O
PRTs O
) O
. O

Acyclic B
nucleoside I
phosphonates I
( O
ANPs B
) O
that O
contain O
a O
6 B
- I
oxopurine I
base O
are O
good O
inhibitors O
of O
the O
Plasmodium O
falciparum O
( O
Pf O
) O
and O
Plasmodium O
vivax O
( O
Pv O
) O
6 B
- I
oxopurine I
phosphoribosyltransf O
( O
PRTs O
) O
. O

The O
hydrophobic O
phase O
is O
retained O
in O
the O
interior O
of O
the O
porous O
nanostructure O
, O
and O
HF B
( O
aq O
) O
attacks O
only O
the O
exposed O
surfaces O
of O
the O
oxidized O
porous O
Si B
sample O
, O
generating O
a O
hydrophobic O
, O
hydrogen B
- O
terminated O
( O
Si B
- I
H I
) O
outer O
layer O
. O

The O
reaction O
is O
self O
- O
limiting O
due O
to O
the O
immiscibility O
of O
octane B
and O
water O
, O
and O
the O
extent O
of O
penetration O
of O
the O
Si B
- I
H I
surface O
into O
the O
porous O
layer O
is O
dependent O
on O
the O
time O
of O
exposure O
to O
HF B
( O
aq O
) O
. O

The O
Si B
- I
H I
surface O
can O
then O
be O
modified O
by O
thermal O
hydrosilylation O
( O
1 B
- I
dodecene I
or O
10 B
- I
bromo I
- I
1 I
- I
decene I
) O
in O
a O
subsequent O
step O
, O
resulting O
in O
a O
bifunctional O
porous O
Si B
film O
containing O
hydrophobic O
pore O
entrances O
to O
hydrophilic O
inner O
pores O
. O

The O
Si B
- I
H I
surface O
can O
then O
be O
modified O
by O
thermal O
hydrosilylation O
( O
1 B
- I
dodecene I
or O
10 B
- I
bromo I
- I
1 I
- I
decene I
) O
in O
a O
subsequent O
step O
, O
resulting O
in O
a O
bifunctional O
porous O
Si B
film O
containing O
hydrophobic O
pore O
entrances O
to O
hydrophilic O
inner O
pores O
. O

What O
Can O
We O
Learn O
about O
Dispersion O
from O
the O
Conformer O
Surface O
of O
n B
- I
Pentane I
? O

To O
gain O
greater O
insight O
into O
the O
nature O
of O
the O
phenomenon O
, O
we O
have O
mapped O
the O
torsional O
surface O
of O
n B
- I
pentane I
to O
10 O
- O
degree O
resolution O
at O
the O
CCSD O
( O
T O
) O
- O
F12 O
level O
near O
the O
basis O
set O
limit O
. O

EO O
and O
its O
constituents O
( O
thymol B
, O
p B
- I
cymene I
, O
gamma B
- I
terpinene I
and O
myrcene B
) O
displayed O
cytotoxicity O
to O
different O
tumor O
cell O
lines O
. O

EO O
and O
its O
constituents O
( O
thymol B
, O
p B
- I
cymene I
, O
gamma B
- I
terpinene I
and O
myrcene B
) O
displayed O
cytotoxicity O
to O
different O
tumor O
cell O
lines O
. O

Relative O
expression O
of O
cholesterol B
transport O
- O
related O
proteins O
and O
inflammation O
markers O
through O
the O
induction O
of O
7 B
- I
ketosterol I
- O
mediated O
stress O
in O
Caco O
- O
2 O
cells O
. O

This O
study O
evaluates O
the O
production O
of O
inflammatory O
biomarkers O
( O
IL O
- O
1 O
beta O
, O
IL O
- O
8 O
, O
IL O
- O
10 O
, O
TNF O
alpha O
) O
and O
the O
influence O
of O
gene O
expression O
transporters O
and O
enzymes O
related O
to O
cholesterol B
absorption O
and O
metabolism O
( O
NPC1L1 O
, O
ABCG5 O
/ O
8 O
, O
HMGCoA B
, O
ACAT O
) O
produced O
by O
7 B
- I
ketosterols I
( O
stigmasterol B
/ O
cholesterol B
) O
in O
Caco O
- O
2 O
cells O
. O

Results O
showed O
7 B
- I
ketostigmasterol I
to O
have O
a O
greater O
proinflammatory O
potential O
than O
7 B
- I
ketocholesterol I
. O

Results O
showed O
7 B
- I
ketostigmasterol I
to O
have O
a O
greater O
proinflammatory O
potential O
than O
7 B
- I
ketocholesterol I
. O

In O
non O
- O
pre O
- O
treated O
cells O
, O
only O
efflux O
transporters O
were O
down O
- O
regulated O
by O
7 B
- I
ketosterols I
, O
showing O
a O
greater O
influence O
upon O
ABCG5 O
expression O
. O

Cell O
- O
pre O
- O
incubation O
with O
bradykinin B
induced O
changes O
in O
ABCG O
expression O
levels O
after O
7 B
- I
ketostigmasterol I
- O
incubation O
; O
however O
, O
the O
energetic O
metabolism O
inhibition O
reduced O
NPC1L1 O
expression O
only O
in O
7 B
- I
ketocholesterol I
- O
incubated O
cells O
. O

Cell O
- O
pre O
- O
incubation O
with O
bradykinin B
induced O
changes O
in O
ABCG O
expression O
levels O
after O
7 B
- I
ketostigmasterol I
- O
incubation O
; O
however O
, O
the O
energetic O
metabolism O
inhibition O
reduced O
NPC1L1 O
expression O
only O
in O
7 B
- I
ketocholesterol I
- O
incubated O
cells O
. O

In O
non O
- O
pre O
- O
treated O
cells O
, O
HMG B
- I
CoA I
was O
up O
- O
regulated O
by O
both O
7 B
- I
ketosterols I
. O

In O
non O
- O
pre O
- O
treated O
cells O
, O
HMG B
- I
CoA I
was O
up O
- O
regulated O
by O
both O
7 B
- I
ketosterols I
. O

However O
, O
exposure O
to O
inhibitors O
down O
- O
regulated O
the O
expression O
levels O
, O
mainly O
in O
7 B
- I
ketocholesterol I
- O
incubated O
cells O
. O

These O
results O
suggest O
that O
internalization O
and O
excretion O
of O
7 B
- I
ketostigmasterol I
is O
probably O
influenced O
by O
[ O
Ca B
] O
i O
, O
which O
also O
could O
mediate O
HMGCoA B
activity O
in O
POPs O
metabolism O
. O

However O
, O
energetic O
metabolism O
and O
reducing O
equivalents O
exert O
different O
influences O
upon O
the O
7 B
- I
ketosterol I
internalization O
. O

Characterization O
, O
using O
GC O
- O
MS O
and O
GC O
- O
MS O
/ O
MS O
, O
of O
11oxo B
- I
pregnanes I
and O
11oxo B
- I
pregnenes I
. O

Characterization O
, O
using O
GC O
- O
MS O
and O
GC O
- O
MS O
/ O
MS O
, O
of O
11oxo B
- I
pregnanes I
and O
11oxo B
- I
pregnenes I
. O

In O
21 O
- O
hydroxylase O
deficiency O
, O
urinary O
metabolites O
of O
21 B
- I
deoxycortisol I
, O
mainly O
derived O
from O
its O
11oxo B
form O
21 B
- I
deoxycortisone I
, O
are O
indicators O
of O
intra O
- O
adrenal O
overproduction O
of O
17 B
- I
hydroxyprogesterone I
. O

In O
21 O
- O
hydroxylase O
deficiency O
, O
urinary O
metabolites O
of O
21 B
- I
deoxycortisol I
, O
mainly O
derived O
from O
its O
11oxo B
form O
21 B
- I
deoxycortisone I
, O
are O
indicators O
of O
intra O
- O
adrenal O
overproduction O
of O
17 B
- I
hydroxyprogesterone I
. O

In O
21 O
- O
hydroxylase O
deficiency O
, O
urinary O
metabolites O
of O
21 B
- I
deoxycortisol I
, O
mainly O
derived O
from O
its O
11oxo B
form O
21 B
- I
deoxycortisone I
, O
are O
indicators O
of O
intra O
- O
adrenal O
overproduction O
of O
17 B
- I
hydroxyprogesterone I
. O

Parallels O
were O
found O
between O
the O
metabolism O
of O
21 B
- I
deoxycortisone I
and O
cortisone B
. O

Oxidation O
of O
the O
6 B
- I
hydroxyl I
was O
also O
common O
. O

We O
conclude O
that O
further O
oxygenated O
metabolites O
of O
21 B
- I
deoxycortisone I
have O
potential O
as O
more O
reliable O
markers O
of O
21 O
- O
hydroxylase O
deficiency O
in O
the O
early O
neonatal O
period O
, O
because O
their O
levels O
are O
higher O
during O
that O
period O
of O
life O
than O
for O
the O
classical O
marker O
11oxo B
- I
pregnanetriol I
. O

We O
conclude O
that O
further O
oxygenated O
metabolites O
of O
21 B
- I
deoxycortisone I
have O
potential O
as O
more O
reliable O
markers O
of O
21 O
- O
hydroxylase O
deficiency O
in O
the O
early O
neonatal O
period O
, O
because O
their O
levels O
are O
higher O
during O
that O
period O
of O
life O
than O
for O
the O
classical O
marker O
11oxo B
- I
pregnanetriol I
. O

N B
- I
acetylcysteine I
( O
NAC B
, O
33 O
mM O
) O
and O
the O
c O
- O
jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
inhibitor O
( O
SP600125 B
, O
33 O
mu O
M O
) O
further O
decreased O
the O
viability O
in O
the O
presence O
of O
DEP O
( O
200 O
mu O
g O
/ O
ml O
) O
and O
3 O
. O
3 O
% O
FCS O
. O

In O
addition O
we O
demonstrated O
that O
the O
same O
enzymatic O
activation O
could O
also O
take O
place O
in O
a O
microemulsion O
based O
on O
sodium B
dodecyl I
sulfate I
/ O
tert B
- I
butanol I
/ O
chloroform B
/ O
buffer O
. O

In O
addition O
we O
demonstrated O
that O
the O
same O
enzymatic O
activation O
could O
also O
take O
place O
in O
a O
microemulsion O
based O
on O
sodium B
dodecyl I
sulfate I
/ O
tert B
- I
butanol I
/ O
chloroform B
/ O
buffer O
. O

The O
structure O
of O
the O
PDEA B
- I
grafted I
GO I
( O
GO B
- I
PDEA I
) O
were O
examined O
by O
Fourier O
- O
transform O
infrared O
spectroscopy O
, O
proton O
nuclear O
magnetic O
resonance O
spectroscopy O
, O
X O
- O
ray O
photoelectron O
spectroscopy O
, O
thermogravimetric O
analysis O
and O
atomic O
force O
microscopy O
. O

Simple O
physisorption O
by O
pi O
- O
pi O
stacking O
and O
hydrophobic O
interactions O
on O
GO B
- I
PDEA I
can O
be O
used O
to O
load O
camptothecin B
( O
CPT B
) O
, O
a O
widely O
used O
water O
- O
insoluble O
cancer O
drug O
. O

GO B
- I
PDEA I
did O
not O
show O
practical O
toxicity O
to O
N2a O
cancer O
cells O
but O
the O
GO B
- I
PDEA I
- I
CPT I
complex O
exhibited O
high O
potency O
in O
killing O
N2a O
cancer O
cells O
in O
vitro O
. O

These O
results O
suggest O
that O
the O
GO B
- I
PDEA I
nanocargo O
carrier O
might O
be O
a O
promising O
material O
for O
site O
- O
specific O
anticancer O
drug O
delivery O
and O
controlled O
release O
. O

The O
importance O
of O
dipole O
- O
dipole O
interaction O
between O
an O
amino B
- I
acid I
chain O
and O
hydroxyl B
group O
at O
the O
benzene B
ring O
was O
also O
discussed O
. O

Assessment O
of O
the O
abuse O
liability O
of O
ABT B
- I
288 I
, O
a O
novel O
histamine B
H3 O
receptor O
antagonist O
. O

RATIONALE O
: O
Histamine B
H3 O
receptor O
antagonists O
, O
such O
as O
ABT B
- I
288 I
, O
have O
been O
shown O
to O
possess O
cognitive O
- O
enhancing O
and O
wakefulness O
- O
promoting O
effects O
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
present O
study O
was O
to O
further O
characterize O
whether O
ABT B
- I
288 I
possesses O
stimulant O
- O
like O
properties O
and O
whether O
its O
pharmacology O
gives O
rise O
to O
abuse O
liability O
. O

METHODS O
: O
The O
locomotor O
- O
stimulant O
effects O
of O
ABT B
- I
288 I
were O
measured O
in O
mice O
and O
rats O
, O
and O
potential O
development O
of O
sensitization O
was O
addressed O
. O

Drug O
discrimination O
was O
used O
to O
assess O
amphetamine B
- O
like O
stimulus O
properties O
, O
and O
drug O
self O
- O
administration O
was O
used O
to O
evaluate O
reinforcing O
effects O
of O
ABT B
- I
288 I
. O

RESULTS O
: O
ABT B
- I
288 I
lacked O
locomotor O
- O
stimulant O
effects O
in O
both O
rats O
and O
mice O
. O

Repeated O
administration O
of O
ABT B
- I
288 I
did O
not O
result O
in O
cross O
- O
sensitization O
to O
the O
stimulant O
effects O
of O
d B
- I
amphetamine I
in O
mice O
, O
suggesting O
that O
there O
is O
little O
overlap O
in O
circuitries O
upon O
which O
the O
two O
drugs O
interact O
for O
motor O
activity O
. O

Repeated O
administration O
of O
ABT B
- I
288 I
did O
not O
result O
in O
cross O
- O
sensitization O
to O
the O
stimulant O
effects O
of O
d B
- I
amphetamine I
in O
mice O
, O
suggesting O
that O
there O
is O
little O
overlap O
in O
circuitries O
upon O
which O
the O
two O
drugs O
interact O
for O
motor O
activity O
. O

ABT B
- I
288 I
did O
not O
produce O
amphetamine B
- O
like O
discriminative O
stimulus O
effects O
in O
drug O
discrimination O
studies O
nor O
was O
it O
self O
- O
administered O
by O
rats O
trained O
to O
self O
- O
administer O
cocaine B
. O

There O
were O
no O
signs O
of O
physical O
dependence O
upon O
termination O
of O
repeated O
administration O
of O
ABT B
- I
288 I
for O
30 O
days O
. O

CONCLUSIONS O
: O
The O
sum O
of O
these O
preclinical O
data O
, O
the O
first O
of O
their O
kind O
applied O
to O
H3 O
antagonists O
, O
indicates O
that O
ABT B
- I
288 I
is O
unlikely O
to O
possess O
a O
high O
potential O
for O
abuse O
in O
the O
human O
population O
and O
suggests O
that O
H3 O
antagonists O
, O
as O
a O
class O
, O
are O
similar O
in O
this O
regard O
. O

The O
synthesis O
involves O
three O
major O
steps O
: O
1 O
) O
preparation O
of O
Au B
- I
Ag I
alloyed O
nanocages O
using O
a O
galvanic O
replacement O
reaction O
between O
Ag B
nanocubes O
and O
HAuCl4 B
; O
2 O
) O
deposition O
of O
thin O
layers O
of O
pure O
Au B
onto O
the O
surfaces O
of O
the O
nanocages O
by O
reducing O
HAuCl4 B
with O
ascorbic B
acid I
, O
and O
; O
3 O
) O
formation O
of O
Au B
cubic O
nanoframes O
through O
a O
dealloying O
process O
with O
HAuCl4 B
. O

The O
key O
to O
the O
formation O
of O
Au B
cubic O
nanoframes O
is O
to O
coat O
the O
surfaces O
of O
the O
Au B
- I
Ag I
nanocages O
with O
sufficiently O
thick O
layers O
of O
Au B
before O
they O
are O
dealloyed O
. O

The O
as O
- O
prepared O
Au B
cubic O
nanoframes O
exhibit O
tunable O
localized O
surface O
plasmon O
resonance O
peaks O
in O
the O
near O
- O
infrared O
region O
, O
but O
with O
much O
lower O
Ag B
content O
as O
compared O
with O
the O
initial O
Au B
- I
Ag I
nanocages O
. O

The O
coemulsification O
method O
suitable O
for O
the O
formulation O
of O
microcapsules O
of O
n B
- I
eicosane I
coated O
with O
a O
polysiloxane B
is O
developed O
. O

The O
microcapsules O
are O
formed O
in O
aqueous O
phase O
by O
the O
precipitation O
of O
n B
- I
eicosane I
together O
with O
modified O
polyhydromethylsilox B
from O
a O
common O
solvent O
which O
is O
miscible O
with O
aqueous O
media O
. O

Additionally O
, O
using O
Fluo B
- I
4 I
, O
a O
calcium B
- O
sensitive O
fluorophore O
, O
it O
was O
shown O
that O
treatment O
of O
cells O
with O
phospholipase O
- O
D O
induced O
an O
increase O
in O
the O
calcium B
concentration O
in O
the O
cytoplasm O
, O
but O
without O
altering O
viability O
or O
causing O
damage O
to O
cells O
. O

Specifically O
, O
increased O
succinic B
acid I
semialdehyde I
, O
a O
metabolism O
product O
of O
GABA B
, O
was O
observed O
in O
hippocampus O
. O

N B
- I
Acetyl I
- I
aspartate I
, O
a O
marker O
of O
neuronal O
viability O
, O
decreased O
in O
the O
three O
regions O
; O
however O
, O
myo B
- I
inositol I
, O
a O
glial O
cell O
marker O
, O
increased O
in O
hippocampus O
and O
PFC O
. O

Tricarboxylic B
acid I
cycle O
intermediate O
products O
, O
such O
as O
alpha B
- I
ketoglutarate I
, O
succinate B
, O
citrate B
and O
the O
methionine B
significantly O
decreased O
in O
above O
three O
brain O
regions O
after O
MAP B
administration O
; O
however O
, O
ADP B
decreased O
in O
hippocampus O
. O

Clinical O
proof O
- O
of O
- O
concept O
study O
with O
MSDC B
- I
0160 I
, O
a O
prototype O
mTOT O
- O
modulating O
insulin O
sensitizer O
. O

In O
this O
phase O
IIb O
clinical O
trial O
, O
258 O
patients O
with O
type O
2 O
diabetes O
completed O
a O
12 O
- O
week O
protocol O
with O
50 O
, O
100 O
, O
or O
150 O
mg O
of O
MSDC B
- I
0160 I
( O
an O
mTOT O
modulator O
) O
, O
45 O
mg O
pioglitazone B
HCl I
( O
a O
PPAR O
- O
gamma O
agonist O
) O
, O
or O
a O
placebo O
. O

The O
decreases O
in O
glycated O
hemoglobin O
( O
HbA1c O
) O
observed O
with O
the O
two O
higher O
doses O
of O
MSDC B
- I
0160 I
were O
not O
different O
from O
those O
associated O
with O
pioglitazone B
. O

By O
contrast O
, O
fluid O
retention O
as O
evidenced O
by O
reduction O
in O
hematocrit O
, O
red O
blood O
cells O
, O
and O
total O
hemoglobin O
was O
50 O
% O
less O
in O
the O
MSDC B
- I
0160 I
- O
treated O
groups O
. O

There O
was O
also O
a O
smaller O
increase O
in O
high O
- O
molecular O
- O
weight O
( O
HMW O
) O
adiponectin O
with O
MSDC B
- I
0160 I
than O
with O
pioglitazone B
( O
P O
< O
0 O
. O
0001 O
) O
, O
suggesting O
that O
MSDC B
- I
0160 I
produces O
less O
expansion O
of O
white O
adipose O
tissue O
. O

There O
was O
also O
a O
smaller O
increase O
in O
high O
- O
molecular O
- O
weight O
( O
HMW O
) O
adiponectin O
with O
MSDC B
- I
0160 I
than O
with O
pioglitazone B
( O
P O
< O
0 O
. O
0001 O
) O
, O
suggesting O
that O
MSDC B
- I
0160 I
produces O
less O
expansion O
of O
white O
adipose O
tissue O
. O

Photoconductors O
using O
vertical O
arrays O
of O
InAs B
/ O
InAs1 B
- I
xSbx I
nanowires O
with O
varying O
Sb B
composition O
x O
have O
been O
fabricated O
and O
characterized O
. O

The O
aim O
of O
this O
work O
is O
the O
in O
vitro O
and O
ex O
vivo O
assessment O
of O
the O
leishmanicidal O
activity O
of O
camptothecin B
and O
three O
analogues O
used O
in O
cancer O
therapy O
: O
topotecan B
( O
Hycantim B
( O
( O
R O
) O
) O
) O
, O
gimatecan B
( O
ST1481 B
) O
and O
the O
pro O
- O
drug O
irinotecan B
( O
Camptosar B
( O
( O
R O
) O
) O
) O
as O
well O
as O
its O
active O
metabolite O
SN B
- I
38 I
against O
Leishmania O
infantum O
. O

Influence O
of O
aqueous O
media O
properties O
on O
aggregation O
and O
solubility O
of O
four O
structurally O
related O
meso B
- I
porphyrin I
photosensitizers O
evaluated O
by O
spectrophotometric O
measurements O
. O

The O
aggregation O
and O
solubilization O
of O
four O
structurally O
related O
meso B
- I
tetraphenyl I
porphyrin I
photosensitizers O
with O
nonionic O
( O
4 B
- I
hydroxy I
) O
, O
anionic O
( O
4 B
- I
sulphonate I
; O
4 B
- I
carboxy I
) O
and O
cationic O
( O
4 B
- I
trimethylanilinium I
) O
substituents O
were O
evaluated O
in O
various O
vehicles O
by O
use O
of O
UV O
- O
Vis O
spectroscopy O
. O

The O
aggregation O
and O
solubilization O
of O
four O
structurally O
related O
meso B
- I
tetraphenyl I
porphyrin I
photosensitizers O
with O
nonionic O
( O
4 B
- I
hydroxy I
) O
, O
anionic O
( O
4 B
- I
sulphonate I
; O
4 B
- I
carboxy I
) O
and O
cationic O
( O
4 B
- I
trimethylanilinium I
) O
substituents O
were O
evaluated O
in O
various O
vehicles O
by O
use O
of O
UV O
- O
Vis O
spectroscopy O
. O

The O
aggregation O
and O
solubilization O
of O
four O
structurally O
related O
meso B
- I
tetraphenyl I
porphyrin I
photosensitizers O
with O
nonionic O
( O
4 B
- I
hydroxy I
) O
, O
anionic O
( O
4 B
- I
sulphonate I
; O
4 B
- I
carboxy I
) O
and O
cationic O
( O
4 B
- I
trimethylanilinium I
) O
substituents O
were O
evaluated O
in O
various O
vehicles O
by O
use O
of O
UV O
- O
Vis O
spectroscopy O
. O

The O
aggregation O
and O
solubilization O
of O
four O
structurally O
related O
meso B
- I
tetraphenyl I
porphyrin I
photosensitizers O
with O
nonionic O
( O
4 B
- I
hydroxy I
) O
, O
anionic O
( O
4 B
- I
sulphonate I
; O
4 B
- I
carboxy I
) O
and O
cationic O
( O
4 B
- I
trimethylanilinium I
) O
substituents O
were O
evaluated O
in O
various O
vehicles O
by O
use O
of O
UV O
- O
Vis O
spectroscopy O
. O

Folate B
Conjugation O
to O
Polymeric O
Micelles O
via O
Boronic B
Acid I
Ester I
to O
Deliver O
Platinum B
Drugs O
to O
Ovarian O
Cancer O
Cell O
Lines O
. O

Reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
was O
used O
to O
synthesize O
two O
various O
sized O
water O
- O
soluble O
block O
copolymer O
of O
oligoethylene B
glycol I
methylether I
methacylate I
and O
methyl B
acrylic I
acid I
( O
POEGMEMA35 B
- I
b I
- I
PMAA200 I
and O
POEGMEMA26 B
- I
b I
- I
PMAA90 I
) O
. O

As O
functionalized O
chitosans O
hold O
great O
potential O
for O
the O
development O
of O
effective O
and O
broad O
- O
spectrum O
antibiotics O
, O
representative O
chitosan O
derivatives O
were O
tested O
for O
antimicrobial O
activity O
in O
neutral O
media O
: O
trimethyl B
chitosan O
( O
TMC O
) O
, O
carboxy B
- I
methyl I
chitosan O
( O
CMC O
) O
, O
and O
chitosan O
- O
thioglycolic B
acid I
( O
TGA B
; O
medium O
molecular O
weight O
: O
MMW O
- O
TGA B
; O
low O
molecular O
weight O
: O
LMW O
- O
TGA B
) O
. O

NSC B
109555 I
ditosylate I
- O
Chk2 O
inhibitor O
partly O
dismissed O
G2 O
/ O
M O
arrest O
induced O
by O
oroxylin B
A I
, O
reversed O
the O
increased O
trend O
of O
p O
- O
Chk2 O
and O
p O
- O
P53 O
( O
Ser20 O
) O
, O
inhibited O
the O
decreasing O
effect O
of O
oroxylin B
A I
on O
the O
expression O
of O
P O
- O
gp O
and O
decreased O
the O
reversal O
fold O
of O
90 O
mu O
M O
oroxylin B
A I
from O
4 O
. O
68 O
fold O
to O
1 O
. O
73 O
fold O
. O

The O
concentrations O
of O
renal O
malondialdehyde B
, O
reactive O
oxygen B
species O
, O
8 B
- I
hydroxydeoxyguanosin I
, O
serum O
creatinine B
, O
blood O
urea B
nitrogen B
, O
and O
renal O
arsenic B
accumulation O
were O
significantly O
decreased O
and O
reduced O
renal O
morphologic O
injury O
was O
observed O
compared O
with O
the O
As2O3 B
- O
treated O
group O
. O

Hypoxic O
and O
VHL O
- O
deficient O
cells O
use O
glutamine B
to O
generate O
citrate B
and O
lipids O
through O
reductive O
carboxylation O
( O
RC O
) O
of O
alpha B
- I
ketoglutarate I
. O

Molecular O
interactions O
in O
1 B
- I
butanol I
+ O
IL O
solutions O
by O
measuring O
and O
modeling O
activity O
coefficients O
. O

Molecular O
interactions O
in O
1 B
- I
butanol I
+ O
ionic O
liquid O
( O
IL O
) O
solutions O
have O
been O
investigated O
by O
measuring O
and O
modeling O
activity O
- O
coefficient O
data O
. O

The O
activity O
coefficients O
in O
binary O
solutions O
containing O
1 B
- I
butanol I
and O
an O
IL O
were O
determined O
experimentally O
: O
the O
ILs O
studied O
were O
1 B
- I
decyl I
- I
3 I
- I
methyl I
- I
imidazolium I
tetracyanoborate I
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
4 B
- I
decyl I
- I
4 I
- I
methyl I
- I
morpholinium I
tetracyanoborate I
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb B
] O
( O
- O
) O
) O
, O
1 B
- I
decyl I
- I
3 I
- I
methyl I
- I
imidazolium I
bis I

The O
results O
from O
all O
of O
these O
techniques O
were O
combined O
to O
obtain O
activity O
- O
coefficient O
data O
over O
the O
entire O
IL O
concentration O
range O
, O
and O
the O
ion O
- O
specific O
interactions O
of O
the O
ILs O
investigated O
were O
identified O
with O
1 B
- I
butanol I
. O

The O
highest O
( O
1 B
- I
butanol I
) O
- O
IL O
interactions O
of O
the O
ILs O
considered O
in O
this O
work O
were O
found O
for O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
; O
thus O
, O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
showed O
the O
highest O
affinity O
for O
1 B
- I
butanol I
in O
a O
binary O
mixture O
. O

The O
highest O
( O
1 B
- I
butanol I
) O
- O
IL O
interactions O
of O
the O
ILs O
considered O
in O
this O
work O
were O
found O
for O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
; O
thus O
, O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
showed O
the O
highest O
affinity O
for O
1 B
- I
butanol I
in O
a O
binary O
mixture O
. O

PC O
- O
SAFT O
was O
able O
to O
accurately O
describe O
the O
pure O
IL O
and O
( O
1 B
- I
butanol I
) O
- O
IL O
data O
. O

These O
glycosides O
are O
found O
to O
have O
sugar B
moieties O
of O
both O
beta B
- I
l I
- I
and I
beta I
- I
d I
- I
arabinopyranoses I
by O
HPLC O
analysis O
of O
their O
thiocarbamoyl B
- I
thiazolidine I
derivatives O
and O
those O
of O
authentic O
d B
- I
and I
l I
- I
arabinoses I
, O
leading O
to O
the O
structure O
revision O
of O
junceelloside B
C I
( O
1 O
) O
. O

We O
have O
induced O
liver O
tumors O
in O
mice O
by O
treatment O
with O
the O
liver O
carcinogen O
N B
- I
nitrosodiethylamine I
followed O
by O
chronic O
treatment O
with O
the O
tumor O
promoter O
phenobarbital B
. O

Flavonoids B
and O
3 B
- I
Arylcoumarin I
from O
Pterocarpus O
soyauxii O
. O

Phytochemical O
study O
on O
the O
constituents O
of O
the O
heartwood O
of O
Pterocarpus O
soyauxii O
led O
to O
the O
isolation O
of O
five O
new O
isoflavonoids B
and O
one O
new O
3 B
- I
arylcoumarin I
, O
pterosonins B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
together O
with O
17 O
known O
analogues O
, O
among O
which O
8 O
, O
9 O
, O
and O
18 O
were O
reported O
as O
natural O
products O
for O
the O
first O
time O
. O

Here O
, O
we O
have O
determined O
the O
first O
three O
- O
dimensional O
structures O
of O
lacto O
- O
N B
- O
biosidase O
from O
Bifidobacterium O
bifidum O
JCM1254 O
in O
complex O
with O
LNB B
and O
LNB B
- I
thiazoline I
( O
Gal B
- I
beta I
1 I
, I
3 I
- I
GlcNAc I
- I
thiazoline I
) O
at O
1 O
. O
8 O
- O
A O
resolution O
. O

When O
bound O
with O
biotinylated O
cetuximab O
these O
spores O
could O
specifically O
target O
to O
the O
epidermal O
growth O
factor O
receptor O
on O
HT O
29 O
colon O
cancer O
cells O
, O
thereby O
delivered O
paclitaxel B
to O
the O
cells O
with O
4 O
- O
fold O
higher O
efficiency O
, O
as O
indicated O
by O
fluorescent O
intensity O
of O
paclitaxel B
Oregon B
Green I
488 I
bound O
to O
HT29 O
cells O
. O

The O
presence O
of O
a O
basic O
functional O
group O
or O
a O
quaternary B
ammonium I
substituent O
on O
the O
6 B
- I
phenylnaphthalene I
was O
required O
for O
significant O
antibacterial O
activity O
. O

Characterization O
of O
the O
5 B
- I
hydroxymethylcytosin I
- O
specific O
DNA O
restriction O
endonucleases O
. O

In O
T4 O
bacteriophage O
, O
5 B
- I
hydroxymethylcytosin I
( O
5hmC B
) O
is O
incorporated O
into O
DNA O
during O
replication O
. O

PvuRts1I O
was O
the O
first O
identified O
restriction O
enzyme O
to O
exhibit O
specificity O
toward O
hmC B
over O
5 B
- I
methylcytosine I
( O
5mC B
) O
and O
cytosine B
. O

Interestingly O
, O
the O
specificity O
determination O
unveiled O
a O
new O
layer O
of O
complexity O
where O
the O
enzymes O
not O
only O
have O
specificity O
for O
5 B
- I
beta I
- I
glucosylated I
hmC I
( O
5 B
beta I
ghmC I
) O
but O
also O
5 B
- I
alpha I
- I
glucosylated I
hmC I
( O
5 B
alpha I
ghmC I
) O
. O

Interestingly O
, O
the O
specificity O
determination O
unveiled O
a O
new O
layer O
of O
complexity O
where O
the O
enzymes O
not O
only O
have O
specificity O
for O
5 B
- I
beta I
- I
glucosylated I
hmC I
( O
5 B
beta I
ghmC I
) O
but O
also O
5 B
- I
alpha I
- I
glucosylated I
hmC I
( O
5 B
alpha I
ghmC I
) O
. O

In O
some O
cases O
, O
the O
enzymes O
are O
inhibited O
by O
5 B
beta I
ghmC I
, O
whereas O
in O
others O
they O
are O
inhibited O
by O
5 B
alpha I
ghmC I
. O

In O
some O
cases O
, O
the O
enzymes O
are O
inhibited O
by O
5 B
beta I
ghmC I
, O
whereas O
in O
others O
they O
are O
inhibited O
by O
5 B
alpha I
ghmC I
. O

Epigallocatechin B
gallate I
( O
EGCG B
) O
, O
the O
major O
catechin B
contained O
in O
tea O
leaves O
, O
is O
known O
to O
possess O
the O
synergistic O
anti O
- O
staphylococcal O
activity O
in O
combination O
with O
various O
beta B
- I
lactam I
antibiotics O
and O
tetracycline B
. O

Synthesis O
and O
application O
of O
FePt B
/ O
CNTs O
nanocomposite O
as O
a O
sensor O
and O
novel O
amide B
ligand O
as O
a O
mediator O
for O
simultaneous O
determination O
of O
glutathione B
, O
nicotinamide B
adenine I
dinucleotide I
and O
tryptophan B
. O

In O
this O
study O
, O
we O
report O
the O
synthesis O
and O
application O
of O
a O
FePt B
/ O
CNTs O
nanocomposite O
as O
a O
highly O
sensitive O
sensor O
and O
novel O
amide B
ligand O
( B
9 I
, I
10 I
- I
dihydro I
- I
9 I
, I
10 I
- I
ethanoanthracene I
- I
11 I
, I
12 I
- I
dicarboximido I
) I
- I
4 I
- I
ethylbenzene I
- I
1 I
, I
2 I
- I
diol I
as O
a O
mediator O
for O
the O
determination O
of O
glutathione B
( O
GSH B
) O
, O
nicotinamide B
adenine I
dinucleotide I
( O
NADH B
) O
and O
tryptophan B
( O
Trp B
) O

In O
the O
final O
step O
of O
the O
synthetic O
route O
, O
an O
uncommon O
monoacylation O
of O
beta B
- I
aminoamidine I
8 O
at O
the O
less O
reactive O
beta B
- I
phenylamino I
- O
group O
took O
place O
. O

In O
the O
final O
step O
of O
the O
synthetic O
route O
, O
an O
uncommon O
monoacylation O
of O
beta B
- I
aminoamidine I
8 O
at O
the O
less O
reactive O
beta B
- I
phenylamino I
- O
group O
took O
place O
. O

To O
rationalize O
this O
result O
, O
a O
mechanism O
which O
involves O
initial O
acylation O
at O
the O
more O
active O
amidine B
- O
function O
followed O
by O
intramolecular O
acyl B
- O
group O
transfer O
to O
beta B
- I
phenylamino I
- O
group O
was O
suggested O
. O

All O
three O
beta B
- I
amidoamidines I
4d O
- O
f O
bearing O
long O
linear O
aliphatic O
chain O
( O
from O
n B
- I
C8H17 I
to O
n B
- I
C12H25 I
) O
revealed O
significant O
in O
vitro O
activity O
against O
influenza O
A O
virus O
( O
H3N2 O
) O
and O
modest O
cytotoxicity O
. O

All O
three O
beta B
- I
amidoamidines I
4d O
- O
f O
bearing O
long O
linear O
aliphatic O
chain O
( O
from O
n B
- I
C8H17 I
to O
n B
- I
C12H25 I
) O
revealed O
significant O
in O
vitro O
activity O
against O
influenza O
A O
virus O
( O
H3N2 O
) O
and O
modest O
cytotoxicity O
. O

All O
three O
beta B
- I
amidoamidines I
4d O
- O
f O
bearing O
long O
linear O
aliphatic O
chain O
( O
from O
n B
- I
C8H17 I
to O
n B
- I
C12H25 I
) O
revealed O
significant O
in O
vitro O
activity O
against O
influenza O
A O
virus O
( O
H3N2 O
) O
and O
modest O
cytotoxicity O
. O

Statins O
( O
HMG B
- I
CoA I
reductase O
inhibitors O
) O
have O
consistently O
been O
shown O
to O
decrease O
both O
LDL O
- O
C O
and O
CVD O
risk O
in O
almost O
all O
patient O
categories O
, O
with O
the O
exception O
of O
heart O
and O
kidney O
failure O
as O
well O
as O
advanced O
aortic O
stenosis O
. O

The O
effects O
of O
solvation O
and O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
on O
the O
energetics O
, O
structural O
features O
of O
the O
peptide O
planes O
, O
values O
of O
the O
psi O
and O
phi O
dihedrals O
, O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
and O
theoretically O
predicted O
vibrational O
spectra O
of O
the O
dipeptides B
are O
investigated O
. O

Two O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
N B
. O
. O
. O
H B
- I
N I
and O
O B
. O
. O
. O
H B
- I
C I
, O
are O
found O
to O
play O
important O
roles O
in O
influencing O
the O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
of O
the O
dipeptides B
. O

Two O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
N B
. O
. O
. O
H B
- I
N I
and O
O B
. O
. O
. O
H B
- I
C I
, O
are O
found O
to O
play O
important O
roles O
in O
influencing O
the O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
of O
the O
dipeptides B
. O

Two O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
N B
. O
. O
. O
H B
- I
N I
and O
O B
. O
. O
. O
H B
- I
C I
, O
are O
found O
to O
play O
important O
roles O
in O
influencing O
the O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
of O
the O
dipeptides B
. O

The O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
influences O
the O
values O
of O
phi O
, O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
C7 O
alpha B
- I
carbon I
atoms O
while O
the O
solvation O
effects O
are O
evident O
on O
the O
values O
of O
bond O
lengths O
and O
bond O
angles O
of O
the O
amide B
planes O
. O

Phase O
- O
controlled O
nickel B
sulfide I
( O
Ni3 B
S4 I
and O
NiS1 B
. I
03 I
) O
nanoparticle O
( O
NP O
) O
/ O
nitrogen B
- I
doped I
graphene I
( O
NG O
) O
composites O
are O
prepared O
through O
a O
facile O
one O
- O
pot O
hydrothermal O
process O
. O

The O
composites O
show O
ultrahigh O
capacity O
retentions O
of O
98 O
. O
87 O
% O
and O
95 O
. O
94 O
% O
for O
Ni3 B
S4 I
/ O
NG O
and O
NiS1 B
. I
03 I
/ O
NG O
electrodes O
, O
respectively O
, O
as O
anode O
materials O
for O
lithium B
ion O
batteries O
. O

The O
complete O
assignment O
of O
the O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
of O
various O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamide I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamides I
with O
p B
- I
methoxy I
, O
o B
- I
chloro I
and O
m B
- I
chloro I
substituents O
is O
reported O
. O

The O
complete O
assignment O
of O
the O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
of O
various O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamide I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamides I
with O
p B
- I
methoxy I
, O
o B
- I
chloro I
and O
m B
- I
chloro I
substituents O
is O
reported O
. O

The O
complete O
assignment O
of O
the O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
of O
various O
2 B
- I
acetamido I
- I
3 I
- I
mercapto I
- I
3 I
- I
methyl I
- I
N I
- I
aryl I
- I
butanamides I
and O
2 B
- I
acetamide I
- I
3 I
- I
methyl I
- I
3 I
- I
nitrososulfanyl I
- I
N I
- I
aryl I
- I
butanamides I
with O
p B
- I
methoxy I
, O
o B
- I
chloro I
and O
m B
- I
chloro I
substituents O
is O
reported O
. O

Powder O
formulations O
of O
both O
species O
revealed O
the O
presence O
of O
essential O
nutrients O
, O
such O
as O
proteins O
, O
carbohydrates B
and O
unsaturated B
fatty I
acids I
. O

This O
novel O
instrumental O
approach O
enabled O
rapid O
fingerprinting O
of O
examined O
samples O
and O
detection O
of O
numerous O
sample O
components O
, O
such O
as O
triacylglycerols B
( O
TAGs B
) O
, O
phytosterols O
, O
free B
fatty I
acids I
( O
FFA B
) O
, O
and O
their O
respective O
oxidation O
products O
. O

Calcium B
hydroxy I
palmitate I
: O
possible O
precursor O
phase O
in O
calcium B
precipitation O
by O
palmitate B
. O

In O
this O
study O
, O
Wistar O
- O
Kyoto O
rats O
received O
intracerebroventricu O
( O
I O
. O
C O
. O
V O
. O
) O
infusion O
of O
artificial O
cerebrospinal O
fluid O
( O
aCSF O
) O
while O
SHRs O
received O
I O
. O
C O
. O
V O
. O
infusion O
of O
aCSF O
, O
Ang O
- O
( O
1 O
- O
7 O
) O
, O
Mas O
receptor O
antagonist O
A B
- I
779 I
, O
or O
angiotensin O
II O
type O
2 O
receptor O
antagonist O
PD123319 B
for O
4 O
weeks O
. O

Of O
note O
, O
the O
anti O
- O
autophagic O
effects O
of O
Ang O
- O
( O
1 O
- O
7 O
) O
were O
independent O
of O
blood O
pressure O
reduction O
and O
can O
be O
inhibited O
by O
A B
- I
779 I
and O
PD123319 B
. O

Compounds O
4 O
, O
6 O
, O
16 O
, O
and O
17 O
( O
10 O
mu O
M O
) O
had O
moderate O
hepatoprotective O
activities O
against O
d B
- I
galactosamine I
- O
induced O
HL O
- O
7702 O
cell O
damage O
. O

The O
profile O
of O
enzymatically O
formed O
oxysterols B
in O
the O
SLOS O
mouse O
resembles O
that O
in O
the O
wild O
type O
but O
the O
level O
of O
24S B
- I
hydroxycholesterol I
, O
the O
dominating O
cholesterol B
metabolite O
, O
is O
reduced O
in O
a O
similar O
proportion O
to O
that O
of O
cholesterol B
. O

A O
number O
of O
oxysterols B
abundant O
in O
the O
SLOS O
mouse O
are O
probably O
derived O
from O
7 B
- I
dehydrocholesterol I
, O
however O
, O
the O
mechanism O
of O
their O
formation O
is O
unclear O
. O

The O
enzyme O
gamma O
- O
glutamyltransferase O
( O
GGT O
) O
catalyzes O
the O
hydrolysis O
of O
the O
gamma B
- I
glutamyl I
isopeptide O
bond O
of O
glutathione B
conjugates O
( O
donor O
substrates O
) O
, O
releasing O
glutamic B
acid I
, O
or O
the O
transfer O
of O
the O
donor O
' O
s O
gamma B
- I
glutamyl I
group O
to O
an O
acceptor O
substrate O
, O
such O
as O
a O
dipeptide B
. O

The O
enzyme O
gamma O
- O
glutamyltransferase O
( O
GGT O
) O
catalyzes O
the O
hydrolysis O
of O
the O
gamma B
- I
glutamyl I
isopeptide O
bond O
of O
glutathione B
conjugates O
( O
donor O
substrates O
) O
, O
releasing O
glutamic B
acid I
, O
or O
the O
transfer O
of O
the O
donor O
' O
s O
gamma B
- I
glutamyl I
group O
to O
an O
acceptor O
substrate O
, O
such O
as O
a O
dipeptide B
. O

Michaelis O
constants O
( O
Km O
) O
were O
obtained O
for O
4 B
- I
nitrobenzylglutathio I
( O
0 O
. O
075mM O
) O
, O
2 B
, I
4 I
- I
dinitrophenylglutath I
( O
0 O
. O
30mM O
) O
, O
4 B
- I
methylbiphenylylglut I
( O
0 O
. O
12mM O
) O
, O
1 B
- I
menaphthylglutathion I
( O
0 O
. O
23mM O
) O
, O
and O
9 B
- I
methylanthracenylglu I
( O
0 O
. O
22mM O
) O
, O
indicating O
a O
trend O
towards O
higher O
values O
for O
bulkier O
substrates O
. O

Michaelis O
constants O
( O
Km O
) O
were O
obtained O
for O
4 B
- I
nitrobenzylglutathio I
( O
0 O
. O
075mM O
) O
, O
2 B
, I
4 I
- I
dinitrophenylglutath I
( O
0 O
. O
30mM O
) O
, O
4 B
- I
methylbiphenylylglut I
( O
0 O
. O
12mM O
) O
, O
1 B
- I
menaphthylglutathion I
( O
0 O
. O
23mM O
) O
, O
and O
9 B
- I
methylanthracenylglu I
( O
0 O
. O
22mM O
) O
, O
indicating O
a O
trend O
towards O
higher O
values O
for O
bulkier O
substrates O
. O

Michaelis O
constants O
( O
Km O
) O
were O
obtained O
for O
4 B
- I
nitrobenzylglutathio I
( O
0 O
. O
075mM O
) O
, O
2 B
, I
4 I
- I
dinitrophenylglutath I
( O
0 O
. O
30mM O
) O
, O
4 B
- I
methylbiphenylylglut I
( O
0 O
. O
12mM O
) O
, O
1 B
- I
menaphthylglutathion I
( O
0 O
. O
23mM O
) O
, O
and O
9 B
- I
methylanthracenylglu I
( O
0 O
. O
22mM O
) O
, O
indicating O
a O
trend O
towards O
higher O
values O
for O
bulkier O
substrates O
. O

Michaelis O
constants O
( O
Km O
) O
were O
obtained O
for O
4 B
- I
nitrobenzylglutathio I
( O
0 O
. O
075mM O
) O
, O
2 B
, I
4 I
- I
dinitrophenylglutath I
( O
0 O
. O
30mM O
) O
, O
4 B
- I
methylbiphenylylglut I
( O
0 O
. O
12mM O
) O
, O
1 B
- I
menaphthylglutathion I
( O
0 O
. O
23mM O
) O
, O
and O
9 B
- I
methylanthracenylglu I
( O
0 O
. O
22mM O
) O
, O
indicating O
a O
trend O
towards O
higher O
values O
for O
bulkier O
substrates O
. O

Dietary O
exposure O
of O
juvenile O
female O
mice O
to O
polyhalogenated O
seafood O
contaminants O
( O
HBCD B
, O
BDE B
- I
47 I
, O
PCB B
- I
153 I
, O
TCDD B
) O
: O
Comparative O
assessment O
of O
effects O
in O
potential O
target O
tissues O
. O

Dietary O
exposure O
of O
juvenile O
female O
mice O
to O
polyhalogenated O
seafood O
contaminants O
( O
HBCD B
, O
BDE B
- I
47 I
, O
PCB B
- I
153 I
, O
TCDD B
) O
: O
Comparative O
assessment O
of O
effects O
in O
potential O
target O
tissues O
. O

The O
study O
compared O
the O
effects O
of O
two O
legacy O
and O
two O
emerging O
fish O
pollutants O
( O
Hexabromocyclododeca B
HBCD B
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
ether I
BDE B
- I
47 I
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I
Hexachlorobiphenyl I
PCB B
- I
153 I
; O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
doxin I
TCDD B
) O
in O
juvenile O
female O
mice O
exposed O
through O
a O
salmon O
based O
rodent O
diet O
for O
28days O
( O

The O
study O
compared O
the O
effects O
of O
two O
legacy O
and O
two O
emerging O
fish O
pollutants O
( O
Hexabromocyclododeca B
HBCD B
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
ether I
BDE B
- I
47 I
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I
Hexachlorobiphenyl I
PCB B
- I
153 I
; O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
doxin I
TCDD B
) O
in O
juvenile O
female O
mice O
exposed O
through O
a O
salmon O
based O
rodent O
diet O
for O
28days O
( O

dietary O
doses O
: O
HBCD B
199mg O
/ O
kg O
bw O
/ O
day O
; O
BDE B
- I
47 I
450 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
PCB B
- I
153 I
195 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
TCDD B
90ng O
/ O
kg O
bw O
/ O
day O
) O
. O

dietary O
doses O
: O
HBCD B
199mg O
/ O
kg O
bw O
/ O
day O
; O
BDE B
- I
47 I
450 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
PCB B
- I
153 I
195 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
TCDD B
90ng O
/ O
kg O
bw O
/ O
day O
) O
. O

All O
compounds O
caused O
changes O
in O
liver O
, O
thymus O
and O
thyroid O
; O
spleen O
was O
affected O
by O
BDE B
- I
47 I
and O
PCB B
- I
153 I
; O
no O
effects O
were O
seen O
in O
uterus O
and O
adrenals O
. O

All O
compounds O
caused O
changes O
in O
liver O
, O
thymus O
and O
thyroid O
; O
spleen O
was O
affected O
by O
BDE B
- I
47 I
and O
PCB B
- I
153 I
; O
no O
effects O
were O
seen O
in O
uterus O
and O
adrenals O
. O

Strongest O
effects O
in O
thyroid O
follicles O
were O
elicited O
by O
PCB B
- I
153 I
, O
in O
thymus O
and O
liver O
by O
BDE B
- I
47 I
. O

Strongest O
effects O
in O
thyroid O
follicles O
were O
elicited O
by O
PCB B
- I
153 I
, O
in O
thymus O
and O
liver O
by O
BDE B
- I
47 I
. O

HBCD B
and O
BDE B
- I
47 I
induced O
liver O
fatty O
changes O
, O
but O
appeared O
to O
be O
less O
potent O
in O
the O
other O
tissues O
. O

HBCD B
, O
BDE B
- I
47 I
and O
TCDD B
increased O
serum O
testosterone B
levels O
and O
the O
testosterone B
/ O
estradiol B
ratio O
, O
suggesting O
a O
potential O
involvement O
of O
pathways O
related O
to O
sex O
steroid B
biosynthesis O
and O
/ O
or O
metabolism O
. O

The O
incorporation O
of O
a O
d B
- I
ribofuranose I
into O
the O
hinged O
hybrids O
provided O
the O
corresponding O
nucleosides B
with O
the O
beta O
configuration O
, O
one O
of O
which O
inhibited O
HCV O
replication O
with O
an O
EC50 O
value O
of O
20 O
mu O
M O
. O

The O
protective O
role O
of O
l B
- I
carnitine I
against O
cylindrospermopsin B
- O
induced O
oxidative O
stress O
in O
tilapia O
( O
Oreochromis O
niloticus O
) O
. O

We O
investigated O
the O
protective O
effects O
of O
l B
- I
carnitine I
( O
LC O
) O
pre O
- O
treatment O
on O
A O
. O
ovalisporum O
- O
induced O
oxidative O
stress O
in O
cells O
containing O
CYN B
and O
deoxy B
- I
CYN I
, O
or O
pure O
standard O
CYN B
, O
in O
tilapia O
( O
Oreochromis O
niloticus O
) O
that O
had O
been O
acutely O
exposed O
via O
oral O
administration O
. O

We O
investigated O
the O
protective O
effects O
of O
l B
- I
carnitine I
( O
LC O
) O
pre O
- O
treatment O
on O
A O
. O
ovalisporum O
- O
induced O
oxidative O
stress O
in O
cells O
containing O
CYN B
and O
deoxy B
- I
CYN I
, O
or O
pure O
standard O
CYN B
, O
in O
tilapia O
( O
Oreochromis O
niloticus O
) O
that O
had O
been O
acutely O
exposed O
via O
oral O
administration O
. O

We O
have O
now O
developed O
an O
isotope O
- O
dilution O
, O
liquid O
chromatography O
- O
coupled O
, O
tandem O
quadrupole O
mass O
spectrometric O
method O
to O
quantify O
representative O
species O
across O
the O
spectrum O
of O
RNA O
damage O
products O
predicted O
to O
arise O
at O
sites O
of O
inflammation O
, O
including O
nucleobase B
deamination O
( O
xanthosine B
and O
inosine B
) O
, O
oxidation O
( O
8 B
- I
oxoguanosine I
) O
, O
and O
alkylation O
( O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenosine I
) O
. O

Further O
, O
the O
nitric B
oxide I
synthase O
inhibitor O
, O
N B
- I
methylarginine I
, O
did O
not O
significantly O
affect O
the O
levels O
of O
inosine B
in O
control O
and O
RcsX O
- O
treated O
mice O
. O

Compared O
to O
control O
HDLs O
, O
ABLP O
HDLs O
showed O
a O
40 O
% O
decrease O
of O
alpha B
- I
tocopherol I
and O
an O
11 O
- O
fold O
increased O
malondialdehyde B
concentration O
. O

We O
found O
that O
Egr1 O
, O
a O
transcription O
factor O
whose O
promoter O
activity O
was O
positively O
regulated O
by O
the O
5 O
- O
HT2A O
receptor O
agonist O
TCB B
- I
2 I
, O
binds O
less O
to O
the O
mGlu2 O
promoter O
in O
frontal O
cortex O
of O
5 O
- O
HT2A O
- O
KO O
as O
compared O
to O
wild O
- O
type O
mice O
. O

DHEA B
- I
S I
is O
the O
most O
abundant O
steroid B
hormone O
in O
human O
circulation O
. O

Although O
a O
relationship O
of O
DHEA B
- I
S I
with O
obesity O
- O
related O
diseases O
has O
been O
reported O
, O
the O
metabolic O
role O
of O
this O
hormone O
remains O
unclear O
, O
particularly O
in O
children O
. O

In O
our O
study O
, O
we O
have O
investigated O
the O
relationship O
of O
DHEA B
- I
S I
levels O
with O
anthropometric O
variables O
, O
insulin O
, O
HOMA O
, O
and O
free B
fatty I
acids I
in O
adolescents O
. O

In O
our O
study O
, O
we O
have O
investigated O
the O
relationship O
of O
DHEA B
- I
S I
levels O
with O
anthropometric O
variables O
, O
insulin O
, O
HOMA O
, O
and O
free B
fatty I
acids I
in O
adolescents O
. O

Plasma O
DHEA B
- I
S I
was O
determined O
by O
RIA O
, O
insulin O
concentrations O
by O
IRMA O
, O
and O
free B
fatty I
acids I
by O
using O
a O
commercial O
kit O
. O

Plasma O
DHEA B
- I
S I
was O
determined O
by O
RIA O
, O
insulin O
concentrations O
by O
IRMA O
, O
and O
free B
fatty I
acids I
by O
using O
a O
commercial O
kit O
. O

No O
significant O
differences O
in O
plasma O
DHEA B
- I
S I
levels O
were O
found O
between O
sexes O
. O

DHEA B
- I
S I
levels O
in O
overweight O
children O
were O
significantly O
higher O
than O
in O
normal O
- O
weight O
children O
. O

DHEA B
- I
S I
levels O
were O
significantly O
correlated O
with O
weight O
and O
BMI O
after O
adjusting O
for O
age O
. O

Significant O
positive O
correlations O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
were O
found O
after O
adjusting O
for O
age O
and O
BMI O
, O
particularly O
in O
boys O
, O
but O
not O
between O
DHEA B
- I
S I
levels O
and O
insulin O
or O
HOMA O
in O
either O
gender O
. O

Significant O
positive O
correlations O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
were O
found O
after O
adjusting O
for O
age O
and O
BMI O
, O
particularly O
in O
boys O
, O
but O
not O
between O
DHEA B
- I
S I
levels O
and O
insulin O
or O
HOMA O
in O
either O
gender O
. O

Significant O
positive O
correlations O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
were O
found O
after O
adjusting O
for O
age O
and O
BMI O
, O
particularly O
in O
boys O
, O
but O
not O
between O
DHEA B
- I
S I
levels O
and O
insulin O
or O
HOMA O
in O
either O
gender O
. O

DHEA B
- I
S I
levels O
in O
12 O
- O
16 O
- O
year O
- O
old O
children O
are O
correlated O
with O
weight O
and O
BMI O
independently O
of O
age O
. O

We O
failed O
to O
find O
any O
association O
between O
DHEA B
- I
S I
and O
insulin O
levels O
, O
but O
we O
did O
find O
a O
- O
significant O
correlation O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
, O
suggesting O
that O
its O
association O
with O
free B
fatty I
acids I
may O
be O
related O
to O
the O
onset O
of O
the O
association O
of O
DHEA B
- I
S I
with O
insulin O
resi O
- O
stance O
. O

We O
failed O
to O
find O
any O
association O
between O
DHEA B
- I
S I
and O
insulin O
levels O
, O
but O
we O
did O
find O
a O
- O
significant O
correlation O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
, O
suggesting O
that O
its O
association O
with O
free B
fatty I
acids I
may O
be O
related O
to O
the O
onset O
of O
the O
association O
of O
DHEA B
- I
S I
with O
insulin O
resi O
- O
stance O
. O

We O
failed O
to O
find O
any O
association O
between O
DHEA B
- I
S I
and O
insulin O
levels O
, O
but O
we O
did O
find O
a O
- O
significant O
correlation O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
, O
suggesting O
that O
its O
association O
with O
free B
fatty I
acids I
may O
be O
related O
to O
the O
onset O
of O
the O
association O
of O
DHEA B
- I
S I
with O
insulin O
resi O
- O
stance O
. O

We O
failed O
to O
find O
any O
association O
between O
DHEA B
- I
S I
and O
insulin O
levels O
, O
but O
we O
did O
find O
a O
- O
significant O
correlation O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
, O
suggesting O
that O
its O
association O
with O
free B
fatty I
acids I
may O
be O
related O
to O
the O
onset O
of O
the O
association O
of O
DHEA B
- I
S I
with O
insulin O
resi O
- O
stance O
. O

We O
failed O
to O
find O
any O
association O
between O
DHEA B
- I
S I
and O
insulin O
levels O
, O
but O
we O
did O
find O
a O
- O
significant O
correlation O
between O
DHEA B
- I
S I
and O
free B
fatty I
acids I
levels O
, O
suggesting O
that O
its O
association O
with O
free B
fatty I
acids I
may O
be O
related O
to O
the O
onset O
of O
the O
association O
of O
DHEA B
- I
S I
with O
insulin O
resi O
- O
stance O
. O

Chemical O
enhancement O
: O
Designed O
to O
target O
HIV O
- O
1 O
protease O
, O
a O
novel O
gamma B
- I
hydroxyphosphonate I
has O
been O
found O
to O
significantly O
enhance O
viral O
replication O
in O
a O
panel O
of O
clinically O
relevant O
R5 O
HIV O
- O
1 O
isolates O
. O

Acoustic O
properties O
of O
three O
( O
1 B
- I
ethyl I
- O
, O
1 B
- I
butyl I
- O
, O
and O
1 B
- I
octyl I
- O
) O
1 B
- I
alkyl I
- I
3 I
- I
methylimidazolium I
bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
room O
- O
temperature O
ionic O
liquids O
are O
reported O
and O
discussed O
. O

Acoustic O
properties O
of O
three O
( O
1 B
- I
ethyl I
- O
, O
1 B
- I
butyl I
- O
, O
and O
1 B
- I
octyl I
- O
) O
1 B
- I
alkyl I
- I
3 I
- I
methylimidazolium I
bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
room O
- O
temperature O
ionic O
liquids O
are O
reported O
and O
discussed O
. O

Acoustic O
properties O
of O
three O
( O
1 B
- I
ethyl I
- O
, O
1 B
- I
butyl I
- O
, O
and O
1 B
- I
octyl I
- O
) O
1 B
- I
alkyl I
- I
3 I
- I
methylimidazolium I
bis I
[ I
( I
trifluoromethyl I
) I
sulfonyl I
] I
imide I
room O
- O
temperature O
ionic O
liquids O
are O
reported O
and O
discussed O
. O

Insight O
into O
the O
Aqua B
- I
Hydroxo I
< O
- O
- O
> O
Hydroxyl B
Equilibrium O
: O
A O
Combined O
Experimental O
and O
Theoretical O
Study O
. O

A O
metal O
- O
organic O
framework O
( O
MOF O
) O
bearing O
the O
aqua B
- I
hydroxo I
species O
( B
O2H3 I
) I
( I
- I
) I
in O
the O
framework O
, O
as O
well O
as O
the O
processes O
that O
govern O
the O
equilibrium O
aqua B
- I
hydroxo I
( B
O2H3 I
) I
( I
- I
) I
< O
- O
- O
> O
hydroxyl B
( O
OH B
) O
in O
Sc B
- O
MOFs O
, O
are O
studied O
experimentally O
and O
theoretically O
. O

A O
metal O
- O
organic O
framework O
( O
MOF O
) O
bearing O
the O
aqua B
- I
hydroxo I
species O
( B
O2H3 I
) I
( I
- I
) I
in O
the O
framework O
, O
as O
well O
as O
the O
processes O
that O
govern O
the O
equilibrium O
aqua B
- I
hydroxo I
( B
O2H3 I
) I
( I
- I
) I
< O
- O
- O
> O
hydroxyl B
( O
OH B
) O
in O
Sc B
- O
MOFs O
, O
are O
studied O
experimentally O
and O
theoretically O
. O

Reversible O
gelation O
and O
dissolution O
are O
achieved O
both O
in O
dimethylformamide B
and O
in O
aqueous O
medium O
via O
a O
thiol B
- I
disulphide I
interconversion O
in O
the O
side O
chain O
of O
the O
polymers O
. O

Two O
different O
composite O
scaffolds O
, O
solid O
- O
freeform O
- O
fabricated O
PCL B
/ O
beta B
- I
TCP I
supplemented O
with O
and O
without O
collagen O
nanofibers O
are O
fabricated O
. O

These O
scaffolds O
are O
evaluated O
whether O
a O
combination O
of O
collagen O
nanofibers O
with O
PCL B
/ O
beta B
- I
TCP I
can O
promote O
osteogenesis O
in O
a O
mastoid O
obliteration O
. O

Experimental O
mastoid O
obliteration O
is O
performed O
using O
guinea O
pigs O
that O
are O
divided O
group O
A O
( O
PCL B
/ O
beta B
- I
TCP I
/ O
collagen O
- O
nanofiber O
scaffold O
) O
and O
group O
B O
( O
PCL B
/ O
beta B
- I
TCP I
scaffold O
) O
. O

Experimental O
mastoid O
obliteration O
is O
performed O
using O
guinea O
pigs O
that O
are O
divided O
group O
A O
( O
PCL B
/ O
beta B
- I
TCP I
/ O
collagen O
- O
nanofiber O
scaffold O
) O
and O
group O
B O
( O
PCL B
/ O
beta B
- I
TCP I
scaffold O
) O
. O

The O
results O
reveal O
that O
PCL B
/ O
beta B
- I
TCP I
/ O
collagen O
scaffold O
provide O
much O
broader O
cell O
attachment O
sites O
than O
PCL B
/ O
beta B
- I
TCP I
scaffold O
. O

The O
results O
reveal O
that O
PCL B
/ O
beta B
- I
TCP I
/ O
collagen O
scaffold O
provide O
much O
broader O
cell O
attachment O
sites O
than O
PCL B
/ O
beta B
- I
TCP I
scaffold O
. O

In O
addition O
, O
based O
on O
the O
results O
of O
the O
histological O
and O
micro O
- O
CT O
at O
12 O
weeks O
post O
- O
surgery O
, O
the O
effective O
regeneration O
of O
bone O
in O
the O
PCL B
/ O
beta B
- I
TCP I
/ O
collagen O
scaffold O
is O
appeared O
. O

Further O
research O
suggested O
the O
antidepressant O
and O
cognition O
- O
enhancing O
effects O
of O
post O
- O
serotonin B
metabolite O
, O
N B
- I
acetylserotonin I
( O
NAS B
) O
, O
an O
agonist O
to O
tyrosine B
kinase O
B O
( O
TrkB O
) O
receptor O
; O
and O
link O
between O
depression O
and O
chronic O
inflammation O
- O
associated O
disorders O
( O
e O
. O
g O
. O
, O
insulin O
resistance O
, O
hepatitis O
C O
virus O
) O
via O
inflammation O
- O
induced O
activation O
of O
indoleamine B
2 O
, O
3 O
- O
dioxygenase O
, O
brain O
located O
rate O
- O
limiting O
enzyme O
of O
TRY B
- O
KYN B
metabolism O
. O

Efficacy O
of O
D B
- I
penicillamine I
, O
a O
sequestering O
acetaldehyde B
agent O
, O
in O
the O
prevention O
of O
alcohol B
relapse O
- O
like O
drinking O
in O
rats O
. O

Although O
these O
compounds O
are O
able O
to O
attenuate O
or O
prevent O
most O
of O
the O
behavioral O
and O
neurochemical O
effects O
of O
ethanol B
, O
the O
efficacy O
of O
acetaldehyde B
sequestration O
, O
by O
using O
agents O
such O
as O
D B
- I
penicillamine I
( O
DP O
) O
, O
in O
relapse O
prevention O
has O
not O
been O
studied O
yet O
. O

The O
structure O
- O
activity O
relationships O
showed O
that O
a O
leucinol B
moiety O
attached O
to O
the O
core O
- O
structure O
in O
the O
7 O
- O
position O
together O
with O
alpha B
- I
methyl I
branched O
benzyl B
derivatives O
in O
the O
5 O
- O
position O
displayed O
promising O
affinity O
, O
and O
selectivity O
as O
well O
as O
physicochemical O
properties O
, O
as O
exemplified O
by O
compounds O
18a O
and O
24h O
. O

Most O
of O
the O
dithiazine B
analogues O
were O
found O
to O
be O
inactive O
on O
the O
pancreatic O
tissue O
, O
although O
some O
compounds O
bearing O
a O
1 B
- I
phenylethylamino I
side O
chain O
at O
the O
3 O
- O
position O
exerted O
a O
marked O
myorelaxant O
activity O
. O

Structure O
- O
activity O
relationship O
analysis O
revealed O
that O
nitroaryl B
substituted I
diindolylmethanes I
showed O
potent O
antileishmanial O
activity O
. O

Sixty O
one O
compounds O
, O
grouped O
as O
the O
6H O
, O
6 B
- I
dialkylaminoalkyl I
, O
6 B
- I
acylaminoalkyl I
and O
sulfonylaminoalkyl B
derivatives O
, O
were O
tested O
for O
cytotoxicity O
, O
their O
effects O
on O
phytohemagglutin O
A O
( O
PHA O
) O
- O
induced O
proliferative O
response O
of O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
- O
alpha O
) O
production O
by O
these O
cells O
. O

Sixty O
one O
compounds O
, O
grouped O
as O
the O
6H O
, O
6 B
- I
dialkylaminoalkyl I
, O
6 B
- I
acylaminoalkyl I
and O
sulfonylaminoalkyl B
derivatives O
, O
were O
tested O
for O
cytotoxicity O
, O
their O
effects O
on O
phytohemagglutin O
A O
( O
PHA O
) O
- O
induced O
proliferative O
response O
of O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
- O
alpha O
) O
production O
by O
these O
cells O
. O

AAPH B
mediated O
lutein B
fragmented O
ions O
were O
identified O
as O
551 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
- O
H2O B
) O
, O
391 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 B
- I
C22H32O I
) O
and O
276 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 B
- I
C12H20O I
) O
and O
its O
isomers O
as O
13 B
- I
Z I
lutein I
, O
13 B
- I
Z I
zeaxanthin I
, O
13 B
' I
- I
Z I
zeaxanthin I
and O
all B
- I
E I
zeaxanthin I
. O

AAPH B
mediated O
lutein B
fragmented O
ions O
were O
identified O
as O
551 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
- O
H2O B
) O
, O
391 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 B
- I
C22H32O I
) O
and O
276 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 B
- I
C12H20O I
) O
and O
its O
isomers O
as O
13 B
- I
Z I
lutein I
, O
13 B
- I
Z I
zeaxanthin I
, O
13 B
' I
- I
Z I
zeaxanthin I
and O
all B
- I
E I
zeaxanthin I
. O

Neuroprotective O
effect O
of O
sulforaphane B
in O
6 B
- I
hydroxydopamine I
- O
lesioned O
mouse O
model O
of O
Parkinson O
' O
s O
disease O
. O

This O
study O
was O
undertaken O
to O
examine O
the O
effects O
of O
SFN B
on O
behavioral O
changes O
and O
dopaminergic O
neurotoxicity O
in O
mice O
exposed O
to O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
. O

This O
study O
was O
undertaken O
to O
examine O
the O
effects O
of O
SFN B
on O
behavioral O
changes O
and O
dopaminergic O
neurotoxicity O
in O
mice O
exposed O
to O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
. O

For O
this O
purpose O
, O
mice O
were O
treated O
with O
SFN B
( O
5mg O
/ O
kg O
twice O
a O
week O
) O
for O
four O
weeks O
after O
the O
unilateral O
intrastriatal O
injection O
of O
6 B
- I
OHDA I
. O

The O
increase O
in O
6 B
- I
OHDA I
- O
induced O
rotations O
and O
deficits O
in O
motor O
coordination O
were O
ameliorated O
significantly O
by O
SFN B
treatment O
. O

In O
addition O
, O
SFN B
protected O
6 B
- I
OHDA I
- O
induced O
apoptosis O
via O
blocking O
DNA O
fragmentation O
and O
caspase O
- O
3 O
activation O
. O

These O
results O
were O
further O
supported O
by O
immunohistochemical O
findings O
in O
the O
substantia O
nigra O
that O
showed O
that O
SFN B
protected O
neurons O
from O
neurotoxic O
effects O
of O
6 B
- I
OHDA I
. O

The O
endpoints O
examined O
were O
the O
DNA O
breakage O
estimated O
by O
the O
comet O
assay O
, O
the O
oxidative O
base O
damage O
recognized O
by O
formamido B
- I
pyrimidine I
glycosylase O
( O
FPG O
) O
and O
estimated O
with O
the O
FPG O
+ O
comet O
assay O
, O
and O
the O
frequencies O
of O
histone O
gamma O
H2AX O
foci O
and O
micronuclei O
. O

Our O
studies O
revealed O
that O
both O
4 B
- I
aminothiophenol I
and O
3 B
- I
propanedithiol I
functionalized O
Zn3P2 B
nanowires O
were O
stable O
over O
a O
120 O
day O
duration O
without O
any O
agglomeration O
or O
degradation O
. O

Our O
studies O
revealed O
that O
both O
4 B
- I
aminothiophenol I
and O
3 B
- I
propanedithiol I
functionalized O
Zn3P2 B
nanowires O
were O
stable O
over O
a O
120 O
day O
duration O
without O
any O
agglomeration O
or O
degradation O
. O

Combinations O
of O
elisidepsin B
with O
lapatinib B
and O
several O
chemotherapies O
including O
5 B
- I
FU I
and O
oxaliplatin B
resulted O
in O
synergistic O
effects O
that O
offer O
the O
potential O
of O
clinical O
use O
of O
elisidepsin B
in O
combination O
settings O
. O

6 B
- I
Gingerol I
Inhibits O
Rosiglitazone B
- O
Induced O
Adipogenesis O
in O
3T3 O
- O
L1 O
Adipocytes O
. O

We O
investigated O
the O
effects O
of O
6 B
- I
gingerol I
( O
( B
S I
) I
- I
5 I
- I
hydroxy I
- I
1 I
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenyl I
) I
- I
3 I
- I
decanone I
) O
on O
the O
inhibition O
of O
rosiglitazone B
( O
RGZ B
) O
- O
induced O
adipogenesis O
in O
3T3 O
- O
L1 O
cells O
. O

The O
morphological O
changes O
were O
photographed O
based O
on O
staining O
lipid O
accumulation O
by O
Oil B
- I
Red I
O I
in O
RGZ B
( O
1 O
micro O
mol O
/ O
l O
) O
- O
treated O
3T3 O
- O
L1 O
cells O
without O
or O
with O
various O
concentrations O
of O
6 B
- I
gingerol I
on O
differentiation O
day O
8 O
. O

6 B
- I
gingerol I
( O
50 O
micro O
mol O
/ O
l O
) O
effectively O
suppressed O
oil O
droplet O
accumulation O
and O
reduced O
the O
sizes O
of O
the O
droplets O
in O
RGZ B
- O
induced O
adipocyte O
differentiation O
in O
3T3 O
- O
L1 O
cells O
. O

The O
triglyceride B
accumulation O
induced O
by O
RGZ B
in O
differentiated O
3T3 O
- O
L1 O
cells O
was O
also O
reduced O
by O
6 B
- I
gingerol I
( O
50 O
micro O
mol O
/ O
l O
) O
. O

Treatment O
of O
differentiated O
3T3 O
- O
L1 O
cells O
with O
6 B
- I
gingerol I
( O
50 O
micro O
mol O
/ O
l O
) O
antagonized O
RGZ B
- O
induced O
gene O
expression O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
gamma O
and O
CCAAT O
/ O
enhancer O
- O
binding O
protein O
alpha O
. O

Additionally O
, O
the O
increased O
levels O
of O
mRNA O
and O
protein O
in O
adipocyte O
- O
specific O
fatty B
acid I
binding O
protein O
4 O
and O
fatty B
acid I
synthase O
induced O
by O
RGZ B
in O
3T3 O
- O
L1 O
cells O
were O
decreased O
upon O
treatment O
with O
6 B
- I
gingerol I
. O

Our O
data O
suggests O
that O
6 B
- I
gingerol I
may O
be O
beneficial O
in O
obesity O
, O
by O
reducing O
adipogenesis O
partly O
through O
the O
down O
- O
regulating O
PPAR O
gamma O
activity O
. O

In O
these O
models O
, O
maximal O
reversal O
of O
pain O
- O
related O
behaviors O
corresponded O
with O
maximum O
rates O
- O
of O
- O
increase O
in O
brain O
and O
plasma O
D B
- I
serine I
concentrations O
, O
indicative O
of O
full O
inhibition O
of O
DAAO O
activity O
. O

pyrazolopyrimidine B
- O
based O
TSPO O
ligand O
, O
6a O
( O
DPA B
- I
714 I
) O
. O

Radiolabeling O
with O
fluorine B
- I
18 I
( O
( B
18 I
) I
F I
) O
facilitated O
production O
of O
2 B
- I
( I
5 I
, I
7 I
- I
diethyl I
- I
2 I
- I
( I
4 I
- I
( I
2 I
- I
[ I
( I
18 I
) I
F I
] I
fluoroethoxy I
) I
phenyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
- I
N I
, I
N I
- I
diethylacetamide I
( O
( B
18 I
) I
F I
- O
6b O
) O
in O
high O
radiochemical O
yield O
and O
specific O
activity O
. O

A O
phytochemical O
study O
of O
Baeckea O
frutescens O
afforded O
a O
new O
biflavonoid B
named O
as O
baeckein B
E I
( O
1 O
) O
, O
along O
with O
four O
known O
C B
- I
methylated I
flavonols I
, O
baeckeins B
A I
( O
2 O
) O
and O
B O
( O
3 O
) O
, O
6 B
- I
methylquercetin I
( O
6 O
) O
and O
6 B
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
7 O
) O
, O
and O
two O
known O
biflavonoids O
baeckeins B
C I
( O
4 O
) O
and O
D O
( O
5 O
) O
. O

Activation O
of O
PPAR O
gamma O
is O
required O
for O
hydroxysafflor B
yellow I
A I
of O
Carthamus O
tinctorius O
to O
attenuate O
hepatic O
fibrosis O
induced O
by O
oxidative O
stress O
. O

Hydroxysafflor B
yellow I
A I
( O
HSYA B
) O
as O
a O
nature O
active O
ingredient O
with O
antioxidant O
capacity O
was O
able O
to O
effectively O
attenuate O
oxidative O
stress O
mediated O
injury O
. O

The O
ROS O
production O
was O
confirmed O
by O
DCF B
- I
DA I
probing O
assay O
in O
Sod O
- O
deficient O
strains O
. O

The O
systemic O
( O
subcutaneous O
) O
or O
local O
( O
intraplantar O
) O
administration O
of O
sigma O
1 O
antagonists O
( O
BD B
- I
1063 I
, O
BD B
- I
1047 I
, O
NE B
- I
100 I
and O
S1RA B
) O
was O
devoid O
of O
antinociceptive O
effects O
in O
WT O
mice O
. O

The O
systemic O
( O
subcutaneous O
) O
or O
local O
( O
intraplantar O
) O
administration O
of O
sigma O
1 O
antagonists O
( O
BD B
- I
1063 I
, O
BD B
- I
1047 I
, O
NE B
- I
100 I
and O
S1RA B
) O
was O
devoid O
of O
antinociceptive O
effects O
in O
WT O
mice O
. O

The O
systemic O
( O
subcutaneous O
) O
or O
local O
( O
intraplantar O
) O
administration O
of O
sigma O
1 O
antagonists O
( O
BD B
- I
1063 I
, O
BD B
- I
1047 I
, O
NE B
- I
100 I
and O
S1RA B
) O
was O
devoid O
of O
antinociceptive O
effects O
in O
WT O
mice O
. O

Similarly O
, O
systemic O
treatment O
of O
WT O
mice O
with O
sigma O
1 O
antagonists O
markedly O
potentiated O
morphine B
- O
induced O
antinociception O
, O
and O
its O
effects O
were O
reversed O
by O
the O
selective O
sigma O
1 O
agonist O
PRE B
- I
084 I
. O

Lysergic B
acid I
diethylamide I
( O
LSD B
) O
and O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
are O
serotonergic O
hallucinogens O
and O
activation O
of O
5HT2A O
receptors O
likely O
underlies O
their O
hallucinogenic O
effects O
. O

Equivalent O
increases O
in O
HFO O
power O
were O
observed O
after O
TCB B
- I
2 I
( O
5HT2A O
receptor O
agonist O
, O
0 O
. O
1 O
- O
1 O
. O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
CP B
809101 I
( O
5H2C O
receptor O
agonist O
, O
0 O
. O
1 O
- O
3 O
mg O
/ O
kg O
) O
. O

The O
first O
series O
comprises O
substrate O
analogue O
inhibitors O
containing O
a O
4 B
- I
amidinobenzylamide I
moiety O
in O
P1 O
position O
, O
whereby O
some O
of O
these O
analogues O
possess O
inhibition O
constants O
around O
20 O
nM O
. O

Based O
on O
the O
inhibitor O
studies O
a O
series O
of O
new O
fluorogenic O
substrates O
containing O
a O
d B
- I
arginine I
residue O
in O
P3 O
position O
was O
synthesized O
, O
some O
of O
them O
were O
efficiently O
cleaved O
by O
TMPRSS2 O
. O

The O
aggregation O
behavior O
of O
cationic O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidac I
with O
chloride B
( O
TTBC B
- I
Cl I
) O
or O
iodide B
counterions O
( O
TTBC B
- I
I I
) O
in O
aqueous O
solution O
is O
investigated O
by O
absorption O
, O
linear O
dichroism O
, O
and O
fluorescence O
spectroscopies O
, O
as O
well O
as O
cryogenic O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

The O
aggregation O
behavior O
of O
cationic O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidac I
with O
chloride B
( O
TTBC B
- I
Cl I
) O
or O
iodide B
counterions O
( O
TTBC B
- I
I I
) O
in O
aqueous O
solution O
is O
investigated O
by O
absorption O
, O
linear O
dichroism O
, O
and O
fluorescence O
spectroscopies O
, O
as O
well O
as O
cryogenic O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

TTBC B
- I
Cl I
is O
found O
to O
form O
J O
- O
aggregates O
with O
a O
classical O
Davydov O
- O
split O
absorption O
band O
( O
type O
I O
spectrum O
) O
even O
under O
different O
preparation O
conditions O
. O

Unlike O
the O
chloride B
salt O
, O
the O
iodide B
salt O
TTBC B
- I
I I
forms O
two O
different O
types O
of O
J O
- O
aggregates O
depending O
on O
the O
pH O
of O
the O
aqueous O
solution O
. O

The O
TTBC B
- I
I I
aggregates O
prepared O
in O
pure O
water O
( O
pH O
= O
6 O
) O
are O
characterized O
by O
a O
single O
redshifted O
absorption O
band O
( O
type O
III O
spectrum O
) O
, O
whereas O
those O
prepared O
in O
alkaline O
solution O
at O
pH O
= O
13 O
show O
a O
typical O
Davydov O
- O
split O
( O
type O
I O
) O
absorption O
band O
. O

Of O
the O
indolyl B
- I
3 I
- I
acetonitriles I
synthesized O
, O
compound O
2k O
, O
which O
possesses O
a O
hydroxyl B
group O
at O
C O
- O
7 O
position O
of O
the O
indole B
ring O
and O
an O
N B
- I
methyl I
substituent O
, O
more O
potently O
inhibited O
NO B
and O
PGE2 B
productions O
and O
was O
less O
cytotoxic O
than O
arvelexin B
on O
macrophage O
cells O
. O

Discovery O
of O
a O
synthetic O
Aminopeptidase O
N O
inhibitor O
LB B
- I
4b I
as O
a O
potential O
anticancer O
agent O
. O

LB B
- I
4b I
is O
the O
first O
synthetic O
APN O
inhibitor O
to O
be O
evaluated O
for O
both O
of O
its O
anti O
- O
invasion O
and O
anti O
- O
angiogenesis O
effects O
. O

As O
a O
potent O
synthetic O
APN O
inhibitor O
( O
IC50 O
= O
850nM O
, O
versus O
bestatin B
of O
8 O
. O
1 O
mu O
M O
) O
, O
LB B
- I
4b I
was O
determined O
to O
have O
more O
significant O
block O
effects O
to O
cancer O
cell O
invasion O
and O
angiogenesis O
than O
bestatin B
. O

This O
gastroprotective O
effect O
was O
attenuated O
by O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
, O
indomethacin B
and O
N B
- I
ethylmaleimide I
, O
indicating O
that O
NO B
, O
prostaglandins B
and O
sulfhydryl B
groups O
are O
involved O
in O
the O
mechanisms O
of O
action O
. O

Pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
detecting O
malignant O
thyroid O
nodules O
were O
85 O
. O
1 O
% O
[ O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
: O
81 O
. O
1 O
- O
88 O
. O
5 O
% O
] O
and O
45 O
. O
7 O
% O
( O
95 O
% O
CI O
: O
42 O
. O
7 O
- O
48 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
, O
irrespective O
of O
eventual O
results O
of O
previous O
technetium B
pertechnetate I
( O
( B
99m I
) I
TcO4 I
) O
or O
iodine B
- I
123 I
( O
( B
123 I
) I
I I
) O
scan O
. O

Multitarget O
Global O
Sensitivity O
Analysis O
of O
n B
- I
Butanol I
Combustion O
. O

Design O
, O
Synthesis O
, O
Biological O
Evaluation O
, O
and O
Docking O
Studies O
of O
( B
S I
) I
- I
Phenylalanine I
Derivatives O
with O
a O
2 B
- I
Cyanopyrrolidine I
Moiety O
as O
Potent O
Dipeptidyl O
Peptidase O
4 O
Inhibitors O
. O

A O
novel O
series O
of O
( B
S I
) I
- I
phenylalanine I
derivatives O
with O
a O
2 B
- I
cyanopyrrolidine I
moiety O
were O
designed O
and O
synthesized O
through O
a O
rational O
drug O
design O
strategy O
. O

Using O
whole O
mount O
in O
situ O
hybridization O
to O
examine O
thyroid B
hormone I
deiodinase O
expression O
in O
embryonic O
and O
larval O
zebrafish O
: O
A O
tool O
for O
examining O
OH B
- I
BDE I
toxicity O
to O
early O
life O
stages O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
and O
their O
oxidative O
metabolites O
( O
hydroxylated B
PBDEs I
; O
OH B
- I
BDEs I
) O
are O
known O
endocrine O
disrupting O
contaminants O
that O
have O
been O
shown O
to O
disrupt O
thyroid B
hormone I
regulation O
both O
in O
mammals O
and O
in O
fish O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
and O
their O
oxidative O
metabolites O
( O
hydroxylated B
PBDEs I
; O
OH B
- I
BDEs I
) O
are O
known O
endocrine O
disrupting O
contaminants O
that O
have O
been O
shown O
to O
disrupt O
thyroid B
hormone I
regulation O
both O
in O
mammals O
and O
in O
fish O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
precise O
organ O
and O
tissue O
locations O
that O
express O
genes O
critical O
to O
thyroid B
hormone I
regulation O
in O
developing O
zebrafish O
( O
Danio O
rerio O
) O
, O
and O
to O
determine O
the O
effects O
of O
an O
OH B
- I
BDE I
on O
their O
expression O
. O

While O
PBDEs B
and O
OH B
- I
BDEs I
have O
been O
shown O
to O
inhibit O
the O
activity O
and O
expression O
of O
deiodionases O
, O
a O
family O
of O
enzymes O
that O
regulate O
thyroid B
hormone I
concentrations O
intracellularly O
, O
it O
is O
unclear O
whether O
or O
not O
they O
can O
affect O
regional O
expression O
of O
the O
different O
isoforms O
during O
early O
development O
. O

Our O
results O
demonstrate O
effects O
of O
OH B
- I
BDEs I
on O
thyroid O
regulating O
gene O
expression O
and O
provide O
more O
insight O
into O
potential O
sites O
of O
injury O
during O
early O
life O
stages O
. O

In O
some O
genetic O
disorders O
, O
including O
cystic O
fibrosis O
and O
Duchenne O
muscular O
dystrophy O
, O
restoration O
of O
full O
- O
length O
protein O
has O
been O
achieved O
by O
aminoglycoside B
antibiotics O
, O
such O
as O
gentamicin B
and O
G B
- I
418 I
( O
Geneticin B
) O
. O

Gentamicin B
and O
G B
- I
418 I
induced O
read O
- O
through O
of O
nonsense O
PAH O
mutations O
in O
HEK293 O
cells O
. O

Enantiocomplementary O
access O
to O
carba O
- O
analogs O
of O
C B
- I
nucleoside I
derivatives O
by O
recombinant O
Baeyer O
- O
Villiger O
monooxygenases O
. O

In O
the O
present O
study O
a O
new O
method O
has O
been O
developed O
and O
validated O
for O
detecting O
free O
microcystins B
( O
MCs O
) O
( O
MC B
- I
RR I
, O
MC B
- I
LR I
and O
MC B
- I
YR I
) O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
in O
the O
cyprinid O
Tinca O
tinca O
and O
in O
the O
crayfish O
Procambarus O
clarkii O
collected O
from O
three O
ponds O
in O
Extremadura O
( O
Spain O
) O
where O
the O
presence O
of O
the O
cyanobacteria O
species O
Microcystis O
aeruginosa O
and O
Anabaena O
spiroides O
has O
been O
confirmed O

In O
the O
present O
study O
a O
new O
method O
has O
been O
developed O
and O
validated O
for O
detecting O
free O
microcystins B
( O
MCs O
) O
( O
MC B
- I
RR I
, O
MC B
- I
LR I
and O
MC B
- I
YR I
) O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
in O
the O
cyprinid O
Tinca O
tinca O
and O
in O
the O
crayfish O
Procambarus O
clarkii O
collected O
from O
three O
ponds O
in O
Extremadura O
( O
Spain O
) O
where O
the O
presence O
of O
the O
cyanobacteria O
species O
Microcystis O
aeruginosa O
and O
Anabaena O
spiroides O
has O
been O
confirmed O

In O
the O
present O
study O
a O
new O
method O
has O
been O
developed O
and O
validated O
for O
detecting O
free O
microcystins B
( O
MCs O
) O
( O
MC B
- I
RR I
, O
MC B
- I
LR I
and O
MC B
- I
YR I
) O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
in O
the O
cyprinid O
Tinca O
tinca O
and O
in O
the O
crayfish O
Procambarus O
clarkii O
collected O
from O
three O
ponds O
in O
Extremadura O
( O
Spain O
) O
where O
the O
presence O
of O
the O
cyanobacteria O
species O
Microcystis O
aeruginosa O
and O
Anabaena O
spiroides O
has O
been O
confirmed O

It O
was O
confirmed O
that O
P O
. O
clarkii O
accumulated O
MCs O
in O
their O
tissues O
without O
losing O
their O
organoleptic O
characteristics O
, O
with O
MC B
- I
LR I
( O
2 O
. O
3 O
- O
18 O
. O
1 O
mu O
g O
MC B
- I
LR I
/ O
g O
body O
weight O
) O
being O
the O
predominant O
MC O
variant O
detected O
in O
all O
the O
crayfish O
samples O
. O

It O
was O
confirmed O
that O
P O
. O
clarkii O
accumulated O
MCs O
in O
their O
tissues O
without O
losing O
their O
organoleptic O
characteristics O
, O
with O
MC B
- I
LR I
( O
2 O
. O
3 O
- O
18 O
. O
1 O
mu O
g O
MC B
- I
LR I
/ O
g O
body O
weight O
) O
being O
the O
predominant O
MC O
variant O
detected O
in O
all O
the O
crayfish O
samples O
. O

MC B
- I
RR I
was O
measured O
in O
50 O
% O
of O
the O
samples O
analyzed O
, O
ranging O
between O
1 O
. O
4 O
and O
7 O
. O
8 O
mu O
g O
MC B
- I
RR I
/ O
g O
body O
weight O
and O
no O
MC B
- I
YR I
was O
detected O
. O

MC B
- I
RR I
was O
measured O
in O
50 O
% O
of O
the O
samples O
analyzed O
, O
ranging O
between O
1 O
. O
4 O
and O
7 O
. O
8 O
mu O
g O
MC B
- I
RR I
/ O
g O
body O
weight O
and O
no O
MC B
- I
YR I
was O
detected O
. O

MC B
- I
RR I
was O
measured O
in O
50 O
% O
of O
the O
samples O
analyzed O
, O
ranging O
between O
1 O
. O
4 O
and O
7 O
. O
8 O
mu O
g O
MC B
- I
RR I
/ O
g O
body O
weight O
and O
no O
MC B
- I
YR I
was O
detected O
. O

The O
involvement O
of O
heme B
oxygenase O
1 O
but O
not O
nitric B
oxide I
synthase O
2 O
in O
a O
hepatoprotective O
action O
of O
quercetin B
in O
lipopolysaccharide O
- O
induced O
hepatotoxicity O
of O
d B
- I
galactosamine I
sensitized O
rats O
. O

Liver O
insult O
was O
induced O
by O
in O
vivo O
administration O
of O
d B
- I
galactosamine I
( O
d B
- I
GalN I
, O
400mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lipopolysaccharide O
( O
LPS O
, O
10 O
mu O
g O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

Liver O
insult O
was O
induced O
by O
in O
vivo O
administration O
of O
d B
- I
galactosamine I
( O
d B
- I
GalN I
, O
400mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lipopolysaccharide O
( O
LPS O
, O
10 O
mu O
g O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

The O
effects O
of O
quercetin B
( O
50mg O
/ O
kg O
, O
i O
. O
p O
) O
on O
d B
- I
GalN I
toxicity O
was O
evaluated O
by O
standard O
biochemical O
, O
RT O
- O
PCR O
and O
Western O
blot O
methods O
. O

Administration O
of O
d B
- I
GalN I
/ O
LPS O
combination O
resulted O
in O
significantly O
higher O
plasma O
levels O
of O
aminotransferases O
, O
as O
well O
as O
increased O
mRNA O
and O
protein O
expressions O
of O
both O
HO O
- O
1 O
and O
NOS O
- O
2 O
enzymes O
. O

Additionally O
, O
quercetin B
treatment O
in O
d B
- I
GalN I
/ O
LPS O
treated O
rats O
significantly O
increased O
HO O
- O
1 O
mRNA O
and O
its O
protein O
expressions O
. O

On O
the O
contrary O
, O
quercetin B
did O
not O
exhibit O
any O
significant O
effects O
on O
the O
levels O
of O
nitrites B
, O
and O
NOS O
- O
2 O
mRNA O
and O
protein O
expressions O
in O
d B
- I
GalN I
/ O
LPS O
treated O
rats O
. O

It O
can O
be O
concluded O
that O
the O
quercetin B
' O
s O
induction O
of O
HO O
- O
1 O
and O
its O
byproducts O
, O
without O
concomitant O
NOS O
- O
2 O
activity O
reduction O
, O
is O
among O
mechanisms O
contributing O
to O
the O
hepatoprotective O
effect O
in O
d B
- I
GalN I
/ O
LPS O
hepatotoxicity O
. O

The O
review O
charts O
advances O
in O
pharmaceutical O
development O
from O
the O
introduction O
of O
once O
- O
daily O
formulations O
of O
amphetamine B
through O
to O
lisdexamfetamine B
, O
which O
is O
the O
first O
d B
- I
amphetamine I
prodrug O
approved O
for O
the O
management O
of O
ADHD O
in O
children O
, O
adolescents O
and O
adults O
. O

The O
unusual O
metabolic O
route O
for O
lisdexamfetamine B
to O
deliver O
d B
- I
amphetamine I
makes O
an O
important O
contribution O
to O
its O
pharmacology O
. O

Bbil O
- O
TX O
( O
5 O
mu O
g O
/ O
ml O
) O
- O
induced O
blockade O
was O
markedly O
inhibited O
at O
22 O
- O
24 O
degrees O
C O
and O
pretreatment O
with O
p B
- I
bromophenacyl I
bromide I
( O
p B
- I
BPB I
) O
abolished O
the O
neuromuscular O
blockade O
. O

We O
demonstrate O
the O
difficulty O
of O
realising O
a O
phosphorylation O
step O
on O
the O
anomeric O
position O
of O
2 B
- I
deoxyribose I
, O
and O
we O
discover O
that O
introduction O
of O
fluorine B
atoms O
on O
the O
2 O
position O
of O
2 B
- I
deoxyribose I
enables O
the O
phosphorylation O
step O
: O
in O
fact O
, O
the O
stability O
of O
the O
prodrugs O
increases O
with O
the O
degree O
of O
2 O
- O
fluorination O
. O

We O
demonstrate O
the O
difficulty O
of O
realising O
a O
phosphorylation O
step O
on O
the O
anomeric O
position O
of O
2 B
- I
deoxyribose I
, O
and O
we O
discover O
that O
introduction O
of O
fluorine B
atoms O
on O
the O
2 O
position O
of O
2 B
- I
deoxyribose I
enables O
the O
phosphorylation O
step O
: O
in O
fact O
, O
the O
stability O
of O
the O
prodrugs O
increases O
with O
the O
degree O
of O
2 O
- O
fluorination O
. O

The O
neurospecific O
cholesterol B
24 O
- O
hydroxylase O
converts O
excess O
brain O
cholesterol B
into O
24S B
- I
hydroxycholesterol I
( O
24OHC B
) O
which O
, O
via O
the O
liver O
X O
receptor O
( O
LXR O
) O
, O
can O
increase O
the O
expression O
and O
synthesis O
of O
astrocyte O
ApoE O
. O

Less O
than O
1 O
% O
of O
the O
total O
brain O
excretion O
of O
24OHC B
occurs O
via O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
whereas O
almost O
all O
27 B
- I
hydroxycholesterol I
( O
27OHC B
) O
excretion O
is O
dependent O
on O
the O
function O
of O
the O
blood O
- O
cerebrospinal O
fluid O
barrier O
. O

In O
this O
paper O
, O
a O
novel O
method O
was O
proposed O
to O
prepare O
artificial O
antigens O
of O
gonyaulax O
parlaytic O
shellfish O
toxin O
2 O
and O
3 O
( O
GTX2 B
, I
3 I
) O
. O

In O
conclusion O
, O
the O
synthesized O
complete O
antigens O
have O
strong O
immunogenicity O
, O
which O
provides O
a O
solid O
foundation O
for O
preparing O
GTX2 B
, I
3 I
monoclonal O
antibody O
and O
rapid O
detection O
kit O
. O

Pharmacokinetic O
characterization O
of O
CK2 O
inhibitor O
CX B
- I
4945 I
. O

CX B
- I
4945 I
, O
a O
potent O
and O
selective O
orally O
bioavailable O
ATP B
- O
competitive O
inhibitor O
of O
CK2 O
, O
inhibits O
the O
oncogenic O
cellular O
events O
such O
as O
proliferation O
and O
angiogenesis O
, O
and O
the O
increase O
of O
tumor O
growth O
in O
mouse O
xenograft O
model O
. O

In O
this O
study O
, O
the O
pharmacokinetic O
information O
about O
CX B
- I
4945 I
was O
provided O
; O
at O
10 O
mu O
M O
, O
CX B
- I
4945 I
with O
high O
stability O
in O
human O
and O
rat O
liver O
microsome O
exhibited O
low O
percentage O
of O
inhibition O
( O
< O
10 O
% O
) O
in O
CYP450 O
isoforms O
( O
1A2 O
, O
2C19 O
, O
3A4 O
) O
, O
but O
considerable O
inhibition O
( O
~ O
70 O
% O
) O
in O
CYP450 O
2C9 O
and O
2D6 O
. O

In O
this O
study O
, O
the O
pharmacokinetic O
information O
about O
CX B
- I
4945 I
was O
provided O
; O
at O
10 O
mu O
M O
, O
CX B
- I
4945 I
with O
high O
stability O
in O
human O
and O
rat O
liver O
microsome O
exhibited O
low O
percentage O
of O
inhibition O
( O
< O
10 O
% O
) O
in O
CYP450 O
isoforms O
( O
1A2 O
, O
2C19 O
, O
3A4 O
) O
, O
but O
considerable O
inhibition O
( O
~ O
70 O
% O
) O
in O
CYP450 O
2C9 O
and O
2D6 O
. O

In O
hERG O
potassium B
channel O
inhibition O
assay O
, O
CX B
- I
4945 I
exhibited O
relatively O
low O
inhibition O
rate O
. O

Additionally O
, O
CX B
- I
4945 I
showed O
high O
MDCK O
cell O
permeability O
( O
> O
10 O
x O
10 O
( O
- O
6 O
) O
cm O
/ O
s O
) O
and O
above O
98 O
% O
of O
plasma O
protein O
binding O
in O
the O
rat O
. O

Moreover O
, O
orally O
administrated O
CX B
- I
4945 I
showed O
high O
bioavailability O
( O
> O
70 O
% O
) O
and O
these O
data O
might O
be O
related O
to O
the O
MDCK O
cell O
permeability O
results O
. O

In O
particular O
, O
the O
2 B
- I
pyridinylpiperazinyl I
substituents O
provided O
the O
resulting O
chromone B
derivatives O
with O
selective O
antiviral O
activity O
. O

Taken O
together O
, O
this O
result O
indicates O
the O
possible O
pharmacophoric O
role O
of O
the O
2 B
- I
pyridinylpiperazine I
functionality O
attached O
to O
the O
chromone B
scaffold O
, O
which O
warrants O
further O
in O
- O
depth O
structure O
- O
activity O
relationship O
study O
. O

Our O
data O
suggest O
that O
both O
E2 O
and O
E2BSA O
enhance O
the O
entrance O
of O
the O
fluorescent O
glucose B
analogue O
2 B
- I
NBDG I
, O
and O
also O
activates O
s O
PI3K O
/ O
Akt O
signaling O
pathway O
, O
leading O
to O
translocation O
of O
GLUT4 O
to O
the O
plasma O
membrane O
in O
an O
ER O
alpha O
dependent O
manner O
. O

Crystallization O
succeeded O
only O
( O
i O
) O
when O
an O
oxidation O
- O
and O
protease O
- O
insensitive O
protein O
variant O
( O
C183S O
- O
FixK2His6 O
) O
was O
used O
, O
in O
which O
C183 O
was O
replaced O
by O
serine B
and O
the O
C B
- O
terminus O
fused O
with O
a O
hexa B
- I
histidine I
tag O
, O
and O
( O
ii O
) O
when O
this O
protein O
was O
allowed O
to O
form O
a O
complex O
with O
a O
30mer O
double O
- O
strand O
target O
DNA O
. O

Therefore O
, O
we O
propose O
a O
mechanism O
whereby O
the O
oxo B
- I
acids I
generated O
after O
oxidation O
of O
the O
cysteine B
thiol I
cause O
an O
electrostatic O
repulsion O
, O
thus O
preventing O
specific O
DNA O
binding O
. O

Discovery O
of O
the O
First O
C B
- I
Nucleoside I
HCV O
Polymerase O
Inhibitor O
( O
GS B
- I
6620 I
) O
with O
Demonstrated O
Antiviral O
Response O
in O
HCV O
Infected O
Patients O
. O

Discovery O
of O
the O
First O
C B
- I
Nucleoside I
HCV O
Polymerase O
Inhibitor O
( O
GS B
- I
6620 I
) O
with O
Demonstrated O
Antiviral O
Response O
in O
HCV O
Infected O
Patients O
. O

NI O
candidates O
that O
have O
entered O
clinical O
development O
thus O
far O
have O
all O
been O
N B
- I
nucleoside I
derivatives O
. O

Herein O
, O
we O
report O
the O
discovery O
of O
a O
C B
- I
nucleoside I
class O
of O
NS5B O
inhibitors O
. O

Further O
pharmacokinetic O
optimization O
for O
sufficient O
oral O
absorption O
and O
liver O
triphosphate B
loading O
led O
to O
identification O
of O
a O
clinical O
development O
candidate O
GS B
- I
6620 I
. O

The O
process O
began O
with O
modification O
of O
the O
SBA B
- I
15 I
template O
with O
carbon B
polymers O
and O
Pt B
nanoparticles O
accompanied O
by O
adsorption O
of O
W B
( I
6 I
+ I
) I
, O
which O
was O
then O
converted O
into O
m B
- I
Pt I
- I
WO3 I
composites O
by O
heat O
treatment O
and O
subsequent O
template O
removal O
. O

Aromatic B
amino I
acids I
are O
known O
for O
their O
hydrophobicity O
and O
the O
active O
role O
they O
play O
in O
protein O
folding O
. O

Benzo B
[ I
a I
] I
pyrene I
( O
BaP B
) O
is O
a O
prototype O
for O
studying O
carcinogenesis O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
. O

Blockade O
of O
autophagy O
with O
bafilomycin B
A1 I
or O
3 B
- I
methyladenine I
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O

U B
- I
73122 I
, O
a O
phospholipase O
C O
( O
PLC O
) O
inhibitor O
, O
and O
2 B
- I
aminoethoxydiphenyl I
borate I
, O
an O
inositol B
1 I
, I
4 I
, I
5 I
trisphosphate I
( O
IP3 O
) O
receptor O
antagonist O
, O
attenuated O
hUII O
- O
induced O
MAP O
and O
RVR O
elevations O
, O
RBF O
and O
CBF O
reductions O
, O
but O
not O
MBF O
increase O
. O

Liposomes O
were O
composed O
of O
phosphatidylcholine B
, O
hydrogenated O
soy O
phosphatidylcholine B
( O
HSPC O
) O
, O
stearylamine B
, O
alpha B
- I
tocopherol I
and O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphoethanolamine I
- I
N I
- I
[ I
amino I
( I
polyethylene I
glycol I
) I
- I
2000 I
] I
( O
PEG B
- I
DSPE I
) O
or O
folate B
- I
polyethylene I
glycol I
- I
cholesteryl I
hemisuccinate I
( O
F B
- I

Liposomes O
were O
composed O
of O
phosphatidylcholine B
, O
hydrogenated O
soy O
phosphatidylcholine B
( O
HSPC O
) O
, O
stearylamine B
, O
alpha B
- I
tocopherol I
and O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphoethanolamine I
- I
N I
- I
[ I
amino I
( I
polyethylene I
glycol I
) I
- I
2000 I
] I
( O
PEG B
- I
DSPE I
) O
or O
folate B
- I
polyethylene I
glycol I
- I
cholesteryl I
hemisuccinate I
( O
F B
- I

The O
antioxidant O
capacities O
of O
the O
extract O
were O
evaluated O
using O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
, O
beta B
- I
carotene I
/ O
linoleic B
acid I
and O
reducing O
power O
and O
metal O
chelating O
activity O
assays O
. O

Inhibition O
of O
the O
key O
hydrolytic O
enzymes O
of O
the O
endocannabinoid O
system O
, O
fatty B
acid I
amide I
hydrolase O
( O
FAAH O
) O
and O
monoacylglycerol B
lipase O
( O
MAGL O
) O
, O
has O
been O
proposed O
as O
potential O
mode O
of O
action O
for O
various O
therapeutic O
applications O
. O

Antitumor O
effect O
of O
5 B
- I
fluorouracil I
is O
enhanced O
by O
rosemary O
extract O
in O
both O
drug O
sensitive O
and O
resistant O
colon O
cancer O
cells O
. O

5 B
- I
Fluorouracil I
( O
5 B
- I
FU I
) O
is O
the O
most O
used O
chemotherapeutic O
agent O
in O
colorectal O
cancer O
. O

5 B
- I
Fluorouracil I
( O
5 B
- I
FU I
) O
is O
the O
most O
used O
chemotherapeutic O
agent O
in O
colorectal O
cancer O
. O

The O
aim O
of O
this O
work O
was O
to O
determine O
the O
antitumor O
properties O
of O
a O
supercritical O
fluid O
rosemary O
extract O
( O
SFRE O
) O
, O
alone O
and O
in O
combination O
with O
5 B
- I
FU I
, O
as O
a O
potential O
adjuvant O
therapy O
useful O
for O
colon O
cancer O
patients O
. O

The O
effects O
of O
SFRE O
both O
alone O
and O
in O
combination O
with O
5 B
- I
FU I
were O
evaluated O
in O
different O
human O
colon O
cancer O
cells O
in O
terms O
of O
cell O
viability O
, O
cytotoxicity O
, O
and O
cell O
transformation O
. O

Additionally O
, O
colon O
cancer O
cells O
resistant O
to O
5 B
- I
FU I
were O
used O
to O
assay O
the O
effects O
of O
SFRE O
on O
drug O
resistance O
. O

Finally O
, O
qRT O
- O
PCR O
was O
performed O
to O
ascertain O
the O
mechanism O
by O
which O
SFRE O
potentiates O
the O
effect O
of O
5 B
- I
FU I
. O

Our O
results O
show O
that O
SFRE O
displays O
dose O
- O
dependent O
antitumor O
activities O
and O
exerts O
a O
synergistic O
effect O
in O
combination O
with O
5 B
- I
FU I
on O
colon O
cancer O
cells O
. O

Furthermore O
, O
SFRE O
sensitizes O
5 B
- I
FU I
- O
resistant O
cells O
to O
the O
therapeutic O
activity O
of O
this O
drug O
, O
constituting O
a O
beneficial O
agent O
against O
both O
5 B
- I
FU I
sensitive O
and O
resistant O
tumor O
cells O
. O

Furthermore O
, O
SFRE O
sensitizes O
5 B
- I
FU I
- O
resistant O
cells O
to O
the O
therapeutic O
activity O
of O
this O
drug O
, O
constituting O
a O
beneficial O
agent O
against O
both O
5 B
- I
FU I
sensitive O
and O
resistant O
tumor O
cells O
. O

Gene O
expression O
analysis O
indicates O
that O
the O
enhancement O
of O
the O
effect O
of O
5 B
- I
FU I
by O
SFRE O
might O
be O
explained O
by O
the O
downregulation O
of O
TYMS O
and O
TK1 O
, O
enzymes O
related O
to O
5 B
- I
FU I
resistance O
. O

Gene O
expression O
analysis O
indicates O
that O
the O
enhancement O
of O
the O
effect O
of O
5 B
- I
FU I
by O
SFRE O
might O
be O
explained O
by O
the O
downregulation O
of O
TYMS O
and O
TK1 O
, O
enzymes O
related O
to O
5 B
- I
FU I
resistance O
. O

The O
most O
active O
were O
7 B
- I
iodo I
and O
7 B
- I
ethynyl I
derivatives O
. O

The O
most O
active O
were O
7 B
- I
iodo I
and O
7 B
- I
ethynyl I
derivatives O
. O

Although O
OTA B
is O
twisted O
with O
respect O
to O
the O
base O
in O
the O
nucleobase B
model O
, O
addition O
of O
the O
deoxyribose B
sugar I
induces O
a O
further O
twist O
and O
restricts O
rotation O
about O
the O
C B
- I
C I
linkage O
due O
to O
close O
contacts O
between O
OTA B
and O
the O
sugar O
. O

Nevertheless O
, O
MD O
simulations O
and O
free O
energy O
analysis O
predict O
that O
both O
syn O
- O
and O
anti O
- O
conformations O
of O
OTB B
- I
dG I
are O
equally O
stable O
in O
helices O
when O
paired O
opposite O
cytosine B
. O

Antioxidant O
activity O
( O
AA O
% O
) O
of O
free O
and O
bound O
phenolic B
compounds O
was O
measured O
using O
the O
linoleic B
acid I
/ O
beta B
- I
carotene I
assay O
. O

Intracellular O
radical O
activation O
in O
661W O
, O
evaluated O
using O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
- O
sensitive O
probe O
5 B
- I
( I
and I
- I
6 I
) I
- I
chloromethyl I
- I
2 I
, I
7 I
- I
dichlorodihydro I
fluorescein I
diacetate I
acetyl I
ester I
( O
CM B
- I
H2DCFDA I
) O
, O
was O
reduced O
by O
MBE O
and O
its O
anthocyanins B
. O

Fresh O
muscles O
contained O
14 O
. O
83mg O
/ O
kg O
trans B
- I
UCA I
, O
2 O
. O
23mg O
/ O
kg O
cis B
- I
UCA I
and O
1 O
. O
86mg O
/ O
kg O
cadaverine B
. O

Fresh O
muscles O
contained O
14 O
. O
83mg O
/ O
kg O
trans B
- I
UCA I
, O
2 O
. O
23mg O
/ O
kg O
cis B
- I
UCA I
and O
1 O
. O
86mg O
/ O
kg O
cadaverine B
. O

After O
15days O
at O
0 O
and O
3 O
degrees O
C O
, O
trans B
- I
UCA I
content O
increased O
to O
52 O
. O
83 O
and O
189 O
. O
51mg O
/ O
kg O
, O
respectively O
, O
and O
decreased O
to O
< O
2mg O
/ O
kg O
at O
the O
other O
two O
temperatures O
. O

Storage O
at O
10 O
degrees O
C O
also O
resulted O
in O
an O
increase O
in O
trans B
- I
UCA I
after O
3days O
, O
only O
to O
decrease O
after O
6days O
. O

The O
concentration O
of O
cis B
- I
UCA I
increased O
nearly O
13 O
- O
fold O
after O
15days O
at O
0 O
and O
3 O
degrees O
C O
, O
decreased O
at O
10 O
degrees O
C O
and O
remained O
unchanged O
at O
23 O
degrees O
C O
. O

Characterisation O
of O
non O
- O
polar O
dimers O
formed O
during O
thermo O
- O
oxidative O
degradation O
of O
beta B
- I
sitosterol I
. O

The O
aim O
of O
this O
work O
was O
to O
decipher O
the O
chemical O
structure O
of O
non O
- O
polar O
dimers O
formed O
during O
beta B
- I
sitosterol I
oxidation O
at O
180 O
degrees O
C O
in O
the O
presence O
of O
oxygen B
. O

NMR O
data O
confirmed O
that O
the O
predominant O
non O
- O
polar O
dimer O
formed O
during O
beta B
- I
sitosterol I
oxidative O
degradation O
has O
a O
configuration O
of O
3 B
beta I
, I
3 I
beta I
' I
- I
disitosteryl I
ether I
. O

By O
inducing O
a O
PP O
from O
previously O
isolated O
cepathiolanes B
and O
l B
- I
valine I
, O
it O
was O
confirmed O
that O
cepathiolanes B
constitute O
at O
least O
a O
part O
of O
the O
CDs O
. O

The O
seed O
oils O
from O
pea O
samples O
contained O
palmitic B
and I
stearic I
acids I
as O
major O
saturated B
fatty I
acids I
. O

Oleic B
, I
linoleic I
and I
linolenic I
acids I
were O
the O
major O
unsaturated B
fatty I
acids I
found O
. O

Tert B
- I
butylhydroquinone I
recognition O
of O
molecular O
imprinting O
electrochemical O
sensor O
based O
on O
core O
- O
shell O
nanoparticles O
. O

One O
novel O
electrochemistry O
- O
molecular O
imprinting O
sensor O
for O
determining O
tert B
- I
butylhydroquinone I
( O
TBHQ B
) O
in O
foodstuff O
was O
developed O
. O

The O
silica B
nanoparticles O
were O
modified O
with O
( B
3 I
- I
chloropropyl I
) I
trimethoxysilan I
and O
polyethylenimine B
, O
respectively O
, O
and O
polymerised O
to O
form O
the O
TICSNs O
with O
ethylene B
glycol I
dimethacrylate I
as O
cross O
- O
linker O
. O

The O
potential O
of O
solvent O
- O
minimized O
extraction O
methods O
in O
the O
determination O
of O
polycyclic B
aromatic I
hydrocarbons I
in O
fish O
oils O
. O

The O
determination O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
in O
fish O
oils O
is O
complicated O
due O
to O
the O
fat O
matrix O
, O
which O
affects O
both O
extraction O
efficiency O
and O
analytical O
quality O
. O

In O
baking O
applications O
involving O
starch O
gelatinisation O
, O
surfactants O
such O
as O
sodium B
stearoyl I
lactylate I
( O
SSL B
) O
and O
monoacylglycerols B
( O
MAG B
) O
and O
Bacillus O
stearothermophilus O
maltogenic O
alpha O
- O
amylase O
( O
BStA O
) O
can O
be O
used O
jointly O
. O

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
n B
- I
hexane I
extracts O
from O
bones O
and O
internal O
organs O
of O
Japanese O
eel O
, O
Anguilla O
japonica O
( O
HEE O
) O
, O
on O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
- O
dependent O
prostaglandin B
D2 I
( O
PGD2 B
) O
generation O
in O
stem O
cell O
factor O
( O
SCF O
) O
, O
IL O
- O
10 O
, O
plus O
LPS O
- O
induced O
mouse O
bone O
marrow O
- O
derived O
mast O
cells O
( O
BMMCs O
) O
and O
on O
passive O
cutaneous O
anaphylaxis O
( O
PCA O
) O
in O
mice O
. O

A O
series O
of O
novel O
ureido B
- I
sulfonamides I
was O
prepared O
by O
reaction O
of O
aminobenzenesulfonam B
with O
alkyl B
/ I
aryl I
isocyanate I
. O

High O
glucose B
, O
insulin O
and O
free B
fatty I
acid I
concentrations O
synergistically O
enhance O
perilipin O
3 O
expression O
and O
lipid O
accumulation O
in O
macrophages O
. O

Since O
metabolic O
derangements O
found O
in O
metabolic O
syndrome O
, O
such O
as O
high O
serum O
levels O
of O
glucose B
, O
insulin O
and O
free B
fatty I
acids I
( O
FFAs B
) O
, O
are O
major O
risk O
factors O
promoting O
atherosclerosis O
, O
we O
investigated O
whether O
PLIN3 O
expression O
is O
affected O
by O
glucose B
, O
insulin O
and O
oleic B
acid I
( O
OA O
) O
using O
RAW264 O
. O
7 O
cells O
. O

Stable O
colloidal O
particles O
( O
< O
350nm O
) O
containing O
drug O
, O
polyvinylpyrrolidone B
( B
PVP I
) I
K12 I
and O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
in O
1 O
: O
2 O
. O
75 O
: O
0 O
. O
25 O
ratio O
were O
produced O
after O
2h O
of O
co O
- O
grinding O
. O

Polyhydroxy B
pregnane I
glycoside I
( O
PPG B
) O
, O
a O
steroidal B
glycoside I
was O
isolated O
from O
Wattakaka O
volubilis O
Linn O
. O

Cellular O
content O
of O
granuloma O
was O
measured O
by O
assaying O
activity O
of O
N B
- I
acetyl I
glucosaminidase O
( O
NAG O
) O
and O
total O
nucleic O
acid O
content O
. O

Ornidazole B
[ O
R B
, I
S I
- I
1 I
- I
chloro I
- I
3 I
- I
( I
2 I
- I
methyl I
- I
5 I
- I
nitro I
- I
1H I
- I
imidazol I
- I
1 I
- I
yl I
) I
propan I
- I
2 I
- I
ol I
] O
is O
a O
chiral O
5 B
- I
nitroimidazole I
class O
antimicrobial O
agent O
. O

Screening O
assays O
with O
12 O
available O
human O
recombinant O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
demonstrated O
that O
UGT1A9 O
was O
the O
predominant O
UGT O
isoform O
involved O
in O
R B
- I
ornidazole I
glucuronidation O
, O
whereas O
S B
- I
ornidazole I
glucuronidation O
was O
almost O
exclusively O
catalyzed O
by O
UGT2B7 O
. O

Screening O
assays O
with O
12 O
available O
human O
recombinant O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
demonstrated O
that O
UGT1A9 O
was O
the O
predominant O
UGT O
isoform O
involved O
in O
R B
- I
ornidazole I
glucuronidation O
, O
whereas O
S B
- I
ornidazole I
glucuronidation O
was O
almost O
exclusively O
catalyzed O
by O
UGT2B7 O
. O

The O
Km O
values O
for O
UGT1A9 O
( O
15 O
. O
6 O
+ O
/ O
- O
1 O
. O
6 O
mM O
for O
R B
- I
ornidazole I
) O
and O
2B7 O
( O
3 O
. O
8 O
+ O
/ O
- O
0 O
. O
9 O
mM O
for O
S B
- I
ornidazole I
) O
were O
quite O
similar O
to O
those O
determined O
in O
HLMs O
and O
HKMs O
( O
20 O
. O
1 O
+ O
/ O
- O
1 O
. O
4 O
and O
17 O
. O
7 O
+ O
/ O
- O
4 O
. O
0 O
mM O
for O
R B
- I
ornidazole I
; O
6 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
and O
3 O
. O
2 O
+ O
/ O
- O
0 O
. O
4 O
mM O
for O
S B
- I

The O
Km O
values O
for O
UGT1A9 O
( O
15 O
. O
6 O
+ O
/ O
- O
1 O
. O
6 O
mM O
for O
R B
- I
ornidazole I
) O
and O
2B7 O
( O
3 O
. O
8 O
+ O
/ O
- O
0 O
. O
9 O
mM O
for O
S B
- I
ornidazole I
) O
were O
quite O
similar O
to O
those O
determined O
in O
HLMs O
and O
HKMs O
( O
20 O
. O
1 O
+ O
/ O
- O
1 O
. O
4 O
and O
17 O
. O
7 O
+ O
/ O
- O
4 O
. O
0 O
mM O
for O
R B
- I
ornidazole I
; O
6 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
and O
3 O
. O
2 O
+ O
/ O
- O
0 O
. O
4 O
mM O
for O
S B
- I

The O
Km O
values O
for O
UGT1A9 O
( O
15 O
. O
6 O
+ O
/ O
- O
1 O
. O
6 O
mM O
for O
R B
- I
ornidazole I
) O
and O
2B7 O
( O
3 O
. O
8 O
+ O
/ O
- O
0 O
. O
9 O
mM O
for O
S B
- I
ornidazole I
) O
were O
quite O
similar O
to O
those O
determined O
in O
HLMs O
and O
HKMs O
( O
20 O
. O
1 O
+ O
/ O
- O
1 O
. O
4 O
and O
17 O
. O
7 O
+ O
/ O
- O
4 O
. O
0 O
mM O
for O
R B
- I
ornidazole I
; O
6 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
and O
3 O
. O
2 O
+ O
/ O
- O
0 O
. O
4 O
mM O
for O
S B
- I

Perinatal O
exposure O
to O
BDE B
- I
99 I
causes O
learning O
disorders O
and O
decreases O
serum O
thyroid B
hormone I
levels O
and O
BDNF O
gene O
expression O
in O
hippocampus O
in O
rat O
offspring O
. O

Exposure O
of O
pregnant O
women O
to O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
may O
mean O
serious O
health O
risks O
. O

The O
main O
goal O
of O
the O
present O
study O
was O
to O
examine O
the O
neurobehavioral O
changes O
in O
rat O
offspring O
that O
were O
perinatally O
exposed O
to O
one O
of O
the O
most O
prevalent O
PBDEs B
congeners O
found O
in O
humans O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
- I
pentaBDE I
( O
BDE B
- I
99 I
) O
. O

Rat O
dams O
were O
exposed O
to O
0 O
, O
1 O
and O
2mg O
/ O
kg O
/ O
day O
of O
BDE B
- I
99 I
from O
gestation O
day O
6 O
to O
post O
- O
natal O
day O
21 O
. O

The O
results O
showed O
that O
maternal O
transference O
of O
BDE B
- I
99 I
produced O
a O
delay O
in O
the O
spatial O
learning O
task O
in O
the O
water O
maze O
test O
. O

Phytotoxic O
effects O
of O
the O
cyanobacterial O
neurotoxin O
anatoxin B
- I
a I
: O
Morphological O
, O
physiological O
and O
biochemical O
responses O
in O
aquatic O
macrophyte O
, O
Ceratophyllum O
demersum O
. O

Anatoxin B
- I
a I
is O
one O
of O
the O
common O
and O
major O
cyanobacterial O
neurotoxins O
acting O
as O
a O
powerful O
agonist O
at O
nicotinic O
acetylcholine B
receptors O
( O
nAChR O
) O
. O

Anatoxin B
- I
a I
is O
suspected O
to O
have O
a O
distinct O
toxic O
mechanism O
depending O
on O
physiological O
and O
nervous O
systems O
in O
exposed O
organisms O
. O

The O
numerous O
researches O
have O
been O
actively O
conducted O
with O
respect O
to O
the O
toxic O
effects O
of O
anatoxin B
- I
a I
on O
mammals O
; O
however O
, O
little O
research O
has O
aimed O
at O
its O
possible O
effects O
on O
aquatic O
plants O
, O
wherein O
well O
- O
structured O
nervous O
system O
is O
absent O
with O
the O
lack O
of O
various O
components O
of O
the O
acetylcholine B
mechanism O
. O

In O
this O
study O
, O
submerged O
macrophyte O
Ceratophyllum O
demersum O
( O
C O
. O
demersum O
) O
was O
adopted O
to O
examine O
the O
effects O
of O
anatoxin B
- I
a I
on O
morphological O
( O
growth O
) O
, O
physiological O
( O
photosynthetic O
pigment O
contents O
) O
and O
biochemical O
( O
hydrogen B
peroxide I
level O
, O
biotransformation O
and O
antioxidative O
enzymes O
) O
responses O
in O
the O
aquatic O
plant O
at O
environmentally O
relevant O
concentrations O
( O
0 O
. O
005 O
, O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mu O
g O
/ O
L O
) O
. O

The O
significant O
elevation O
of O
antioxidative O
enzymes O
in O
parallel O
with O
increased O
formation O
of O
hydrogen B
peroxide I
appeared O
from O
0 O
. O
5 O
mu O
g O
/ O
L O
of O
anatoxin B
- I
a I
. O

Accordingly O
, O
the O
alteration O
in O
growth O
was O
manifested O
in O
the O
presence O
of O
5 O
and O
50 O
mu O
g O
/ O
L O
of O
anatoxin B
- I
a I
. O

The O
results O
clearly O
indicate O
that O
anatoxin B
- I
a I
can O
disrupt O
homeostasis O
of O
C O
. O
demersum O
through O
induction O
of O
oxidative O
stress O
; O
furthermore O
this O
aquatic O
plant O
possesses O
effective O
defense O
mechanisms O
to O
cope O
with O
low O
concentrations O
of O
anatoxin B
- I
a I
. O

The O
results O
clearly O
indicate O
that O
anatoxin B
- I
a I
can O
disrupt O
homeostasis O
of O
C O
. O
demersum O
through O
induction O
of O
oxidative O
stress O
; O
furthermore O
this O
aquatic O
plant O
possesses O
effective O
defense O
mechanisms O
to O
cope O
with O
low O
concentrations O
of O
anatoxin B
- I
a I
. O

Results O
showed O
that O
oral O
administration O
of O
plant O
stanyl B
hemisuccinate I
( O
2 O
x O
, O
5 O
x O
) O
and O
plant O
stanyl B
sorbitol I
succinate I
( O
2 O
x O
, O
5 O
x O
) O
effectively O
attenuated O
the O
serum O
total O
cholesterol B
and O
low O
density O
lipoprotein O
cholesterol B
levels O
, O
while O
had O
no O
effect O
on O
the O
serum O
triacylglycerol B
and O
high O
density O
lipoprotein O
cholesterol B
. O

Meanwhile O
, O
both O
plant O
stanyl B
hemisuccinate I
and O
plant O
stanyl B
sorbitol I
succinate I
could O
remarkably O
promote O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
expression O
, O
and O
increased O
cholesterol B
7 O
alpha O
- O
hydroxylase O
( O
CYP7A1 O
) O
expression O
and O
faecal O
total O
bile B
acid I
output O
to O
varying O
degrees O
. O

Wines O
stored O
at O
5 O
degrees O
C O
for O
6months O
did O
not O
show O
significant O
changes O
in O
flavor O
; O
otherwise O
, O
the O
samples O
stored O
at O
15 O
and O
25 O
degrees O
C O
, O
showed O
a O
significant O
decrease O
in O
linalool B
, O
beta B
- I
damascenone I
, O
ethyl B
hexanoate I
, O
and O
ethyl B
octanoate I
levels O
. O

In O
these O
last O
samples O
, O
alpha B
- I
terpineol I
, O
hotrienol B
, O
nerol B
oxide I
, O
furanic B
linalool I
oxides I
A I
/ I
B I
and O
rose B
oxide I
concentrations O
significantly O
increased O
. O

A O
new O
method O
for O
the O
detection O
of O
alternariol B
( O
AOH B
) O
, O
alternariol B
monomethyl I
ether I
( O
AME B
) O
, O
altenuene B
( O
ALT B
) O
, O
tentoxin B
( O
TEN B
) O
, O
and O
tenuazonic B
acid I
( O
TeA B
) O
, O
five O
alternaria O
toxins O
( O
ATs O
) O
was O
developed O
by O
liquid O
chromatography O
- O
triple O
quadrupole O
mass O
spectrometry O
equipped O
with O
atmospheric O
pressure O
chemical O
ionisation O
( O
APCI O
) O
. O

This O
report O
is O
aimed O
at O
intra O
- O
laboratory O
and O
inter O
- O
laboratory O
comparison O
of O
the O
results O
obtained O
during O
spectrophotometric O
and O
HPLC O
analyses O
of O
lycopene B
, O
beta B
- I
carotene I
and O
total O
carotenoids O
in O
tomato O
products O
and O
yellow O
maize O
flours O
/ O
grits O
. O

Nitric B
oxide I
could O
be O
involved O
in O
the O
acquisition O
and O
maintenance O
of O
behavioral O
cocaine B
effects O
, O
probably O
by O
activation O
of O
neuronal O
nitric B
oxide I
synthase O
( O
nNOS O
) O
/ O
NO B
/ O
soluble O
guanylyl B
cyclase O
( O
sGC O
) O
/ O
cyclic B
guanosine I
monophosphate I
( O
cGMP B
) O
signaling O
pathway O
, O
since O
inhibition O
of O
the O
nNOS O
enzyme O
attenuates O
development O
of O
sensitization O
in O
rats O
. O

The O
statistical O
approach O
is O
based O
on O
the O
percolation O
theory O
with O
Monte O
Carlo O
methods O
and O
is O
examined O
by O
applying O
it O
to O
the O
experimental O
results O
of O
three O
solid O
samples O
having O
unique O
hydrogen B
arrangement O
for O
1 O
- O
3 O
dimensions O
: O
the O
n B
- I
alkane I
/ O
d B
- I
urea I
inclusion O
complex O
as O
a O
one O
- O
dimensional O
( O
1D O
) O
system O
, O
whose O
( B
1 I
) I
H I
nuclei O
align O
approximately O
in O
1D O
, O
and O
magnesium B
hydroxide I
and O
adamantane B
as O
a O
two O
- O
dimensional O
( O
2D O
) O
and O
a O
three O
- O
dimensional O
( O
3D O
) O
system O
, O
respectively O
. O

The O
statistical O
approach O
is O
based O
on O
the O
percolation O
theory O
with O
Monte O
Carlo O
methods O
and O
is O
examined O
by O
applying O
it O
to O
the O
experimental O
results O
of O
three O
solid O
samples O
having O
unique O
hydrogen B
arrangement O
for O
1 O
- O
3 O
dimensions O
: O
the O
n B
- I
alkane I
/ O
d B
- I
urea I
inclusion O
complex O
as O
a O
one O
- O
dimensional O
( O
1D O
) O
system O
, O
whose O
( B
1 I
) I
H I
nuclei O
align O
approximately O
in O
1D O
, O
and O
magnesium B
hydroxide I
and O
adamantane B
as O
a O
two O
- O
dimensional O
( O
2D O
) O
and O
a O
three O
- O
dimensional O
( O
3D O
) O
system O
, O
respectively O
. O

For O
n B
- I
C20H42 I
/ O
d B
- I
urea I
, O
these O
4 O
lattice O
models O
fail O
to O
express O
its O
result O
. O

For O
n B
- I
C20H42 I
/ O
d B
- I
urea I
, O
these O
4 O
lattice O
models O
fail O
to O
express O
its O
result O
. O

It O
is O
shown O
that O
a O
more O
realistic O
model O
representing O
the O
( B
1 I
) I
H I
arrangement O
of O
n B
- I
C20H42 I
/ O
d B
- I
urea I
can O
describe O
the O
result O
. O

It O
is O
shown O
that O
a O
more O
realistic O
model O
representing O
the O
( B
1 I
) I
H I
arrangement O
of O
n B
- I
C20H42 I
/ O
d B
- I
urea I
can O
describe O
the O
result O
. O

Design O
, O
Synthesis O
, O
and O
Structure O
- O
Activity O
Relationship O
Studies O
of O
Novel O
3 B
- I
Alkylindole I
Derivatives O
as O
Selective O
and O
Highly O
Potent O
Myeloperoxidase O
Inhibitors O
. O

Via O
structure O
- O
based O
drug O
design O
, O
a O
new O
series O
of O
MPO O
inhibitors O
derived O
from O
3 B
- I
alkylindole I
were O
synthesized O
and O
their O
effects O
were O
assessed O
on O
MPO O
- O
mediated O
taurine B
chlorination O
and O
low O
- O
density O
lipoprotein O
oxidation O
as O
well O
as O
on O
inhibition O
of O
SERT O
. O

Design O
and O
synthesis O
of O
a O
tetrahydroisoquinoli B
- O
based O
hydroxamate B
derivative O
( O
ZYJ B
- I
34v I
) O
, O
an O
oral O
active O
histone O
deacetylase O
inhibitor O
with O
potent O
antitumor O
activity O
. O

In O
our O
previous O
study O
we O
developed O
a O
novel O
series O
of O
tetrahydroisoquinoli B
- O
based O
hydroxamic B
acid I
derivatives O
as O
histone O
deacetylase O
( O
HDAC O
) O
inhibitors O
( O
Bioorg O
. O
Med O
. O
Chem O
. O
, O
2010 O
, O
18 O
, O
1761 O
- O
1772 O
. O
, O
J O
. O
Med O
. O
Chem O
. O
, O
2011 O
, O
54 O
, O
2823 O
- O
2838 O
. O
) O
, O
among O
which O
compound O
ZYJ B
- I
34c I
( O
1 O
) O
was O
identified O
and O
validated O
as O
the O
most O
potent O
one O
with O
marked O
in O
vitro O
and O
in O
vivo O
antitumor O
potency O
( O
J O
. O
Med O
. O

Herein O
further O
modification O
of O
1 O
afforded O
another O
oral O
active O
analogue O
ZYJ B
- I
34v I
( O
2 O
) O
with O
simplified O
structure O
and O
lower O
molecular O
weight O
. O

In O
liver O
tissue O
slices O
, O
hydroxylated B
PCB I
( O
OH B
- I
PCB I
) O
profiles O
depended O
on O
sex O
and O
inducer O
pretreatment O
, O
and O
OH B
- I
PCB I
levels O
followed O
the O
rank O
orders O
male O
> O
female O
and O
PB O
> O
DEX B
> O
CTL O
. O

In O
liver O
tissue O
slices O
, O
hydroxylated B
PCB I
( O
OH B
- I
PCB I
) O
profiles O
depended O
on O
sex O
and O
inducer O
pretreatment O
, O
and O
OH B
- I
PCB I
levels O
followed O
the O
rank O
orders O
male O
> O
female O
and O
PB O
> O
DEX B
> O
CTL O
. O

Only O
small O
amounts O
of O
PCB B
136 I
partitioned O
into O
hippocampal O
tissue O
slices O
and O
no O
OH B
- I
PCB I
metabolites O
were O
detected O
. O

Two O
different O
dyes O
, O
1 B
- I
aminomethylpyrene I
( O
AMP B
) O
and O
5 B
- I
azidofluorescein I
( O
AF O
) O
, O
were O
covalently O
attached O
to O
the O
polymer O
brushes O
through O
aminolysis O
and O
dual O
desilylation O
/ O
copper B
( I
I I
) I
- O
catalyzed O
alkyne B
/ O
azide B
cycloaddition O
( O
CuAAC O
) O
in O
one O
pot O
. O

Two O
different O
dyes O
, O
1 B
- I
aminomethylpyrene I
( O
AMP B
) O
and O
5 B
- I
azidofluorescein I
( O
AF O
) O
, O
were O
covalently O
attached O
to O
the O
polymer O
brushes O
through O
aminolysis O
and O
dual O
desilylation O
/ O
copper B
( I
I I
) I
- O
catalyzed O
alkyne B
/ O
azide B
cycloaddition O
( O
CuAAC O
) O
in O
one O
pot O
. O

THBDC B
- I
DHPM I
demonstrated O
the O
most O
potent O
inhibitory O
activity O
with O
an O
IC50 O
value O
of O
1 O
. O
34 O
+ O
/ O
- O
0 O
. O
03 O
mu O
M O
which O
was O
more O
active O
than O
the O
approved O
drug O
galanthamine B
( O
IC50 O
= O
1 O
. O
45 O
+ O
/ O
- O
0 O
. O
04 O
mu O
M O
) O
. O

We O
have O
previously O
shown O
that O
methotrexate B
( O
MTX B
) O
conjugated O
to O
a O
cancer O
- O
specific O
poly B
amido I
amine I
( O
PAMAM B
) O
dendrimer O
has O
a O
higher O
therapeutic O
index O
than O
MTX B
alone O
. O

Further O
, O
we O
assessed O
if O
a O
treatment O
with O
the O
P2X7 O
receptor O
antagonist O
Brilliant B
Blue I
G I
- O
a O
dye O
that O
can O
cross O
the O
blood O
- O
brain O
barrier O
, O
has O
low O
toxicity O
, O
and O
has O
exhibited O
therapeutic O
effects O
in O
animal O
models O
of O
neurodegenerative O
diseases O
- O
impact O
on O
the O
disease O
progression O
, O
in O
male O
and O
female O
ALS O
mice O
. O

We O
found O
that O
( O
1 O
) O
the O
onset O
and O
the O
disease O
progression O
, O
and O
the O
survival O
were O
dependent O
on O
gender O
: O
male O
performed O
worst O
than O
female O
, O
lost O
body O
weight O
and O
died O
before O
; O
( O
2 O
) O
treatment O
with O
the O
P2X7 O
receptor O
antagonist O
Brilliant B
Blue I
G I
ameliorated O
the O
disease O
progression O
. O

These O
pro O
- O
inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca B
( I
2 I
+ I
) I
blockers O
, O
bis B
- I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetra I
- I
acetic I
acid I
acetoxymethyl I
ester I
( O
BAPTA B
- I
AM I
) O
and O
nifedipine B
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca B
( I
2 I
+ I
) I
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

Consistent O
with O
two O
glucose B
uptake O
pathways O
, O
induced O
uptake O
of O
2 B
- I
NBDG I
, O
a O
fluorescent O
glucose B
derivative O
, O
was O
decreased O
by O
inhibition O
of O
HCs O
or O
glucose B
transporter O
( O
GLUT4 O
) O
, O
and O
blocked O
by O
dual O
blockade O
. O

Antibacterial O
oxazolidinone B
analogues O
having O
a O
N B
- I
hydroxyacetyl I
- O
substituted O
seven O
- O
membered O
[ B
1 I
, I
2 I
, I
5 I
] I
triazepane I
or O
[ B
1 I
, I
2 I
, I
5 I
] I
oxadiazepane I
C B
- O
ring O
unit O
. O

Fine O
Tuning O
of O
the O
Structure O
of O
Pt B
- I
Cu I
Alloy O
Nanocrystals O
by O
Glycine B
- O
Mediated O
Sequential O
Reduction O
Kinetics O
. O

Uniform O
Pt B
- I
Cu I
alloy O
nanocrystals O
in O
the O
shape O
of O
dendrite O
, O
, O
yolk O
- O
cage O
, O
and O
box O
structures O
are O
prepared O
via O
a O
facile O
wet O
- O
chemical O
reduction O
route O
in O
which O
glycine B
is O
demonstrated O
to O
alter O
the O
reduction O
kinetics O
of O
metal O
cations O
, O
critical O
to O
the O
morphology O
of O
the O
obtained O
product O
. O

PATIENTS O
AND O
METHODS O
: O
Renal O
and O
glomerular O
hemodynamics O
were O
assessed O
by O
simultaneous O
measurements O
of O
plasma O
clearance O
of O
para B
- I
aminohippurate I
( O
CPAH O
) O
and O
inulin O
( O
Cin O
) O
in O
26 O
patients O
with O
serum O
creatinine B
< O
1 O
. O
00 O
mg O
/ O
dl O
and O
without O
thyroid O
disease O
. O

It O
was O
revealed O
that O
the O
connecting O
group O
between O
the O
N B
- I
methylpyrazole I
part O
and O
the O
hydrophobic O
alkyl B
chain O
bearing O
the O
THF B
ring O
influenced O
their O
biological O
activities O
significantly O
. O

In O
this O
work O
, O
the O
electronic O
properties O
of O
l B
- I
diphenylalanine I
nanotubes O
( O
FF O
- O
NTs O
) O
have O
been O
studied O
using O
the O
Self O
- O
Consistent O
Charge O
Density O
- O
Functional O
- O
based O
Tight O
- O
Binding O
method O
augmented O
with O
dispersion O
interaction O
. O

PURPOSE O
: O
Recent O
studies O
in O
patients O
with O
inflammatory O
bowel O
diseases O
( O
IBD O
) O
on O
thiopurine B
therapy O
suggest O
that O
too O
low O
6 B
- I
thioguanine I
nucleotide I
concentrations O
( O
6 B
- I
TGN I
) O
and O
too O
high O
methylmercaptopurine B
nucleotide I
concentrations O
( O
MMPN B
) O
can O
be O
reversed O
by O
a O
combination O
therapy O
of O
allopurinol B
and O
low O
- O
dose O
thiopurines B
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
minimal O
allopurinol B
doses O
necessary O
to O
achieve O
adequate O
6 B
- I
TGN I
concentrations O
in O
combination O
with O
low O
- O
dose O
azathioprine B
. O

METHODS O
: O
A O
stepwise O
dose O
- O
escalation O
of O
allopurinol B
was O
performed O
in O
11 O
azathioprine B
- O
pretreated O
IBD O
patients O
with O
inadequately O
low O
6 B
- I
TGN I
concentrations O
( O
< O
235 O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
) O
and O
/ O
or O
elevated O
MMPN B
concentrations O
( O
> O
5 O
, O
000 O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
) O
and O
/ O
or O
elevated O
liver O
enzymes O
( O
alanine B
aminotransferase O
and O
/ O
or O
aspartate B
aminotransferase O
levels O
one O
- O
to O
threefold O
the O
upper O
limit O
of O

RESULTS O
: O
Adequate O
6 B
- I
TGN I
concentrations O
were O
achieved O
with O
a O
combination O
of O
25 O
mg O
allopurinol B
and O
50 O
mg O
azathioprine B
in O
one O
patient O
and O
with O
50 O
mg O
allopurinol B
and O
50 O
mg O
azathioprine B
in O
nine O
patients O
. O

Median O
6 B
- I
TGN I
concentrations O
( O
range O
) O
were O
336 O
( O
290 O
- O
488 O
) O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
after O
an O
8 O
- O
week O
- O
long O
intake O
of O
the O
final O
dose O
combination O
. O

PURPOSE O
: O
To O
build O
a O
population O
pharmacokinetic O
( O
PK O
) O
model O
of O
cyclophosphamide B
( O
CY O
) O
and O
its O
metabolite O
, O
4 B
- I
hydroxycyclophospham I
( O
HCY B
) O
, O
in O
patients O
undergoing O
allogeneic O
haematopoietic O
stem O
cell O
transplantation O
( O
HSCT O
) O
and O
to O
identify O
covariates O
, O
including O
genetic O
polymorphisms O
, O
which O
affect O
CY O
and O
HCY B
PK O
parameters O
. O

Aim O
: O
Present O
study O
was O
conducted O
to O
evaluate O
the O
dermatoprotective O
effects O
of O
plant O
extracts O
( O
Ficus O
religiosa O
, O
Ficus O
benghalensis O
, O
and O
Ficus O
racemosa O
) O
against O
known O
irritants O
such O
as O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
atrazine B
, O
and O
petrol O
. O

Modulation O
of O
carbon B
tetrachloride I
- O
induced O
nephrotoxicity O
in O
rats O
by O
n B
- I
hexane I
extract O
of O
Sonchus O
asper O
. O

Group O
I O
( O
control O
group O
) O
was O
given O
saline O
( O
1 O
ml O
/ O
kg O
body O
weight O
( O
b O
. O
w O
. O
) O
, O
0 O
. O
85 O
% O
NaCl B
) O
and O
dimethyl B
sulfoxide I
( O
1 O
ml O
/ O
kg O
b O
. O
w O
. O
) O
; O
group O
II O
was O
treated O
with O
CCl4 B
( O
1 O
ml O
/ O
kg O
b O
. O
w O
. O
intraperitoneally O
) O
; O
groups O
III O
and O
IV O
were O
administered O
with O
CCl4 B
and O
after O
48 O
h O
with O
S O
. O
asper O
n B
- I
hexane I
extract O
( O
SHE O
; O
100 O
and O
200 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
. O

Theoretical O
and O
Kinetic O
Study O
of O
the O
Reaction O
of O
Ethyl B
Methyl I
Ketone I
with O
HO2 B
for O
T O
= O
600 O
- O
1 O
, O
600 O
K O
. O

The O
temperature O
and O
pressure O
dependence O
of O
the O
addition O
reaction O
of O
ethyl B
methyl I
ketone I
( O
EMK B
) O
with O
HO2 B
radical O
has O
been O
calculated O
with O
the O
master O
equation O
method O
employing O
conventional O
transition O
state O
theory O
estimates O
for O
the O
microcanonical O
rate O
coefficients O
in O
the O
temperature O
range O
of O
600 O
- O
1600 O
K O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

12 B
- I
Hydroxystearic I
acid I
( O
12 B
- I
HSA I
) O
xerogels O
derived O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
highly O
effective O
sorbent O
materials O
capable O
of O
adsorbing O
apolar O
, O
spilled O
materials O
in O
aqueous O
environments O
. O

12 B
- I
Hydroxystearic I
acid I
( O
12 B
- I
HSA I
) O
xerogels O
derived O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
highly O
effective O
sorbent O
materials O
capable O
of O
adsorbing O
apolar O
, O
spilled O
materials O
in O
aqueous O
environments O
. O

12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
more O
effective O
than O
12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
pentane B
organogels O
because O
of O
the O
highly O
branched O
fibrillar O
networks O
established O
in O
acetonitrile B
molecular O
gels O
. O

12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
more O
effective O
than O
12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
pentane B
organogels O
because O
of O
the O
highly O
branched O
fibrillar O
networks O
established O
in O
acetonitrile B
molecular O
gels O
. O

12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
more O
effective O
than O
12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
pentane B
organogels O
because O
of O
the O
highly O
branched O
fibrillar O
networks O
established O
in O
acetonitrile B
molecular O
gels O
. O

12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
acetronitrile B
organogels O
are O
more O
effective O
than O
12 B
- I
HSA I
xerogels O
made O
from O
12 B
- I
HSA I
- O
pentane B
organogels O
because O
of O
the O
highly O
branched O
fibrillar O
networks O
established O
in O
acetonitrile B
molecular O
gels O
. O

This O
difference O
arises O
because O
of O
dissimilarities O
in O
the O
network O
structure O
between O
12 B
- I
HSA I
in O
various O
solvents O
. O

The O
antagonism O
of O
GABACls O
and O
GluCls O
by O
4 B
- I
isobutyl I
- I
3 I
- I
isopropylbicyclophos I
( O
PS B
- I
14 I
) O
was O
examined O
in O
cultured O
cockroach O
and O
rat O
neurons O
using O
a O
whole O
- O
cell O
patch O
- O
clamp O
method O
. O

The O
results O
indicated O
that O
PS B
- I
14 I
selectively O
blocks O
cockroach O
GABACls O
relative O
to O
cockroach O
GluCls O
and O
rat O
GABACls O
. O

PS B
- I
14 I
represents O
a O
useful O
probe O
for O
the O
study O
of O
insect O
GABA B
receptors O
. O

Moreover O
, O
3 O
- O
substituted O
6dTalp B
was O
2 O
- O
O O
- O
acetylated O
and O
additional O
O B
- I
acetyl I
groups O
were O
identified O
at O
O O
- O
2 O
and O
O O
- O
4 O
( O
or O
O O
- O
3 O
) O
positions O
of O
the O
terminal O
6dTalp B
. O

We O
demonstrated O
recently O
that O
the O
4 B
- I
anilinoquinazolines I
lapatinib B
( O
GW572016 B
, O
1 O
) O
and O
canertinib B
( O
CI B
- I
1033 I
) O
kill O
T O
. O
brucei O
with O
low O
micromolar O
EC50 O
values O
. O

We O
demonstrated O
recently O
that O
the O
4 B
- I
anilinoquinazolines I
lapatinib B
( O
GW572016 B
, O
1 O
) O
and O
canertinib B
( O
CI B
- I
1033 I
) O
kill O
T O
. O
brucei O
with O
low O
micromolar O
EC50 O
values O
. O

Our O
compound O
optimization O
that O
has O
led O
to O
synthesis O
of O
several O
potent O
4 B
- I
anilinoquinazolines I
, O
including O
NEU617 B
, O
23a O
, O
a O
highly O
potent O
, O
orally O
bioavailable O
inhibitor O
of O
trypanosome O
replication O
. O

Molecular O
Mechanisms O
in O
the O
Pyrolysis O
of O
Unsaturated B
Chlorinated I
Hydrocarbons I
: O
Formation O
of O
Benzene B
Rings O
Part O
II O
- O
Experimental O
and O
Kinetic O
Modeling O
Studies O
. O

CH B
- I
01 I
is O
a O
hypoxia O
- O
activated O
prodrug O
that O
sensitizes O
cells O
to O
hypoxia O
/ O
reoxygenation O
through O
inhibition O
of O
Chk1 O
and O
Aurora O
A O
. O

To O
achieve O
this O
activity O
, O
a O
key O
functionality O
on O
the O
Chk1 O
inhibitor O
( O
CH B
- I
01 I
) O
is O
masked O
by O
a O
bioreductive O
group O
, O
rendering O
the O
compound O
inactive O
as O
a O
Chk1 O
/ O
Aurora O
A O
inhibitor O
. O

Most O
importantly O
, O
we O
show O
a O
significant O
loss O
of O
viability O
in O
cancer O
cell O
lines O
exposed O
to O
hypoxia O
in O
the O
presence O
of O
CH B
- I
01 I
. O

After O
4weeks O
of O
DMH B
administrations O
, O
the O
groups O
were O
fed O
with O
standard O
diet O
, O
a O
diet O
containing O
2 O
. O
5 O
% O
or O
5 O
. O
0 O
% O
AP O
or O
a O
diet O
containing O
0 O
. O
2 O
% O
N B
- I
acetylcysteine I
( O
NAC B
) O
for O
10weeks O
, O
using O
aberrant O
crypt O
foci O
( O
ACF O
) O
as O
the O
endpoint O
. O

Cy3 B
and O
Cy5 B
. I
5 I
dyes O
were O
tethered O
to O
the O
plasmonic O
antennas O
through O
oligonucleotide O
spacers O
to O
act O
as O
on O
- O
chip O
light O
sources O
. O

The O
intensity O
of O
Cy3 B
was O
found O
to O
be O
increased O
relative O
to O
that O
of O
Cy5 B
. I
5 I
in O
the O
vicinity O
of O
the O
plasmonic O
antennas O
where O
strongly O
enhanced O
electric O
field O
intensity O
and O
optical O
density O
of O
states O
selectively O
increase O
the O
excitation O
and O
emission O
rates O
of O
Cy3 B
due O
to O
spectral O
overlap O
with O
the O
plasmon O
. O

Three O
new O
sulfated B
triterpene I
glycosides I
, O
asprellanosides B
C I
- I
E I
( O
1 O
- O
3 O
) O
, O
were O
isolated O
from O
the O
roots O
of O
Ilex O
asprella O
. O

Total O
nitrogen B
vs O
. O
amino B
- I
acid I
profile O
as O
indicator O
of O
protein O
content O
of O
beef O
. O

A O
study O
on O
the O
nutrient O
composition O
of O
beef O
analysed O
the O
full O
amino B
- I
acid I
profile O
of O
fifteen O
retail O
cuts O
from O
three O
age O
groups O
and O
six O
fat O
codes O
, O
as O
well O
as O
determined O
total O
nitrogen B
content O
to O
determine O
proximate O
protein O
composition O
. O

Our O
functional O
analysis O
of O
these O
FMOs O
( O
ActVA O
- O
ORF5 O
, O
Gra B
- O
ORF21 O
, O
Med B
- O
ORF7 O
, O
and O
AlnT O
) O
in O
S O
. O
coelicolor O
unambiguously O
demonstrated O
that O
ActVA O
- O
ORF5 O
and O
Gra B
- O
ORF21 O
are O
bifunctional O
and O
capable O
of O
both O
p B
- I
quinone I
formation O
at O
C O
- O
6 O
in O
the O
central O
ring O
and O
C O
- O
8 O
hydroxylation O
in O
the O
lateral O
ring O
, O
whereas O
Med B
- O
ORF7 O
catalyzes O
only O
p B
- I
quinone I
formation O
. O

Our O
functional O
analysis O
of O
these O
FMOs O
( O
ActVA O
- O
ORF5 O
, O
Gra B
- O
ORF21 O
, O
Med B
- O
ORF7 O
, O
and O
AlnT O
) O
in O
S O
. O
coelicolor O
unambiguously O
demonstrated O
that O
ActVA O
- O
ORF5 O
and O
Gra B
- O
ORF21 O
are O
bifunctional O
and O
capable O
of O
both O
p B
- I
quinone I
formation O
at O
C O
- O
6 O
in O
the O
central O
ring O
and O
C O
- O
8 O
hydroxylation O
in O
the O
lateral O
ring O
, O
whereas O
Med B
- O
ORF7 O
catalyzes O
only O
p B
- I
quinone I
formation O
. O

No O
p B
- I
quinone I
formation O
on O
a O
BIQ B
substrate O
was O
observed O
for O
AlnT O
, O
which O
is O
involved O
in O
lateral O
p B
- I
quinone I
formation O
in O
ALN B
. O

No O
p B
- I
quinone I
formation O
on O
a O
BIQ B
substrate O
was O
observed O
for O
AlnT O
, O
which O
is O
involved O
in O
lateral O
p B
- I
quinone I
formation O
in O
ALN B
. O

Genome O
- O
wide O
Analysis O
Reveals O
TET O
- O
and O
TDG O
- O
Dependent O
5 B
- I
Methylcytosine I
Oxidation O
Dynamics O
. O

TET O
dioxygenases O
successively O
oxidize O
5 B
- I
methylcytosine I
( O
5mC B
) O
in O
mammalian O
genomes O
to O
5 B
- I
hydroxymethylcytosin I
( O
5hmC B
) O
, O
5 B
- I
formylcytosine I
( O
5fC B
) O
, O
and O
5 B
- I
carboxylcytosine I
( O
5caC B
) O
. O

TET O
dioxygenases O
successively O
oxidize O
5 B
- I
methylcytosine I
( O
5mC B
) O
in O
mammalian O
genomes O
to O
5 B
- I
hydroxymethylcytosin I
( O
5hmC B
) O
, O
5 B
- I
formylcytosine I
( O
5fC B
) O
, O
and O
5 B
- I
carboxylcytosine I
( O
5caC B
) O
. O

TET O
dioxygenases O
successively O
oxidize O
5 B
- I
methylcytosine I
( O
5mC B
) O
in O
mammalian O
genomes O
to O
5 B
- I
hydroxymethylcytosin I
( O
5hmC B
) O
, O
5 B
- I
formylcytosine I
( O
5fC B
) O
, O
and O
5 B
- I
carboxylcytosine I
( O
5caC B
) O
. O

TET O
dioxygenases O
successively O
oxidize O
5 B
- I
methylcytosine I
( O
5mC B
) O
in O
mammalian O
genomes O
to O
5 B
- I
hydroxymethylcytosin I
( O
5hmC B
) O
, O
5 B
- I
formylcytosine I
( O
5fC B
) O
, O
and O
5 B
- I
carboxylcytosine I
( O
5caC B
) O
. O

The O
antinociception O
caused O
by O
the O
ethanol B
extract O
( O
30mg O
/ O
kg O
) O
in O
the O
abdominal O
constriction O
test O
was O
significantly O
attenuated O
( O
P O
< O
0 O
. O
001 O
) O
by O
intraperitoneal O
treatment O
of O
mice O
with O
l B
- I
arginine I
( O
600mg O
/ O
kg O
) O
. O

New O
anticancer O
active O
and O
selective O
phenylene B
- I
bisbenzothiazoles I
: O
Synthesis O
, O
antiproliferative O
evaluation O
and O
DNA O
binding O
. O

Novel O
amidino B
- O
derivatives O
of O
phenylene B
- I
bisbenzothiazoles I
were O
synthesized O
and O
tested O
for O
their O
antiproliferative O
activity O
against O
several O
human O
cancer O
cell O
lines O
, O
as O
well O
as O
DNA O
- O
binding O
properties O
. O

OBJECTIVES O
: O
The O
present O
study O
was O
designed O
to O
assess O
dysphoric O
properties O
of O
a O
selective O
kappa O
agonist O
, O
U62 B
, I
066 I
, O
in O
adolescent O
and O
adult O
rats O
using O
both O
conditioned O
taste O
aversion O
( O
CTA O
) O
and O
conditioned O
place O
aversion O
( O
CPA O
) O
paradigms O
. O

METHODS O
: O
For O
CTA O
, O
water O
- O
restricted O
rats O
were O
administered O
U62 B
, I
066 I
following O
30 O
min O
access O
to O
a O
saccharin B
solution O
, O
with O
subsequent O
saccharin B
consumption O
used O
to O
index O
aversion O
. O

For O
conditioning O
, O
subjects O
were O
administered O
U62 B
, I
066 I
prior O
to O
confinement O
to O
one O
side O
of O
the O
chamber O
and O
saline O
prior O
to O
confinement O
to O
the O
other O
side O
for O
a O
total O
of O
four O
pairings O
. O

Adults O
demonstrated O
taste O
aversions O
to O
the O
0 O
. O
2 O
and O
0 O
. O
3 O
mg O
/ O
kg O
doses O
of O
U62 B
, I
066 I
, O
whereas O
adolescents O
did O
not O
display O
aversions O
to O
any O
tested O
doses O
. O

Adults O
demonstrated O
a O
place O
aversion O
to O
the O
0 O
. O
1 O
and O
0 O
. O
2 O
mg O
/ O
kg O
dose O
of O
U62 B
, I
066 I
when O
paired O
with O
the O
preferred O
side O
of O
the O
conditioning O
chamber O
. O

In O
addition O
, O
changes O
in O
salivary O
99m B
Tc I
pertechnetate I
uptake O
and O
excretion O
were O
observed O
by O
single O
- O
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
. O

In O
addition O
, O
patterns O
of O
99m B
Tc I
pertechnetate I
uptake O
and O
excretion O
in O
the O
RI O
- O
group O
were O
quite O
different O
from O
those O
observed O
in O
controls O
at O
1 O
and O
12 O
months O
post O
- O
RI O
. O

In O
the O
present O
study O
, O
we O
chemically O
synthesized O
novel O
17 B
- I
fluorinated I
steroids I
and O
evaluated O
the O
cytotoxicity O
profiles O
of O
these O
compounds O
in O
T47D O
breast O
cancer O
cells O
compared O
to O
the O
activity O
of O
known O
antiprogestins B
, O
including O
ZK230 B
211 I
, O
RU B
- I
486 I
, O
CDB2914 B
, O
CDB4124 B
and O
ORG33628 B
. O

This O
study O
describes O
the O
structure O
- O
activity O
relationship O
for O
carefully O
characterized O
N B
- I
alkyl I
- O
N B
- O
quaternary O
chitosan O
derivatives O
as O
permeation O
enhancers O
for O
drugs O
that O
are O
mainly O
absorbed O
through O
the O
paracellular O
pathway O
, O
such O
as O
macromolecular O
drugs O
and O
hydrophilic O
drugs O
, O
in O
a O
well O
defined O
bronchial O
epithelial O
cell O
line O
. O

The O
O B
- I
methyl I
free O
derivatives O
used O
in O
the O
study O
were O
fully O
trimethylated O
( O
100 O
% O
) O
N B
, I
N I
, I
N I
- I
trimethyl I
chitosan O
( O
TMC O
) O
and O
N B
- I
propyl I
- I
( I
QuatPropyl I
) I
, O
N B
- I
butyl I
- I
( I
QuatButyl I
) I
and O
N B
- I
hexyl I
( I
QuatHexyl I
) I
- I
N I
, I
N I
- I
dimethyl I
chitosan O
, O
with O
85 O
- O
91 O
% O
degree O
of O
quaternization O
. O

For O
the O
Ar19Kr B
n I
Xe19 I
, O
Ar19Kr19Xe B
n I
, O
and O
Ar B
n I
Kr19Xe19 I
( O
n O
= O
0 O
- O
17 O
) O
clusters O
investigated O
, O
the O
results O
show O
that O
only O
two O
minimum O
energy O
configurations O
exist O
, O
i O
. O
e O
. O
, O
polytetrahedron O
and O
six O
- O
fold O
pancake O
. O

For O
the O
Ar19Kr B
n I
Xe19 I
, O
Ar19Kr19Xe B
n I
, O
and O
Ar B
n I
Kr19Xe19 I
( O
n O
= O
0 O
- O
17 O
) O
clusters O
investigated O
, O
the O
results O
show O
that O
only O
two O
minimum O
energy O
configurations O
exist O
, O
i O
. O
e O
. O
, O
polytetrahedron O
and O
six O
- O
fold O
pancake O
. O

Its O
therapeutic O
effects O
might O
be O
due O
, O
at O
least O
in O
part O
, O
to O
adaptive O
changes O
in O
serotonergic O
neurotransmission O
, O
through O
the O
activation O
of O
the O
different O
5 B
- I
HT I
receptor O
subtypes O
. O

A O
library O
of O
ten O
2 B
- I
aminoimidazolone I
products O
( O
3 O
- O
12 O
) O
was O
prepared O
by O
coupling O
glycocyamidine B
and O
a O
variety O
of O
aldehydes B
using O
a O
one O
- O
step O
stereoselective O
aldol O
condensation O
reaction O
under O
microwave O
conditions O
. O

METHODS O
: O
We O
compared O
the O
displacement O
of O
radioligand O
binding O
to O
various O
mammalian O
CNS O
sites O
, O
acute O
stimulation O
of O
accumbens O
shell O
dopamine B
levels O
, O
and O
place O
conditioning O
in O
rats O
among O
cocaine B
and O
four O
BZT B
analogs O
with O
Cl B
substitutions O
on O
the O
diphenyl B
- I
ether I
system O
including O
two O
with O
carboalkoxy B
substitutions O
at O
the O
2 O
- O
position O
of O
the O
tropane B
ring O
. O

We O
observe O
changes O
in O
the O
molecular O
conductivity O
of O
individual O
oligophenylene B
- I
vinylene I
( O
OPV B
) O
molecules O
due O
to O
interactions O
with O
small O
aromatic O
molecules O
. O

In O
vitro O
effect O
of O
N B
- I
acetylcysteine I
on O
hepatocyte O
injury O
caused O
by O
dichlorodiphenyltric B
and O
its O
metabolites O
. O

N B
- I
Acetylcysteine I
( O
NAC B
) O
is O
a O
recognized O
hepatoprotective O
agent O
that O
has O
been O
reported O
to O
reduce O
hepatotoxicity O
initiated O
by O
many O
different O
compounds O
. O

Elucidation O
of O
in O
situ O
polycyclic B
aromatic I
hydrocarbon I
degradation O
by O
functional O
metaproteomics O
( O
protein O
- O
SIP O
) O
. O

Current O
knowledge O
of O
the O
physiology O
and O
phylogeny O
of O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH B
) O
degrading O
bacteria O
often O
relies O
on O
laboratory O
enrichments O
and O
isolations O
. O

We O
find O
that O
the O
higher O
activity O
of O
interfacial O
sites O
in O
Au13 B
/ I
TiO2 I
( I
110 I
) I
towards O
methanol B
decomposition O
originates O
from O
charge O
- O
transfer O
- O
induced O
Coulomb O
interaction O
among O
the O
gold O
, O
reactant O
, O
and O
reducible O
TiO2 B
support O
, O
brought O
about O
through O
the O
formation O
of O
an O
ionic O
O B
- I
Au I
bond O
between O
gold O
and O
methoxy B
in O
such O
sites O
, O
which O
turns O
the O
participating O
perimeter O
gold O
atom O
cationic O
. O

A O
direct O
result O
of O
such O
charge O
- O
transfer O
- O
induced O
repulsive O
interaction O
between O
cationic O
gold O
and O
positively O
charged O
C B
moiety O
of O
methoxy B
is O
activation O
of O
the O
positively O
charged O
C B
moiety O
of O
methoxy B
, O
as O
manifested O
by O
the O
pronounced O
elongation O
of O
O B
- I
C I
bond O
length O
and O
the O
tilting O
of O
the O
methoxy B
axis O
, O
which O
facilitate O
reaction O
of O
methoxy B
through O
C B
- I
H I
scission O
with O
the O
bridge O
oxygen B
atoms O
that O
are O
readily O
available O
from O
the O
reducible O
support O
. O

A O
direct O
result O
of O
such O
charge O
- O
transfer O
- O
induced O
repulsive O
interaction O
between O
cationic O
gold O
and O
positively O
charged O
C B
moiety O
of O
methoxy B
is O
activation O
of O
the O
positively O
charged O
C B
moiety O
of O
methoxy B
, O
as O
manifested O
by O
the O
pronounced O
elongation O
of O
O B
- I
C I
bond O
length O
and O
the O
tilting O
of O
the O
methoxy B
axis O
, O
which O
facilitate O
reaction O
of O
methoxy B
through O
C B
- I
H I
scission O
with O
the O
bridge O
oxygen B
atoms O
that O
are O
readily O
available O
from O
the O
reducible O
support O
. O

N B
- I
Acetylcysteine I
, O
an O
antioxidant O
agent O
, O
reduced O
intracellular O
ROS O
levels O
and O
decreased O
QD O
- O
induced O
autophagy O
but O
enhanced O
QD O
- O
induced O
cell O
death O
. O

Moreover O
, O
3 B
- I
methylamphetamine I
( O
an O
autophagy O
inhibitor O
) O
also O
reduced O
the O
cell O
viability O
in O
QD O
- O
treated O
cells O
. O

Two O
new O
vinblastine B
- O
type O
N B
- I
oxide I
alkaloids I
, O
17 B
- I
desacetoxyvinblastin I
[ O
Formula O
: O
see O
text O
] O
- O
oxide B
( O
1 O
) O
and O
20 B
' I
- I
deoxyvinblastine I
[ O
Formula O
: O
see O
text O
] O
- O
oxide B
( O
2 O
) O
, O
were O
isolated O
from O
the O
leaves O
of O
Catharanthus O
roseus O
. O

Synthesis O
and O
evaluation O
of O
Janus B
type I
nucleosides I
as O
potential O
HCV O
NS5B O
polymerase O
inhibitors O
. O

One O
new O
compound O
, O
ethyl B
13 I
( I
2 I
) I
( I
S I
) I
- I
hydroxy I
- I
chlorophyllide I
a I
( O
1 O
) O
, O
along O
with O
10 O
known O
compounds O
, O
i O
. O
e O
. O
2 B
- I
methyl I
- I
3 I
- I
methoxyanthraquinone I
( O
2 O
) O
, O
2 B
- I
hydroxymethylanthraq I
( O
3 O
) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
( O
4 O
) O
, O
2 B
- I
hydroxymethy I
- I
1 I
- I
hydroxyanthraquinone I
( O
5 O
) O
, O
1 B
- I
methoxy I
- I
2 I
- I
hydroxyanthraquinone I
( O
6 O

Although O
Cyr61 O
was O
found O
by O
us O
to O
be O
overproduced O
in O
androgen B
- O
independent O
PC O
- O
3 O
cells O
treated O
with O
N B
- I
acetylcysteine I
( O
NAC B
) O
, O
its O
significance O
is O
still O
unclear O
. O

Naltrexone B
, O
a O
nonselective O
opioid O
receptors O
antagonist O
, O
totally O
blocked O
compound O
31 O
antinociceptive O
effects O
on O
the O
hot O
plate O
test O
, O
but O
naltrindole B
( O
delta O
opioid O
antagonist O
) O
and O
nor B
- I
binaltorphimine I
( O
kappa O
opioid O
antagonist O
) O
did O
not O
. O

RESULTS O
: O
VTA O
NMDAR O
blockade O
with O
AP B
- I
5 I
decreased O
, O
while O
VTA O
NMDAR O
activation O
with O
NMDA B
increased O
NAc O
peak O
phasic O
DA O
release O
. O

Co O
- O
infusion O
of O
AP B
- I
5 I
and O
alpha O
- O
ctx O
MII O
produced O
a O
similar O
phasic O
DA O
decrease O
as O
either O
drug O
alone O
, O
with O
no O
additive O
effect O
. O

The O
crude O
extract O
of O
T O
. O
stocksianum O
( O
Ts O
. O
Cr O
) O
and O
its O
subsequent O
organic O
fractions O
: O
n B
- I
hexane I
( O
Ts O
. O
Hex B
) O
, O
chloroform B
( O
Ts O
. O
CHCl3 B
) O
and O
ethyl B
acetate I
( O
Ts O
. O
EtAc B
) O
exhibited O
1 B
, I
1 I
- I
diphenyl I
, I
2 I
- I
picrylhydrazyl I
free O
radical O
scavenging O
activity O
with O
different O
potencies O
. O

Crystal O
structures O
of O
the O
agonist O
binding O
domains O
( O
ABDs O
) O
of O
GluN2A O
and O
GluN2D O
do O
not O
reveal O
any O
differences O
in O
the O
overall O
domain O
conformation O
induced O
by O
binding O
of O
the O
full O
agonist O
glutamate B
or O
the O
partial O
agonist O
propyl B
- I
NHP5G I
, O
which O
is O
strikingly O
different O
from O
ABD O
structures O
of O
AMPA B
and O
kainate B
receptors O
bound O
to O
full O
and O
partial O
agonists O
. O

Conclusions O
: O
According O
to O
the O
new O
ATA O
and O
AACE O
guidelines O
, O
L B
- I
T4 I
therapy O
would O
be O
considered O
for O
92 O
% O
of O
women O
with O
SCH O
and O
TSH O
< O
= O
10 O
mIU O
/ O
L O
. O

It O
is O
humbling O
to O
think O
that O
30 O
years O
have O
passed O
since O
the O
paper O
by O
Collingridge O
, O
Kehl O
and O
McLennan O
showing O
that O
one O
of O
Jeff O
Watkins O
most O
interesting O
compounds O
, O
R B
- I
2 I
- I
amino I
- I
5 I
- I
phosphonopentanoate I
( O
d B
- I
AP5 I
) O
, O
blocked O
the O
induction O
of O
long O
- O
term O
potentiation O
in O
vitro O
at O
synapses O
from O
area O
CA3 O
of O
the O
hippocampus O
to O
CA1 O
without O
apparent O
effect O
on O
baseline O
synaptic O
transmission O
( O
Collingridge O
et O
al O
. O
, O
1983 O
) O
. O

We O
previously O
reported O
that O
joint O
effects O
of O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
, O
ecstasy B
) O
and O
three O
other O
often O
co O
- O
ingested O
amphetamines B
( O
methamphetamine B
, O
4 B
- I
methylthyoamphetamin I
and O
D B
- I
amphetamine I
) O
could O
be O
predicted O
by O
the O
concentration O
addition O
( O
CA O
) O
model O
in O
HepG2 O
cells O
. O

We O
previously O
reported O
that O
joint O
effects O
of O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
, O
ecstasy B
) O
and O
three O
other O
often O
co O
- O
ingested O
amphetamines B
( O
methamphetamine B
, O
4 B
- I
methylthyoamphetamin I
and O
D B
- I
amphetamine I
) O
could O
be O
predicted O
by O
the O
concentration O
addition O
( O
CA O
) O
model O
in O
HepG2 O
cells O
. O

SLNs O
were O
fluorescence O
labeled O
with O
a O
newly O
synthesized O
fluorescent O
probe O
, O
14 B
- I
DACA I
. O

Immediately O
following O
the O
synthesis O
, O
carbonate B
- O
substituted O
( O
B O
- O
type O
) O
hydroxyapatite B
particles O
are O
mechanochemically O
synthesized O
by O
wet O
milling O
dicalcium B
phosphate I
dihydrate I
and O
calcium B
carbonate I
in O
a O
dispersed O
suspension O
of O
magnetite B
nanoparticles O
, O
during O
which O
the O
magnetite B
nanoparticles O
are O
incorporated O
into O
the O
hydroxyapatite B
matrix O
. O

AFM O
measurements O
of O
the O
force O
acting O
between O
silica B
surfaces O
in O
the O
presence O
of O
varied O
alkali B
- I
chloride I
salts O
and O
pH O
' O
s O
elucidate O
the O
origin O
of O
the O
Hofmeister O
adsorption O
series O
and O
its O
reversal O
. O

This O
extract O
afforded O
six O
new O
isoflavonoids B
, O
sedonans B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
a O
new O
but B
- I
2 I
- I
enolide I
, O
4 B
' I
- I
O I
- I
methylpuerol I
A I
( O
7 O
) O
, O
and O
the O
new O
pterocarpan O
ent B
- I
sandwicensin I
( O
8 O
) O
. O

Sedonans B
A I
- I
F I
and O
ent B
- I
sandwicensin I
were O
also O
active O
against O
Saccharomyces O
cerevisiae O
strains O
that O
express O
differing O
ABC O
transporter O
- O
associated O
resistance O
mechanisms O
but O
differed O
in O
their O
susceptibility O
to O
Cdr1p O
- O
mediated O
detoxification O
. O

A O
sedonan B
A I
( O
1 O
) O
/ O
ent B
- I
sandwicensin I
( O
8 O
) O
combination O
exhibited O
synergistic O
growth O
inhibition O
. O

This O
study O
examines O
the O
potential O
neuroprotective O
and O
immunomodulatory O
effects O
of O
( B
RS I
) I
- I
glucoraphanin I
from O
Tuscan O
black O
kale O
( O
Brassica O
oleracea O
L O
. O
var O
. O
acephala O
sabellica O
) O
bioactivated O
with O
myrosinase O
( O
bioactive O
RS B
- I
GRA I
) O
( O
10 O
mg O
/ O
kg O
/ O
day O
intraperitoneally O
) O
, O
in O
an O
experimental O
autoimmune O
encephalomyelitis O
( O
EAE O
) O
, O
a O
model O
of O
multiple O
sclerosis O
. O

RESULTS O
: O
By O
Western O
blot O
analysis O
of O
spinal O
cord O
tissues O
, O
we O
have O
demonstrated O
that O
treatment O
with O
bioactive O
RS B
- I
GRA I
significantly O
decreased O
nuclear O
factor O
( O
NF O
) O
- O
kB O
translocation O
, O
pro O
- O
inflammatory O
cytokine O
production O
such O
as O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
, O
and O
apoptosis O
( O
Bax O
and O
caspase O
3 O
expression O
) O
. O

CONCLUSION O
: O
Our O
results O
clearly O
demonstrate O
that O
bioactive O
RS B
- I
GRA I
treatment O
may O
represent O
a O
useful O
therapeutic O
perspective O
in O
the O
treatment O
of O
this O
disease O
. O

Their O
structures O
were O
characterised O
as O
16 B
- I
deethylindanomycin I
( O
2 O
) O
, O
iso B
- I
16 I
- I
deethylindanomycin I
( O
3 O
) O
, O
16 B
- I
deethylindanomycin I
methyl I
ester I
( O
4 O
) O
and O
iso B
- I
16 I
- I
deethylindanomycin I
methyl I
ester I
( O
5 O
) O
on O
the O
basis O
of O
NMR O
, O
HR O
- O
ESI O
- O
MS O
and O
CD O
evidences O
. O

Increased O
levels O
of O
free B
fatty I
acids I
( O
FFAs B
) O
, O
specifically O
saturated B
free I
fatty I
acids I
such O
as O
palmitate B
are O
associated O
with O
insulin O
resistance O
of O
muscle O
, O
fat O
and O
liver O
. O

However O
, O
oil B
red I
O I
staining O
showed O
that O
the O
increased O
lipid O
deposition O
in O
the O
kidney O
of O
nephrectomized O
rats O
improved O
on O
Hachimi O
- O
jio O
- O
gan O
and O
Bakumi O
- O
jio O
- O
gan O
administration O
. O

The O
preventive O
effect O
of O
uncarboxylated O
osteocalcin O
against O
free B
fatty I
acid I
- O
induced O
endothelial O
apoptosis O
through O
the O
activation O
of O
phosphatidylinositol B
3 O
- O
kinase O
/ O
Akt O
signaling O
pathway O
: O
Uncarboxylated O
osteocalcin O
and O
endothelial O
apoptosis O
. O

Linoleic B
acid I
( O
LA O
) O
was O
used O
as O
a O
representative O
free B
fatty I
acid I
. O

A O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
crossover O
study O
of O
alpha O
4 O
beta O
2 O
* O
nicotinic O
acetylcholine B
receptor O
agonist O
AZD1446 B
( O
TC B
- I
6683 I
) O
in O
adults O
with O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
. O

Out O
of O
the O
tested O
compounds O
, O
three O
benzophenanthridine B
alkaloids I
( O
1 O
, O
4 O
, O
and O
7 O
) O
, O
a O
dibenzyl B
butyrolactone I
lignan I
( O
10 O
) O
, O
and O
two O
2 B
- I
arylbenzofuran I
neolignans I
( O
12 O
and O
13 O
) O
displayed O
significant O
cytotoxicity O
to O
HCT116 O
cells O
, O
confirmed O
by O
the O
Guava O
ViaCount O
viability O
assay O
. O

Morphologic O
evaluation O
of O
HCT116 O
nuclei O
following O
Hoechst O
staining O
and O
fluorescence O
microscopy O
revealed O
that O
compounds O
1 O
, O
4 O
, O
7 O
, O
10 O
, O
12 O
, O
and O
13 O
induced O
apoptosis O
in O
HCT116 O
colon O
carcinoma O
cells O
, O
producing O
similar O
, O
or O
higher O
, O
apoptosis O
levels O
when O
compared O
with O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
, O
the O
cornerstone O
cytotoxic O
used O
in O
colon O
cancer O
treatment O
for O
several O
decades O
. O

Morphologic O
evaluation O
of O
HCT116 O
nuclei O
following O
Hoechst O
staining O
and O
fluorescence O
microscopy O
revealed O
that O
compounds O
1 O
, O
4 O
, O
7 O
, O
10 O
, O
12 O
, O
and O
13 O
induced O
apoptosis O
in O
HCT116 O
colon O
carcinoma O
cells O
, O
producing O
similar O
, O
or O
higher O
, O
apoptosis O
levels O
when O
compared O
with O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
, O
the O
cornerstone O
cytotoxic O
used O
in O
colon O
cancer O
treatment O
for O
several O
decades O
. O

Importantly O
, O
compounds O
4 O
and O
13 O
at O
20 O
mu O
M O
were O
the O
most O
promising O
in O
this O
study O
, O
inducing O
respectively O
~ O
11 O
- O
and O
7 O
- O
fold O
increases O
in O
apoptotic O
cells O
as O
compared O
to O
vehicle O
control O
, O
whereas O
5 B
- I
FU I
increased O
apoptosis O
by O
~ O
2 O
- O
fold O
. O

Hydroxytyrosyl B
alkyl I
ether I
derivatives O
inhibit O
platelet O
activation O
after O
oral O
administration O
to O
rats O
. O

Methamphetamine B
( O
Meth B
) O
is O
a O
widely O
abused O
psychostimulant O
that O
causes O
long O
- O
term O
dopamine B
( O
DA O
) O
and O
serotonin B
( O
5 B
- I
HT I
) O
depletions O
. O

The O
enhanced O
DA O
and O
5 B
- I
HT I
depletions O
in O
the O
striatum O
, O
but O
not O
the O
hippocampus O
, O
were O
prevented O
by O
pretreatment O
with O
COX O
inhibitor O
, O
ketoprofen B
, O
during O
stress O
or O
during O
Meth B
; O
however O
, O
ketoprofen B
did O
not O
attenuate O
the O
monoaminergic O
damage O
caused O
by O
Meth B
alone O
. O

In O
addition O
, O
the O
EP1 O
receptor O
antagonist O
, O
SC B
- I
51089 I
, O
did O
not O
attenuate O
DA O
or O
5 B
- I
HT I
depletions O
caused O
by O
stress O
and O
Meth B
. O

In O
addition O
, O
the O
EP1 O
receptor O
antagonist O
, O
SC B
- I
51089 I
, O
did O
not O
attenuate O
DA O
or O
5 B
- I
HT I
depletions O
caused O
by O
stress O
and O
Meth B
. O

Dorsal O
raphe O
nucleus O
( O
DRN O
) O
serotonin B
( O
5 B
- I
HT I
) O
neurons O
projecting O
to O
the O
prefrontal O
cortex O
( O
PFC O
) O
comprise O
the O
important O
neurocircuitry O
underlying O
the O
pathophysiology O
of O
depression O
. O

To O
evaluate O
the O
DRN O
- O
PFC O
5 B
- I
HT I
system O
in O
WKY O
rats O
, O
we O
examined O
the O
effects O
of O
escitalopram B
( O
ESCIT B
) O
on O
the O
extracellular O
5 B
- I
HT I
level O
in O
comparison O
with O
Wistar O
rats O
using O
dual O
- O
probe O
microdialysis O
. O

To O
evaluate O
the O
DRN O
- O
PFC O
5 B
- I
HT I
system O
in O
WKY O
rats O
, O
we O
examined O
the O
effects O
of O
escitalopram B
( O
ESCIT B
) O
on O
the O
extracellular O
5 B
- I
HT I
level O
in O
comparison O
with O
Wistar O
rats O
using O
dual O
- O
probe O
microdialysis O
. O

The O
basal O
levels O
of O
5 B
- I
HT I
in O
the O
DRN O
, O
but O
not O
in O
the O
PFC O
, O
in O
WKY O
rats O
was O
reduced O
as O
low O
as O
30 O
% O
of O
Wistar O
rats O
. O

Responses O
of O
5 B
- I
HT I
in O
the O
DRN O
and O
PFC O
to O
ESCIT B
administered O
systemically O
and O
locally O
were O
attenuated O
in O
WKY O
rats O
. O

Feedback O
inhibition O
of O
DRN O
5 B
- I
HT I
release O
induced O
by O
ESCIT B
into O
the O
PFC O
was O
also O
attenuated O
in O
WKY O
rats O
. O

Chronic O
ESCIT B
induced O
upregulation O
of O
the O
DRN O
- O
PFC O
5 B
- I
HT I
system O
in O
WKY O
rats O
, O
with O
increases O
in O
basal O
5 B
- I
HT I
in O
the O
DRN O
, O
responsiveness O
to O
ESCIT B
in O
the O
DRN O
and O
PFC O
, O
and O
feedback O
inhibition O
, O
whereas O
downregulation O
of O
these O
effects O
was O
induced O
in O
Wistar O
rats O
. O

Chronic O
ESCIT B
induced O
upregulation O
of O
the O
DRN O
- O
PFC O
5 B
- I
HT I
system O
in O
WKY O
rats O
, O
with O
increases O
in O
basal O
5 B
- I
HT I
in O
the O
DRN O
, O
responsiveness O
to O
ESCIT B
in O
the O
DRN O
and O
PFC O
, O
and O
feedback O
inhibition O
, O
whereas O
downregulation O
of O
these O
effects O
was O
induced O
in O
Wistar O
rats O
. O

The O
finding O
that O
chronic O
ESCIT B
upregulates O
the O
5 B
- I
HT I
system O
in O
hyposerotonergic O
WKY O
rats O
may O
contribute O
to O
improved O
understanding O
of O
mechanisms O
of O
action O
of O
antidepressants O
, O
especially O
in O
depression O
with O
5 B
- I
HT I
deficiency O
. O

The O
finding O
that O
chronic O
ESCIT B
upregulates O
the O
5 B
- I
HT I
system O
in O
hyposerotonergic O
WKY O
rats O
may O
contribute O
to O
improved O
understanding O
of O
mechanisms O
of O
action O
of O
antidepressants O
, O
especially O
in O
depression O
with O
5 B
- I
HT I
deficiency O
. O

4 B
- I
Aminoalkoxy I
substituents O
provided O
the O
most O
potent O
derivatives O
, O
with O
the O
4 B
- I
O I
( I
CH2 I
) I
3NMe2 I
analog O
( O
compound O
14 O
) O
being O
identified O
as O
displaying O
the O
best O
overall O
activity O
in O
combination O
with O
good O
aqueous O
solubility O
( O
25 O
mg O
/ O
mL O
for O
the O
hydrochloride B
salt O
) O
. O

We O
isolated O
five O
phenolic B
glycosides I
( O
acteoside B
, O
eutigoside B
B I
, O
isoacteoside B
, O
rutin B
and O
cornoside B
) O
from O
Abeliophyllum O
distichum O
leaves O
by O
high O
- O
speed O
counter O
current O
chromatography O
( O
HSCCC O
) O
using O
a O
solvent O
system O
of O
ethyl B
acetate I
: O
n B
- I
butanol I
: O
water O
( O
8 O
: O
0 O
. O
7 O
: O
5 O
) O
. O

The O
inhibitors O
KN B
- I
92 I
and O
H89 B
were O
able O
to O
block O
both O
pathways O
in O
mutant O
TRPC6 O
expressing O
cells O
, O
as O
well O
as O
the O
prolonged O
elevation O
of O
intracellular O
calcium B
levels O
upon O
carbachol B
stimulation O
seen O
in O
these O
cells O
. O

